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ABSTRACT 
Deoxyribonucleic acid (DNA) is the store of genetic material, needed for cellular 
survival and replication. Cellular DNA is under constant attack from genotoxic agents, 
arising endogenously or exogenously in relation to the cell. Maintaining the stability of 
the genome is imperative to ensure accurate inheritance of the genetic code for future 
progeny and ensures that crucial biological processes are undisturbed. To uphold the 
integrity of the genome, cells have developed numerous DNA surveillance and repair 
mechanisms. The base excision repair (BER) pathway is one of the pathways that 
has evolved to remove minor types of DNA damage. The main sub-pathway of BER 
involves recognition and removal of the oxidised DNA base lesion, incision of the 
phosphodiester backbone, followed by insertion of the correct complementary 
nucleotide, before the nick in the DNA backbone is restored.  
During BER, the recognition of damaged bases relies on DNA glycosylase enzymes. 
Human endonuclease III (NTH1) is a DNA glycosylase enzyme which specifically 
recognises oxidised base lesions, caused by reactive oxygen species (ROS). 
Crucially, NTH1 excises thymine glycol (Tg), which is a particularly mutagenic base 
lesion. 
Regulation of enzymes implicated in the BER pathway is important to prevent 
excessive DNA damage. Reports have demonstrated the importance of post 
translational modifications (PTMs) in controlling the levels, activity and interactivity of 
BER proteins. Ubiquitylation is a PTM that has been implicated in the regulation of 
several BER enzymes. Ubiquitylation is completed by the ubiquitin proteasome 
pathway (UPP); whereby E3 ligase enzymes attach of moieties of ubiquitin to lysine 
residues of substrate proteins. The attachment of multiple moieties of ubiquitin 
(polyubiquitylation) is associated with the regulation of protein levels, whereas, the 
attachment of singular subunits of ubiquitin (monoubiquitylation) can have variable 
consequences.  
Despite this understanding, evidence of PTMs that target human NTH1 are deficient. 
A proteomic study demonstrated that NTH1 is subject to ubiquitylation dependent 
regulation, but the specific UPP enzymes involved were not identified. The 
overarching aim of this project was to understand the molecular mechanisms 
employed by human cells to regulate levels of NTH1 via ubiquitylation, with specific 
emphasis on discovering the E3 ligase enzymes involved. 
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Using a well refined purification technique, human cell extracts were fractionated 
using a series of column chromatography columns. Candidate E3 ligase activity was 
examined using in vitro ubiquitylation assays of chromatography fractions, with 
recombinant NTH1 as the substrate protein. Eventually, mass spectrometry analysis 
of an isolated ubiquitylated fraction, identified tripartite motif containing 26 (TRIM26) 
as the only candidate E3 ligase enzyme present in the active fraction. We 
strengthened this finding by repeating ubiquitylation assays using recombinant 
TRIM26. Together, these findings identify TRIM26 as the major E3 in human cell 
extracts that catalyses the ubiquitylation of NTH1. Following this, site directed 
mutagenesis identified lysine 67 as the major site of TRIM26 dependent ubiquitylation 
of NTH1.  
Aside to this, the cellular implications of TRIM26 dependent regulation of NTH1 were 
investigated. Elevated levels of cellular NTH1 following proteasome inhibition 
confirmed that NTH1 levels may be regulated in cells by ubiquitylation dependent 
degradation. However, depletion of cellular TRIM26 via siRNA had no significant 
impact on the steady state levels of the glycosylase. Fractionation of cellular extracts 
confirmed that cellular NTH1 is located primarily in the nucleus and may be associated 
with chromatin. Depletion of TRIM26 resulted in no alteration in the cellular distribution 
of the glycosylase. 
Since TRIM26 dependent ubiquitylation did not appear to regulate the steady state 
levels of NTH1, further examination using hydrogen peroxide as a DNA damaging 
agent showed that DNA damage responsive levels of NTH1 protein expression 
increased following TRIM26 depletion. The clonogenic assay demonstrated that cells 
had increased survival capacity in the absence of TRIM26. Importantly, this 
observation was recapitulated with a partial overexpression of NTH1. Similarly, the 
alkaline single gel electrophoresis (comet) assay, in combination with an siRNA 
mediated depletion of TRIM26, concluded that cells with reduced TRIM26 levels have 
improved ability to manage oxidative stress. Once more, a similar level of improved 
DNA repair kinetics could be achieved by partially overexpressing NTH1. 
Overall, I successfully purified and identified TRIM26 as the major E3 ligase that 
ubiquitylates NTH1. The major site of TRIM26 dependent ubiquitylation is lysine 67; 
as substitution of this residue substantially impeded in vitro ubiquitylation via TRIM26. 
Cellular studies confirmed that levels of NTH1 may be regulated by ubiquitylation 
dependent degradation, although, TRIM26 dependent ubiquitylation was not 
implicated in the regulation of steady state levels of NTH1. Rather, it appears that 
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TRIM26 may be implicated in the regulation of DNA damage responsive levels of 
NTH1. Interestingly, a separate investigation in our laboratory previously identified 
TRIM26 as one of the major E3 ligase enzymes involved in regulation of the steady 
state levels of another BER glycosylase, endonuclease VIII-like protein 1 (NEIL1).   
Excitingly, the outcomes of this work have now been peer-reviewed and accepted for 
publication in the Molecular and Cellular Biology scientific journal (see appendix).  
In summary, an increasingly dynamic role of TRIM26 is now becoming apparent; 
whereby, the E3 ligase is involved in the regulation of multiple BER glycosylases with 
different effects in relation to the DNA damage response. Despite this increased 
perception, the cellular mechanism which dictates the outcome of ubiquitylation of 
either glycosylase under the regulation of TRIM26 remains to be fully understood and 
demands further inspection.  
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CHAPTER 1 – INTRODUCTION 
 
1.1. The cellular genome  
 
Cells are described as the smallest functional unit of every organism. Cells consist of 
a viscous aqueous material encapsulated within a cellular membrane. The majority of 
organisms exist as single cells, however, other organisms consist of multiple cells that 
are differentiated and grouped together to achieve specialised functions. The 
structures of different cell types are often related to their function. It is estimated that 
the human body is made up of more than 1013 cells. Remarkably, every cell within a 
multicellular organism originates from cellular divisions from one original embryonic 
cell. To achieve this, every single cell contains the hereditary instructions and 
materials needed to construct a complete copy of itself during cellular divisions.  
The hereditary information of all living cells is stored as strands of deoxyribonucleic 
acid (DNA). Each DNA molecule is composed of a double helix formed from two 
complementary antiparallel strands of repeating units of nucleotide monomers called 
bases (Figure 1). There are four types of bases; adenine (A), thymine (T), cytosine 
(C) and guanine (G) (Figure 2). The two strands of DNA are held together by 
hydrogen bonds between these bases, which exhibit base pairing specificity; G-C and 
A-T (Figure 3). The order in which these bases are arranged dictates the genetic 
code of the cell. Autonomous cellular divisions are dependent on the duplication of 
the genetic information encoded by DNA, which relies on one of the DNA strands 
acting as a template to generate an identical complementary strand.  
The genetic information encoded by DNA not only enables cellular replication, but it 
also contains the instructions needed for the cell to synthesise the fundamental 
proteins required for survival. The sequence of nucleotides on the DNA strands 
determines the sequence of the protein; three DNA bases encode one amino acid, 
which are the monomeric units of proteins. Sections of DNA, termed genes, encode 
the instructions for the manufacture of one or a few cellular proteins.   
Proteins are linear molecules consisting of repeating units of amino acids; of which 
there are 20, joined together by peptide bonds to create a polypeptide chain. The 
sequence of the polypeptide chain dictates the final three-dimensional structure of the 
protein, which ultimately determines protein function. Reactive sites on the surface of 
proteins enable them to bind with high specificity to other molecules, so that they may 
act as enzymes to direct biochemical reactions within the cell. In addition, cellular 
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proteins play vital roles in maintaining structures, enabling movement or sensing 
signals.   
The survival and maintenance of an organism is dependent on the ability of cells to 
store, replicate and express the genetic code. To survive and perform their designated 
function, every cell must respond to stimuli. Cellular responses are primarily 
dependent on the regulation of the levels, activity, localisation or interactions of 
proteins within the cell. Protein interactions are mostly grouped together to form 
protein cascades. There is a substantial amount of cross-talk between protein 
pathways, generating a complex and dynamic cellular protein network. It is estimated 
that at any given time, a human cell may exhibit 130 000 binary protein interactions 
(160). 
Despite the importance of DNA, the molecule is not exempt from spontaneous 
changes or attack by reactive molecules generated within the cell. DNA is also subject 
to damage by thermal disruption, chemical insults or radiation exposure. The survival 
of a cell is dependent on preventing changes to the nucleotide sequence of DNA. A 
permanent change or mutation in the sequence of DNA bases of a gene can have 
detrimental consequences depending on its position on the DNA sequence. 
Ultimately, a genetic mutation can disrupt the composition of a polypeptide chain that 
the gene encodes. Changes in the sequence of amino acids generated may influence 
the tertiary structure of the affected protein, resulting in altered activity, regulation or 
ability to interact effectively with other cellular components. The impact the genetic 
mutation has on the cell, largely depends on the role of the mutated protein. Due to 
the complexity of the proteome, the impact of an abnormal protein may be 
exaggerated by affecting multiple biochemical cascades.  
Cancer is a familiar example of the impact genetic mutations can induce in somatic 
cells. Mutations in genes encoding proteins involved in cell growth, proliferation or 
programmed cell death can give cells a selective advantage over the surrounding 
tissue. This leads to uncontrolled cellular growth and division, resulting in the 
development of malignant tumours. Cells with cancerous mutations may demonstrate 
increased invasive potential and ability to spread to other areas of the body via 
metastasis. Cancer continues to be a major source of human morbidity and mortality 
worldwide. In 2012 alone, it was estimated that 14.1 million new cases of cancer 
occurred, with 8.2 million related deaths (155). With this being considered, a 
substantial amount of scientific research remains focused on improving our 
understanding of cancer and seeking better treatments. Current non-invasive curative 
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treatments, such as chemotherapy or radiotherapy, eradicate cancerous cells by 
inducing detrimental DNA damage to highly proliferative cancer cells. The objective 
of current treatments highlights the importance of research related to DNA damage 
and its effects.  
1.2. The structure of DNA  
 
In 1953, the structure of DNA was characterised by Watson and Crick (172). The 
monomeric building blocks of DNA are nucleotides, which consist of a ribose sugar, 
phosphate group and a nitrogen containing nucleobase (Figure 1). There are a total 
of four DNA nucleobases: A, T, C and G (Figure 2). The nucleobases are all cyclical 
compounds that are characterised according to the number of cyclical rings in their 
structure. For instance, C and T are pyrimidines with one cyclical ring, whereas, A 
and G are purines with two cyclical rings (Figure 2). The cyclical bases attach to the 
first carbon atom on the deoxyribose sugar by an N-glycosidic bond.  A phosphate 
group attaches to the sugar molecule in place of the –OH group on the 5’ atom via a 
phosphoester bond (Figure 1). In basic terms, a DNA strand is simply a string of 
nucleotides. The nucleotides covalently attach to each other by a phosphodiester 
bond between the 5’-phosphate group of one nucleotide and the 3’-hydroxyl group on 
the sugar of the adjacent nucleotide. This gives rise to a sugar-phosphate backbone 
from which the bases protrude (Figure 3). The order in which the nucleotides are 
arranged dictates the genetic code. 
 
Figure 1. Schematic representing the composition of a nucleotide. Nucleotides 
are composed of a five-carbon deoxyribose sugar, from which a nitrogenous base 
(adenine, thymine, cytosine or guanine) is attached to the first carbon via an N-
glycosidic bond. A phosphate group is attached to the fifth carbon via an ester bond. 
Repeating units of nucleotides are the building blocks of DNA strands. The order that 
they are arranged dictates the genetic code.  
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Figure 2. Schematic of the four nitrogenous bases which compose DNA. The 
pyrimidine bases, cytosine (C) and thymine (T), each have a single six-member ring, 
whereas, the purine bases, guanine (G) and adenine (A) consist of a five-atom ring 
attached to a six-atom ring.  
DNA molecules are made up of two antiparallel strands of nucleotides that run in 
opposite directions. The two DNA strands are arranged in an energetically favourable 
manner, whereby the hydrophilic sugar-phosphate backbones reside on the outside 
with the hydrophobic bases located within the interior. The two opposite strands of 
DNA are held together via hydrogen bonds between the nucleobases (Figure 3). To 
maintain consistent distance between the two nucleotide strands and ensure 
maximum stability, the nucleobases demonstrate base pairing specificity. A two-ring 
purine base always bonds with a single-ring pyrimidine base. In this way, A binds to 
T using two hydrogen bonds and C pairs with G by three hydrogen bonds (Figure 3). 
Base pairing specificity aids the fidelity of the DNA molecule and ensures that the 
nucleotide sequences of partner strands of DNA are complementary.  
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Figure 3. The chemical structure of duplex DNA. Repeating units of nucleotides 
attached via phosphodiester bonds make up strands of DNA (only two nucleotides 
each shown). Molecules of DNA consist of two strands of nucleotides arranged with 
the bases protruding from sugar-phosphate backbones. The two strands of 
nucleotides are held together by hydrogen bonds between the protruding bases. The 
bases demonstrate base pairing specificity; adenine (A) binds to thymine (T) using 
two hydrogen bonds, whereas, cytosine (C) binds to guanine (G) via three hydrogen 
bonds. 
  
To ensure efficient packing of the base pairs, the DNA molecule winds around itself 
every ten base pairs, giving rise to the iconic double helix structure. The chemical 
polarity of the DNA strands is dictated by the orientation of the deoxyribose sugar 
located at each terminus, giving rise to so called 5’ and 3’ ends. This orientation is 
particularly important during events such as replication or transcription which always 
run from the 5’ end to the 3’ end of the DNA strand. Stacking between adjacent bases 
is primarily responsible for the stability of the DNA molecule at this level (183).  
To package the long, linear strands of DNA into each cell, it is condensed into 
chromatin consisting of DNA in complex with organisational proteins. To form 
chromatin, DNA is tightly wound around positively charged proteins called histones. 
Double stranded DNA wraps around an octamer of 8 histone 1.65 times to form a 
nucleosome. Coils of nucleosomes then further arrange themselves to give rise to a 
30 nm chromatin fibre that forms loops averaging 300 nm in diameter. The fibres are 
compressed and bundled to form chromosomes. Principally, this level of organisation 
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safeguards the integrity of the DNA by reducing the exposure of the surface area of 
the DNA molecule to the physiological environment, providing a certain level of 
physical protection from genotoxic agents. Furthermore, accessibility of specific 
regions of DNA can be more tightly regulated with respect to cellular function. The 
total number of chromosomes containing all of the genetic material required for the 
survival of an organism is referred to as its genome. The human genome consists of 
approximately 3.2 x 109 DNA nucleotide pairs arranged between 23 pairs of 
chromosomes.  
Sections of DNA encoding heritable traits are termed genes. It is worth noting that 
somatic cells contain two complete sets (diploid state) of chromosomes; with one set 
inherited from each parent. For this reason, gamete cells contain only one set of 
chromosomes (haploid state). Since one set of chromosomes is inherited from each 
parent, every individual inherits two different versions of each gene, which are termed 
alleles. Alleles may be recessive or dominant which contribute to which observable 
phenotype the progeny exhibits.  
1.3. DNA DAMAGE  
 
Maintaining the stability of the genome is imperative to ensure accurate inheritance 
of the genetic code for future progeny and ensures that crucial biological processes 
are undisturbed. However, like any biological molecule, DNA is susceptible to 
spontaneous chemical reactions arising from endogenous reaction products or 
exogenous elements in the environment. Examples of forms of DNA damage include 
sugar or base modifications, single strand breaks, double strand breaks, abasic sites 
or cross-linking. The bases in DNA are extremely susceptible to chemical 
modification, which results in the formation of DNA base lesions. DNA base lesions 
can be transformed into mutations via replication errors or faulty DNA repair. Genomic 
mutations are permanent alterations to the DNA code and may continually influence 
biological function. The impact of a genetic mutation is dictated by the type of DNA 
lesion and the gene it affects. For instance, mutations causing the activation of 
oncogene function or loss of tumor-supressor genes can trigger unregulated cellular 
proliferation and malignant growth. In this way, DNA lesions can induce mutations 
related to cancer.  
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1.3.1 Endogenous DNA damage  
Cellular DNA is susceptible to damage from genotoxic agents within the cell or 
following exposure to external sources. Genotoxic sources within the cell are referred 
to as endogenous sources of DNA damaging agents. Endogenous genotoxic sources 
include reactive biological molecules, such as ROS, which are discussed in the 
following sections.  
1.3.1.1 Hydrolysis  
 
The majority of endogenous DNA damage arises from spontaneous hydrolysis. The 
N-glycosidic bond, connecting DNA bases to the deoxyribose sugar, is particularly 
labile and susceptible to acid-catalysed hydrolysis, resulting in the loss of DNA bases 
and the generation of abasic sites. The reaction occurs more readily at purine bases; 
resulting in the loss of 2,000 to 10,000 purine DNA bases per cell, per day, under 
normal physiological conditions (88). Another study using liver cells, proposed that in 
fact 50,000 abasic sites occur per cell, per day, at steady state levels (110). 
Comparing the rates of depurination of ssDNA to dsDNA suggests that the double 
helix structure protects against hydrolytic release of bases. The velocity of 
depurination is four times faster in single stranded DNA, compared to duplex DNA 
(87). Abasic sites are cytotoxic and have the potential to block transcription and DNA 
replication. Likewise, abasic sites are noncoding lesions with mutagenic potential and 
can facilitate the incorporation of an incorrect nucleotide by DNA polymerases. Due 
to its frequency, hydrolytic loss of DNA bases can be thought of as one of the most 
important mutagenic events endangering the stability of the genome.   
In addition to the inherent lability of the glyosidic bonds, DNA bases themselves are 
subject to spontaneous hydrolytic deamination events. Cytosine most frequently 
undergoes hydrolytic deamination, yielding uracil residues. Hydrolytic conversion of 
cytosine to uracil residues involves direct deamination, followed by an acid catalysed 
attack by water on the protonated base (143). Interestingly, the epigenetically 
methylated form of cytosine, 5-methylcytosine, which accounts for approximately 1 % 
of total human DNA, is deaminated to form thymine residues four times more rapidly 
than its cytosine precursor (87, 144). Deamination of adenine to hypoxanthine and 
thymine to xanthine is much less frequent, occurring at only 3 % of the rate of cytosine 
deamination (77). However, hypoxanthine is a highly mutagenic lesion as it 
preferentially pairs with cytosine, resulting in a post-replicative transversion mutation 
(77).  
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1.3.1.2 Oxidation  
 
Oxygen is an element needed for many cellular processes, including cellular 
metabolism, cellular signalling and the immune response. Though, constant exposure 
to molecular oxygen creates an unavoidable source of genotoxic molecules in the 
form of reactive oxygen species (ROS), generated by oxygen reduction. Types of 
ROS include the superoxide anion (O2•-), hydrogen peroxide (H2O2) and hydroxyl 
radicals (•OH). The superoxide anion, can further react with cellular molecules to form 
secondary types of ROS. For instance, the superoxide anion can be reduced to 
hydrogen peroxide. Further to this, hydrogen peroxide is converted to hydroxyl 
radicals, via a transition metal catalysed Fenton reaction.  
All ROS are highly reactive and can induce oxidative damage to cellular molecules, 
including; lipids, proteins, RNA and DNA. Unrepaired ROS induced damage to cellular 
macromolecules can result in cell death, genetic mutation, changes in gene 
expression and chromosome instability.  
Sources of ROS can be either endogenous or exogenous. Endogenous sources of 
ROS originate from normal cellular metabolism, peroxisomes and inflammatory cells. 
During cellular oxidative metabolism, approximately 4-5 % of oxygen escapes 
reduction to water via the mitochondrial electron transport chain. Instead, it is 
converted to ROS (mainly the superoxide anion). Inflammatory cells are major 
contributors to cellular ROS levels. For example, in response to stimuli, phagocytes 
undergo respiratory bursts to release ROS. It is believed that the ROS released by 
this process support the destruction of the microbial insult by generating ROS induced 
damage to the bacterial biomolecules. Undesirably, the ROS from this mechanism 
can diffuse to other localised areas and induce damage to non-bacterial molecules. 
The association between chronic inflammation and carcinogenesis is well 
acknowledged (59). Peroxisomes are also an endogenous contributor of cellular 
ROS. Rodent studies demonstrated that peroxisomes account for nearly 35 % of 
hydrogen peroxide production (139). Other studies have highlighted that 
administration of therapeutics instigating increased peroxisome proliferation result in 
carcinogenesis (45). In addition, exogenous sources of DNA damaging agents, such 
as ionizing or ultraviolet radiation, can generate ROS as by-products. For example, 
ionising radiation rapidly generates ROS through radiolysis of water molecules. Most 
of the harmful effects of ionising radiation are mediated through ROS, which diffuse 
through the cell and cause persistent damage (135, 158).  
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With regards to DNA, all ROS have the potential to cause over 20 distinctive oxidised 
DNA adducts (32), although hydroxyl radicals are the primary ROS that damages 
DNA (93). ROS can directly oxidise DNA components; leading to base modifications, 
deoxyribose sugar alterations, cross-linking or strand breaks. It is estimated that every 
human cell endures 104 oxidised base lesions per day (4). A frequent oxidised DNA 
base lesion that features in the top 10 most common endogenous DNA damage 
insults, is 8-oxo-7,8-dihydrogaunine (8-oxoG; Figure 6) (148). The lesion is formed 
via the addition of a hydroxyl radical at the C8 position of the guanine ring, which is 
then reduced. The 8-oxoG lesion has high mutagenic potential and preferentially pairs 
with A (instead of C). Incorrect base pairing with A results in a transversion mutation, 
if 8-oxoG is not repaired prior to DNA replication (28). Unsurprisingly, elevated levels 
of 8-oxoG have been documented in numerous cancers (37, 105, 150). Measuring 
levels of 8-oxoG has been a useful biomarker to estimate oxidative burden (159). 
Another common base lesion used to estimate oxidative stress is 5, 6-dihydroxy-5,6-
dihydrothymine (thymine glycol, Tg; Figure 6), which is caused by the interaction of 
the hydroxyl radical with thymine. Tg lowers the thermal stability of DNA and induces 
large structural changes, which blocks the action of replicative polymerases (76).  
1.3.1.3 Alkylation  
 
Alkylation is another type of DNA damage induced due to the presence of 
endogenous reactive molecules. Alkylation is a process whereby an alkyl group is 
transferred from a reactive molecule to regions of the DNA molecule. The primary 
sites of alkylation are the oxygen and nitrogen atoms of the nucleobases. The addition 
of bulky alkyl adducts to the DNA nucleobases can disrupt base pairing specificity. 
One of the most abundant alkylating agents is S-adenosylmethionine (SAM). It is well 
known that SAM is used as a cofactor in most cellular transmethylation reactions. All 
DNA methyltransferase enzymes use SAM as the methyl donor during regulation of 
gene expression, via DNA methylation. Still, non-enzymatic methylation of DNA by 
SAM can cause two major DNA base lesions; 7-methylguanine and 3-methyladenine 
(Figure 4). It is expected that SAM generates 600 3-methyladenine residues and up 
to 4,000 7-methylguanine base lesions, per mammalian cell, each day (136). The 7-
methylguanine lesion is not immediately harmful, as it does not affect base pairing 
specificity and the N-methylpurine DNA glycosylase (MPG) is dedicated to the 
removal of 7-methylguanine. However, 7-methylguanine can influence the lability of 
the N-glycosidic bond, leading to abasic sites. In comparison, 3-methyladenine is 
highly cytotoxic and blocks cellular replication. Due to this, MPG is also dedicated to 
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the excision of 3-methyladenine lesions. Interestingly, it has been suggested that the 
effectiveness of MPG decreases with age in human cells (8). To a lesser extent, SAM 
can generate alkylated pyrimidine lesions, such as 3-methylthymine or 3-
methylcytosine, which have the capacity to prevent DNA replication. Other alkylated 
DNA base lesions from endogenous origin include; O6-methylguanine, O4-
methylthymine and O4-ethylthymine. Base lesions formed from methylation of oxygen 
molecules are notoriously difficult to examine due to low frequency and rapid repair 
rate (86). Despite this, it has been established that they are associated with transition 
mutations during DNA replication (111, 131).  
1.3.1.4 Single strand breaks 
Single strand breaks (SSBs) are one of the most frequent types of DNA damage and 
can arise from endogenous agents (such as ROS or other intracellular metabolites), 
exposure to exogenous agents (such as ionising radiation), or due to miscellaneous 
activity of particular enzymes (for example, DNA topoisomerases) (Figure 4). 
Furthermore, SSBs can be spontaneously generated through miscellaneous DNA 
repair. SSBs are an unavoidable intermediate following incision of the abasic site 
during the BER pathway (24). Likewise, SSBs can occur due to collapsed DNA 
replication forks, leading to excessive protein poly-ADP-ribose polymerase 1 (PARP1) 
activation (24).  
 
Figure 4. Single strand breaks (SSBs). A schematic showing the formation of a 
DNA SSB. Bases are represented by four different shapes and the DNA backbone is 
represented by a thick black line. A single strand break is formed on one side of the 
DNA backbone, which is normally associated with the loss of a DNA base and 
damage to the 5’ and 3’ terminal ends of the DNA strand.   
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1.3.1.5 Double strand breaks 
Double strand breaks (DSBs) are one of the most lethal forms of genomic damage 
associated with genomic instability and cellular transformation. DSBs arise when the 
phosphate backbones of the two complementary DNA strands are broken 
simultaneously, in close (within 0-20 base pairs) proximity (Figure 5). Base-pairing 
and chromatin structure are unable to keep the two DNA ends connected (70). As a 
consequence, the two DNA ends are liable to become physically dissociated from one 
another, hindering repair processes and increasing the opportunity for inappropriate 
recombination (Figure 5). Therefore, DSBs are particularly cytotoxic or mutagenic 
and are associated with chromosomal relocations. Alike to other types of DNA 
damage, DSBs arise pathologically following exposure to exogenous genotoxic 
agents, such as ionising radiation or due to intracellular metabolites. The major 
endogenous source arises when DNA replication forks collapse. Due to the lethality 
of DSBs, cells have evolved important repair mechanisms; homologous 
recombination (HR) and nonhomologous end-joining (NHEJ) (70). 
 
 
Figure 5: DNA Double Strand Breaks (DSBs). A schematic showing the formation 
of a DNA SSB. Bases are represented by four different shapes and the DNA 
backbone is represented by a thick black line. A DSB is formed when the 
phosphodiester backbone is broken simultaneously on both strands of DNA. Base-
pairing and chromatin structure are insufficient to keep the two DNA ends juxtaposed. 
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Figure 6. Schematic of DNA base lesions. The chemical structures of the four 
undamaged nucleotides are featured above with some of the damaged derivatives of 
each nucleotide represented below. The colours utilised represents the type of 
damage encountered; red represents oxidative damage, blue represents deamination 
and green for alkylation.  
 
1.3.2 Exogenous DNA damage  
Cellular DNA is under constant attack from genotoxic agents. Reactive molecules that 
damage the genome can arise from exposure to exogenous sources, such as ionising 
radiation. Different types of exogenous agents and the DNA damage they induce are 
discussed in the proceeding sections.   
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1.3.2.1 Ultraviolet light exposure  
 
Ultraviolet light (UV) is an unavoidable DNA damaging agent arising from exposure 
to the sun. Direct damage to the DNA macromolecule is predominantly induced by 
highly reactive UV-B wavelengths of radiation (134). UV-A radiation interacts poorly 
with DNA, but can still induce genomic damage by indirect photosensitising reactions, 
via singlet oxygen molecules.  
Two of the most abundant types of DNA lesions, cyclobutane pyrimidine dimers 
(CPD’s) and 6–4 pyrimidine photoproducts, are induced by UV exposure. Both 
pyrimidine adducts are defined by the formation of atypical covalent bonds between 
adjacent pyrimidine bases. Areas consisting of adjacent pyridines, particularly two 
cytosine residues, are prone to UV-induced damage. CPD’s occur up to 3 times more 
frequently than 6-4 photoproducts, but both types of dimers are equally pre-mutagenic 
and potentially cytotoxic by significantly distorting the double-helix (134). Due to the 
disproportion in frequency, CPD’s are believed to have the greatest mutagenic effect. 
Related to this, 6-4 photoproducts are more rapidly repaired by DNA repair pathways, 
compared to CPD’s (100). The formation of modified purine bases in response to UV 
radiation has also been acknowledged, but these occur infrequently (17, 56).  
If UV-induced lesions are not repaired, they result in permanent mutations within the 
genome following replication of the DNA strand. The cumulative effects of DNA 
damage following recurrent exposure to UV contributes to photoaging, 
immunosuppression and the development of skin cancers (100).  
1.3.2.2 Ionising radiation  
 
Ionising radiation arises from environmental sources, such as cosmic radiation, or 
from man-made sources, including X-rays. When tracks of ionisation pass through 
cells, they can interact with biomolecules. The most significant effects of ionising 
radiation are observed when tracks of radiation interact with genomic DNA. It is now 
understood that radiation can cause a spectrum of DNA damage, including base 
lesions, SSBs and DSBs. It is estimated that one gray (Gy) of ionising radiation with 
low linear energy transfer (LET) can induce 1,300 DNA base lesions, 1,000 SSBs, 
and up to 40 DSBs per cell (92). Of all of the DNA aberrations caused by ionising 
radiation, DSBs are considered to be the major mutagenic risk to the genome 
(Section 1.3.1.5). This is due to one of the DSB repair pathways being particularly 
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error prone, risking chromosomal aberrations. As the dose of radiation exposure 
increases so does the yield of DSBs (92).  
A distinctive feature of genomic damage following exposure to a single radiation track, 
is the formation of two or more DNA lesions that are clustered within 1-2 helical turns 
of DNA. The number of lesions contributing to a site of clustered (complex) DNA 
damage is related to the LET of the radiation. Approximately 90 % of the energy 
deposited by radiation with high LET induces clustered (complex) DNA damage, 
whereas 30 % of the energy deposited by radiation tracks with low LET is associated 
with the formation of these lesions (92). Importantly, sites of complex DNA damage, 
including DSBs, are less readily repaired. Complex DNA lesions are believed to 
persist 8 times longer than single base lesions (91). As the LET of radiation increases, 
so does the complexity of the DNA lesions (113).  
In addition to directly interacting with cellular structures, ionising radiation can 
indirectly cause biological changes through by-products created when the track of 
radiation interacts with other cellular biomolecules. Ionising radiation can interact with 
water molecules within the cell, to generate ROS. The hydroxyl radicals produced can 
diffuse through the cell and damage proteins or DNA (135). The indirect effects of 
radiation are particularly relevant to ionising radiation with low LET.  
It has now been established that the biological effects of ionising radiation are further 
amplified by the radiation-induced bystander effect (9). Studies identified that 
neighbouring cells, not exposed to tracks of radiation, also experience levels of 
damage resulting in chromosomal breakages and tumour formation. It is believed that 
the bystander effects of radiation are attributed to the release of signalling molecules 
by irradiated cells. These signalling molecules include inflammatory cytokines, that 
stimulate production of nitric oxide and ROS, which can diffuse to neighbouring cells 
and induce DNA damage (65). Likewise, damage to mitochondria results in increased 
production of hydrogen peroxide, which can diffuse across cellular membranes (65).  
1.4. DNA damage repair 
 
To ensure survival, organisms must preserve the stability of the genome against the 
DNA lesions which form every day. Indeed, most DNA lesions are repaired 
immediately via specialised repair mechanisms, meaning only a small proportion of 
them accumulate as permanent mutations propagated within cell progeny. The 
importance of repairing DNA lesions is highlighted by the cellular investment made to 
maintain numerous DNA repair enzymes. The importance of each DNA repair enzyme 
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is evident by increased mutation rates following its inactivation. The association of 
inactivation of DNA repair proteins and human diseases has been well characterised.   
Coincidentally, the structure of DNA is well suited to enable accurate repair due to the 
preservation of two copies of the genetic information on separate strands. In this way, 
the complementary strand can act as a template during DNA repair and directs the 
insertion of correct complementary nucleotides onto the damaged DNA strand. The 
advantage of storing genetic information in this way is emphasised by the preservation 
of the double-stranded helix structure of DNA in most organisms.  
Cells have developed several processes to deal with different types of DNA lesions. 
Two of the most common pathways are the base excision repair (BER) pathway, 
which eliminates minor examples of damaged base lesions (118), and the nucleotide 
excision repair (NER) pathway, which removes larger lesions to genomic DNA (84). 
In both repair pathways, the damaged nucleotides are excised then polymerases use 
the complementary strand of DNA as a template to insert the correct nucleotide on 
the damaged DNA strand. Then DNA ligase enzymes seal the break in the sugar-
phosphate backbone and restore the double-helix (Figure 7).  
Of course, when DNA is exceptionally damaged, it is not always possible to use the 
undamaged DNA strand as a template. In this circumstance, cells have developed 
alternative repair strategies that rely on translesion polymerases to bypass the DNA 
damage and enable cell survival. Translesion polymerases are less accurate, as they 
estimate which nucleotide to incorporate into the damaged site (170). In this respect, 
translesion polymerases compromise the integrity of the genome and contribute to 
the accumulation of base-substitutions or deletion mutations. 
Likewise, a template strand of DNA is understandably unavailable when both strands 
of the DNA helix are broken. This makes DSBs particularly destructive to the integrity 
of the genome, often leading to cell death. To process DSBs, cells have developed a 
NHEJ strategy, which essentially ligates the two ends of DNA together, usually 
resulting in the deletion of one or several nucleotides (35). Further inaccuracy of this 
pathway arises from the fact that it has no mechanism to ensure the ends of the DNA 
strands it ligates together were formerly adjacent to each other. This means NHEJ 
can cause entire rearrangements of the genome. In contrast, HR is employed to 
process DSBs with better accuracy. HR is critical in recovering faulty replication forks 
or inter-strand cross links. However, HR is only applied to newly replicated DNA (in 
the S and G2 phases of the cell cycle), as it relies on the use of sister chromatids as 
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template DNA (138). HR avoids creating deletions, but can still pose the threat of 
chromosomal rearrangements or loss of heterozygosity via gene conversion. 
To minimise the probability of permanent mutations being inherited by future cell 
progeny during cellular divisions, most cells initiate a transient delay in cell cycle 
progression when DNA damage is incurred. This allocates time to enable DNA repair 
before the cell divides. Throughout the cell cycle (G1, S, G2, M) there are many 
checkpoints, which the cell utilises to monitor status. The G1 checkpoint monitors DNA 
integrity and dictates whether the cell will initiate DNA replication in S-phase, before 
undergoing mitosis. If DNA damage is detected, then either DNA repair mechanisms 
will be initiated or the cell will undergo apoptosis. 
1.4.1 Nucleotide excision repair 
 
NER is a DNA repair mechanism which counteracts a diverse spectrum of DNA 
lesions. Although, lesions which significantly distort the DNA helix appear particularly 
relevant to NER, such as bulky CPDs or (6-4) photoproducts. For this reason, patients 
with defects in genes implicated with NER exhibit photosensitivity and susceptibility 
to skin cancer. In fact, studies based upon patients with these clinical manifestations 
formed the basis of identification of many factors of NER. NER can also remove bulky 
chemical adducts, intra-strand cross-links, inter-strand cross-links and different types 
of oxidative damage (Figure 7).  
In general, two sub-pathways of NER can be distinguished; global genome repair 
(GGR), targets lesions across the entire genome, whereas, transcription-coupled 
repair (TCR) targets transcriptionally active regions of DNA (41).  Due to their different 
repair targets, the two modes of NER differ in the way that the DNA lesions are 
recognised, but the subsequent stages are shared (Figure 7). Remarkably, it has 
been shown that the components needed for NER can assemble and eliminate 
genomic damage within 4 minutes (66).  
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Figure 7. The mechanism of nucleotide excision repair (NER). Schematic 
representation of the two sub-pathways of NER; (A) global genomic repair (GGR) and 
(B) transcription-coupled repair (TCR). In GGR, damage is recognised by the XP-C 
and XP-E complex; XP-A recruits the transcription factor IIH (TFIIH) complex that 
contains the XP-B and XP-D ATPase-dependent helicases, which unwind 
approximately 30 nucleotides surrounding the genomic damage. The XPG 
endonuclease cleaves the DNA backbone 3’ to the lesion, whilst the XPF-ERCC1 
endonuclease heterodimer cleaves the DNA backbone 5’ to the lesion. Nucleotides 
are inserted by replicative polymerases delta and epsilon (Pol δ and Pol ε). The nick 
in the DNA backbone is repaired by DNA ligase I or III. Whereas, TCR recognises a 
stalled replication fork via CSA and CSB proteins. The TFIIH complex is recruited and 
completion of repair continues as per GGR. Following repair, the RNA polymerase 
can continue to transcribe RNA. Figure is adapted from (31).  
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CSA = Cockayne syndrome complementation group A; CSB = Cockayne syndrome 
complementation group B; DDB = DNA binding protein; ERCC1 = excision repair 
cross-complementation group 1; HR23B = homologous recombinational repair group 
23B; mRNA = messenger RNA; PCNA = proliferating cell nuclear antigen; pol = 
polymerase; RNAPII = RNA polymerase II; RPA = replication protein A; TFIIH = 
transcription initiation factor IIH; TFIIS = transcription initiation factor IIS; XP = 
xeroderma pigmentosum (groups A–G). 
In GGR, damage recognition is instigated by the XP-C and XP-E complex, which 
continually scans the DNA for obvious structural distortions. In response to damage 
recognition, XP-A recruits the TFIIH complex that contains the XP-B and XP-D 
ATPase-dependent helicases, which unwind approximately 30 nucleotides 
surrounding the genomic damage (Figure 7). The XPG endonuclease cleaves the 
DNA backbone 3’ to the lesion, whilst the XPF-ERCC1 endonuclease heterodimer 
cleaves the DNA backbone 5’ to the lesion. The excised nucleotides are replaced by 
the action of replicative Pol δ and Pol ε. Finally, the nick in the DNA backbone is 
restored via the action of DNA ligase I or III (41). In contrast, identification of a stalled 
replication fork by TCR, is achieved by CSA and CSB proteins. After this, the TFIIH 
complex is recruited and completion of repair continues as per GGR (Figure 7). 
Following repair, the RNA polymerase can continue to transcribe RNA (41).  
1.4.2 Mismatch repair  
 
The mismatch repair pathway (MMR) corrects mismatched bases incorporated during 
DNA synthesis or caused by agents which disturb base binding affinities. Mutation 
rates are up to 1000 times greater in MMR deficient tumour cells (137). The 
significance of MMR in preventing the accumulation of mutations is highlighted by 
patients with Lynch syndrome, caused by heritable defects in multiple MMR genes. 
The disease is associated with early onset of hereditary non-polyposis colorectal 
carcinoma (HNPCC).  
The action of MMR is instigated by two heterodimers; the MutL heterodimers (MutLα, 
MutLβ and MutLγ) and the MutS heterodimers (MutSα and MutSβ). MutS is present 
in two forms; MutSα and MutSβ. The MutSα heterodimer, is primarily involved in the 
repair of base substitutions, whereas, the MutSβ has been shown to repair larger 
types of mismatch damage, including insertion-deletion loops that are up to 10 
nucleotides (137). Following recognition of mismatches, multiple MutL heterodimers 
are recruited. The MutL heterodimer possesses inherent endonuclease activity and 
incises the DNA backbone. Following this, exonuclease 1, removes a region of 
nucleotides containing the mismatch and stops upon encountering the start of an 
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Okazaki fragment generated during replication. Repair is completed by replicative 
polymerases and ligases. The replication protein A protects the exposed single 
stranded DNA until repair is finalised.  
1.4.3 Double strand break repair 
 
DSBs are one of the most biologically cytotoxic forms of DNA damage induced by 
intracellular ROS or following exposure to ionising radiation. Repair of DSBs is 
imperative to cellular survival; if left unresolved DSBs can induce genomic 
rearrangements, chromosomal aberrations, cellular apoptosis or promote 
mutagenesis. Regrettably, the generation of DSBs is inevitable during biological 
processes dependent on genomic rearrangements, such as meiosis. To counteract 
the potentially lethal effects of DSBs, two repair pathways have evolved; NHEJ and 
HR.  
Of the two pathways, NHEJ is mechanistically the simplest and consists of direct re-
ligation of the broken ends of DNA regardless of sequence homology. In this way, 
NHEJ is particularly error prone, but is predominant throughout most stages of the 
cell cycle. The first step of NHEJ is recognition of the DSB by the Ku heterodimer; 
which consists of two proteins, Ku70 and Ku80 (Figure 8). The binding of Ku 
facilitates the formation of a ring structure that is threaded onto the end of the DNA. 
The attachment of Ku also attracts the DNA protein kinase catalytic subunit (DNA-
PKcs) to bridge the two ends of DNA and phosphorylates X-ray cross complementing 
protein 4 (XRCC4) to stimulate DNA end ligation and resolution (71).  
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Figure 8: Non-homologous end joining (NHEJ). Double strand breaks are 
recognised by a heterodimer of Ku70 and Ku80 which form a ring structure that 
threads onto the DNA strands. Presence of Ku70/80 attracts DNA-PKcs which bridge 
the terminal ends and initiates phosphorylation of XRCC4 to stimulate DNA ligation 
and restoration of two intact strands of DNA Figure adapted from (70).   
 
Conversely, HR is only active during late S-G2 phases of the cell cycle, as it relies on 
the presence of a sister chromatid as a repair template. However, this method of 
action means that HR results in accurate and non-mutagenic repair. The events of 
HR are complex and based on studies in multiple organisms, under different biological 
circumstances. Therefore, the mechanistic details of HR are still debated. In general 
terms, HR is initiated when the MRN complex recognises DSBs and resects the DNA 
to form 3’ single strand overhangs (Figure 6), which are coated with RPA (71, 96).  
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Figure 9: Homologous recombination (HR). Double strand breaks are recognised 
by the MRN complex which resects DNA to form 3’ single strand overhangs which are 
coated by RPA. Afterwards, RPA is replaced by RAD51 which invades the sister 
chromatid, to form a D-loop, so that the sister chromatid can be utilised as a template 
for repair. After DNA crossovers, the Holliday junctions are resolved and cleaved DNA 
is ligated to restore two intact strands of genomic DNA. Figure adapted from (70).  
 
Following this, HR involves the generation of a Holliday junction. During this, RAD51 
replaces RPA and initiates the invasion of the sister chromatid to be utilised as 
template. After DNA crossovers, the Holliday junctions are resolved by cleavage and 
ligation to restore two intact DNA molecules. Recent work has demonstrated strong 
correlations between HR and the breast susceptibility proteins, BRCA1 and BRCA2 
(129). It is not yet apparent how these effects occur, although they might reflect 
potential binding of BRCA1/2 to RAD51 (129). Loss of HR results in a cellular inability 
to successfully enter S-phase, due to the inability to restart collapsed replication forks. 
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As expected, inactivation of HR genes such as RAD51, BRAC1 and BRCA2 leads to 
embryonic lethality in animal models and non-viable cells in culture (129). 
1.4.4 Base excision Repair  
 
As mentioned earlier, BER is one of the major DNA repair pathways applied to 
managing small, non-distorting DNA base lesions created by deamination, alkylation 
or oxidation. Likewise, the latter stages of BER are also employed to manage abasic 
sites formed by spontaneous reactions, such as hydrolysis.  
In 1974, the initial stages of BER were discovered by Dr. Thomas Lindahl (85). Lindahl 
was the first to identify a DNA glycosylase implicated in the removal of uracil (U) 
residues from DNA. Following excision of the base lesion, Lindahl further recognised 
that endonuclease, polymerase and ligase enzymes restore the DNA. This discovery 
ultimately led to the outline of the fundamental stages of BER that are acknowledged 
in the present day. Since this discovery, the function of numerous enzymes implicated 
in BER have been characterised.  
The first stage of BER consists of recognition and removal of the damaged nucleotide 
by 11 damage-specific glycosylase enzymes, which scan along the DNA molecule 
and cleave the N-glycosidic bond upon detection of damage (Figure 10). Each BER 
glycosylase enzyme exhibits specificity towards certain types of DNA base damage 
and utilise a “base-flipping” mechanism to identify and remove base lesions. 
Generally, there are two types of BER DNA glycosylases; monofunctional 
glycosylases possess DNA glycosylase activity only, or bifunctional glycosylases 
cleave the DNA strand as well as excising the damaged DNA base (25). Generally, 
excision of DNA base lesions via monofunctional glycosylases enzymes results in the 
formation of an abasic site which is recognised by AP endonuclease 1 (APE1). APE1 
then cleaves the phosphodiester backbone resulting in the formation of a nucleotide 
gap flanked by 3’-hydroxyl and 5’-deoxyribosephosphate (5’dRP) terminal ends (25). 
Alternatively, removal of base lesions via bifunctional glycosylases with inherent lyase 
activity, results in the formation of a single nucleotide gap flanked by either a 5’-
phosphate and a 3’-α,β-unsaturated aldehyde (following β-elimination) or 5’-
phosphate and 3’-phosphate terminal groups (following β,δ-elimination). Glycosylase 
enzymes known to possess β-elimination activities include; NTH1 and 8-OxoG DNA 
glycosylase 1 (OGG1) (Table 1). After their actions, the 3’-α, β-unsaturated aldehyde 
is processed by APE1, to generate a 3’-hydroxyl group. Due to the low efficiency of 
β-elimination, APE1 generally bypasses this stage and cleaves the AP site (163). 
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Bifunctional enzymes, which excise DNA base lesions via β, δ-elimination are the 
endonuclease VIII-like proteins 1 to 3 (NEIL1-3) (Table 1). The 3’-phosphate terminal 
group generated by their activity is removed by polynucleotide kinase phosphatase 
(PNKP) (176). Regardless of if BER is initiated by mono-/bi-functional glycosylase 
activities, a single nucleotide gap with a 3’-hydroxyl end is always the final product 
formed, owing to subsequent terminal end processing by APE1 or PNKP. This 
terminal end is required as a suitable substrate for DNA polymerase activity. The 
major DNA polymerase employed in BER is Pol β, which acts to remove 5’-dRP 
terminal ends and inserts the correct undamaged nucleotide. The remaining nick in 
the DNA backbone is sealed by a complex of Lig IIIα and XRCC1. SSBs to the 
phosphodiester backbone are protected via binding by the poly (ADP-ribose) 
polymerase, PARP-1. It has been shown that PARP-1 acts in combination with 
XRCC1 to stabilise the abasic site and secure it for processing by BER enzymes 
downstream in the pathway (19).  
 
 
 
 
 
 
36 
 
 
Figure 10. Base excision repair (BER). Monofunctional, damage-specific DNA 
glycosylases recognise and excise the damaged base by cleavage of the N-glycosidic 
bond leaving an abasic site. This is incised by APE1 to generate a single stranded 
break, containing a 5’-dRP moiety. PARP-1 binds to the incised phosphodiester 
backbone to protect the single strand break from further damage and stabilises it for 
further processing. The 5’-dRP moiety is removed by the d-RP lyase activity of DNA 
Pol β, which inserts the correct complementary nucleotide (Short-patch BER, 
monofunctional glycosylase). Bifunctional, damage-specific DNA glycosylases 
(such as NTH1, OGG1 and NEIL1-3), possess inherent lyase activity and can 
simultaneously remove the damaged DNA base lesion whilst incising the DNA 
backbone. The terminal ends require processing by APE1 or PNKP, before nucleotide 
insertion by Pol β (Short-patch BER, bifunctional glycosylase). Finally, the nick in 
the phosphodiester backbone is restored by a complex of DNA Ligase IIIα and 
XRCC1. If the terminal ends of the DNA backbone generated by APE1 incision are 
resistant to Pol β processing then long-patch BER occurs, whereby, up to 13 
nucleotides are inserted into the repair gap by the action of DNA Pol δ/ε (Long-patch 
BER). This generates a 5’ flap of displaces nucleotides which is removed by the action 
of flap endonuclease (FEN1) in the presence of proliferating cell nuclear antigen 
(PCNA). The gap in the DNA backbone is subsequently repaired by a complex of DNA 
Ligase I (Lig I) and PCNA. Adapted from (25).  
 
These stages, termed short-patch BER, detail the preferred mechanism used to repair 
up to 80 % of damaged nucleotides (38). In some instances, the terminal groups are 
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not compliant to the latter stages of BER. For example, if the 5’-dRP residue is 
oxidised or reduced, it becomes resistant to Pol β excision. In this situation, a 
changeover to replicative enzyme Pol δ or Pol ε ensues (128) and long-patch BER 
occurs. The two BER sub-pathways differ in the BER enzymes used and the number 
of nucleotides inserted within the damaged region. Long-patch BER results in the 
replacement of at least 2 nucleotide monomers; Pol δ/ε typically adds 2-8 nucleotides 
into the single nucleotide gap, resulting in a 5’-flap structure, which is removed via the 
action of flap endonuclease (FEN1) in a proliferating cell nuclear antigen (PCNA) 
dependent manner. The resulting nick in the DNA backbone is subsequently repaired 
by Lig I in association with PCNA (25). 
1.4.4.1. Enzymes of BER 
The following sections concentrate on the specific enzymes implicated in each stage 
of the BER pathway in more detail, with specific reference to enzymes involved in 
short-patch BER since the majority of damage (80%) is repaired via this sub-pathway 
(37). 
 
1.4.4.1.i DNA Glycosylases 
 
The initial stage of BER relies on recognition and removal of the damaged DNA 
nucleotide via DNA glycosylase enzymes. There are 11 distinct mammalian DNA 
glycosylase enzymes that are specific to the type of DNA lesion they excise (Table 
1). The DNA glycosylases are subdivided into 4 distinct families, elected by structural 
characteristics. These are the Uracil DNA glycosylases (UDG), Helix-hairpin-helix 
glycosylases (HhH), 3-methyl-purine glycosylase (MPG) and the NEIL glycosylases 
(Table 1). The enzymatic core between glycosylases is well conserved, but compared 
to prokaryotic counterparts, mammalian glycosylases display additional disordered 
terminal extensions that function in protein interactions, PTMs, DNA recognition and 
determining subcellular localisation (64).  
The nucleophile each DNA glycosylase uses to cleave the N-glycosidic bond 
subdivides them into either monofunctional or bifunctional enzymes. Monofunctional 
glycosylases utilise activated water molecules, whereas, bifunctional glycosylases 
possess inherent AP lyase activity and incise the DNA sugar-phosphate backbone, 
as well as removing the base lesion (147). Bifunctional glycosylases utilise the amino 
group of a lysine side chain for nucleophilic attack of the N-glycosidic bond, forming 
a covalent Schiff-base intermediate with the damaged nucleobase. Resolution of the 
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Schiff base (by β or δ elimination) results in incision of the DNA backbone. Data 
suggests that the incision of the DNA backbone by mammalian glycosylases does not 
always occur simultaneously, but the rate of cleavage of the DNA backbone may be 
slower than the removal of the damaged nucleotide (98, 190).  
The glycosylase enzymes involved in BER all face a similar problem; how to efficiently 
identify minor changes to damaged bases that do not significantly distort the DNA 
helix. Interestingly, the glycosylases share a unified mechanism for detecting DNA 
base damage. The enzymes rotate nucleobases out of the DNA helix into a selective 
catalytic pocket that increases the surface area for molecular interactions. This 
facilitates analysis of aromaticity and detection of small base irregularities. To some 
extent, the selectivity of each glycosylase is dictated by steric exclusion from the base 
binding pocket; if the damaged base fits within the catalytic pocket then the N-
glycosidic bond can be cleaved (10, 54). Conserved residues positioned around the 
entry of the catalytic pocket often enable selection of damaged substrates without full 
insertion of the nucleotide into the cavity, thus improving the time taken for recognizing 
damaged nucleobases (10, 54). 
The methods used by DNA glycosylases to scan genomic DNA are still debated. 
Biochemical evidence suggests that non-specific interactions enable DNA 
glycosylases to slide along the DNA helix. However, due to the functional diversity of 
glycosylases this is unlikely to be utilised by every member (54). It has been proposed 
that glycosylases containing iron-sulphur clusters could co-operatively locate DNA 
lesions through redox signalling mechanisms (15). This concept was first speculated 
based on observations that the oxidation state of the iron-sulphur clusters change 
upon contact with DNA (16).  
Another trait that appears synonymous with BER glycosylases is bending of the DNA 
helix following binding to the base lesion. Indeed, UNG induces a 45° bend to the 
DNA, plus a bend of 70° has been reported following association of OGG1 (21, 117). 
It is suggested that bending of the DNA molecule may serve as a structural signal to 
coordinate initiation of the next stages of BER.  
Following the removal of the DNA lesion, DNA glycosylases generally remain bound 
to the abasic site. In fact, a number of glycosylases demonstrate increased binding 
affinity to abasic sites compared to their respective DNA substrates (117, 171). Some 
studies have suggested that the release of abasic sites by glycosylases is a rate 
limiting step within the BER pathway. Although, this is debateable as other rate limiting 
steps could be inflicted by Pol β activity or DNA ligation stages. Since abasic sites are 
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unstable and potentially mutagenic, it is reasonable to assume that the binding of the 
glycosylase may have a protective effect. As expected, the recruitment of downstream 
proteins involved in BER stimulates removal of the glycosylase (117, 171). Superior 
to this, PTMs have also been shown to regulate the dissociation of glycosylases (25, 
62).   
Cells lacking DNA glycosylase expression exhibit increased levels of DNA damage, 
elevated mutations and hypersensitivity to DNA damaging agents. Surprisingly, 
animal models of glycosylase knockouts are viable, with relatively unaffected 
phenotype and slight increased mutation frequency. This is largely due to redundancy 
between different glycosylase members (123, 149). Although, an exception to this is 
knockout murine models of thymine DNA glycosylase (TDG), which is embryonically 
lethal. This is potentially due to the epigenetic function of TDG (33). 
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Table 1. A comprehensive list of mammalian glycosylases and their modes of 
action as well as their physiological substrates. There are eleven distinct 
mammalian glycosylases which demonstrate specificity to particular physiological 
substrates. Their mode of action is either monofunctional (M) or bifunctional (B) 
depending on the nucleophile utilised to disrupt the N-glycosidic bond of damaged 
DNA bases. Adapted from (72). 
 
Type of 
base 
lesion 
Glycosylase 
Mono (M) 
or 
bi (B) 
functional 
Physiological 
substrates 
Uracil in 
ssDNA or 
dsDNA 
 
Uracil-N glycosylase (UNG) 
 
 
Single-strand-specific monofunctional uracil 
DNA glycosylase 1 (SMUG1) 
 
 
M 
 
 
M 
 
U, 5-FU, ss and dsDNA 
 
 
 
U, 5--hmU, 5-FU, ss 
and dsDNA 
Pyrimidine 
derivates in 
mismatches 
 
Methyl-binding domain glycosylase 4 
(MBD4) 
 
Thymine DNA glycosylase (TDG) 
 
 
M 
 
 
M 
 
T, U, 5-FU, εC, 
opposite G, dsDNA 
 
 
T, U, 5-FU, εC, 5-hmU, 
5-fC, 5-caC; opposite 
G, dsDNA 
 
Oxidative 
purine base 
damage 
 
8-OxoG DNA glycosylase 1 (OGG1) 
 
MutY homolog DNA glycosylase (MYH) 
 
 
B 
 
M 
 
8-oxoG, FaPy, opposite 
C, dsDNA 
 
A opposite 8-oxoG, C 
or G, 2-hA opposite G, 
dsDNA 
 
Alkylated 
purines 
 
Methylpurine glycosylase (MPG) 
 
 
M 
 
3-meA, 7-meG, 3-meG, 
hypoxanthine, εA, ss 
and dsDNA 
 
Oxidized, 
ring-
fragmented 
or -
saturated 
pyrimidines 
 
Endonuclease III-like 1 (NTH1) 
 
Endonuclease VIII-like glycosylase 1 
(NEIL1) 
 
Endonuclease VIII-like glycosylase 2 
(NEIL2) 
 
Endonuclease VIII-like glycosylase 3 
(NEIL3) 
 
B 
 
B 
 
B 
 
B 
 
 
Tg, FaPyG, 5-hC, 5-hU, 
dsDNA 
 
Tg, FaPyG, FaPyA, 8-
oxoG, 5-hU, 5-hC, ss 
and dsDNA 
 
As NTHL1 and NEIL1 
 
FaPyG, FaPyA, prefers 
ssDNA 
 
U, uracil; A, adenine; T, thymine; C, cytosine; G, guanine; ss, single stranded; ds, double stranded; 
5-hm, 5-hydroxymethyl; 5-FU, 5-fluorouracil; ε, etheno; 5-fC, 5-formylcytosine; 5-caC, 5-
carboxylcytosine; 8-oxoG, 8-oxo-7,8-dihydroguanine; Tg, thymine glycol; FaPy, 2,6-diamino-4-
hydroxy-5-N-methylformamidopyrimidine; me, methyl; h, hydroxyl 
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1.4.4.1.ii APE1  
 
Following removal of the damaged nucleotide, an endonuclease enzyme incises the 
DNA backbone 5’ to the abasic site. This generates a strand break to enable a DNA 
polymerase to insert the correct complementary nucleotide. The major endonuclease 
implicated in BER; accounting for over 95 % of the total DNA incising activity within 
the cell, is APE1 (177). APE1 promotes a hydrolytic reaction to incise the 
phosphodiester bonds within the DNA backbone. This hydrolytic mechanism is 
believed to be stabilized by Mg2+ ions (106). Knockout rodent models have 
demonstrated that APE1 expression is essential for survival (94).  
Besides its primary endonuclease activity, APE1 also has several other functions. For 
example, APE1 processes 3’-blocking terminal groups generated by bifunctional 
glycosylases to enable the progression of BER. Furthermore, APE1 is the major 
enzyme which removes 3’-phosphoglycolate ends of DSBs (122). Similarly, the 3’ to 
5’ exonuclease activity of APE1 may proofread for insertion of damaged nucleotides 
or mismatches, during the synthesis stages of the BER pathway (30). Aside to this, 
APE1 has been shown to act as a redox co-activator of several transcription factors, 
including p53 and nuclear factor κB (NF-κB), although the precise mechanism of this 
activity has yet to be resolved (152). It is speculated that APE1 regulates the reduction 
state of cysteine residues located within regulatory or DNA binding domains of the 
transcription factors. These two functionalities of APE1 are believed to occur on two 
distinct domains; a cysteine residue on the N-terminal region of APE1 acts as the 
redox co-activator of different transcription factors. Whereas, the C-terminal region is 
largely devoted to incision of the DNA backbone at abasic sites (152, 180).  
1.4.4.1.iii End processors  
 
Since the functionality of the glycosylase dictates the chemical groups located on the 
ends of the incised DNA backbone, this impacts the subsequent stages of BER. For 
successful insertion of an incoming nucleotide into the abasic site, the terminal groups 
required are 3’-hydroxyl and a 5’-phosphate. To ensure these groups are present, the 
terminal ends of the DNA break are subject to processing.  
If the damaged nucleotide is removed by a glycosylase with monofunctional activity, 
then the DNA backbone is incised 3’ to the abasic site by APE1. Incision by APE1 
generates a 3’-hydroxyl and 5’-deoxyribose phosphate (dRP) terminal group. The 5’-
dRP group prevents ligation of the break in the DNA backbone, before the correct 
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nucleotide has been inserted. The amino terminus of Pol β possesses AP lyase 
activity, which primarily removes the 5’-dRP blocking group, whilst inserting the 
complementary nucleotide into the abasic site (99). Both DNA Pol λ and Pol ι can 
remove the 5’-dRP; although, Pol β is believed to be the dominant polymerase in BER; 
Pol λ and Pol ι participation may be lesion specific. Removal of the damaged base by 
a bifunctional glycosylase, results in the formation of a 3’phospho-α, β-unsaturated 
aldehyde and a 5’-phosphate. The 3’phospho-α, β-unsaturated aldehyde is processed 
by APE1, to create a 3’-hydroxyl group compatible with insertion of the correct 
nucleotide.  
Alternatively, incision of the DNA backbone during β, δ-elimination of the damaged 
nucleotide by NEIL glycosylases, results in the formation of a 3’-phosphate and 5’-
phosphate groups. The 3’-terminus groups created are not compatible substrates for 
Pol β and ligation. The 3’-phosphate is processed by PNKP (173). Human PNKP is 
an enzyme with phosphatase and kinase activity that can be considered as a putative 
DNA repair enzyme. PNKP can phosphorylate DNA at 5'-hydroxyl termini and 
dephosphorylate 3'-phosphate termini (173). Unsurprisingly, PNKP is implicated in 
several DNA repair pathways and interacts with numerous DNA repair enzymes, 
notably XRCC1 and XRCC4 (173). Through its two catalytic activities, PNKP ensures 
that DNA termini are compatible with extension and ligation by either removing 3'-
phosphates, or by phosphorylating 5'-hydroxyl groups as necessary.  
1.4.4.1.iv Polymerase β 
 
A single abasic site flanked by a 5’-phosphate end and 3’-hydroxyl end acts as a 
substrate for DNA polymerase activity. The major DNA polymerase in BER is Pol β 
(146), which belongs to the X family of polymerases. Pol β acts as a replicative 
polymerase to insert the correct nucleotide using the undamaged DNA strand as a 
template. Upon reaction between the incoming nucleotide and the 3’-hydroxyl group, 
energy is released in the form of pyrophosphate. As mentioned earlier, Pol β also 
plays another key role in BER; processing 5’-dRP groups on the ends of DNA strand 
breaks. In addition, it has been shown that the amino terminal region of Pol β is 
implicated in binding regions of single stranded DNA. This can direct the polymerase 
to gaps within DNA and facilitates the synthesis of short regions (1-6 nucleotides long) 
of DNA (67, 89).  
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1.4.4.1.v Nick sealing  
 
The final stage of BER relies on sealing the nick inflicted on the DNA backbone. DNA 
ligase enzymes generate a covalent phosphodiester bond between the 3’-OH end of 
the upstream nucleotide and the 5’-phosphate end of the downstream nucleotide. To 
do this, DNA ligases utilise energy of phosphoanhydride hydrolysis to catalyse the 
formation of the phosphodiester bond, in an ATP or NAD+ dependent manner. The 
ligases involved in the final stage of BER are Lig I and Lig IIIα. DNA Lig I is an ATP-
dependent enzyme and is mainly active in long-patch BER. Whereas, the final stage 
of short patch BER is completed by the ATP-dependent DNA ligase IIIα. The activity 
of DNA Lig IIIα is dependent on the presence of the non-enzymatic, scaffolding 
protein, XRCC1. Indeed, cells deficient in XRCC1 exhibit reduced levels of DNA Lig 
IIIα, resulting in inadequate repair of SSBs and increased sensitivity to DNA modifying 
agents (19). It has been suggested that Pol β enhances recruitment of the Lig IIIα-
XRCC1 complex, by interacting with XRCC1. Indeed, the activity of Pol β is enhanced 
by the presence of the Lig IIIα-XRCC1 complex (40, 119).  
1.5.1.3. Poly (ADP-ribose) polymerases 
Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyse the 
transfer of ADP-ribose to target proteins. There are at least 18 members of the PARP 
family, encoded by different genes. PARPS play key roles in regulating cellular 
processes including; proliferation, apoptosis and modulation of chromatin structure 
(108). However, particular PARP isoforms (PARP-1 and PARP-2) are best known for 
their involvement in DNA repair processes. Evidence for the involvement of PARP 
enzymes in DNA repair, arises from findings that exposure to DNA damaging agents 
results in increased PARP activity (108).  
Although not directly an end processor, PARP-1 activity has been implicated in BER 
by stimulating the recruitment of BER proteins to sites of DNA damage (179). Indeed, 
PARP-1 deficient mice were shown to be increasingly sensitive to carcinogenic 
agents (157). It is acknowledged that during BER, PARP-1 binds to the abasic site 
following APE1 incision of the phosphodiester backbone. This is since PARP-1 
possesses high affinity for SSBs. It is understood that PARP-1 modulates DNA repair 
capacity by preserving SSBs and preventing their conversion into DSBs (120, 179), 
whilst regulating the access of repair proteins (such as Pol β). In this way, PARP-1 is 
thought to be fundamental to the repair of acute DNA damage. Interestingly, studies 
advocate that PARP-1 does not inflict a catalytic advantage on the stimulation of BER, 
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but rather slows down the repair reaction (3). Further to this, it has been shown that 
PARP-1 is implicated in the latter stages of the BER pathway. It is acknowledged that 
PARP-1 recruits the Ligase IIIα-XRCC1 complex to SSBs (39). It is believed that 
PNKP and XRCC1 act to stabilise SSBs whilst the terminal ends are processed (19, 
24). 
Mechanistic studies have shown that PARP-1 binds to DNA strand breaks as a 
homodimer which activates its catalytic activity. Interestingly, PARP-1 auto modifies 
itself via poly ADP-ribosylation, resulting in the accumulation of a negative charge, 
subsequently leading to PARP-1 dissociation from the DNA. Following PARP-1 
dissociation, BER enzymes can then bind to the preserved SSBs (179).  
1.4.4.2 Co-ordination of BER 
 
Earlier predictions suggested that the steps of BER progressed via a ‘passing the 
baton’ mechanism, whereby, each BER protein would interact with the next BER 
protein required for the subsequent stage (178). These predictions were based on 
studies demonstrating that APE1 interacts with Pol β (12), then Pol β interacts with 
Lig IIIα-XRCC1 complex (119). However, this model does not account for the 
incorporation of different damage specific glycosylases or end processors. The model 
was also contradicted by the binding of PARP-1 to SSBs prior to any other BER 
protein (120). Similarly, XRCC1 was shown to interact with multiple BER proteins 
irrespective of their order in the pathway (162). The discovery of XRCC1 as a binding 
protein for multiple BER components provoked the idea of the formation of multi-
protein repair complexes. Although, it was anticipated that numerous complexes 
would need to form in order to manage different types of damage. It is now recognised 
that removal of DNA damage may be co-ordinated by interactions between damage 
specific glycosylases and APE1 at the repair site. Following incision of the DNA 
backbone, the necessary end processors (APE1, Pol β or PNKP) are then recruited. 
This stimulates the recruitment of a complex of Pol β, Lig IIIα- XRCC1, which complete 
the BER process (118).  
1.4.4.3 BER and cancer  
 
The roles of BER proteins in maintaining genome stability and in the aetiology of 
human diseases, have largely been examined using knockout models. The models 
have revealed a correlation between the inactivation of BER proteins and embryonic 
lethality. For example, deletion of APE1 (181), Pol β (146), FEN1 (82), DNA Lig IIIα 
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(132) and XRCC1 (151) are fatal to embryonic development. Likewise, 
haploinsufficiency models of BER proteins APE1, Pol β or XRCC1 showed increased 
sensitivity to DNA damaging agents and spontaneous tumour formation (23).  
Surprisingly, knockout models of individual DNA glycosylase enzymes involved in 
BER are well tolerated, with only slight increases in mutation frequency (123). This 
mild phenotypic effect is largely due to redundancy between BER glycosylases and 
other DNA repair pathways (123). For example, NEIL1 has been shown to act as a 
back-up glycosylase for the removal of Tg residues in NTH1 knockout mice (78, 149), 
with deletion of the genes encoding both NTH1 and NEIL1 resulting in increased 
incidence of tumours compared to the single knockout models (26). Indeed, these 
results are understandable given the overlapping substrate specificities of the BER 
glycosylases and highlight the importance of regulating BER within the cell.  
Inherited defects of BER have not been associated with any human genetic disorders, 
although some mutations of BER glycosylases are associated with genomic instability 
in small scale studies. For instance, a small scale study focused on tumours from 
individuals affected with multiple colorectal adenomas, without an inherited mutation 
of the adenomatous polyposis coli gene, contained somatic inactivating mutations of 
adenomatous polyposis coli, comprising of G:C to A:T transversions. Analysis of 
MYH, showed that individuals were compound heterozygotes for non-conservative 
missense variants, resulting in reduced activity of the glycosylase. These 
observations link the inherited variants in MYH to the pattern of somatic adenomatous 
polyposis coli mutations and implicate defective BER in predisposition to tumours in 
humans (2). Similar to this, small-scale studies have shown that nearly 30 % of human 
tumours express variant DNA Pol β (148). Moreover, a small scale tumour analysis 
suggested that mutations affecting OGG1 may be associated with lung and kidney 
tumours (29).  
1.5 Human endonuclease III homologue (NTH1) 
  
NTH1 is a bifunctional glycosylase that initiates BER. The enzyme was first 
discovered in E.coli, but is well conserved throughout phylogeny. The human NTH1 
glycosylase has broad substrate specificity excising oxidised pyrimidines such as 5-
hydroxycytosine, 5-hydroxy-6-hydrothymine, 5-hydroxyuracil and 5‐formyluracil (42, 
104). Crucially, NTH1 excises Tg (42) which significantly distorts the structural double 
helix arrangement of DNA strands and blocks the action of replicative polymerases 
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(76, 165). Unlike its bacterial homologues, human NTH1 also targets ring fragmented 
purines, or oxidised pyrimidines such as formamidopyrimidine (FaPy) (95).  
Characteristic of bifunctional glycosylases, NTH1 possesses inherent AP lyase 
activity. Alike to other bifunctional DNA glycosylases, the AP lyase activity of NTH1 
does not always occur at the same rate as removal of the damaged nucleotide (190). 
In fact, the rate of the glycosylase activity versus the AP lyase activity is dependent 
on the nucleobase opposite the damaged nucleobase. With regards to NTH1, the 
incision of the DNA backbone is 7 times slower than the glycosylase activity when the 
Tg substrate is opposite an A residue, compared to if the Tg is opposite a G residue 
(98). Another study, also demonstrated that NTH1 preferentially acts on 5-
hydroxycytosine and abasic sites when they are opposite G residues (49). The 
delayed AP lyase activity of NTH1 may have a protective effect to postpone the 
formation of DNA strand breaks until suitable downstream processors of the BER 
pathway are recruited. This is supported by studies showing APE1 circumvents the 
AP lyase activity of NTH1, increasing its glycosylase activity and dissociation from the 
abasic site (97).  
The efficiency of NTH1 in removing Tg in different orientations on mononucleosomes, 
that more closely mimic chromatin structure rather than naked DNA, has been 
examined. Studies show that residues of Tg facing outward from the histone octamer 
were processed with comparable efficiency to naked DNA, using low concentrations 
of NTH1, whereas, Tg lesions facing inwards on the nucleosome were removed at a 
10-fold decreased rate than free DNA. However, increasing NTH1 concentrations to 
near physiological concentrations progressively increased Tg excision at inward 
facing sites (130). Indeed, increasing the concentration of NTH1 to physiological 
relevance caused Tg excision to reach 48 % relative to that of free DNA (130). This 
is concurrent with other studies examining processing of alternative substrates in 
different orientations on nucleosomes by other glycosylases (11).  
1.5.1 NTH1 structure, localisation and cell cycle regulation 
 
Elucidation of the crystal structure of the bacterial homologue of NTH1, endonuclease 
III, using NMR spectroscopy and X-ray crystallography, combined with mutational 
analysis has provided the structural basis to characterise the DNA binding and 
catalytic activity of the enzyme (Figure 11). It has been determined that the enzyme 
consists of two α-helical domains which contain five DNA binding motifs, including a 
Helix-hairpin-helix (HhH) domain and an iron-sulphur 4[Fe-4S] cluster loop (153).  
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Figure 11. Schematic of the domains and DNA binding motifs of endonuclease 
III. The bacterial homologue of the human NTH1 enzyme consists of a 6-helix barrel 
domain (pink), which is made up of antiparallel helices connected in a +1 topology 
which contains the HhH motif (orange). Helices etA and aHcHzJ and the 4[Fe-4S] 
cluster (yellow spheres) comprise the 4[Fe-4S] cluster domain (blue) containing the 
FCL motif (green). Adapted from (Thayer et al. 1995).  
 
These binding motifs are well conserved between bacterial, mouse and human 
counterparts. Furthermore, structural studies based on sequence conservation 
between human and bacterial homologues have suggested that Lys-212 is the 
catalytic residue of human NTH1. Substitution of Lys-212 with Gln-212 inactivated 
NTH1, although it does not impact its DNA binding ability. Likewise, substitution of 
Lys-212 with Arg-212 resulted in reduction of the catalytic specificity of NTH1 (68). 
Despite sharing conserved catalytic residues and DNA binding motifs, human NTH1 
differs to its bacterial counterparts, by an extended N-terminal tail of 95 amino acid 
residues (90) (Figure 12). Controlled proteolysis experiments have revealed that the 
extended N-terminal tail may play an inhibitory role on NTH1 activity. In fact, 
recombinant NTH1 truncations lacking 55 residues from the N-terminus were 5 times 
more active than the wild type protein (90). The rate limiting step of most glycosylase 
enzymes is their dissociation from the abasic site (97). Interestingly, kinetic studies 
have shown that the activity of human homologues of a number of glycosylase 
enzymes, including NTH1, is 100 times reduced compared to bacterial enzymes. It 
has now been considered that the N-terminal extension of human NTH1 may be 
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responsible for this discrepancy (90). Other kinetic studies using truncations of NTH1 
have confirmed that the N-terminal residues are not essential to enzymatic activity, 
but speculated that they are involved in putative targeting signals or protein 
interactions (68). These kinetic studies have also revealed other factors regarding 
NTH1 activity, for example experiments utilising Tg containing substrates show that 
NTH1 has optimal activity at pH 8 and in 75 mM NaCl. Furthermore, NTH1 is impeded 
by the presence of divalent cations (68).  
The gene encoding human NTH1 has been recognised as OCTS3 on chromosome 
16 (7). There are 3 isoforms of human NTH1, generated by the presence of three start 
codons within the first 16 amino acids. It is unclear which isoform is transcribed in 
cells. Studies using HeLa cells confirmed that all NTH1 isoforms are sorted to the 
nucleus (69, 95) with some levels of cytoplasmic NTH1 believed to be primarily 
localised to the mitochondria (68). The nuclear localisation of NTH1 is believed to be 
dependent on the presence of two nuclear localisation signals (69) (Figure 12). The 
cell cycle regulation of NTH1 has been investigated using synchronised cell studies, 
which noted increased transcription of NTH1 during early and mid S-phase (95). 
Furthermore, despite recognition of the cell cycle regulation of NTH1, the PTM 
regulation of NTH1 has not been identified.  
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Figure 12. Schematic representation of the proposed structural domains of 
human NTH1. Based on conserved similarities between bacterial, mouse and human 
counterparts of the glycosylase enzyme the proposed structural domains of human 
NTH1 are represented. Compared to the bacterial counterpart, endonuclease III, 
human NTH1 demonstrates an extended N-terminal region of 95 amino acids. The N-
terminal region contains regions signalling for nuclear localisation (blue). 
Furthermore, NTH1 contains a helix-turn-helix domain (orange) and an iron-sulphur 
4[Fe-4S] cluster (green) instigated in DNA binding. Studies based on sequence 
conservation suggest that Lys-212 is the catalytic residue of human NTH1 (arrow). 
 
1.5.2. NTH1 interactions  
 
Several proteins have been identified that modulate the catalytic activity of NTH1. An 
in vitro yeast-two hybrid screen, identified that the addition of a damage-inducible 
pluripotent transcription factor, Y-box-binding protein 1 (YB-1), stimulated NTH1 
activity. Further analysis suggested that YB-1 stimulated the β-elimination activity of 
NTH1 by increasing Schiff base intermediate formation (98). The relationship between 
YB-1 modulating NTH1 activities may suggest a tentative link between the 
coordination of BER with other cellular processes, including transcription. Likewise, 
APE1 has also been shown to stimulate NTH1 by circumventing the AP lyase activity 
of NTH1, increasing its glycosylase activity and dissociation from the abasic site (97). 
Similarly, direct association of the endonuclease XPG with NTH1 has been shown to 
promote the binding of NTH1 to base lesion substrates as well as doubling its rate of 
activity (13). These studies were founded upon the observations that cells from 
Cockayne syndrome patients with mutations in the XPG gene demonstrate a 
reduction in repair of Tg (13). Interestingly, XPG is an endonuclease enzyme which 
plays a critical role in DNA strand cleavage during the NER pathway. With this in mind, 
the way in which XPG interacts with NTH1 is not fully understood and why it would 
impact the rate of activity of NTH1 has not been fully comprehended. Similarly, 
another study investigating this novel interaction also suggested that XPG may serve 
as a co-factor which promotes the binding of NTH1 to the damaged DNA (80). The 
fact that this interaction has been observed in multiple studies advances the credibility 
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that the interaction is relevant. The concept of cross-talk between DNA repair 
pathways is not entirely irrational as it would make sense for all of the DNA repair 
pathways to work collaboratively to maintain the genome with optimum efficiency. 
However, the exact mechanisms behind these interactions need to be fully resolved 
in order to gain a full insight into the cross-communication between DNA repair 
pathways.  
1.5.3. NTH1 and cancer  
 
As with most BER proteins, the role of NTH1 in relation to human disease, including 
cancer, has been examined through the use of animal models. As mentioned earlier, 
murine knockout models of NTH1 display no overt abnormalities, presumably due to 
compensation by other back up enzymes, such as the NEIL glycosylases (149). It has 
been suggested that NTH1 and NEIL1 glycosylases display isomer specificity towards 
Tg substrates (78). In fact, the concept of redundancy between glycosylases is 
supported by double knockout models (26). Strains of mice lacking both NTH1 and 
NEIL1 expression (NTH1-/-NEIL1-/-) displayed a higher incidence of pulmonary and 
hepatocellular tumours, compared to single knockouts of NTH1 or NEIL1 alone (26). 
These results suggest that there is redundancy between BER glycosylases to ensure 
the accurate repair of base lesions. This is alike to a number of glycosylase deficient 
mouse models which have proved surprisingly resilient to the loss of the major DNA 
glycosylase activities (123).   
Interestingly, a single nucleotide polymorphism (D239Y) of NTH1 has been identified 
within 6.2 % of the global population, with 0.6 % of people being homozygous (55). 
The D239Y variant arises from the substitution of Asp for a Tyr residue within the 
suspected active site of human NTH1. It is suspected that the Asp residue acts as the 
active nucleophile enabling the glycosylase activity of NTH1. In agreement with this, 
studies using oligonucleotides containing oxidised nucleobase substrates 
demonstrated that the D239Y NTH1 variant lacks glycosylase or inherent lyase 
capability. This loss of activity has the expected effect when the D239Y NTH1 variant 
is expressed in cells; resulting in genomic instability, accumulation of DSBs and 
chromosomal aberrations (55). Expression of the D239Y polymorphism also results 
in increased sensitivity to damaging agents, such as hydrogen peroxide. Further to 
this, cells expressing the D239Y variant display increased invasive potential, with 
increased foci formation and anchorage independent growth (55).  
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More specifically, another NTH1 germline mutation has been linked to predisposition 
to familial adenomatous polyposis and colorectal cancer. A whole exome sequencing 
study using peripheral blood derived DNA revealed a germ line mutation in NTH1 may 
lead to susceptibility to multiple adenomatous adenomas; precursors of colorectal 
cancer (175). Of 51 individuals screened, 7 individuals recessively inherited the 
mutation (encoding Gln 90) resulting in nonsense mediated decay of NTH1. All of the 
subjects that were homozygous for the NTH1 mutation developed multiple colonic 
adenomas and 4 individuals had colorectal carcinomas (175). All of the women 
affected also developed endometrial lesions. Database studies predicted that 
homozygous inheritance of this trait is likely to occur once in every 75,076 individuals 
(175).  
Altered NTH1 expression has furthermore been linked to development of gastric 
cancer. A causative factor of gastric cancer is believed to be the accumulation of 
oxidatively damaged DNA in gastric epithelium. Based on this, NTH1 levels were 
investigated in 8 gastric cancer cells lines, which revealed reduced NTH1 expression. 
Furthermore, NTH1 was abnormally localised to the cytoplasm in over 20 % of the 
primary gastric cancers (58). 
1.5.4 Post translational regulation of NTH1  
 
It is well acknowledged that PTMs such as ubiquitylation, phosphorylation, 
methylation, acetylation or SUMOylation are important mechanisms in the regulation 
of the BER pathway. It has been shown that PTMs are implicated in the regulation of 
the levels, localisation, activity and interactivity of BER proteins. The PTM dependent 
regulation of a number of BER glycosylase enzymes including OGG1, MutY, NEIL2 
and MPG have been examined; reviewed in (25). Despite this, PTMs implicated in the 
regulation of NTH1 have not yet been reported. The only evidence of PTM dependent 
regulation of NTH1 has arisen from a proteomic screen which documents that NTH1 
is subject to intracellular ubiquitylation. However, the biological effect of ubiquitylation 
of NTH1 protein were not examined further (34). 
1.6. The Ubiquitin Proteasome Pathway (UPP) 
 
Ubiquitylation is an essential modification used to modulate the activity of intracellular 
proteins implicated in nearly all vital cellular processes including the cell cycle, cell 
signalling, cell survival and DNA repair (127). Ubiquitin, a small 8 kDa protein, 
composed of 76 amino acids, is used to modify substrate proteins through covalent 
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attachment to specific lysine residues via an isopeptide bond. In humans, ubiquitin is 
encoded by 4 genes; two of which UbB and UbC, encode ubiquitin chains composed 
of 3-9 repeats of ubiquitin. Free ubiquitin is generated from these gene products by 
peptidases belonging to family of enzymes termed deubiquitylases (DUBS), of which 
there are more than 90, which also act to reverse the attachment of ubiquitin on 
substrate proteins (107). 
 In general terms, cellular ubiquitin inhabits three different forms; free ubiquitin, 
activated ubiquitin linked to enzymes involved in the ubiquitylation process and finally 
conjugated ubiquitin attached to substrate proteins. In mammalian cell lines, most of 
the ubiquitin is conjugated to substrate proteins (monoubiquitylation; Figure 13). 
Single ubiquitin moieties can also be added to multiple lysine residues (multi-
monoubiquitylation). Indeed, in human embryonic kidney HEK293 cells, more than 60 
% of the total cellular ubiquitin is conjugated via monoubiquitylation, with 
approximately half associated with a histone-enriched fraction (75). More than likely, 
most of this fraction consists of ubiquitylated histone H2A, which is one of the most 
abundant cellular proteins. In a number of mammalian cell lines, approximately 15 % 
of all H2A is monoubiquitylated, except during mitosis when the ubiquitin is removed 
via a highly co-ordinated process using the DUB, USP16 (74).  
Further intricacy of ubiquitylation arises from the fact that ubiquitin itself contains 
seven internal lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), which 
can themselves be utilised for the attachment of other ubiquitin moieties (Figure 14). 
This leads to the generation of ubiquitin chains (polyubiquitylation; Figure 13). Chains 
of ubiquitin moieties can be linear, composed of the same repeating linkages, or 
branched ubiquitin chains made up of different linkages, creating different topologies 
(81). Similarly, a small fraction of linear ubiquitin chains (typically <0.5 % of totally 
polyubiquitylation), may also be generated by the conjugation of the C-terminal 
glycine of one ubiquitin to the N-terminal methionine of another ubiquitin moiety (M1-
linked) (164). The array of possible combinations of linkages between ubiquitin 
moieties creates variability in the exposed surfaces available to ubiquitin binding 
proteins. This permits processing enzymes to demonstrate specificity towards 
particular linkage types. Thus, distinct chain types are associated with specific 
biological outcomes and regulation of certain cellular processes. The proportions of 
possible linkages between ubiquitin chains may vary significantly depending on the 
cell cycle and following differentiation.  
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Figure 13. A schematic representation of different topologies of ubiquitylation 
of a typical substrate protein. Blue spheres represent substrate proteins (S) with 
attached ubiquitin moieties (U) to specific lysine residues (K).  Single moieties of 
ubiquitin can be added to lysine residues of substrate proteins, which generally 
influence the localisation, activity or interactivity of the substrate protein. Multi-
monoubiquitylation events can also occur whereby individual ubiquitin moieties are 
attached to multiple lysine residues of substrates. Alternatively, ubiquitin itself also 
possesses several lysine residues which can attach subsequent ubiquitin molecules, 
creating chains of ubiquitin moieties, termed polyubiquitylation. Homotypic chains of 
more than four K48-linked ubiquitin moieties targets substrate proteins for 
degradation by the 26S proteasome. Homotypic K63-linked ubiquitin chains have 
been implicated in the formation of complexes with effector proteins. Heterotypic 
ubiquitin chains composed of multiple linkage types can also be generated which can 
give rise to branched ubiquitin chains. Heterotypic ubiquitin chains are believed to 
have multiple biological effects including signal co-ordination. Adapted from (186)  
 
Figure 14. The structure of ubiquitin showing the position of the methionine 1 
residue and seven lysine residues (6, 11, 27, 29, 33, 48, 63). Blue spheres 
represent amino groups implicated in the formation of chains of ubiquitin molecules 
(81).  
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Monoubiquitylation events are typically associated with regulation of molecular 
interactions that affect the localisation, interaction or activity of modified proteins. 
Generally, this impacts diverse cellular functions such as cell growth, cell division, 
genomic repair and gene expression. Monoubiquitylation can have opposing effects 
depending on the substrate protein. For example, monoubiquitylation of PCNA at 
stalled replication forks promotes its interaction with translesion synthesis DNA 
polymerases and regulates the translesion synthesis pathway (14). Whereas, 
monoubiquitylation of a transcription factor termed SMAD4, prevents its interaction 
with its signalling partner; meaning that monoubiquitylation acts as a regulative step 
in managing the transforming growth factor β (TGFβ) signalling pathway (44). The 
TGFβ signalling pathway is implicated in several cellular processes including cell 
growth, cell division and programmed cell death (44). 
Polyubiquitylation of substrate proteins results in a range of outcomes, although one 
of the major effects is the regulation of protein levels, through ubiquitin signalled 
degradation. Proteasomal degradation is a crucial mechanism for protein 
homeostasis and is necessary for the removal of misfolded or damaged proteins. 
Homotypic linear chains of 4 or more ubiquitin moieties, linked through their Lys48 
residues, targets proteins for degradation via the 26S proteasome (154). The 26S 
proteasome consists of a hollow cylinder deemed the 20S protein subunit which is 
flanked by two 19S regulatory caps. Ubiquitin receptors featured on the 19S subunits 
recognise and bind to ubiquitylated proteins, which they then unfold in an ATP-
dependent manner. Removal of the bulky polyubiquitin chains on tagged proteins is 
necessary to permit entry of the peptide into the 20S catalytic core. To aid the removal 
of ubiquitin chains, three DUBS are associated with the 19S subunit of the 
proteasome; POH1, UCHL5 and USP14. It has been shown that USP14 and UCHL5 
activity results in progressive shortening of ubiquitin chains. UCHL5 can cleave both 
Lys48 and Lys63 linkage types, whereas USP14 is selective for Lys48 linked ubiquitin 
only (142). Interestingly, UCHL5 or USP14 dependent trimming of ubiquitin chains, 
appears to delay degradation, resulting in prolonged binding of substrate proteins to 
the 19S subunit, offering potential exclusion from degradation (142). It has been 
suggested that this mechanism may act as an important proof-reading mechanism to 
ensure accurate degradation of cellular proteins. The amino acids and free ubiquitin 
formed as a result of proteasomal degradation are recycled within the cellular milieu. 
Alternatively, homotypic polyubiquitin chains, linked through different lysine residues 
are associated with non-proteolytic functions. Linear chains of M1-linked ubiquitin 
moieties have been implicated in the regulation of several innate and adaptive 
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immune signalling pathways (57, 60). Likewise, it is acknowledged that Lys63 linked 
polyubiquitin chains regulate DNA repair, protein sorting and the innate immune 
response. In particular, Lys63 ubiquitylation has been implicated in the activation of 
the NF-κB transcription factor which regulate genes involved in immunity, 
inflammation and cell survival (36, 61). For example, a chain of 3 ubiquitin molecules 
linked through their Lys63 residues are required for the activation of the retinoic acid 
inducible gene 1 (RIG-1) in response to invading viral RNA, which in turn activates 
NF-κB (189). Interestingly, unanchored Lys63 linked chains can also possess activity 
and may act as signalling molecules in innate immunity (189). Homotypic polyubiquitin 
chains connected by Lys11 linkages are generally associated with signalling for 
proteasomal degradation. Although Lys11 linkages in the context of mixed ubiquitin 
chains are associated with regulation of proteins involved in membrane trafficking 
events, DNA repair and cell signalling (20). It is known that the formation of ubiquitin 
chains with mixed linkages is dependent on the co-ordination between E2 enzymes, 
with different linkage specificities. The role of mixed, branched chains of ubiquitin is 
now beginning to be explored in more detail, however, there is no consensus 
regarding the cellular effects branched ubiquitin chains induce. For example, it was 
reported that the addition of Lys11 linked branched chains onto particular target 
proteins by the anaphase-promoting complex, promoted the degradation of cell-cycle 
regulators during early mitosis quicker than homotypic polyubiquitin chains (103). 
Whereas, a separate study suggested that substrates tagged with branched ubiquitin 
chains were degraded slower than those tagged with linear polyubiquitin chain. This 
suggests that mixed, branched ubiquitin conjugates may impede proteasomal 
degradation (79).  
1.6.1. The ubiquitylation cascade  
 
Ubiquitylation of substrate proteins is implemented by a cascade of enzymes, 
collectively termed the ubiquitin proteasome pathway (UPP; Figure 12). The cascade 
consists of three main steps accomplished by three types of enzymes; E1 activating 
enzymes (2 members), E2 conjugating enzymes (approximately 40 members) and E3 
ligase enzymes (>600 members). The number of members in each step is not 
representative of the copy numbers associated with each stage of the UPP cascade; 
in fact it is estimated that the ratio of E1: E2: E3 enzymes is around 1:3:2 in HeLa 
cells (83). In HeLa cells the total aggregate of proteins involved in ubiquitylation 
represents approximately 1.3 % of the total global proteins (83).  
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Figure 15. The ubiquitin proteasome pathway (UPP). Ubiquitin (Ub) is activated by 
E1 activating enzymes (E1) before being transferred to E2 conjugating enzymes (E2), 
which carries the activated Ub to an E3 ubiquitin ligase enzyme (E3), which facilitates 
the transfer of Ub from the E2 to a specific lysine residue on the target substrate 
protein (S). The attachment of one Ub moiety generally impacts signalling or 
localisation events, whereas, the addition of multiple Ub moieties in certain topologies, 
can signal for protein degradation by the 26S proteasome.  
 
The first stage of the conjugation of ubiquitin to substrate proteins is instigated by E1 
activating enzymes, which utilise ATP in a series of reactions to generate the 
formation of a thioester bond between the C-terminus of ubiquitin and the catalytic 
cysteine residue of the E1. In humans, there are two E1 enzymes, UBA1 and UBA6. 
It is worth noting that UBA1 features in the top 2 % of most abundant proteins in HeLa 
cells. In proliferating mammalian cells, nearly all UBA1 has ubiquitin bound to its 
active cysteine (73). Following the attachment of ubiquitin to the E1 enzyme, 
subsequent structural rearrangements lead to increased affinity for E2 conjugating 
enzymes, thus, facilitating the transfer of the ubiquitin moiety to the catalytic cysteine 
residue of an E2 enzyme via a thioesterification reaction. Finally, E3 ligase enzymes 
assist the transfer of the ubiquitin from the E2 enzyme to the ε-amino group of a lysine 
residue of a substrate protein via an isopeptide bond (127).  
Of the 40 members of the E2 family present in the human genome, 35 of them are 
dedicated to ubiquitylation. The characteristics that dictate whether the E2 enzyme is 
confined to monoubiquitylation or polyubiquitylation are not well defined. It has been 
noted that some E2 enzymes are solely dedicated to building chains of ubiquitin 
57 
 
moieties with specific linkage types, whereas other E2 enzymes demonstrate 
flexibility in the substrates they are able to interact with. Members of the E2 enzyme 
family have been subdivided into different classes depending on structural 
appendages present either side of their catalytic site. These attachments may dictate 
the activity of the E2 enzymes; for instance, a number of E2 enzymes belonging to 
the class II category are restricted to monoubiquitylation, potentially because 
extensions of their N-terminal domains prevent ubiquitin binding (141). Furthermore, 
a subset of E2 enzymes have demonstrated that they are unable to attach ubiquitin 
to anything besides other ubiquitin moieties; therefore they are solely dedicated to the 
extension of ubiquitin chains (187).  
There are three main families of E3 ligase enzymes which transfer the ubiquitin 
moieties onto substrate proteins using different mechanisms. Alike to E2 conjugating 
enzymes, homologous to E6-AP carboxyl terminus (HECT) and RING between RING 
(RBR) E3 ligases also possess an active site cysteine residue that binds to the 
ubiquitin moiety before transferring it to the substrate protein. On the other hand, the 
most abundant family of E3 ligases lack a catalytic cysteine residue and instead act 
as adaptor proteins to align the E2 conjugating enzyme with the substrate protein 
(22). To facilitate this, these E3 ligases feature a type of zinc-finger domain, termed a 
really interesting new gene (RING) domain, although a few have a U-box domain 
which is structurally similar to the RING motif but does not coordinate zinc ions. As 
expected, E2 enzymes bind to a conserved surface of the RING/U-box domains to 
initiate ubiquitin transfer. Several studies have suggested that dimerization of some 
RING domains is essential to enable E2 enzyme binding (22). It has also been 
proposed that RING E3 ligases may act to allosterically activate the E2 enzyme 
assisting the destabilisation of the thioester bond (116). In most cases, the ubiquitin 
is transferred from the E2 directly to the amino group of the target lysine, thus in 
scenarios involving RING E3 ligases the E2 enzyme largely dictates the substrate 
specificity (5). To some extent, the type of E3 ligase required for ubiquitylation of 
substrate proteins is dictated by the E2 enzyme, for example UBCH7 (UBE2L3) lacks 
reactivity to lysine, therefore, is reliant on transfer of ubiquitin via a transthiolation 
reaction utilising HECT E3 ligases (174).  
 
1.6.2. Ubiquitylation and BER  
 
Over the last few years, there has been increasing evidence demonstrating that 
ubiquitylation plays a vital role in regulating several DNA repair pathways, including 
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BER. The specific UPP enzymes involved in the regulation of a number of key BER 
proteins have been identified and their effects have been examined (25, 48). 
Firstly, it is well known that levels of APE1 are regulated through polyubiquitylation of 
the N-terminal residues of the protein. The major E3 ligase enzyme that instigates this 
is the ubiquitin protein ligase E3 component n-recognin 3 (UBR3) (102). Initially, the 
regulation of APE1 via UBR3 was established through the use of in vitro assays using 
APE1 as a substrate with fractionated whole cell extracts which purified candidate E3 
ligase enzymes specific to APE1. Then in cells evidence arose from studies 
demonstrating that mouse embryonic fibroblasts lacking the Ubr3 gene exhibit 
amplified levels of APE1, with increased DSB formation as a result (102).  
Employment of in vitro ubiquitylation assays using cell extracts fractionated via 
column chromatography has been a key technique to elucidate other E3 ligase 
enzymes specific to BER enzymes. For example, using Pol β as a substrate, this 
technique identified carboxyl terminus of Hsc70 interacting protein (CHIP) as the 
major E3 ligase responsible for polyubiquitylation of Pol β (125). Likewise, using the 
same technique ARF-BP1/HectH9 (Mule) was also defined as another E3 ubiquitin 
ligase for Pol β. Although, Mule activity was primarily associated with 
monoubiquitylation of Pol β at lysines 41, 61 and 81 (126). Interestingly, 
monoubiquitylation of Pol β retains it in the cytoplasmic compartment of the cell and 
further acts as a prerequisite for polyubiquitylation via CHIP, which targets it for 
proteasomal degradation (126). Crucially, this suggests a complex mechanism where 
monoubiquitylation acts as a cellular marker signalling degradation of excessive BER 
proteins. In this way, monoubiquitylation enables discrimination between proteins 
relocating to sites of damage or those suitable for degradation and serves as a fine-
tuning mechanism to closely regulate BER protein levels in relation to DNA damage 
levels. In support of this, it is known that Mule activity is tightly regulated by the tumour 
suppressor, ARF (27), which upon DNA damage detection translocates from the 
nucleoli to the cytoplasm, where it inhibits Mule activity. Consequently, 
monoubiquitylation of Pol β ceases, resulting in reduced CHIP-dependent 
degradation and ultimately the accumulation of Pol β levels in response to DNA 
damage (126). The use of in vitro assays with chromatography fractions has 
additionally been utilised to investigate the UPP enzymes involved in reversing 
ubiquitylation of BER proteins. In this way, the ubiquitin-specific protease 47 was 
purified as the major DUB activity for Pol β; further expanding our understanding of 
regulation of key BER components to respond appropriately to genomic damage 
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levels and prevent instability (121). Currently, USP47 is recognised as the only DUB 
that has been characterised in controlling the efficiency of BER.  
Further investigations have suggested crosstalk between different post translational 
modifications and ubiquitylation. An example of this is the stabilisation of levels of the 
end processor, PNKP, due to inhibition of ubiquitylation through phosphorylation of 
serine residues 114 and 126 by the protein kinase ataxia telangiectasia mutated 
(124). Phosphorylation of PNKP inhibits ubiquitin dependent proteasomal degradation 
of PNKP in response to oxidative DNA stress, enabling accumulation of levels of the 
end processor needed for DNA repair. The candidate E3 ligase was identified as a 
complex of Cul4a with DNA damage binding protein 1 (DDB1). Specificity of the 
ubiquitylation reaction was reliant on the presence of serine-threonine kinase receptor 
associated protein (STRAP) as an adaptor for the Cul4A-DDB1 complex (124). 
Embryonic murine fibroblasts deficient in STRAP consequently show elevated PNKP 
levels and resistance to oxidative damage (124).  
Despite accumulating evidence of regulation of BER via ubiquitylation, investigations 
regarding the ubiquitylation dependent regulation of proteins present relatively 
upstream in the BER process are lacking in comparison to more well characterised 
BER proteins (25). For instance, ubiquitylation of some glycosylase enzymes (NTH1, 
MBD4, TDG, NEIL2, and NEIL3) has only been suggested via proteome-wide 
ubiquitylation screens and not explored further (34). The limitations of such screens 
resulting in false positives and even undetected candidates should not be overlooked. 
For instance, proteomic screens did not suggest that OGG1 was subject to 
ubiquitylation, however, other studies later confirmed that OGG1 is in fact 
ubiquitylated by the E3 ubiquitin ligase CHIP. Interestingly, mild hyperthermia induced 
rapid inactivation of OGG1 by relocalisation followed by degradation instigated by 
CHIP dependent ubiquitylation (52). Another HhH glycosylase, MutYH, has been 
shown to be ubiquitylated between residues 475-535 by Mule. Experimentation using 
MutYH with mutated lysine residues demonstrated that ubiquitylation regulates 
MutYH localisation as well as its degradation (43).  
Despite proteome-wide ubiquitylation screens recurrently demonstrating that all 
members of the uracil DNA glycosylases are potentially regulated by the UPP, 
candidate E3 ligase enzymes have only been revealed for two members; UNG and 
SMUG1. Ubiquitylation and subsequent proteasomal degradation of UNG and 
SMUG1 is instigated by the E3 ligases cullin 1 (Cul 1) and cullin 4 (Cul 4) which is 
stimulated by binding to the human immunodeficiency virus (HIV) accessory protein 
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Vpr. This process is hypothesised to facilitate virus replication by reducing the 
frequency of abasic sites in viral reverse transcripts due to UNG and SMUG1 activity 
on uracil residues generated by the apolipoprotein B mRNA editing enzyme-3 (140).  
Most recently, colleagues within our laboratory successfully purified and identified two 
E3 ligase enzymes, Mule and TRIM26, instigated in the regulation of the DNA 
glycosylase, NEIL1 (46). The candidate E3 ligase enzymes were purified from HeLa 
whole cell extract fractionation using a typical column chromatography approach in 
combination with in vitro ubiquitylation assays. Using this approach two NEIL1 specific 
ubiquitylation activities were observed and the E3 ligases responsible were identified 
via nano LC–MS/MS tandem mass spectrometry. Using purified recombinant versions 
of each E3 ligase it was determined using in vitro ubiquitylation assays that Mule 
activity required the H5 class of E2 enzymes as well as H7. Likewise, recombinant 
TRIM26 ubiquitylation was dependent on the H5 class of E2 enzymes and on H6. 
Site-directed mutagenesis of NEIL1, to create mutant NEIL-1 containing sequential 
lysine to arginine mutations determined that NEIL1 is ubiquitylated at the same seven 
lysine residues (between 319 and 376) by both Mule and TRIM26 (46). Consistent 
with observations that both E3 ligases were catalysing the polyubiquitylation of NEIL1, 
siRNA mediated knockdown of Mule or TRIM26 individually in cells resulted in 
increased NEIL1 stability. The same experiment was utilised in the presence of 
increasing levels of DNA-damage induced by ionising radiation to investigate the 
effects of the E3 ligases in regulating DNA-damage responsive levels of NEIL-1. It 
was found that decreased expression of TRIM26 had no significant effect on NEIL-1 
levels post-irradiation, whereas, knockdown of Mule supressed NEIL1 elevation, 
demonstrating that Mule activity may indirectly co-ordinate DNA-damage induced 
levels of NEIL1. Consistent with this result, the radiosensitivity of cells was examined 
using clonogenic assays and which demonstrated no difference in response to Mule 
siRNA treatment, whereas, cells with reduced TRIM26 expression were 
radioresistant. The use of alkaline single cell gel electrophoresis (comet) assays to 
examine levels of single-stranded DNA breaks post-DNA damage induced by ionising 
radiation demonstrated no difference upon the siRNA mediated knockdown of 
TRIM26 expression; suggesting that the increase in NEIL1 levels caused by depletion 
of TRIM26 do not contribute greatly to the general repair of damaged DNA but may 
be involved in the repair of specific DNA damage substrates. Overall, it was 
established that both E3 ligase enzymes purified in this study were important in 
regulating both the cellular state and DNA damage responsive levels of NEIL1 (46). 
Despite accumulating knowledge, the regulation of other BER proteins via 
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ubiquitylation, particularly a number of DNA glycosylases, including NTH1, is 
unknown.  
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CHAPTER 2 – PROJECT AIMS 
 
BER is a key DNA repair pathway involved in the maintenance of genome stability, 
which prevents the development of human diseases including; premature ageing, 
neurodegenerative diseases and cancer. Observations have documented altered 
BER protein levels in cells extracted from patients suffering from these diseases. 
Interestingly, accumulating evidence suggests that PTMs, such as ubiquitylation, can 
regulate BER protein activity. Investigations regarding understanding the regulation 
of components of the BER pathway, particularly DNA glycosylases, by ubiquitylation 
are still limited and the specific UPP enzymes involved remain unclear. As previously 
stated, proteomic screens have identified that NTH1 is ubiquitylated, but the E3 ligase 
enzyme(s) implicated in this process have not been examined. Expanding our 
understanding of the enzymes involved in the ubiquitylation dependent regulation of 
NTH1, and other BER proteins, may help us to identify particular E3 ligases that 
control specific classes of BER enzymes, or reveal if each BER protein is regulated 
by its own unique complement of UPP enzymes. Maximising our knowledge may help 
to select novel drug targets or small molecule inhibitors, which could be combined 
with other treatments, such as radiotherapy or chemotherapy, to improve current 
management of patients with diseases associated with irregular BER protein 
expression.  
The overarching aim of this project is to understand the molecular mechanisms 
employed by human cells to regulate the steady-state and DNA-damage induced 
levels of the BER glycosylase, NTH1. Particular emphasis will be focused on the role 
of ubiquitylation and the ubiquitin E3 ligase enzyme(s) involved. Specifically, the main 
objectives of the study were to;  
1. Purify, identify and characterise the E3 ubiquitin ligase enzyme(s) that 
ubiquitylate NTH1 
2. Elucidate the site-specific lysine residues of NTH1 that are ubiquitylated by 
the E3 ubiquitin ligase enzyme(s) 
3. Determine the role of the identified E3 ubiquitin ligase enzyme(s) in controlling 
the cellular steady state and DNA-damage responsive protein levels of NTH1. 
4. Understand the impact of the ubiquitylation dependent regulation of NTH1 on 
DNA damage repair kinetics and sensitivity to oxidative stress.   
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CHAPTER 3 – MATERIALS AND METHODS 
3.1. Materials  
3.1.1. Reagents  
 
General laboratory reagents were obtained from either Bio-Rad Laboratories Ltd 
(Hertfordshire, UK), Fisher Scientific (Loughborough, UK) or Sigma Aldrich (Poole, 
UK) as stated. Chromatography columns were obtained from GE Healthcare (Little 
Chafont, UK). The CHT ceramic hydroxyapatite was obtained from Bio-Rad 
(Hertfordshire, UK).  
3.1.2. Plasmids and proteins  
 
Histidine tagged recombinant NTH1 was generated from the pET28a plasmid (Figure 
16) containing the coding sequence for NTH1 (starting at Met9, since the consensus 
in the literature is that this represents the translational start) that was kindly provided 
by Dr. Sarah Allinson (Lancaster University). Mutant NTH1 was generated from this 
by creating truncated versions of NTH1 using cloning techniques, or via site directed 
mutagenesis. The mammalian expression plasmid for TRIM26 was kindly provided 
by Prof A. Garcia-Sastre (The Icahn School of Medicine at Mount Sinai, USA). The 
full-length cDNA for TRIM26 was re-cloned from this into a pET28a bacterial 
expression plasmid by ligation-independent cloning (LIC) (46). Full 
length NTH1 cDNA was also re-cloned from the bacterial expression vector using the 
same approach into a pCMV-Tag3a vector for mammalian expression. A partial 
intracellular expression of human influenza hemagglutinin (HA) tagged ubiquitin was 
generated from the mammalian expression plasmid PMT-HA-Ub. 
His-tagged recombinant NTH1 and TRIM26 were overexpressed in Rosetta (DE3) 
pLysS bacterial cells (Merck-Millipore, Watford, UK) and the proteins purified using 
HisTrap column chromatography (GE healthcare, Little Chafont, UK). TRIM26 was 
additionally purified using ion exchange (Mono Q 5/5 GL) chromatography (GE 
Healthcare, Little Chalfont, UK). 
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Figure 16. Schematic of the pET28a bacterial expression vector used for 
recombinant protein expression. The pET28a bacterial expression vector was 
obtained from Novagen (Middlesex, UK). Target genes are cloned into pET plasmids 
under control of strong bacteriophage T7 transcription and expression induced by 
providing a strong source of T7 RNA polymerase in the host cell. The pET28 vector 
carries an N-terminal Histidine tag/thrombin/T7 tag configuration.   
 
3.1.3. Antibodies  
 
The reactivity and source of the primary antibodies used throughout this study are 
summarised in Table 2. Antibodies were used to probe for the presence and 
expression levels of specific proteins analysed via Western blotting. The dilutions of 
each antibody for Western blotting are also detailed in Table 2.  
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Table 2. A summary of the primary antibodies used.  The reactivity, dilution and 
molecular weight of each primary antibody used throughout are detailed below. The 
source of each primary antibody is also provided.  
 
The secondary antibodies used throughout this study are summarised in Table 3. 
Fluorescently tagged secondary antibodies were applied to Western blotting 
membranes (Sigma Aldrich, St. Louis, Missouri, USA) after primary antibody 
incubation. The corresponding reactivity was selected so that the secondary antibody 
bound to the primary antibody.  
Table 3. A summary of the secondary antibodies used. The reactivity, source and 
dilutions used for Western blotting are detailed below.  
 
 
 
 
 
3.1.4. Cells  
 
HeLa, human colon carcinoma (HCT116p53 +/+) cells and human female osteosarcoma 
(U2OS) cells were cultured as a monolayer in Dulbeccos Modified Eagle Medium 
(DMEM) with HEPES modification, 4500 mg/L glucose, 25 mM HEPES and sodium 
bicarbonate further supplemented with 10% fetal bovine serum (FBS, non-USA origin, 
sterile filtered), 2 mM L-glutamine, 100 U penicillin, 0.1 mg streptomycin and 1 % 
Antibody 
Reactivity and 
clonality 
Dilution Source 
Actin Mouse monoclonal 1:20,000 Sigma Aldrich 
Histidine-tag Mouse monoclonal 1:1000 Millipore 
Mule Rabbit polyclonal 1:2000 Bethyl Labs 
HA Tag Rabbit polyclonal 1: 10,000 Abcam 
Lamin A/C  Mouse monoclonal 1:1000 Santa Cruz 
NTH1 Mouse monoclonal 1:1000 Abcam 
NTH1 Rabbit polyclonal 1:1000 Santa Cruz 
TRIM26 Mouse polyclonal 1:500 Abcam 
TRIM26 - N-
terminal 
Rabbit polyclonal 1:250 Abcam 
Tubulin Mouse monoclonal 1:10,000 Sigma 
Ubiquitin Mouse monoclonal 1:5,000 Abcam 
Ubiquitin Rabbit polyclonal 1:1000 Santa Cruz 
Antibody Dilution Source 
Alexafluor 680 goat anti-mouse IgG 1:10 000 Invitrogen 
Alexafluor 680 goat anti-rabbit IgG 1:10 000 Invitrogen 
IR dye 800 goat anti-mouse IgG 1:10 000 Li-Cor 
IR dye 800 goat anti-rabbit IgG 1:10 000 Li-Cor 
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MEM non-essential amino acid solution (all tissue culture reagents obtained from 
Sigma Aldrich St. Louis, Missouri, USA). All cell culture work was performed using 
aseptic technique in a class II hood with laminar flow, cleaned with 70 % ethanol 
before each use. All plastics used were of tissue culture grade. Other cell culture 
reagents include; Dulbecco’s PBS and Trypsin -EDTA solution 0.25 % (2.5 g porcine 
trypsin and 0.2 g EDTA. 4Na /L of Hank balanced salt solution with phenol red). All 
cell culture solutions were warmed at 37°C in a water bath prior to use. All cells were 
stored in a humidified cell culture incubator at 5 % CO2 at 37°C.  
3.1.5. Primers  
3.1.5.1. Ligase independent cloning (LIC) primer sequences  
 
LIC primers were used to produce bacterial expression plasmids for TRIM26, full-
length NTH1 and truncated versions of NTH1 in a pET28a backbone (Table 4). They 
were also used to generate mammalian expression plasmid, pCMV3Tag3A, 
containing TRIM26 and full-length NTH1, which were used to induce a partial 
overexpression of these proteins in cells (Figure 17).  A summary of the LIC cloning 
primers used is provided in Table 3. All primers were obtained from Eurogentec 
(Seraing, Belgium).  
Table 4. A summary of the custom ligase independent cloning (LIC) 
oligonucleotides used throughout this study. The target gene, primer sequence 
for both forward and reverse are shown in the table. All primers were obtained from 
Eurogentec (Seraing, Belgium).  
Mutant 
Forward LIC 
oligonucleotide sequence 
(5’-3’) 
Reverse LIC oligonucleotide 
sequence (5’-3’) 
TRIM26 TACTTCCAATCCATGGCCAC
GTCAGCCCCACTAC 
TATCCACCTTTACTGGGGGTCTTA
GCAGGAGGCGTGTTC 
pET28a AGTAAAGGTGGATACCCCGA
ATTCGAGCTCCGTCGAC 
ATGGATTGGAAGTACCCGCTGCT
GCCCATGGTATATCTCC 
pCM3Tag3A AGTAAAGGTGGATACCATCG
ATACCGTCGACCTCGAGGAT 
ATGGATTGGAAGTACCCGTGGAG
CTCCAGCTTTTGTTCCC 
NTH1 TACTTCCAATCCATGTGTAGT
CCGCAGGAGTCCG 
TATCCACCTTTACTGGGAGACCCT
GGGCGGCCG 
9-93 TACTTCCAATCCATGTGTAGT
CCGCAGGAGTCCG 
TATCCACCTTTACTGGTCAGGCAC
GGATGTTGACCAGCTG 
9-174 TACTTCCAATCCATGTGTAGT
CCGCAGGAGTCCG 
TATCCACCTTTACTGGTCACCAGA
AACCGACGG-GGTAGATGAG 
185-305 TACTTCCAATCCATGGCCATC
CTGCAGCAGCACTAC 
TATCCACCTTTACTGGGAGACCCT
GGGCGGCCG 
99-305 TACTTCCAATCCATGGCACCT
GTGGACCATCTGGGG 
TATCCACCTTTACTGGGAGACCCT
GGGCGGCCG 
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3.1.5.2. Site-directed mutagenesis primers  
 
Site-directed mutagenesis primers were used to generate pET28NTH1 containing 
point mutations at specific lysine residues. Lysine residues were replaced with 
arginine residues. The pET28NTH1 plasmid was kindly provided by Dr. Sarah 
Allinson (Lancaster University). All primers were obtained from Eurogentec (Seraing, 
Belgium). A summary of the site-directed mutagenesis primers used throughout this 
study is provided in Table 5. 
Table 5. A summary of the custom site directed mutagenesis oligonucleotides 
used throughout this study. The target gene, primer sequence for both forward and 
reverse are shown in the table. All primers were obtained from Eurogentec (Seraing, 
Belgium).  
Mutant 
Forward oligonucleotide 
sequence (5’-3’) 
Reverse oligonucleotide 
sequence (5’-3’) 
K42R 
CAGAAGCGAGGAGAAGCCACAG
CCCC 
GGGGCTGTGGCTTCTCCTCGC
TTCTGC 
K48R 
ACAGCCCCGTGAGGCGTCCGC
GG 
CCGCGGACGCCTCACGGGGC 
K52R 
GCGTCCGCGGAGAGCACAGAG
ACTGC 
GCAGTCTCTGTGCTCTCCGCG
GACGC 
K48, 
52R 
GCCCCGTGAGGCGTCCGCGGA
GAGCACAG 
CTGTGCTCTCCGCGGACGCCT
CACGGGGC 
K67R 
GGGCTCGGACAGTGAGAGAGGT
GAGGG 
CCCTCACCTCTCTCACTGTCC
GAGCCC 
K245, 
246R 
CTGAGGTGGACCAGGAGGGCAA
CCAAGTCCC 
GACTTGGTTGCCCTCCTGGTC
CACCTCAGCC 
D239Y 
CAGGCATTGCAGTGTACACGCA
TGTGCACAG 
CTGTGCACATGCGTGTACACT
GCAATGCCTG 
 
3.1.5.3. Real-time PCR primer sequences  
 
Real time PCR primers were employed to measure the efficiency of an siRNA 
mediated knockdown of TRIM26 in HCT116p53+/+ human colon carcinoma cells.  Actin 
was used as an expression control and all results were normalised to this CT value. 
The primer sequences are in Table 6. 
Table 6. Real-time primer sequences used for target gene. The target gene, 
primer sequence for both forward and reverse and the length of the target sequence 
of gene are shown in the table. All primers were obtained from Eurogentec (Seraing, 
Belgium).  
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3.2. Methods 
3.2.1. Measuring protein and DNA concentration 
 
Protein concentrations were measured by the Bradford Assay using Bio-Rad Protein 
assay reagent (Bio-Rad, Hertfordshire, UK) for measurement at an optical density 
(OD) of 595 nm using a UV spectrophotometer (Cecil CE 2021 2000 series). A 
standard BSA protein sample (0.2 mg/ml) was used as a reference to calculate the 
protein concentration using the following calculation: 
 
BSA = 0.2/AbBSA = V 
Samples concentration = V X Absample x dilution factor  
 
Where applicable, protein or DNA concentration of samples was measured using the 
Nanodrop ND-1000 spectrometer (software version V3.7.1) purchased from Thermo-
Scientific (Massachusetts, USA).  
 
3.2.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
3.2.2.1. SDS-PAGE  
 
Proteins extracts (typically 40 μg) or in vitro ubiquitylation reactions were separated 
via sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The 
separating portion of SDS-PAGE gels was prepared by mixing 377 mM Tris HCl (pH 
8.8), 0.2 % SDS, 2 mM EDTA, 6 % or 10% or 16% acrylamide/bis solution (30:0.8) 
from Bio-Rad Laboratories (UK), 1 % APS and 0.1% TEMED, made up to a final 
volume with distilled water. Three quarters of a 1.5 mm gel cassette (Fisher Scientific, 
Loughborough, UK) was filled with the separating solution. A volume of 100 % ethanol 
Gene RT-PCR primer sequence 
Amplicon 
(bp) 
Source 
TRIM26 
 
Forward. 5’-CCA-TGG-ATC-TAT-AGG-AGA-
GCA-AG-3’ 
Reverse. 5’- CAG-CTC-CAG-CAC-TCA-GTC-
AA-3’ 
71  Eurogentec 
Actin 
 
 Forward.5'-AGGCACCAGGGCGTGAT-3' 
  Reverse.5'-CGCCCACATAGGAATCCTTCT-3' 
52 
 
Eurogentec  
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was layered on top whilst the gel set. The acrylamide percentage (6 %, 10 % or 16 
%) was selected depending on the molecular weight (kDa) of protein being analysed. 
The ethanol was removed by washing with distilled water before the 5 % stacking gel 
consisting of; 62.5 mM Tris HCl (pH 6.8), 0.2 % SDS, 2 mM EDTA, 5 % acrylamide/bis 
solution (30:0.8), 10 % APS, 1 % TEMED, made up to final volume with distilled water, 
was added to the remaining quarter of the gel cassette and either a 10-well or 15-well 
comb added before setting.  
Protein samples, extracts or reactions were diluted in SDS-PAGE loading buffer (25 
mM Tris pH 6.8, 1 % SDS, 10 % glycerol, 2.5 % mercaptoethanol, 0.5 mg/ml 
bromophenol blue and 1 mM EDTA) and proteins were denatured by heating at 95°C 
for 5 mins before being loaded onto the polyacrylamide gel. Electrophoresis was 
performed at 125 V for 2 h in 1x Tris-glycine SDS running buffer (0.025 M Tris, 0.192 
M glycine, and 0.1 % SDS, pH 8.3) (Fisher Scientific UK, Loughborough, UK). The 
Precision Plus Protein All Blue Pre-Stained Protein Standards (Bio-Rad, Laboratories 
Ltd) were used as standard markers ranging from 10 kDa to 250 kDa. Following SDS-
PAGE, protein levels were analysed via protein staining or Western blotting.  
3.2.2.2. SDS-PAGE gel protein staining 
 
The SDS-PAGE gel was rinsed in distilled water and incubated in Instant Blue 
(Expedeon, San Diego, California, USA) on a rotating platform for 1 h. The gel was 
then washed in 1x PBS until the background intensity was reduced. The gel was 
imaged using the Odyssey image analysis system (Li-Cor Biosciences, Cambridge, 
UK). 
3.2.2.3. Western blotting  
 
Proteins were transferred from an SDS-PAGE gel onto an activated Immobilon-FL 
polyvinylidene diflouride (PVDF) membrane (Millipore, Watford, UK). The PVDF 
membrane was activated by washing in 100 % methanol for 15 sec, distilled water for 
2 min followed by SDS-transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 20 % 
methanol). Electrophoresis was carried out at 25 V for 90 min in SDS-transfer buffer. 
The PVDF membrane was blocked in Odyssey blocking buffer (Li-Cor Biosciences, 
Cambridge, UK) diluted 1:1 in PBS for 1 h at room temperature. Blocking buffer was 
removed and the membrane was probed with the relevant primary antibody diluted to 
the recommended concentration (See Table 2) in Odyssey blocking buffer and PBS 
(1:1), 0.1 % Tween-20 and incubated on a rotating platform overnight at 4°C. The 
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membrane was washed thrice for 5 min in PBS containing 0.1 % Tween-20 solution. 
The membrane was probed for 1 h at room temperature with the appropriate 
secondary antibody diluted in Odyssey blocking buffer and PBS (1:1) containing 0.1% 
Tween-20 to the recommended concentration (See Table 3). The membrane was 
washed twice for 5 min in PBS containing 0.1 % Tween-20 solution with an additional 
5 min wash in PBS to finish. Proteins were visualized and quantified using the 
Odyssey image analysis system (Li-cor Biosciences, Cambridge, UK). 
3.2.3 Transformation of competent cells 
 
DH5α cells (Invitrogen, Waltham, Massachusetts, USA) or Rosetta2 (DE3) pLysS 
(Merck-Millipore, Watford, UK), were thawed on ice and mixed gently using a pipette 
tip. DH5α cells were transfected with 1 ng of purified plasmid (or one tenth of a PCR 
reaction) and incubated on ice for 30 min. The cells were then heat shocked at 42°C 
for 20 s then returned to ice for a further 2 min. To this, pre-warmed (to 37°C) lysogeny 
broth (LB) (2.5 % w/v LB granule, 0.5 % (w/v) NaOH, pH 7.2) (Fisher Scientific UK, 
Loughborough, UK) was added and cells incubated at 37°C in a shaking incubator for 
1 h. From this, 100 μl was removed and spread onto LB agar plates (2.5 % w/v LB 
granules, 1.5 % w/v agar, 0.5 % NaOH) containing the correct selective antibiotic; 50 
μg/ml ampicillin or 34 μg/ml kanamycin (Fisher Scientific UK, Loughborough, UK). 
These plates were inverted and incubated at 37°C for 12 h. Colonies were selected 
and grown overnight in 5 ml LB containing 50 μg/ml ampicillin or 34 μg/ml at 37°C on 
a shaking platform, at 225 rpm, overnight. 
3.2.4. Site-directed mutagenesis  
 
DNA was prepared by PCR reactions containing 250 pg/µl of the plasmid of interest 
incubated with 0.3 µM of forward primer, 0.3 µM of reverse primer, 1x Phusion buffer, 
200 µM dNTPs and 0.02 U/ µl high fidelity Phusion polymerase. PCR reactions were 
performed by 1 cycle at 98°C for 2 mins, followed by 18 cycles of; 98°C for 2 mins, 
55°C for 1 min, 72°C for 5 min, followed by a final extension 72°C for 20 min.  
The PCR products were transformed into DH5α cells (Section 3.2.3) and selected for 
by growth on LB agar plates containing the correct selective antibiotic; 50 μg/ml 
ampicillin or 34 μg/ml kanamycin. These plates were inverted and incubated at 37°C 
for 12 h. Colonies were selected and grown overnight in 5 ml LB containing 50 μg/ml 
ampicillin or 34 μg/ml at 37°C on a shaking platform, at 225 rpm, overnight. Plasmid 
DNA was then extracted from bacterial contaminants by mini-prepping (Section 
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3.2.9). The success of the site directed mutagenesis reaction was confirmed by 
sequencing the purified plasmid using the Sanger Sequencing Service provided by 
Source Bioscience (Nottingham, UK). 
3.2.5. Analysis of PCR products using agarose gels  
Broad range agarose was prepared at 1 % in Tris-acetate-EDTA (TAE) buffer.  
Samples were diluted in 6x DNA loading dye, loaded onto the gel and electrophoresed 
at 75 V for 1 h in a Mini Gel Tank. All reagents and Mini Gel Tanks were obtained 
from Thermo Fisher Scientific (Cheshire, UK, WA7 1TA). 
3.2.6. Purifying DNA from bacterial cultures  
 
The overnight cultures were then centrifuged at 5000 x g for 5 min and supernatant 
removed. The DNA was purified using the QIAprep® Spin Miniprep Kit, 
manufacturer’s protocol (Qiagen, Manchester, UK) and eluted in TE buffer. The 
concentration of the DNA was measured using a Nanodrop ND-1000 spectrometer 
(software version V3.7.1), (Thermo Scientific, Runcorn, UK) at a wavelength of OD230 
3.2.7. Preparation of purified NTH1  
3.2.7.1. Overexpression of histidine-tagged NTH1  
 
Histidine-tagged pET28a NTH1 plasmid (provided by Dr Sarah Allinson, The 
University of Lancaster) was transformed into Rosetta2(DE3) pLysS bacterial cells 
and plated onto LB agar plates containing 30 μg/ml kanamycin and 34 μg/ml 
chloramphenicol. A colony was selected and cultured overnight with 5 ml LB, 
composed of 10 g/L Tryptone, 5 g/L yeast extract and 10 g/L sodium chloride (Fisher 
Scientific UK, Loughborough, UK). To this, 30 μg/ml kanamycin and 34 μg/ml 
chloramphenicol were added to select for resistant NTH1 plasmid amplification only. 
If the culture appeared turbid 300 μl culture was transferred to 30 ml LB with 30 μg/ml 
kanamycin and 0.1 % glucose added and grown at 37°C at 225 rpm shaking until 
turbid (OD600 ~ 0.6 to 0.8). The entire culture was expanded to 300 ml with LB 
containing antibiotic plus glucose, then incubated with shaking until turbid (OD600 0.6 
to 0.8). Protein expression was induced with 1 mM IPTG and incubated at 30°C with 
shaking for 3 h. The culture was centrifuged at 5000 x g for 2 mins, the supernatant 
aspirated, and pellets were then stored at -80°C.  
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3.2.7.2. Purification of histidine-tagged NTH1  
 
The bacterial cell pellet containing overexpressed His-tagged NTH1 was 
resuspended in lysis buffer [(25 mM Tris-HCl (pH 8), 0.5 M NaCl, 5 % glycerol, 5 mM 
imidazole, pH 8 (Sigma Aldrich St. Louis, Missouri, USA), 1 mM PMSF and 1 µg/ml 
of each protease inhibitor; leupeptin, chemostatin, pepstatin and aprotinin)]. Then, 2 
mg lysozyme was added and the cells were incubated on ice for 15 min. Cells were 
lysed by sonication for 3x15 sec pulses with 30 sec intervals on ice. Lysates were 
transferred to 50 ml Oakridge tubes and centrifuged at 23,000 x g for 20 min at 4ᴼC. 
The supernatant was collected and filtered through a 1 μM syringe pre-filter, and then 
a 0.45 μM syringe filter. A 1 ml HisTrap column (GE Healthcare, Little Chalfont, UK) 
was attached to the AKTA purifier FPLC and the column washed in the same lysis 
buffer as above with 0.1 mM PMSF added. The lysate was added to the column and 
washed thoroughly until no more protein eluted. Bound proteins were collected by 20 
ml gradient elution using elution buffer (25 mM Tris-HCl pH 8, 0.5 M NaCl, 5 % 
glycerol, 500 mM imidazole and 0.1 mM PMSF) collecting 0.5 ml fractions. Fractions 
were subject to analysis by SDS-PAGE and Western blotting with anti-NTH1 
antibodies to select fractions containing purified his-tagged NTH1. Fractions 
containing NTH1 were concentrated using Amicon Ultra 15 ml centrifugal 
concentrators (10 kDa MWCO) in a swinging bucket rotor at 4000 x g at 4ᴼC until the 
volume reached approximately 500 µl. This volume was then made up to 1 mL in 
JPDB buffer (50 mM Tris HCl pH8, 50 mM KCl, 1mM EDTA, 10 % glycerol) and 
concentrated once more at 4000 x g at 4ᴼC. This process was repeated twice more 
to buffer exchange the fractions. 
3.2.8 Preparation of purified recombinant histidine-tagged TRIM26 
3.2.8.1. Generation of a pET28TRIM26 bacterial expression plasmid  
 
A LIC strategy (6) was employed to generate an expression construct for histidine-
tagged recombinant TRIM26 in a pET28a bacterial expression vector (Novagen). 
During LIC cloning, the vector DNA and inserts are PCR amplified separately using 
custom primers designed with flanking LIC sequences (Figure 14). LIC cloning then 
employs the 3’ to 5’ exonuclease activity of T4 DNA polymerase to create specific 
complementary overhangs, typically of 10-15 bases, between the insert and 
expression vector (Figure 17). The annealing of the insert and the vector is then 
performed by simply mixing the DNA fragments at different ratios and does not require 
73 
 
the need for a ligase enzyme (Figure 17). The process is typically very effective as 
only the desired product can form.  
An empty pET28a vector (from Novagen), was amplified using relevant 
oligonucleotides flanked by corresponding LIC sequences (Table 4). Aside to this, an 
insert of histidine-tagged TRIM26 was PCR amplified from a mammalian expression 
plasmid containing a TRIM26 insert (kindly provided by Prof A. Garcia-Sastre, 
The Icahn School of Medicine at Mount Sinai, USA) using relevant oligonucleotides 
flanked by corresponding LIC sequences (Table 4). 
PCR amplification of each component was performed by incubation of 5 ng of 
template DNA with 200 µM of each dNTP (A, T, G and C) and 1x HF Phusion buffer 
(1.5 mM MgCl2, F-518L, Thermo Fisher Scientific, Runcorn, UK) or 1x GC Phusion 
buffer (1.5 mM MgCl2, F-519L, Thermo Fisher Scientific, Runcorn, UK), with 0.02 U/µl 
Phusion High-fidelity DNA Polymerase. These were mixed with 0.5 µM of custom 
forward and reverse primers in a final reaction volume of 50 µl which was made up 
with nuclease-free water. The Phusion High-fidelity DNA Polymerase and 
corresponding Phusion buffers were obtained from Thermo Fisher Scientific 
(Runcorn, UK). Custom primers were obtained from Eurogentec (Southampton, UK). 
Reactions were mixed briefly on a vortex shaker before being incubated at 98°C for 2 
min, followed by 30 cycles of; 98 °C for 30 s, 57°C for 30 s and 72°C for 30 s per kb 
of DNA. The reactions were then finished with a final incubation at 72°C for 5 min.  
The size of the amplified DNA products was analysed using agarose gels before 
methylated template DNA was then removed via incubation with 0.1 µl of the 
restriction enzyme DpnI (10 U/ µl, Thermo Fisher Scientific, Runcorn, UK) for 1 h at 
37°C. Cohesive ends were then formed by exploiting the 3’ to 5’ exonuclease activity 
of T4 DNA Polymerase. To each PCR reaction, 0.5 µl of T4 DNA Polymerase (5 U/µl, 
Thermo Fisher Scientific, Runcorn, UK) was added with 1 mM DTT, 1.5 mM BSA and 
5 µl DNA sample. For vector DNA 0.5 mM dGTPs were added to this reaction, 
whereas 0.5 mM dCTPs were incubated with insert DNA. This enabled the 
polymerase activity of T4 DNA polymerase to be engaged whilst retaining 
complementary overhangs. The T4 DNA polymerase reactions were heated at 22°C 
for 30 min, then 80°C for 30 min. The complementary overhangs were used to anneal 
the vector and insert DNA by incubation at 22°C for 10 mins at a ratio of 1:1 or 1:3 
(vector: insert).  
The pET28TRIM26 plasmid from the LIC reaction was then transformed into library 
efficient DH5α cells according to manufacturer’s instructions (Thermo Fisher 
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Scientific, Runcorn, UK) and grown on antibiotic containing agar plates overnight at 
37°C. Colonies were inoculated into 5 ml of LB media containing selective antibiotic. 
Plasmid DNA (ranging from 70 bp to 10 kb), was then purified using the QIAquick 
PCR Purification Kit (250) obtained from Qiagen Ltd (Manchester, UK) to remove 
excess primers, enzymes and other impurities. Plasmid DNA was sequenced via the 
Sanger Sequencing Service provided by Source Bioscience (Nottingham, UK). 
Chromatographs were analysed using the BioEdit Sequence Alignment Editor and 
the sequence checked via alignments using the multiple sequence alignment tool, 
Clustal Omega (101).  
 
 
Figure 17. Schematic of Ligase Independent Cloning (LIC). LIC cloning is a 
technique used to generate expression constructs of interest. The process exploits 
the 3’ to 5’ exonuclease activity of T4 DNA polymerase. The vector sequence and the 
insert of interest are PCR amplified separately using oligonucleotides with flanking 
complimentary sequences.  The parental DNA is then removed via digestion using 
DPN1. The 3’ to 5’ activity of T4 polymerase is then utilised to create complementary 
overhangs between the two components. These complementary overhangs are 
maintained when the polymerase activity of the T4 polymerase is engaged by 
incubating them in the presence of one DNA base group only. For vector DNA 0.5 
mM dGTPs were added to the reaction, whereas 0.5 mM dCTPs were incubated with 
Recombinant 
histidine-tagged 
TRIM26 sequence   
pET28a backbone 
sequence 
pET28a backbone sequence + recombinant histidine-tagged TRIM26 sequence   
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insert DNA. The two amplification products are then annealed by simply mixing and 
incubating different ratios of the two components. The process is generally effective 
due to the specific overhangs generated, meaning only one product can form.  
3.2.8.2. Test overexpression of histidine-tagged TRIM26 
 
Initially a test expression was performed to establish the bacterial cells which gave 
the maximal recombinant TRIM26 expression. The pET28TRIM26 construct was 
transformed into a range of Rosetta cells; Rosetta 2(DE3) pLysS cells, Rosetta 2 cells, 
Rosetta-blue cells, Rosetta-gami cells and Origami 2 (DE3) cells.  These were then 
grown in a 5 mL culture of LB media containing the following selective antibiotics; 50 
µg ampillin, 30 µg kanamycin, 34 µg chloramphenicol, and grown overnight at 37°C 
and 250 rpm. Following this, a 40 mL culture was generated in the presence of 150 
μg selective antibiotic incubated at 37°C and 250 rpm, until the OD600nm was 
approximately 0.6. An aliquot of the cell suspension was removed before protein 
expression was induced via 1 mM IPTG for 3 h at 37°C and 250 rpm. An aliquot of 
the induced cell suspension was then removed. The aliquots of cell suspension before 
and after IPTG induction were re-suspended in SDS loading buffer and loaded onto 
a 10% SDS-PAGE gel for analysis of cellular proteins. Samples pre-IPTG and post-
IPTG were analysed in tandem.  
 
3.2.8.3. Overexpression of histidine-tagged TRIM26 
 
His-tagged pET28a TRIM26 plasmid was transformed into Rosetta2(DE3) pLysS 
bacterial cells and plated onto LB agar plates containing 30 μg/ml kanamycin and 34 
μg/ml chloramphenicol. A colony was selected and cultured overnight with 5 ml LB 
composed of 10g/L Tryptone, 5g/L Yeast extract and 10g/L Sodium Chloride (Fisher 
Scientific UK, Loughborough, UK). To this, 30 μg/ml kanamycin and 34 μg/ml 
chloramphenicol were added, to select for resistant TRIM26 plasmid amplification 
only. If the culture appeared turbid 300 μl culture was transferred to three 30 ml LB 
cultures with 30 μg/ml kanamycin, and 0.1 % glucose and grown at 37°C at 225 rpm 
shaking until turbid (OD600 ~ 0.6 to 0.8). The three cultures were expanded to three 
separate 300 ml LB cultures with antibiotic plus glucose added, then incubated with 
shaking until turbid (OD600 ~ 0.6 to 0.8). Protein expression was induced with 1 mM 
IPTG and incubated at 30°C with shaking for 3 h. The culture was centrifuged at 5000 
x g for 2 min, the supernatant aspirated, and pellets were then stored at -80°C.  
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3.2.8.4. Purification of histidine-tagged TRIM26 via affinity chromatography 
 
The bacterial cell pellet containing overexpressed his-tagged TRIM26 was 
resuspended in lysis buffer (25 mM Tris-HCl (pH8), 0.5 M NaCl, 5 % glycerol, 5 mM 
imidazole, pH 8 [(Sigma Aldrich St. Louis, Missouri, USA), 100 mM PMSF and 1 µg/ml 
of each protease inhibitor; leupeptin, chemostatin, pepstatin and aprototin)]. Then, 2 
mg lysozyme was added and the cells were incubated on ice for 15 min. Cells were 
lysed by sonication for 3x15 sec pulses with 30 sec intervals on ice. Lysates were 
transferred to 50 ml Oakridge tubes and centrifuged at 23,000 x g for 20 min at 4ᴼC. 
The supernatant was collected and filtered through a 1 μM syringe pre-filter, and then 
a 0.45 μM syringe filter. A 1 ml HisTrap column (GE Healthcare, Little Chalfont, UK) 
was attached to the AKTA purifier FPLC and the column washed in the same lysis 
buffer as above with 0.1 mM PMSF added. The lysate was added to the column and 
washed thoroughly until no more protein eluted. Bound proteins were collected by a 
20 ml gradient elution using elution buffer (25 mM Tris-HCl pH8, 0.5 M NaCl, 5 % 
glycerol, 500 mM imidazole and 0.1 mM PMSF) collecting 0.5 ml fractions. Fractions 
were subject to analysis by SDS-PAGE and Western blotting with anti-histidine 
antibodies to select fractions with purified his-tagged TRIM26. Fractions containing 
TRIM26 were selected, pooled and concentrated using Amicon Ultra 15 ml centrifugal 
concentrators (10 kDa MWCO) in a swinging bucket rotor at 4000 x g to generate a 
concentrated TRIM26 stock for further purification via ion exchange.  
3.2.8.5. Purification of histidine-tagged TRIM26 via ion exchange 
chromatography 
 
Concentrated affinity chromatography fractions containing his-tagged TRIM26 were 
further separated using a 1 ml ion exchange (MonoQ) chromatography Q 5/50 GL 
column (GE Healthcare, Little Chalfont, UK) pre-equilibrated with MonoQ  buffer I (50 
mM KCl, 50 mM Tris HCl pH 8, 1 mM EDTA, 5 % glycerol, 1 mM DTT and 0.1 mM 
PMSF) using an AKTA-FPLC in a cold cabinet at 4°C. Pooled fractions were 
concentrated using 10 kDa MWCO centrifuge filters and were diluted 10-fold in JPDB 
buffer to minimise NaCl levels. Following this, the sample was added onto the column 
and proteins eluted using a linear gradient of 50–1000 mM KCl using MonoQ buffer II 
(50 mM Tris HCl pH 8, 1 M KCl, 1 mM EDTA, 5 % glycerol, 1 mM DTT, 0.1 mM PMSF) 
over 20 min. Fractions of 0.5 ml were collected using an automated fraction collector 
until the UV signal stabilised. Collected fractions with peaks of protein presence were 
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subject to 14 % SDS-PAGE separation and Western blotting with TRIM26 specific 
antibodies. Fractions containing TRIM26 were selected, pooled and concentrated 
using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in a swinging 
bucket rotor at 4000 x g to generate a concentrated TRIM26 stock for subsequent 
assays. To improve preservation of the activity of the concentrated stock of the 
recombinant ligase, it was stabilised by the addition of a 50 % glycerol solution (1:1), 
aliquoted and stored at -80°C.  
3.2.9. Purification of E3 ligase activity for NTH1 
3.2.9.1 Preparation of HeLa whole cell extract 
 
Commercially obtained 20 g HeLa whole cell pellets (Cilbiotech, Mons, Belgium) were 
thawed on ice and re-suspended in one packed cell volume (PCV) of buffer I 
containing 10 mM Tris HCl (pH 7.8), 200 mM KCl (Sigma Aldrich St. Louis, Missouri, 
USA), 1 μg/ml of each protease inhibitor; pepstatin, aprotinin, chymostatin and 
leupeptin (Sigma Aldrich St. Louis, Missouri, USA), 0.1 mM PMSF and 1 mM DTT. 
Following this, the extract was further suspended in two PCVs of buffer II containing 
10 mM Tris–HCl (pH 7.8), 600 mM KCl, 40 % glycerol, 2 mM EDTA, 0.2 % IGEPAL 
CA-630, 1 μg/ml of each protease inhibitor (as stated), 0.1 mM PMSF and mixed 
thoroughly by rotation for 30 min at 4°C. Following this, the suspension was spun at 
23 000 x g at 4°C for 20 min in pre-cooled Oakridge tubes. The supernatant was 
collected and dialysed to minimise NP-40 and KCl concentrations, using Snakeskin 
dialysis tubing (10 kDa MWCO, 35 mm Dry ID) in 3 L of 150 mM KCl buffer with the 
addition of 1 mM DTT and 0.1 mM of PMSF for 12 h at 4°C. After this, the dialysed 
solution was spun at 23 000 x g at 4°C in pre-cooled Oakridge tubes to remove 
precipitated proteins. The supernatant was filtered through 1 µM syringe pre-filters 
and 0.45 µM filters using a pre-cooled syringe. The filtered extract was then subject 
to separation via column chromatography.  
3.2.9.2. Phosphocellulose Chromatography  
 
A 250 ml P-11 phosphocellulose column (GE Healthcare Little Chalfont, UK), was 
equilibrated by washing in PC150 buffer (50 mM Tris-HCl pH 8, 150 mM KCl, 1 mM 
EDTA, 5 % glycerol, 1 mM DTT, 0.1 mM PMSF) using an AKTA-prime FPLC in a cold 
room at 4°C at ~2 ml/min. HeLa whole cell extract (~2 g protein) was loaded onto the 
equilibrated column. Unbound proteins were eluted and collected (PC150 fraction) 
until the UV signal stabilised. Bound proteins were then eluted and collected (PC1000 
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fraction) by washing the column in PC1000 buffer (1 M KCl, 50 mM Tris-HCl pH8, 1 
mM EDTA, 5% glycerol, 1 mM DTT, 0.1 mM PMSF).  
3.2.9.3. Ion exchange chromatography  
 
A 20 ml HiLoad 16/10 sepharose high performance column (GE Healthcare, Little 
Chalfont, UK) was equilibrated in MonoQ buffer I (50 mM KCl, 50 mM Tris HCl pH 8, 
1 mM EDTA, 5 % glycerol, 1 mM DTT and 0.1 mM PMSF) using an AKTA-purifier 
FPLC in a cold cabinet at 4°C. Following this, the PC150 fraction (obtained from 
Phosphocellulose chromatography) was diluted 1:1 in no salt buffer (50 mM Tri HCl 
pH 8, 1 mM EDTA, 5 % glycerol) and added to the column at a flow rate of 2 ml/min. 
Proteins were eluted using a 400 ml linear gradient of 50–1000 mM KCl using MonoQ 
buffer II (50 mM Tris HCl pH 8, 1M KCl, 1 mM EDTA, 5 % glycerol, 1 mM DTT, 0.1 
mM PMSF) at 2 ml/min. Fractions of 4 ml were collected using an automated fraction 
collector. An aliquot of 500 µl of each fraction was concentrated using Amicon Ultra 
0.5 ml devices (10 kDa MWCO, Millipore, Watford, UK) by centrifugation at 15 000 x 
g, until the fraction volume was 50 µl. The fraction was then buffer exchanged into 
JPDB buffer (50 mM Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) to reduce 
the salt concentration and to stabilise the proteins. This process was repeated once 
more. Fractions were then analysed via an in vitro ubiquitylation assay using NTH1 
as the substrate (section 3.2.6.7).  
3.2.9.4. Size exclusion (Gel filtration) chromatography  
 
A 24 ml Superdex 200 10/300GL column (GE Healthcare, Little Chafont, UK) was 
equilibrated in gel filtration buffer (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, 5 % 
glycerol with 1 mM DTT and 0.1 mM PMSF) at a flow rate of 0.5 ml/min using an 
AKTA-purifier FPLC in a cold cabinet at 4°C. Fractions with potential candidate E3 
ligase activity obtained from the previous MonoQ chromatography were concentrated 
to 500 µl using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in a 
swinging bucket rotor at 4000 x g at 4°C. Concentrated fractions were loaded onto 
the equilibrated gel filtration column, collecting 0.5 ml fractions. Fractions were once 
again tested via an in vitro ubiquitylation assay using NTH1 as the substrate (section 
3.2.6.7). During this separation, gel filtration standards consisting of proteins of known 
molecular weight were also applied to the column. The position from which they eluted 
(in particular fractions) enabled us to estimate the molecular weight of other unknown 
proteins eluted from the cellular extract. 
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3.2.9.5. Hydroxyapatite chromatography 
 
Using an AKTA-purifier FPLC in a cold cabinet at 4°C, a 1 ml CHT ceramic 
hydroxyapatite column (Bio-Rad, Hemel Hempstead, UK) was equilibrated in 
hydroxyapatite buffer I (5 mM K2HPO4, 5 mM KH2PO4, 5 % glycerol) at a flow rate of 
1 ml/min. Fractions from the previous purification step were concentrated using 
Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in a swinging bucket 
rotor at 4000 x g at 4°C until the volume reached approximately 500 µl. This volume 
was then made up to 1 mL in JPDB buffer (50 mM Tris HCl pH 8, 50 mM KCl, 1 mM 
EDTA, 10 % glycerol) and concentrated once more at 4000 x g at 4°C. This process 
was repeated twice more as a way to buffer exchange the fractions. After this, the 
buffer exchanged fractions were added onto the equilibrated 1 mL CHT ceramic 
hydroxyapatite column. Proteins were eluted using a 20 ml linear gradient of 5–500 
mM KPO4 using hydroxyapatite buffer II (500 mM K2HPO4, 500 mM KH2PO4, 5 % 
glycerol) at 1 ml/min. An automated fraction collector was used to collect 0.5 ml 
fractions. Fractions were once again tested via in vitro ubiquitylation assay using 
NTH1 as the substrate (section 3.2.6.7).  
3.2.9.6. Final ion exchange chromatography  
 
Active fractions obtained from previous hydroxyapatite column chromatography were 
pooled and diluted 10-fold in MonoQ buffer I (50 mM KCl, 50 mM Tris HCl pH 8, 1 mM 
EDTA, 5 % glycerol, 1 mM DTT and 0.1 mM PMSF). A 1 ml Mono Q 5/50 GL column 
(GE Healthcare, Little Chalfont, UK) was equilibrated in MonoQ buffer I at a flow rate 
of 1 ml/min using an AKTA-purifier FPLC in a cold cabinet at 4°C. Pooled fractions 
were added onto the column and proteins eluted using a linear gradient of 50–1000 
mM KCl using MonoQ buffer II (50 mM Tris HCl pH 8, 1 M KCl, 1 mM EDTA, 5 % 
glycerol, 1 mM DTT, 0.1 mM PMSF) over 20 min. Fractions of 0.5 ml were collected 
using an automated fraction collector until the UV signal stabilised.  
3.2.9.7. In vitro ubiquitylation assay  
 
In vitro ubiquitylation of his-tagged, recombinant NTH1 (5.8 pmol) by candidate E3 
ligase enzymes was analysed in buffer containing 4 mM ATP, 200 µM CaCl2, 1 mM 
DTT, 5 mM MgCl2, 100 µM MG-132 and 50 mM Tris-HCl (pH8) in pre-cooled low bind 
Eppendorf tubes. To this, 625 pmol of wild-type or mutant ubiquitin was added along 
with 0.7 pmol GST-E1 activating enzyme, 2.5 pmol E2 conjugating enzyme 
(combination of 10 different E2s, unless otherwise stated) and 0.6 nmol ubiquitin 
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(Boston Biochemicals, Cambridge, USA) in buffer containing 25 mM Tris–HCl (pH 
8.0), 4 mM ATP, 5 mM MgCl2, 200 μM CaCl2 and 1 mM DTT were incubated in LoBind 
protein tubes (Eppendorf, Stevenage, UK) for 1 h at 30°C with agitation. A source of 
E3 ligase enzyme was either provided in the form of active HeLa cell fractions 
obtained from column chromatography or in the form of active, purified recombinant 
E3 ligase enzyme (TRIM26; 19 fmol and 26 fmol). Reactions were stopped by the 
addition of SDS-PAGE sample buffer (25 mM Tris–HCl (pH 6.8), 2.5% β-
mercaptoethanol, 1% SDS, 10% glycerol, 1 mM EDTA, 0.05 mg/ml bromophenol 
blue) and heated for 5 min at 95°C prior to SDS-PAGE and Western blotting (section 
3.2.1 and section 3.2.2.2). 
3.2.9.8. E3 ubiquitin ligase identification by tandem mass spectrometry  
 
Active candidate E3 ligase enzymes within fractions obtained from the final ion 
exchange chromatography stage were identified by tandem mass spectrometry. 
Strataclean resin (Agilent Technologies, Stockport, UK) was used to extract proteins 
from purified chromatography fractions and subsequently protein were resuspend in 
0.05 % (w/v) Rapigest in 25 mM ammonium bicarbonate. Samples were then heated 
at 80°C for 10 min, reduced with 3 mM DTT at 60°C for 10 min and alkylated in 9 mM 
iodoacetamide in a dark room for 30 min. Trypsin (1 μg) in 50 mM acetic acid was 
added and samples mixed via rotation at 37°C for 12 h. Following digestion, samples 
were acidified by the addition of trifluoroacetic acid (1 % (v/v) and held at 37°C for 45 
min, then centrifuged at 17 200 x g for 30 min. The pellets were discarded and 
supernatants were diluted to ∼50 ng/μl in 0.1 % (v/v) trifluoroacetic acid (TFA)/3 % 
(v/v) acetonitrile. LC peptide separations were completed using an Ultimate 3000 
nano system (Dionex/Thermo Fisher Scientific, Hemel Hempstead, UK). For each 
analysis, the sample was loaded onto a trap column (Acclaim PepMap 100, 2 cm × 
75 μm inner diameter, C18, 3 μm, 100 Å) at 5 μl/min with an aqueous solution 
containing 0.1 % (v/v) TFA and 2 % (v/v) acetonitrile. Following 3 min, the trap column 
was set in-line with an analytical column (Easy-Spray PepMap® RSLC 50 cm x 75 μm 
inner diameter, C18, 2 μm, 100 Å). Peptide elution was completed using a linear 
gradient of solvent A (HPLC grade water with 0.1 % (v/v) formic acid) and solvent B 
(HPLC grade acetonitrile 80% (v/v) with 0.1 % (v/v) formic acid). Mass spectrometry 
was then performed using the Q Exactive instrument operated in data dependent 
positive (ESI+) mode to routinely switch between full scan MS and MS/MS acquisition. 
Survey full scan MS spectra (m/z 300–2000) were obtained with a resolution of 70 
000 (m/z 200) following accumulation of ions to 1 × 106 target value based on 
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predictive automatic gain control (AGC) values from the previous full scan. Dynamic 
exclusion was set to 20 s. The 10 most intense multiply charged ions (z ≥ 2) were 
sequentially isolated and fragmented in the octopole collision cell by higher energy 
collisional dissociation (HCD) with a fixed injection time of 100 ms and 35 000 
resolutions. Typical mass spectrometric conditions were as follows: spray voltage, 1.9 
kV, no sheath or auxillary gas flow; heated capillary temperature, 275°C; normalised 
HCD collision energy 30 %. The MS/MS ion selection threshold was set to 2 × 
104 counts. A 2 Da isolation width was set. Raw data files were searched in Mascot 
against the UniProt human database. A precursor ion tolerance of 10 ppm and a 
fragment ion tolerance of 0.01 Da were used with carbamidomethyl cysteine set as a 
fixed modification and oxidation of methionine as a variable modification. The false 
discovery rate against a decoy database was 1 %. 
3.2.9.9. Identification of NTH1 ubiquitylation sites by tandem mass 
spectrometry  
 
To isolate ubiquitylated NTH1, in vitro ubiquitylation reactions recombinant Histidine-
NTH1 as the substrate protein and recombinant Histidine-TRIM26 as the active E3 
ligase, the reactions were separated via two 10% SDS-PAGE gels in tandem. One of 
them was further subject to Western blotting analysis with NTH1 specific antibodies. 
The Western blot was utilised to identify the specific region featuring protein bands 
which correspond to ubiquitylated NTH1. This was represented by protein bands 
corresponding to NTH1 which had shifted upwards on the SDS-PAGE gel by 8 kDa 
or multiples of 8 kDa; this is representative of the addition of 8 kDa ubiquitin moieties 
to specific lysine residues of NTH1. Identification of the specific region containing 
ubiquitylated NTH1 bands was applied to the 10% SDS-PAGE gel; where the specific 
region was estimated from visualisation of the Western blot and bands were excised 
using a scalpel. The excised gel pieces were covered with a minimum volume of 25 
mM ammonium bicarbonate in 1.5 ml LoBind Protein tubes (Eppendorf, Stevenage, 
UK) and heated at 37°C for 15 min. The gel pieces were washed twice more in this 
way before 10 mM DTT in 25 mM ammonium bicarbonate was added and samples 
incubated at 56°C for 1 h. Alkylation was then completed by the addition of 55 mM 
ammonium bicarbonate followed by 25 mM ammonium bicarbonate/acetonitrile (2:1 
v/v). For protease digestion, ArgC (10 ng/ul in 25 mM ammonium bicarbonate 
containing 1 mM DTT) was added and incubated for 15 min on ice. Following this, 
samples were covered in a minimum volume of 25 mM ammonium bicarbonate and 
heated at 37°C overnight. Samples were then centrifuged at 17 200 xg, supernatant 
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removed and vacuum centrifuged to near dryness. Acetonitrile (3 % v/v) and TFA (0.1 
% v/v) was added and samples centrifuged for 15 min before transfer to a total 
recovery vial for LC-MS analysis.  
3.2.10. Mammalian cell culture  
 
All tissue culture work was completed in a class II hood with laminar flow (Esco Global, 
Barnsley, UK), cleaned with 70 % ethanol thoroughly before and following use. Tissue 
culture reagents, including trypsin, PBS and complete DMEM media (containing 10 
% FBS, 2 mM glutamine and 1 % pen-strep) were warmed in a water bath at 37°C 
before use. Tissue culture work was performed entirely using aseptic techniques. All 
plastics used were tissue culture grade. Cells were grown in a humidified cell culture 
incubator with 5 % CO2 at 37°C.  
3.2.10.1. Defrosting cell vials  
 
Vials containing frozen cells were obtained from liquid nitrogen storage and rapidly 
defrosted for 1 min at 37°C in a water bath. Cells were promptly centrifuged at 2000 
x g for 5 min and the supernatant discarded to remove DMSO. The cell pellet was 
resuspended in 12 ml of DMEM media supplemented with hydroxyethyl 
piperazineethanesulfonic acid (HEPES) modification, 4500 mg/L 25 mM HEPES and 
sodium bicarbonate, sterile filtered, plus 10 % fetal bovine serum (FBS, non-USA 
origin, sterile filtered) 2mM L-glutamine, 100 U penicillin, 0.1 mg streptomycin and 1 
% MEM Non-essential amino acid solution. The resuspended cells were transferred 
to a T75 flask and placed in a humidified cell culture incubator at 5 % CO2 at 37°C. 
Once cells reached approximately 70-90 % confluency they were subcultured.  
3.2.10.2. Subculturing  
 
Once cells in T75 flasks had reached confluency they were subcultured into fresh T75 
flasks to maintain cell growth. The DMEM media was removed via aspiration then 
cells were washed in 5 ml of PBS. Cells were treated with 2 ml of trypsin-EDTA 
solution (0.25 %) and incubated for 2 min (or until cells had lifted from the flask 
surface) in the humidified cell culture incubator at 5 % CO2 at 37°C. Trypsin was 
neutralized by the addition of 8 ml of supplemented DMEM media and cells were 
subcultured 1:20 in a fresh T75 flask with 12 ml supplemented DMEM media and 
placed in a humidified cell culture incubator at 5 % CO2 at 37°C.  
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3.2.10.3. Seeding cells for experimentation 
 
Exponentially growing cells were trypsinised as described above. The number of cells 
in trypsinised cell suspension was determined by cell counting using a 
haemocytometer. Generally, for 10 cm dishes 0.5 x 106 cells per dish were seeded in 
5 ml of supplemented DMEM media, whereas, for a 3.5 cm sized dish 1.5 x 105 cells 
were seeded in 2 ml of supplemented DMEM media. 
3.2.10.4. Harvesting cells   
 
Outside the tissue culture flow hood, media was removed by aspiration. Cells were 
washed in cold Dulbecco’s PBS (for 10 cm2 dishes used 5 ml of PBS, for 3.5 cm dishes 
used 2 ml of PBS) which was also removed via aspiration. A further volume of PBS 
was added and cells were carefully removed using a cell scraper (Greiner Bio-One) 
and added to a pre-cooled 15 ml tube on ice. This process was repeated once more 
before centrifugation at 2000 x g for 5 min at 4°C. The supernatant was discarded and 
the pellet resuspended in 1 ml of cold Dulbecco’s PBS which was transferred to a pre-
cooled Eppendorf on ice. The suspension was spun at 2000 x g for 5 mins at 4°C and 
the supernatant discarded. Pellets were stored at -80°C for at least 1 h. 
3.2.10.5. Preparation of whole cell extracts  
 
Before use, 1 μg/ml of each protease inhibitor; aprotinin, pepstatin, chymostatin and 
leupeptin, and 1 mM PMSF and 1 mM DTT were added to buffer I (10 mM Tris, pH 
7.8, 200 mM KCl) and buffer II (10 mM Tris, pH 7.8, 600 mM KCl, 2 mM EDTA, 40 % 
glycerol, 0.2 % NP-40). After harvesting cells and freezing the pelleted extracts at  
-80°C for a least 1 h, cell pellets were resuspended in one PCV (no less than 50 µl) 
in buffer I and then two PCVs of buffer II were also added, then the extract was mixed 
thoroughly. The cell suspension was mixed via rotation at 4°C for 1 h, then centrifuged 
at 72 000 x g for 20 min at 4°C. The supernatant containing protein was collected and 
protein concentration measured using a Bradford assay (Section 3.2.1) and stored at 
-80°C. 
3.2.10.6 Biochemical fractionation  
 
Cellular proteins were fractionated into soluble and chromatin bound fractions 
according to previous descriptions (179). Initially, cells were resuspended in 2 packed 
cell volumes (PCV) of Buffer I (20 mM Tri-HCl pH 7.4, 2.5 mM MgCl2, 0.5% Nonidet 
P-40) containing 1 mM PMSF, 1 mM DTT and 1 µg/ml of protease inhibitors 
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(leupeptin, pepstatin, chymostatin and aprotinin). Re-suspended cells were incubated 
on ice for 10 min before centrifugation at 10 000 rpm for 2 min to separate the soluble 
fraction in the supernatant. The nuclear pellet was re-suspended in two PCVs of buffer 
II (20 mM NaPO4 pH 8.0, 0.5 M NaCl, 1 mM EDTA, 0.75 % Triton X-100, 10 % glycerol 
and 2 mM MgCl2) containing 1 mM PMSF, 1 mM DTT and 1 µg/ml of protease 
inhibitors (leupeptin, pepstatin, chymostatin and aprotinin) for 10 min on ice. The 
suspension then centrifuged at 10 000 rpm for 2 min. The supernatant was collected 
as the chromatin bound fraction. Protein concentration was determined by the 
Bradford assay (Section 3.2.1) and extracts were stored at -80°C. 
3.2.10.7. RNA interference for knockdowns  
 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10 % fetal bovine serum (FBS), 2 mM L-glutamine, 1× penicillin-streptomycin and 
1× non-essential amino acids. All cells were cultured at 37°C in 5 % CO2. For siRNA 
induced knockdowns, cells were grown in 10 cm dishes for 24 h until 30-50 % 
confluent and treated with 10 µl Lipofectamine RNAiMAX transfections reagent (Life 
Technologies, Paisley, UK) in the presence of 140 nM non-targeting, control siRNA 
(Qiagen, Manchester, UK) or 140 nM TRIM26 siRNA (consisting of 70 nM of two 
TRIM26 siRNA; 5'-CCGGAGAAUUCUCAGAUAA-3' and 5'-
GAGUCACAGGAACUCAUCU-3') for 72 h at 37°C in a humidified cell incubator. 
3.2.10.8. Plasmid transfection for overexpression  
 
Cells were cultured in 10 cm dishes until 80% confluent. They were transfected with 
plasmids (e.g. 110 fmol pCMV-3Tag3a-TRIM26 or 150 fmol pCMV-3Tag3a-NTH1 or 
1 μg of PMT-HA-Ub) using 10 µl Lipofectamine 2000 (Life Technologies, Paisley, UK) 
for 24 h in serum-containing media at 37°C with 5% CO2 in a humidified cell incubator.  
3.2.10.9. Reverse transcription and real-time PCR   
 
An RNeasy Mini kit (Qiagen, Manchester, UK) was used to extract RNA from cell 
pellets according to the manufacturer’s instructions. Briefly, cells were pelleted 
following an siRNA induced knockdown and resuspended in 350 μl buffer RLT, mixed 
with 350 μl 70 % ethanol, then the mixture was transferred to a RNeasy Mini spin 
column and centrifuged at 8000 x g for 15 sec. All subsequent centrifugation stages 
were completed at this speed and time unless stated otherwise.  
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Following this, 700 μl Buffer RW1 was added to the column and centrifuged, then 500 
μl buffer RPE was added twice and centrifuged after each addition. The column was 
dried by centrifugation for 1 min before 30 μl RNase free water was added and 
centrifuged for 1 min to elute RNA. The RNA concentration was measured via a 
Nanodrop ND-1000 spectrometer (software version V3.7.1) at 260 nm. 
From the extracted RNA, cDNA was generated using the GoScriptTM Reverse 
Transcription System (Promega, Southampton, UK) according to the manufacturer’s 
instructions. Up to 5 μg RNA was incubated with 0.5 μg Oligo(dT)15 at 70°C for 5 min 
then cooled on ice for 5 min. A reverse transcription mix was made consisting of; 4 μl 
GoScriptTM 5x reaction buffer, 1.4 mM MgCl2, 0.5 mM PCR nucleotide mix, 0.5 μl 
Recombinant RNasin ribonuclease inhibitor and 1 μl GoScriptTM reverse transcriptase 
which was made up to 15 μl final volume with nuclease free water. To this the 5 μl 
RNA and primer mix was then added and incubated at 25°C for 5 min for annealing, 
extended by heating at 42ᴼC for 1 h and the reverse transcriptase inactivated by 
incubation at 70°C for 15 min. Following this, SYBR® Select Master Mix (Thermo 
Scientific, Runcorn, UK) was used to amplify cDNA using primers (Table 6) for 
quantitative Real Time PCR analysis using the 7500 Real Time PCR system (Applied 
Biosystems, Warrington, UK) software version v2.3. A cycle threshold value (CT) was 
provided of the run for the gene(s) of interest and the reference gene actin following 
their knockdown by siRNA. Further calculations (provided below) determined relative 
quantities of mRNA (RQ value) so that statistical analysis of knockdown efficiency 
could be calculated. The RQ value allowed us to determine if successful knockdown 
of target genes has been achieved.  
 
ΔCT = CTgene – CT reference gene 
ΔΔCT = ΔCTcontrol – ΔCTtreatment 
RQ = 2ΔΔCT 
 
3.2.10.10. Inhibition of the cellular proteasome  
 
Cells were cultured in serum-containing medium until approximately 80% confluent. 
Cells were washed and treated with either; 10 µl DMSO control or 10 µl MG-132 
(carbobenzoxy-Leu-Leu-leucinal) proteasomal inhibitor diluted in serum-containing 
media for 8 h at 37°C in a humidified cell chamber with 5% CO2. Cells were then 
harvested and whole extracts prepared as described (Section 3.2.10.5). A total of  
40 µg of protein extract obtained from cells with and without MG-132 treatment was 
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then analysed via 10% SDS-PAGE and Western blotting (Sections 3.2.2.2 and 
3.2.2.3) with anti-NTH1 antibodies. Levels of NTH1 protein, represented by a protein 
expression band at a molecular weight of 34.4 kDa on the Western blot, were 
quantified using the Odyssey image analysis system (Li-cor Biosciences, Cambridge, 
UK). 
3.2.10.11. Immunoprecipitation of FLAG-tagged NTH1  
 
Anti-FLAG M2 magnetic beads (Sigma-Aldrich, Dorset, UK) were used for 
immunoprecipitation of FLAG-tagged recombinant NTH1, following a partial 
overexpression of this protein in cells. Cells were harvested and cell extracts prepared 
(Section 3.2.10.5). The protein concentration of each extract was measured via a 
Bradford assay. Samples were diluted to a final volume of 100 µl in 150 mM KCl buffer 
(50 mM Tris pH 8, 150 mM KCl, 1mM EDTA, 5% glycerol) and to equal protein 
concentrations.  
For each immunoprecipitation, 10 µl of Anti-FLAG M2 magnetic beads were aliquoted 
into a clean Eppendorf and washed three times in no salt buffer, using a magnetic 
separation rack to draw the beads across and discarding the excess buffer by 
pipetting. The washed beads were then resuspended in 100 µl of no salt buffer and 
the total volume was added to each cellular extract. Samples were mixed for 2 h on a 
rotating platform at 4°C. The magnetic rack was then used to immobilize the beads 
and the supernatant discarded. Beads were then washed in 100 µl of 150 mM KCl 
buffer by mixing gently with a pipette tip, before immobilising the beads with the 
magnetic rack and discarding the supernatant. This process was repeated thrice. 
Finally, the beads were resuspended in 20 µl of 150 mM KCl buffer, with 10 µl of 3x 
SDS-PAGE loading dye. Samples were heated at 95°C for 5 min, before 15 µl of the 
final volume was loaded onto an SDS-PAGE gel, followed by Western blotting with 
HA-tag antibodies to monitor the amount of immunoprecipitated ubiqutiylated protein.  
3.2.10.12. Oxidative stress treatment of cells  
 
Following treatment of cells grown in 10 cm dishes with the appropriate mammalian 
expression plasmid or siRNA induced knockdown, cells were subject to oxidative 
stress through hydrogen peroxide treatment. The stock solution of hydrogen peroxide 
(30 %) was diluted to 150 µM final concentration in serum containing media. Cells 
were washed in 1x PBS then the 150 µM hydrogen peroxide solution was added. 
Cells were incubated for 15 mins at 37°C in a humidified cell chamber with 5 % CO2. 
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Cells were then washed in 1x PBS and fresh media added. For repair time points, 
cells were returned to the 5 % CO2 incubator and harvested at the required intervals 
(0-8 h). For untreated controls, cells were treated with media only.   
3.2.10.13. Clonogenic survival assays 
 
Following treatment of cells grown in 35 mm dishes with siRNA or mammalian 
expression plasmids, cells were treated with hydrogen peroxide (0-300 nM) for 15 min 
at 37 °C in a humidified cell incubator. Cells were then washed in 1x PBS, trypsinised 
and counted using a haemocytometer. A defined number of cells were seeded in 2 ml 
complete DMEM media at two different cell densities in triplet for each hydrogen 
peroxide treatment in 6-well plates. Number of HCT116p53+/+ cells seeded per well in 
a 6 well plate. For lipofectamine RNAiMAX only; 0 nM H2O2 250 and 500, 50 nM H2O2 
250 and 500, 100 nM H2O2 500 and 1000, 200 nM H2O2 1000 and 2000, 300 nM H2O2 
1000 and 2000. For non-targeting siRNA, TRIM26 siRNA or NTH1 overexpression; 0 
nM H2O2 250 and 500, 50 nM H2O2 500 and 1000, 100 nM H2O2 1000 and 2000, 200 
nM H2O2 1000 and 2000, 300 nM H2O2 2000 and 4000. The cell numbers were 
increased for increasing hydrogen peroxide doses and double the number of cells 
were used for non-targeting siRNA, TRIM26 siRNA or NTH1 overexpression to 
compensate for cell plating efficiencies. The plates were incubated in a tissue culture 
incubator at 37°C, 5 % CO2 for 10-14 days until colonies were clearly visible (>50 
cells/colony). Cells were then fixed and stained by removing media, washing the cells 
in PBS, and adding 0.5 % crystal violet in 6 % glutaraldehyde (Fisher Scientific UK, 
Loughborough, UK) for 1 h. The dye was removed, plates were washed in water and 
left to air dry overnight. Colonies were counted using the GelCount colony analyser 
(Oxford Optronics, Oxford, UK). Relative colony formation (surviving fraction) was 
expressed as colonies per treatment level versus colonies that appeared in the 
untreated control. Statistical analysis was performed using the CFAssay for R 
package (18). 
3.2.10.14. Alkaline single cell gel electrophoresis (comet) assay   
 
Cells grown in 35 mm dishes were trypsinised, diluted to 2x105 cells/ml and 250 µl 
aliquots of the cell suspension, then transferred into the wells of a 24-well plate on 
ice. The cells were treated with 7.5 µM hydrogen peroxide for 5 min on ice. The 
reaction was stopped by mixing the cell suspension with 1 ml molten low melting point 
agarose (at ~35°C), before being transferred to a microscope slide pre-coated with 
normal melting point agarose. A cover slip was then placed over the cell suspension 
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mixture and allowed to set on ice. For DNA repair kinetic studies, cells were allowed 
to undergo DNA repair in-gel for up to 2 h at 37°C in a humidified chamber, prior to 
lysis in buffer containing 2.5 M NaCl, 100 mM EDTA, 10 mM Tris–HCl pH 10.5, 1% 
(v/v) DMSO and 1% (v/v) Triton X-100 for at least 1 h at 4°C (112). Following this, 
slides were transferred to an electrophoresis tank and incubated for 30 min in the 
dark. Slides were then submerged in cold electrophoresis buffer (300 mM NaOH, 1 
mM EDTA, 1% (v/v) DMSO, pH 13) to permit the DNA to unwind. The DNA was 
electrophoresed at 25 V, 300 mA for 25 min and slides neutralised with three 5 min 
washes of 0.5 M Tris–HCl (pH 8.0) then allowed to air dry overnight. Slides were 
rehydrated for 30 min in water (pH 8.0), stained for 30 min with SYBR Gold (Life 
Technologies, Paisley, UK) diluted 1:20 000 in water (pH 8.0) and allowed to dry prior 
to imaging. Cells (50 per slide, two slides per time point) were analysed using the 
Komet 6.0 image analysis software (Andor Technology, Belfast, Northern Ireland) and 
% tail DNA values averaged from at least three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 CHAPTER 4 - RESULTS I 
 
Identification of TRIM26 as the major E3 ubiquitin ligase for NTH1  
4.1 Introduction  
 
NTH1 is a key bifunctional glycosylase implicated in the removal of oxidised 
pyrimidines during the first stages of BER. Removal of base lesions inflicted upon 
DNA is paramount to maintaining the functionality of each cell. Elimination of DNA 
base lesions prevents the accumulation of harmful mutations upon cell division, which 
can result in dysregulated cellular activity leading to cancer development. Crucially, 
NTH1 is the primary enzyme involved in the repair of Tg, which is a particularly 
mutagenic base lesion (42, 76, 165). Owing to the importance of NTH1, the repair 
enzyme is expressed ubiquitously and well conserved across phylogeny.  
Due to continued fluctuations in levels of DNA damage, it is imperative that BER repair 
enzymes are regulated to enable cells to provide effective DNA repair. Indeed, 
previous work has demonstrated that the levels of a number of BER enzymes are 
regulated by the PTM, ubiquitylation (46, 125, 126). For instance, levels of the major 
replicative polymerase implicated in BER, Pol β, have been shown to be regulated by 
ubiquitylation. The addition of singular ubiquitin moieties by the E3 ligase Mule was 
shown to act as a prerequisite for the addition of ubiquitin chains by another E3 
ubiquitin ligase CHIP that signals for proteosomal degradation (126). Conversely, 
deubiquitylation of Pol β by USP47 initiates accumulation of levels of the repair protein 
(121). In this way, it is acknowledged that ubiquitylation can be utilised to efficiently 
modify cellular levels of BER proteins to suitably respond to fluctuating DNA damage 
levels.  
Ubiquitylation involves the covalent attachment of single or multiple moieties of 
ubiquitin onto target proteins. The process is mediated by a cascade of three 
enzymes; an E1 activating enzyme, an E2 conjugating enzyme and finally an E3 
ligase enzyme. Generally, attachment of single ubiquitin molecules regulates activity, 
localisation or protein-protein/protein-DNA interactions, whereas addition of chains of 
ubiquitin moieties often influences protein stability. In this capacity, ubiquitylation is a 
highly dynamic process that regulates numerous cellular activities. Due to the 
influence ubiquitylation has on cellular processes it is particularly important that the 
process is highly specific towards substrate proteins. To facilitate this, specificity of 
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the reaction is largely dictated by the existence of over 600 individual E3 ligase 
enzymes (81). 
Despite accumulating evidence of regulation of BER via ubiquitylation, investigations 
regarding the ubiquitylation dependent regulation of proteins present upstream in the 
BER process, is lacking in comparison to more well characterised BER proteins (48). 
For instance, and central to this thesis, proteomic screens have identified that NTH1 
is ubiquitylated, but the ubiquitylation enzymes involved have not been elucidated 
(34). Most recently, colleagues from our laboratory began to address this discrepancy; 
they purified and identified the major E3 ligases responsible for the ubiquitylation of 
the DNA glycosylase, NEIL1 (46). Identifying the E3 ligase enzymes specific to NTH1 
will serve as an important tool for determining the role that ubiquitylation plays in 
regulating NTH1 activity, localisation, stability or cellular interactions. Therefore, the 
primary aim of the work detailed in this chapter was to purify and identify the E3 
ligase(s) in human cells that act on NTH1. 
4.2. Purification of recombinant NTH1  
 
Recombinant histidine-tagged NTH1 was overexpressed and purified using a 
bacterial expression plasmid (kindly provided by Dr. Allinson, University of Lancaster). 
The expression product of the pET28NTH1 plasmid consisted of the coding sequence 
(P78549-2). The pET28NTH1 expression plasmid was transformed into Rosetta 
(DE3) pLysS competent cells and colonies grown on selective medium, according to 
the antibiotic resistance (kanamycin) of the expression plasmid. Resistant colonies 
were selected and cultured initially in 5 ml of LB media overnight with appropriate 
selective antibiotics at 37°C in a shaking incubator at 250 rpm. The overnight culture 
was then used to generate a 40 mL feeder culture in the presence of appropriate 
antibiotics. Once the OD600nm of the feeder culture reached 0.6, it was diluted to 
generate a 400 mL expression culture. When the OD600nm of the expression culture 
reached 0.6, protein expression was induced via the addition of IPTG and cultured for 
a further 3 h at 30°C. Following this, the bacterial cell culture was harvested and cells 
resuspended in lysis buffer in the presence of protease inhibitors to enable protein 
purification. Expressed, recombinant Histidine-tagged NTH1 was purified by affinity 
chromatography, using a 1 ml HisTrap chromatography column, utilising an AKTA-
purifier FPLC with a gradient elution of 5 mM to 500 mM imidazole (Figure 18, A). 
The purity of fractions containing recombinant NTH1 was analysed by 10 % SDS-
PAGE (Figure 18, B) with Western blotting using antibodies specific to NTH1 
detection (Figure 18, C).  
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The molecular weight of His-tagged NTH1 (P78549-2) is 33.6 kDa. From SDS-PAGE 
separation and Western blot analysis (Figure 18, B and C), it was apparent that 
relatively pure NTH1, represented by the presence of a strong banding pattern at the 
expected molecular weight, was present in chromatography fractions 17-27. This 
strong band was confirmed to be NTH1 by Western blotting using antibodies that 
specifically cross-react with the protein, again in fractions 17-27 (Figure 18, C). 
Consequently, the purest fractions (19-27) were pooled and concentrated using 10 
kDa centrifugal filters, as well as being buffer exchanged into JPDB buffer, to generate 
a concentrated stock of NTH1 for subsequent in vitro ubiquitylation assays.  
 
 
 
 
 
 
 
 
 
92 
 
 
 
 
Figure 18. Purification of histidine-tagged recombinant NTH1 via affinity 
chromatography. A bacterial expression plasmid for histidine-tagged NTH1 
(P78549-2) was transformed into Rosetta2 (DE3) pLySs bacterial cells and grown into 
a 400 ml expression culture before inducing protein expression. Bacterial cell pellets 
were then harvested before cells were lysed in the presence of protease inhibitors. 
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Recombinant NTH1 was then purified using a 1 ml HisTrap affinity chromatography 
column with a linear gradient of 5 mM to 500 mM imidazole. The UV trace is provided, 
with the fraction number shown below in red (A). Chromatography fractions were 
collected and purity analysed by 10% SDS-PAGE (B) and Western blotting using 
antibodies specific to NTH1 (C).  
 
4.3. Purification of the cellular E3 ligase specific to NTH1  
 
Identification of the direct mechanism of ubiquitylation of NTH1, may facilitate further 
studies determining the cellular effects of ubiquitylation-dependent regulation NTH1. 
This largely relies on identification of the E3 ligase enzyme(s) that ubiquitylate of 
NTH1. Since there are believed to be over 600 individual E3 ligase enzymes, this 
process initially involved purification of candidate E3 ligase enzymes from the cellular 
milieu. This was achieved by combining a series of column chromatography 
separation techniques (Figure 19), using an AKTA-purifier FPLC, with an in vitro 
ubiquitylation assay incorporating NTH1 as a substrate protein. Following each 
column chromatography stage within the purification scheme, each fraction obtained 
was subject to an in vitro ubiquitylation assay, containing GST-E1 activating enzyme, 
nine different E2 conjugating enzymes and ubiquitin, with Histidine-tagged, 
recombinant and purified NTH1 as a substrate (Figure 18). The presence of active 
E3 ligase(s) specific to NTH1 was provided in the form of the cellular proteins within 
the chromatography fractions being tested. The ubiquitylation reactions were carried 
out at 30 °C for 1 h and completed reactions were analysed by SDS-PAGE separation, 
followed by Western blot analysis using NTH1 antibodies. The presence of active 
candidate E3 ligase enzymes was determined by fractions which demonstrated bands 
of NTH1 with an increased shift in molecular weight of approximately 8 kDa, or 
multiples of 8 kDa. This characteristic banding pattern likely represents the addition 
of 8 kDa ubiquitin moieties onto specific lysine residues of the substrate protein, 
NTH1. Using this method, it was understandably assumed that these fractions contain 
active E3 ligase(s) specific to NTH1. Active fractions were pooled, concentrated and 
passed over the sequential chromatography column, according to the purification 
scheme (Figure 19) to further purify the candidate E3 ligase(s) to near homogeneity. 
Following the final purification step, candidate peptides were analysed via mass 
spectrometry.   
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Figure 19. Purification scheme utilised for the isolation of candidate E3 ligase 
enzymes specific to recombinant NTH1 from HeLa cells.  HeLa extract was 
prepared from a 20 g HeLa pellet then passed over a fully equilibrated 
Phosphocellulose cation exchange column. Proteins were eluted using a KCl 
containing buffer and the NTH1 specific ubiquitylation activity of eluted proteins was 
evaluated by using the chromatography fractions as an E3 ligase source in an in vitro 
ubiquitylation assay with recombinant NTH1. Completed assays were evaluated by 
SDS-PAGE and western blot analysis with NTH1 antibodies. Active fractions were 
purified further sequentially using a 20 ml Mono-Q anion exchange column eluted 
using a KCl gradient, a 24 ml Superdex 200 gel filtration column, a hydroxyapatite 
column and a final 1 ml Mono-Q anion exchange column. Fractions demonstrating 
ubiquitylation activity at each stage and the presence of a candidate E3 ligase enzyme 
specific to NTH1 were then subject to mass spectrometry (MS) analysis to identify 
candidate peptides. 
  
4.3.1.  Phosphocellulose chromatography  
 
The purification process was initiated by the preparation of a cell extract from a 
commercially obtained 20 g HeLa cell pellet. The HeLa cell pellet was thoroughly 
resuspended in the presence of protease inhibitors, dialysed and precipitated proteins 
removed via centrifugation. The HeLa cell suspension was passed over a pre-
equilibrated Phosphocellulose cation exchange column, which preferentially binds 
positively charged proteins, including those with DNA-binding properties. The column 
was washed with buffer containing 150 mM KCl, to collect unbound proteins (PC150 
fraction), before bound proteins were displaced by a single step-elution using 1000 
mM KCl containing buffer (PC1000 fraction). Both fractions (PC150 and PC1000) 
MS analysis 
20 g HeLa cells 
20 ml Mono-Q  
250 ml Phosphocellulose 
1 ml Hydroxyapatite 
1 ml Mono-Q  
24 ml Superdex 200 
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were subject to an in vitro ubiquitylation assay, using recombinant Histidine-tagged 
NTH1 as the substrate. The completed reactions were separated by 10% SDS-PAGE 
followed by Western blotting using NTH1 specific antibodies (Figure 20). 
 
 
Figure 20. Western blot analysis of the in vitro ubiquitylation assay with 
recombinant NTH1 following cation exchange column chromatography 
separation of HeLa cell extract. Whole cell extract was prepared from a 20 g 
commercially available HeLa cell pellet and loaded onto a pre-equilibrated 
Phosphocellulose cation exchange column. The unbound proteins (PC150) were 
collected by washing the column in buffer containing 150 mM KCl. Bound proteins 
were  eluted in a singular step-elution with buffer containing 1000 mM KCl (PC1000). 
Heat denatured (C) HeLa whole cell extract (WCE) or 2.5 g (+) or 5 g (++) of WCE 
was used as the E3 source in an in vitro ubiquitylation assay. Equally 2.5 g (+) or 5 
g (++) of each fraction (PC150 or PC1000) was subject to the same in vitro 
ubiquitylation reaction containing 0.7 pmol GST-E1 activating enzyme, 2.5 pmol of 
nine separate E2 conjugating enzymes and 0.6 nmol ubiquitin, with 5.8 pmol of 
histidine-tagged, recombinant NTH1 as a substrate. Active E3 ligase specific to NTH1 
was present in the cell extracts within the chromatography fractions tested. The 
ubiquitylation assays were carried out at 30°C for 1 h, before completed reactions 
were separated by 10 % SDS-PAGE and analysed via Western blotting, using NTH1 
specific antibodies. Molecular weight markers (kDa), unmodified histidine-tagged 
NTH1 (NTH1) and ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. A shift 
upwards in molecular weight of 8 kDa, or multiples of 8 kDa, is indicative of 
ubiquitylation.  
 
Heat denatured HeLa whole cell extract was included in this assay as a negative 
control (Figure 20; lane 1). It is anticipated that the heat denaturation of proteins 
within this extract would have impeded any potential E3 ligase activity. Therefore, it 
is expected that there would be no observable ubiquitylation of recombinant NTH1 in 
the presence of heat denatured HeLa extract. Indeed, NTH1 ubiquitylation was not 
observed in this instance. An upward shift in the protein expression band for NTH1 by 
approximately 8 kDa is indicative that ubiquitylation of specific lysine residues by an 
37 kDa 
50 kDa 
NTH1 
NTH1
ub
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WCE PC150 PC1000 
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active E3 ligase may have occurred. Higher molecular weight bands of recombinant 
NTH1 are observed with the addition of whole cell extract containing active E3 
ligase(s) (Figure 20; lanes 2 and 3). A comparable shift in molecular weight of NTH1 
is observed using increasing amounts of the PC150 chromatography fraction (Figure 
20; lanes 4 and 5). Weaker ubiquitylation of NTH1 was observed using the maximal 
amount of PC1000 fraction (Figure 20; lane 7), however, this was not as prominent 
as the ubiquitylation observed in the presence of the PC150 fraction. This suggested 
that the unbound protein eluting from the Phosphocellulose column contained the 
major E3 ligase enzyme enabling the ubiquitylation of NTH1. It is for this reason that 
the PC150 fraction was selected and passed over the subsequent purification 
columns. 
4.3.2. Anion exchange chromatography 
 
The PC150 fraction obtained from cation exchange chromatography was diluted two-
fold with no salt containing buffer to reduce the salt concentration and passed over a 
20 ml Mono-Q anion exchange column pre-washed with buffer containing 50 mM KCl. 
Proteins were eluted using a linear gradient from 50 mM to 1 M KCl (Figure 21, A) 
which generated >80 protein fractions. Alternative fractions were subjected to an in 
vitro ubiquitylation assay using recombinant NTH1 as the substrate. The reactions 
were analysed via 10% SDS-PAGE and Western blotting with NTH1 antibodies 
(Figure 21, B, C and D).  
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Figure 21. Purification of candidate E3 ligase enzymes specific recombinant 
NTH1 from HeLa cell extract by anion exchange chromatography. The unbound 
protein fraction obtained from cation exchange column was diluted two-fold and 
separated on a 20 ml Mono-Q anion exchange chromatography column using a linear 
gradient of 50 mM KCl to 1000 mM KCl. The chromatography trace is provided, with 
the UV at 260 nm represented by the blue line, conductivity represented by the brown 
line and the chromatography fractions are shown in red (A). Alternate fractions were 
subject to an in vitro ubiquitylation assay containing 0.7 pmol GST-E1 activating 
enzyme, 2.5 pmol of nine individual E2 conjugating enzymes and 0.6 nmol ubiquitin, 
with 5.8 pmol histidine-tagged recombinant NTH1 as a substrate. The presence of E3 
ligase enzymes was provided by the cellular proteins within the chromatography 
fractions tested. Ubiquitylation assays were carried out at 30 °C for 1 h before 
completed reactions were separated by 10% SDS-PAGE and analysed via Western 
blotting, using NTH1 specific antibodies (B, C and D). Molecular weight markers 
(kDa), unmodified histidine-tagged NTH1 (NTH1) and ubiquitylated histidine-tagged 
NTH1 (NTH1ub) are indicated. 
  
Following Western blot analysis of completed in vitro ubiquitylation assays, it was 
apparent that there were two separate, major NTH1 ubiquitylation activities (Figure 
21, C and D). An upward shift in the molecular weight bands of NTH1, representing 
an increase in molecular weight of 8 kDa (or multiples of 8 kDa), was observed largely 
in fractions 46-50 (Figure 21; NTH1-E31) and a much stronger activity was observed 
in fractions 54-60 (Figure 21; NTH1-E32). Interestingly, these separate activities 
could indicate the presence of two different active E3 ligases capable of facilitating 
the ubiquitylation of recombinant NTH1. Due to the banding patterns of each activity, 
it was anticipated that NTH1-E31 represents an E3 ligase which monoubiquitylates 
NTH1 due to there being one singular shift of molecular weight of NTH1 suggesting 
the addition of just one ubiquitin moiety. Conversely, it is expected that NTH1-E32 
signifies an E3 ligase which can polyubiquitylate NTH1. This is due to the banding 
pattern demonstrating the addition of multiple 8 kDa ubiquitin moieties (Figure 21; 
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NTH1-E32). There were difficulties in purifying the NTH1-E31 activity further beyond 
this point, as the activity was very weak and unstable, so the primary focus was to 
identify the more prominent, and major E3 ligase activity for NTH1 present as NTH1-
E32. As a result, anion exchange fractions representing the NTH1-E32 activity (Figure 
21, D fractions 54-60, NTH1-E32) were combined and further separated using gel 
filtration (size exclusion) chromatography. 
4.3.3. Gel filtration chromatography  
 
Gel filtration separates proteins on the basis of their molecular size and has the 
additional benefit of being able to indicate the molecular weight of the active E3 ligase 
within separated fractions. The anion exchange fractions representing the major E3 
activity for NTH1 (Figure 21, fractions 54-60, NTH1-E32) were combined and passed 
over the pre-equilibrated gel filtration (size exclusion) chromatography column. The 
fractions with a peak in protein quantity were confirmed by analysis of the peaks in 
UV at 260 nm in the chromatography trace (Figure 22, A). Protein containing fractions 
were subject to the in vitro ubiquitylation assay as previous, utilising recombinant 
NTH1 as the substrate. The completed ubiquitylation assays were separated by 10 % 
SDS-PAGE followed by analysis via Western blotting using antibodies against NTH1 
(Figure 22, B).  
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Figure 22. Purification of candidate E3 ligase enzymes specific recombinant 
NTH1 from HeLa cell extract using size exclusion chromatography. Select 
fractions from anion exchange chromatography were combined and added to a 24 ml 
Superdex 200 size exclusion chromatography column. The chromatography trace is 
provided, with the UV at 260 nm represented by the blue line and the chromatography 
fractions are shown in red (A). Fractions exhibiting a peak in protein were utilised in 
an in vitro ubiquitylation assay containing 0.7 pmol GST-E1 activating enzyme, 2.5 
pmol of nine separate E2 conjugating enzymes and 0.6 nmol ubiquitin, with 5.8 pmol 
recombinant NTH1 as a substrate. The assays were carried out at 30 °C for 1 h before 
completed reactions were separated by 10% SDS-PAGE and analysed via Western 
blotting using NTH1 antibodies (B). As a control (B, lane C), 5 g heat-denatured 
whole HeLa cell extract (which is expected to contain no active enzymatic activity) 
was used in the assay instead of active fraction. Molecular weight markers (kDa), 
unmodified histidine-tagged NTH1 (NTH1) and ubiquitylated histidine-tagged NTH1 
A 
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(NTH1ub) are indicated. In addition, the peak NTH1 ubiquitylation is present in 
fractions containing proteins approximately 443 kDa–150 kDa in size (as indicated) 
.  
Following gel filtration chromatography, a peak of ubiquitylation activity specific to 
recombinant NTH1 was apparent between gel filtration fractions 20-24; demonstrated 
by a characteristic banding pattern of ~8 kDa shifts of increased molecular weight of 
NTH1 indicative of polyubiquitylation (Figure 22, B). Interestingly, fraction 20 
contained proteins with an estimated molecular weight of ~443 kDa, whereas, fraction 
24 contained proteins that were approximately 150 kDa in size (Figure 22, B). Overall, 
this suggests that the E3 ligase specific for the in vitro polyubiquitylation of 
recombinant NTH1 could potentially have a molecular weight of between 150 kDa and 
443 kDa. Gel filtration fractions 20-24 were combined and passed over a pre-
equilibrated ceramic hydroxyapatite chromatography column.  
 
4.3.4 Hydroxyapatite chromatography  
 
Hydroxyapatite is a crystalline form of calcium phosphate which can actually bind both 
acidic and basic proteins. Fractions 20-24 from the previous gel filtration 
chromatography separation (Figure 22, B) were passed over a pre-equilibrated 
hydroxyapatite chromatography column. Proteins were eluted from the column via a 
linear gradient of 5 mM to 500 mM KH2PO4 and fractions were collected (Figure 23, 
A). Fractions containing a peak in eluted protein were subject to an in vitro 
ubiquitylation assay using Histidine-tagged, recombinant NTH1 as a substrate. 
Completed reactions were subject to separation by 10% SDS-PAGE, followed by 
Western blot analysis using antibodies against NTH1 (Figure 23, B).  
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Figure 23. Purification of candidate E3 ligase enzymes specific recombinant 
NTH1 from HeLa cell extract using hydroxyapatite chromatography. Active 
fractions from size exclusion chromatography were combined and passed over a 1 ml 
CHT ceramic hydroxyapatite chromatography column using a linear gradient of 5 mM 
to 500 mM KPO4. The chromatography trace is provided, with the UV at 260 nm 
represented by the blue line, conductivity represented by the brown line and the 
chromatography fractions are shown in red (A). Collected fractions were subject to an 
in vitro ubiquitylation assay with 0.7 pmol GST-E1 activating enzyme, 2.5 pmol of nine 
E2 conjugating enzymes, 0.6 nmol ubiquitin with 5.8 pmol histidine-tagged 
recombinant NTH1 as a substrate. Active E3 ligase specific to NTH1 was present in 
the cell extracts within the chromatography fractions tested. The assay reactions were 
carried out at 30 °C for 1 h before completed reactions were separated by 10% SDS-
PAGE and analysed via Western blotting using NTH1 antibodies (B). As a control (B, 
lane C), 5 g heat-denatured whole HeLa cell extract (which is expected to contain 
no active enzymatic activity) was used in the assay instead of active fraction. 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. 
 
Western blot analysis confirmed that hydroxyapatite fractions 18-20 possess E3 
ligase activity specific to NTH1, signified by a shift in molecular weight of recombinant 
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NTH1 upwards on the SDS-PAGE gel (Figure 23, B). There is a notable decrease in 
the strength of ubiquitylation signal following the hydroxyapatite chromatography 
separation; in particular the amount of polyubiquitylation is substantially reduced 
(compare Figure 22, B and Figure 23, B). This could be due to loss of activity of the 
candidate E3 ligase following interaction with the hydroxyapatite column. Likewise, 
the activity of the ligase enzyme could have been affected by storage and repeated 
thawing throughout the purification process. Following hydroxyapatite separation, the 
active fractions 18-20 (Figure 23, B) were combined and passed over a final 1 ml 
Mono-Q anion exchange chromatography column.  
4.3.5. Final anion exchange chromatography  
 
Chromatography fractions containing active E3 ligase activity following hydroxyapatite 
separation were pooled and passed over a final 1 ml Mono-Q anion exchange 
chromatography column, which has an improved resolution than the previously used 
20 ml Mono-Q column featured in the purification scheme (Figure 19). The 1 ml 
Mono-Q anion exchange chromatography column was pre-equilibrated with 50 mM 
KCl buffer, before samples were added. Proteins were eluted using a linear gradient 
of 50 mM to 1000 mM KCl and fractions were collected. The chromatography trace is 
provided (Figure 24, A), with peaks in UV at 260 nm representing protein presence. 
Fractions featuring a peak in protein were subject to an in vitro ubiquitylation assay 
with Histidine-tagged recombinant NTH1 as a substrate. Completed assays were 
separated by 10% SDS-PAGE analysed by Western blotting using NTH1 specific 
antibodies (Figure 24, B). 
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Figure 24. Purification of candidate E3 ligase enzymes specific recombinant 
NTH1 from HeLa cell extract using final Mono-Q anion exchange 
chromatography fractions. Active fractions from hydroxyapatite chromatography 
were combined and passed over a 1 ml Mono-Q anion exchange chromatography 
column using a linear gradient of 50 mM to 1000 mM KCl. The chromatography trace 
is provided, with the UV at 260 nm represented by the blue line, conductivity 
represented by the brown line and the chromatography fractions are shown in red (A). 
Collected fractions featuring peak protein were subject to an in vitro ubiquitylation 
assay with 0.7 pmol GST-E1 activating enzyme, 2.5 pmol of nine separate E2 
conjugating enzymes and 0.6 nmol ubiquitin, with 5.8 pmol of recombinant NTH1 as 
a substrate. Active E3 ligase presence specific to NTH1 was provided in the cell 
extracts within the chromatography fractions tested. The assay reactions were carried 
out at 30 °C for 1 h before completed reactions were separated by 10% SDS-PAGE 
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and analysed via Western blotting, using NTH1 specific antibodies (B). As a control 
(B, lane C), 5 g heat-denatured whole HeLa cell extract (which is expected to contain 
no active enzymatic activity) was used in the assay instead of active fraction. 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. 
 
From Western blot analysis of the in vitro ubiquitylation assays performed using the 
final Mono-Q anion exchange chromatography fractions, it was apparent that the 
presence of a candidate E3 ligase specific to recombinant NTH1, was isolated in just 
one chromatography fraction (Figure 24, A, fraction 25). Once again, there is an 
observable decrease in the NTH1 ubiquitylation activity within this fraction compared 
to the initial chromatography separations and the amount of polyubiquitylation is not 
as obvious. As mentioned previously, the decrease in activity could largely be due to 
a natural degradation, or loss of activity of the candidate E3 ligase during storage 
throughout the series of purification steps. Furthermore, the candidate E3 ligase 
activity may have diminished due to the loss of other proteins, which form complexes 
with the E3 ligase and support its polyubiquitylation activity. Consequently, the identity 
of the candidate peptides within the active fraction (Figure 24, B; fraction 25) was 
investigated by mass spectrometry analysis. 
4.3.6. Mass spectrometry identification of TRIM26 as an NTH1 specific E3 
ligase  
 
Tandem mass spectrometry was employed to identify candidate E3 ligase enzymes 
present in the peak NTH1 ubiquitylation activity fraction following the final ion 
exchange chromatography stage (Figure 24, B; fraction 25). The mass spectrometry 
analysis was kindly completed by Professor Robert Beynon and Dr. Deborah 
Simpson, based at the Institute of Integrative Biology, University of Liverpool. 
Peptides were formed from the proteins present within the active fraction via 
trypsinisation and were detected by LC-MS/MS mass spectrometry. To identify 
candidate proteins, the spectra of proteins obtained from LC-MS/MS were compared 
using Mascot against the UniProt human database. The list of candidate proteins 
consisted of 45 proteins in total (see Appendix), with only one known to possess any 
E3 ligase activity from studies within the literature (Table 7) which was in the top 
scoring peptides within the list. Indeed this protein, Tripartite motif-containing protein 
26 (TRIM26), has been shown to have E3 ligase activity, mainly implicated in the 
immune response (168). The protein score for detection of TRIM26 was 62 (Table 7) 
with overall sequence coverage of 19 % (Figure 25). This result suggested that 
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TRIM26 was the major candidate protein that was purified from human cell extracts 
that is an active E3 ligase for NTH1. 
Table 7. A list of peptides detected by LC-MS/MS to identify candidate E3 ligase 
enzymes specific to recombinant NTH1. Peptides from an ion exchange 
chromatography fraction, demonstrating ubiquitylation of NTH1, were subject to 
tandem mass spectrometry. Peptides were resuspended, reduced and trypisinsed to 
yield peptides for LC separations using an Ultimate 3000 nano system. Mass 
spectrometry was then performed using the Q Exactive instrument operated in data 
dependent positive (ESI+) mode to routinely switch between full scan MS and MS/MS 
acquisition. Survey full scan MS spectra (m/z 300–2000) were obtained with a 
resolution of 70 000 (m/z 200) following accumulation of ions to 1 × 106 target value 
based on predictive automatic gain control values from the previous full scan. Raw 
data files were searched in Mascot against the UniProt human database. The false 
discovery rate against a decoy database was 1 %. Within a list of 45 candidate 
peptides, tripartite motif-containing protein 26 (TRIM26) was the only peptide with 
known ubiquitylation potential. The peptide score of TRIM26 was 62 with overall 
coverage of 18 %. The position of TRIM26 within the list of candidate proteins is 
highlighted in red text.  
Number  Score  Description  
Q01105 530 Protein SET 
P35527 395 Keratin, type I cytoskeletal 9 
P35908 257 Keratin, type I cytoskeletal 2 
P13645 220 Keratin, type I cytoskeletal 10 
P04264 216 Keratin, type II cytoskeletal 1 
P04259 109 Keratin, type II cytoskeletal 6B 
P02533 107 Keratin, type I cytoskeletal 14 
P08579 101 U2 small nuclear ribonucleoprotein B 
P39687 95 Acid leucine-rich nuclear phosphoprotein 32 
P13647 93 Keratin, type II cytoskeletal 5 
P62318 93 Small nuclear ribonucleoprotein Sm D3 
P09661 90 U2 small nuclear ribonucleoprotein A 
P62318 84 Small nuclear ribonucleoprotein F 
P02538 76 Keratin, type II cytoskeletal 6A 
P62316 74 Small nuclear ribonucleoprotein Sm D2 
O00629 69 Importin subunit alpha-3 
P05455 66 Lupus La protein  
P14678 66 Small nuclear ribonucleoprotein-associated proteins B and B’ 
Q12899 62 Tripartite motif-containing protein 26 
Q92688 61 Acid leucine-rich nuclear phosphoprotein 32 
P07437 59 Tubulin beta chain  
107 
 
P11142 58 Heat shock cognate 71 kDa protein  
P11021 53 78 kDa glucose-related protein 
 
 
Figure 25. Peptides and peptide fragments of TRIM26 detected by LC-MS/MS. 
Peptides from an ion exchange chromatography fraction, demonstrating ubiquitylation 
of NTH1, were subject to tandem mass spectrometry. Peptides were re-suspended, 
reduced and trypsinised to yield peptides for LC separations using an Ultimate 3000 
nano system. Mass spectrometry was then performed using the Q Exactive 
instrument operated in data dependent positive (ESI+) mode to routinely switch 
between full scan MS and MS/MS acquisition. Survey full scan MS spectra (m/z 300–
2000) were obtained with a resolution of 70 000 (m/z 200) following accumulation of 
ions to 1 × 106 target value based on predictive automatic gain control (AGC) values 
from the previous full scan. Raw data files were searched in Mascot against the 
UniProt human database. The false discovery rate (FDR) against a decoy database 
was 1 %. Within a list of 45 candidate peptides, tripartite motif-containing protein 26 
(TRIM26) was the only peptide with known ubiquitylation potential. The peptide score 
of TRIM26 was 141.21 with overall coverage of 19%. Peptide fragments detected 
within the sequence for TRIM26 are highlighted in red.  
 
4.4. TRIM26 is the active E3 ligase purified from HeLa cell extracts that 
ubiquitylates NTH1  
 
Despite mass spectrometry analysis identifying TRIM26 as the only peptide with 
known E3 ligase activity in the final active chromatography fraction, there are still over 
600 E3 ligases proposed to exist. With this in mind, it was possible that the active 
fraction could contain another E3 ligase responsible for NTH1 ubiquitylation, which 
had been overlooked and not able to be detected by mass spectrometry. Therefore, 
it became imperative that we confirmed TRIM26 as the active E3 ligase specific to 
NTH1 using further methods. 
4.4.1. TRIM26 protein in purified active fractions aligns with NTH1 
ubiquitylation activity 
 
1 MATSAPLRSL EEEVTCSICL DYLRDPVTID CGHVFCRSCT TDVRPISGSR  
51 PVCPLCKKPF KKENIRPVWQ LASLVENIER LKVDKGRQPG EVTREQQDAK  
101 LCERHREKLH YYCEDDGKLL CVMCRESREH RPHTAVLMEK AAQPHREKIL  
151 NHLSTLRRDR DKIQGFQAKG EADILAALKK LQDQRQYIVA EFEQGHQFLR  
201 EREEHLLEQL AKLEQELTEG REKFKSRGVG ELARLALVIS ELEGKAQQPA  
251 AELMQDTRDF LNRYPRKKFW VGKPIARVVK KKTGEFSDKL LSLQRGLREF  
301 QGKLLRDLEY KTVSVTLDPQ SASGYLQLSE DWKCVTYTSL YKSAYLHPQQ  
351 FDCEPGVLGS KGFTWGKVYW EVEVEREGWS EDEEEGDEEE EGEEEEEEEE  
401 AGYGDGYDDW ETDEDEESLG DEEEEEEEEE EEVLESCMVG VARDSVKRKG  
451 DLSLRPEDGV WALRLSSSGI WANTSPEAEL FPALRPRRVG IALDYEGGTV  
501 TFTNAESQEL IYTFTATFTR RLVPFLWLKW PGTRLLLRP  
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Firstly, to confirm the presence of TRIM26 in the peak active fraction following the 
final ion exchange chromatography stage, fractions 22-30 (Figure 24, A and B) were 
separated by 10 % SDS-PAGE and analysed via Western blotting. However, on this 
occasion immunoblotting was completed using antibodies specific to TRIM26 (Figure 
26, B). The molecular weight of TRIM26 is known to be approximately 62 kDa and 
indeed the peak presence of TRIM26 protein correlates with the peak NTH1 
ubiquitylation activity when the two Western blot membranes are aligned (Figure 26, 
A and B; comparing fraction 25). It is apparent that TRIM26 presence is in fact within 
multiple fractions (Figure 26; B, fractions 23-28), whereas ubiquitylation of NTH1 is 
largely only visible in fraction 25 (Figure 26; A, fraction 25). This discrepancy could 
be due to a minimum threshold of TRIM26 protein required for activity. This theory is 
supported by the observation that the peak presence of TRIM26 still corresponds with 
NTH1 ubiquitylation (Figure 26, A and B).    
 
Figure 26. Alignment of the Western blot analysis of in vitro ubiquitylation 
reactions using recombinant NTH1 as a substrate (A) with the presence of 
TRIM26 (B). Anion exchange chromatography fractions were subject to an in vitro 
ubiquitylation assay containing 0.7 pmol GST-E1 activating enzyme, 2.5 pmol of nine 
separate E2 conjugating enzymes and 0.6 nmol ubiquitin, with 5.8 pmol of 
recombinant NTH1 as a substrate. The assay reactions were carried out at 30 °C for 
1 h before completed reactions were separated by 10% SDS-PAGE and analysed via 
Western blotting using NTH1 specific antibodies (A). Molecular weight markers (kDa), 
unmodified histidine-tagged NTH1 (NTH1) and ubiquitylated histidine-tagged NTH1 
(NTH1ub) are indicated. Ubiquitylation of NTH1, represented by an upward shift in 
molecular weight of 8 kDa, occurred in fraction 25 (A). To verify that tripartate motif 
containing 26 (TRIM26) is the active E3 ligase within fraction 25, the same anion 
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exchange fractions were separated by 10 % SDS-PAGE and analysed by Western 
blotting with TRIM26 specific antibodies (B). The peak presence of TRIM26 in fraction 
25 aligns with the ubiquitylation of recombinant NTH1 (A and B).  
 
4.4.2. Cloning and purification of His-tagged, recombinant TRIM26 protein 
 
To further prove that TRIM26 is an active E3 ligase specific to ubiquitylation of NTH1, 
recombinant TRIM26 protein was aimed to be expressed and purified from bacterial 
cells. The protein would then be employed in place of active chromatography fractions 
generated from HeLa cell extract fractionation within in vitro ubiquitylation assays with 
NTH1 as a substrate. It was anticipated that TRIM26 would induce observable NTH1 
ubiquitylation in vitro. The first step in this process was the recloning of the TRIM26 
DNA sequence into a bacterial expression plasmid. 
4.4.2.1. LIC cloning of TRIM26 
 
A LIC strategy was employed to clone the trim26 gene from a mammalian expression 
plasmid (kindly provided by Prof A. Garcia-Sastre, The Icahn School of Medicine at 
Mount Sinai, USA), into a bacterial expression plasmid (pET28a). LIC cloning uses 
the exonuclease activity of T4 DNA polymerase to generate complementary 
overhangs to aid the stable association between an expression vector fragment and 
an insert (Figure 17). An empty pET28a vector (from Novagen), was amplified using 
oligonucleotides flanked by LIC sequences (Table 4). Separately to this, an insert of 
histidine-tagged trim26 within the mammalian expression plasmid, was PCR amplified 
using oligonucleotides flanked by the same LIC sequences as those used to amplify 
the expression plasmid (Table 4). Following the separate PCR reactions, the size of 
the DNA products obtained were analysed on agarose gels as an indication that the 
correct sequences had been amplified (Figure 27). The empty pET28 vector is known 
to be 5369 base pairs (Figure 16). Following analysis of five separate PCR 
amplification reactions on agarose gels with a DNA ladder consisting of DNA 
fragments of known base pair lengths, it was apparent that products of 5369 base 
pairs had been obtained in all reactions (Figure 27, A; lanes 1-5). These reactions 
were selected and pooled for subsequent PCR purification. 
Separately to this the trim26 gene insert was PCR amplified. It was apparent that PCR 
products of the expected size of 1617 base pairs had been obtained in all amplification 
reactions (Figure 27, B; lanes 1-4). Despite PCR products of the approximate size of 
1617 base pairs, being visible across all four lanes, reactions 2 and 4 (Figure 27; B, 
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lanes 2 and 4) contained amplification products of this approximate size with the least 
impurities; demonstrated by the lack of other additional bands following agarose gel 
analysis. Therefore, these reactions were selected and pooled for subsequent PCR 
purification.  
The pooled PCR reactions were then subjected to incubation with DpnI, which acts to 
remove methylated, template DNA. Following this, the DNA was further purified using 
a PCR purification kit. Afterwards, complementary overhangs between the pET28 
expression plasmid and the trim26 insert were formed by using the exonuclease 
activity of T4 DNA polymerase. To ensure that complementary overhangs are formed 
by T4 DNA polymerase activity, dCTP was added to the polymerase reaction 
containing the pET28 vector, whereas, dGTP was added to the reaction containing 
the trim26 insert. The addition of one dNTP to each reaction leads to an equilibrium 
of exonuclease and polymerase activity at the site of the first occurrence of this 
nucleotide. The complementary overhangs generated using this method were then 
annealed together by incubating different ratios of insert and vector (1:1 and 1:3).  
 
Figure 27. PCR amplification of a pET28a vector (A) and an insert for TRIM26 
expression (B) for use in a ligase independent cloning (LIC) strategy.  An empty 
pET28a vector was PCR amplified using relevant oligonucleotides flanked by 
corresponding LIC sequences. All five reactions (A, lanes 1-5) were completed in the 
presence of GC buffer only. The size of each reaction product was confirmed using a 
1% agarose gel (A). As bands corresponding to the correct size (5369 bp) were 
apparent in all reactions, they were all subject to DpnI treatment and pooled during 
PCR purification. Similarly, an insert for trim26 gene was also PCR amplified using 
relevant oligonucleotides flanked by corresponding LIC sequences and the size of the 
reaction products analysed on a 1% agarose gel (B). Reaction 1 was performed in 
the presence of HF buffer, with the addition of DMSO in reaction 2 (lanes 1 and 2), 
whereas, reaction 3 was performed with GC buffer, with the addition of DMSO in 
reaction 4 (lanes 3 and 4). From this it was apparent that all four reactions (B, lanes 
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1-4) yielded PCR products displaying DNA bands corresponding to products of the 
expected size (1617). All four reactions were therefore subject to DpnI treatment 
before being pooled during PCR purification. 
   
Constructs of pET28TRIM26 were amplified by transformation into library efficient 
DH5α bacterial cells and grown on selective media. Successful colonies were 
inoculated into a 5 ml culture of LB media containing 150 µg of selective antibiotic 
(kanamycin) and grown overnight at 37°C and 250 rpm. Amplified plasmid DNA was 
then purified from bacterial contaminants using the QIAprep Spin Miniprep Kit. A 
diagnostic digest using an appropriate restriction enzyme, Van91I, was then 
performed as a preliminary method to assess the identity of each plasmid. Products 
of the restriction digest were analysed on a 0.8% agarose gel (Figure 28). From this, 
it was apparent that the correct sized products (6309 and 705 bp) were obtained 
following digestion of plasmids 1, 2 and 4 (Figure 28, lanes 1, 2 and 4). However, the 
presence of bolder bands of the expected sizes following restriction enzyme digestion 
of plasmid 4 (Figure 28, lane 4) suggests the highest concentration of plasmid. For 
this reason, plasmid 4 (Figure 28, lane 4) was selected and sequenced using the 
Sanger Sequencing Service (Source Bioscience Sequencing, Nottingham, UK) which 
further confirmed the correct ligation of the trim26 gene insert into the respective 
pET28a expression vector.  
 
 
A 
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Figure 28. Restriction digest to determine the successful generation of an insert 
corresponding to TRIM26 ligated into a pET28 expression plasmid via a ligase 
independent cloning (LIC) strategy.   Different ratios of PCR purified pET28a vector 
and trim26 gene insert DNA were incubated (1:1, lanes 1 and 2 or 1:3, lanes 3 and 4) 
for 10 mins at 22°C as part of the LIC cloning strategy. Plasmid constructs were 
transformed into library efficient DH5α bacterial cells grown on selective agar. A 5 ml 
overnight culture of successful colonies was generated in the presence of selective 
antibiotics before plasmid DNA was purified via the QIAprep Spin Miniprep Kit. A 
restriction digest of plasmid DNA using Van91 was then performed to preliminary 
assess if the correct construct has been formed. A schematic of the pET28TRIM26 
bacterial expression vector formed is depicted, showing the restriction sites of Van91 
and the expected sizes of the DNA fragments formed (A). Products of the restriction 
digest were analysed on a 0.8% agarose gel. Lanes 1-4 represent four different 
plasmids being assessed (B). From this it was apparent that the correct digest sizes 
(6309bp and 705 bp) were produced via digestion of plasmids 1, 2 and 4 (lanes 1, 2 
and 4). However, plasmid 4 appeared to have a higher concentration represented by 
bolder bands on the agarose gel (lane 4). This plasmid was then sequenced via the 
Sanger Sequencing Service to further confirm the correct sequence.  
 
4.4.2.2. Bacterial expression of TRIM26 
 
A test expression was performed in order to optimise which bacterial cell line provided 
maximum TRIM26 protein expression. The constructs were transformed into a range 
of Rosetta cells which were then grown in a 5 ml culture of LB media containing 150 
μg of selective antibiotic (kanamycin) and grown overnight at 37°C and 250 rpm. 
Following this, a 40 ml culture was generated in the presence of selective antibiotic 
incubated at 37°C and 250 rpm, until the OD600nm was approximately 0.6. An aliquot 
of the cell suspension was removed before protein expression was induced via IPTG 
for 3 h at 37°C and 250 rpm. An aliquot of the induced cell suspension was then 
removed. The aliquots of cell suspension before and after IPTG induction were 
B 
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resuspended in SDS loading buffer, sonicated and denatured at 95ºC for 5 min before 
loading onto a 10% SDS-PAGE gel for analysis of cellular proteins (Figure 28). 
 
Figure 28. Test expression of a pET28TRIM26 plasmid in a range of Rosetta cell 
lines to obtain maximum histidine-tagged TRIM26 protein expression. A 
construct of a pET28a expression vector containing an insert corresponding to 
histidine-tagged TRIM26 protein expression was generated via a Ligase Independent 
Cloning (LIC) strategy. The plasmid was transformed into a range of Rosetta cell lines; 
Rosetta 2(DE3) pLysS cells (lanes 1-2), Rosetta 2 cells (lanes 3-4), Rosetta-blue cells 
(lanes 5-6) Rosetta-gami cells (lanes 7-8) and Origami 2 (DE3) cells (lanes 9-10). 
Following transformation, a 5 ml overnight culture with 150 μg selective antibiotics of 
each transformed cell line was generated, followed by a 40 ml expression culture in 
the presence of selective antibiotics. The expression culture was grown until the 
OD600nm reached 0.6. An aliquot of the culture was then removed before induction of 
protein expression (-) via the addition of 1 mM IPTG for 3 h at 30°C, 225 rpm. After 
this, an aliquot after IPTG induction was also removed (+). Each aliquot was re-
suspended in SDS-loading buffer, sonicated, heated to 95ºC for 5 min before proteins 
were analysed via SDS-PAGE on a 10 % gel. Samples pre-IPTG (-) and post-IPTG 
induction (+) were analysed in tandem. The protein expression of TRIM26, 
represented by a protein band at 62.2 kDa, is most apparent using Rosetta (DE3) 
pLysS cells (lane 2, +); highlighted using a red box.  
 
From the test expression, it was apparent that only Rosetta2 (DE3) pLysS cells 
appeared to provide the optimum expression of histidine-tagged TRIM26 protein 
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(Figure 28; lane 2), represented by the boldest band at a molecular weight of 
approximately 62.2 kDa. Despite this, the protein still appeared not to be significantly 
overexpressed in large amounts. For this reason and to increase protein quantity for 
purification, three 400 ml expression cultures of Rosetta2 (DE3) pLysS containing the 
pET28a-TRIM26 construct were generated. Protein expression of TRIM26 was then 
induced for 3 h at 30°C and 250 rpm, via the addition of 1 mM IPTG. The three cell 
cultures were then combined and the bacterial cells were then pelleted, resuspended 
in lysis buffer with protease inhibitors then cells lysed via incubation with lysozyme 
followed by sonication. Cellular debris was removed by centrifugation and the 
supernatant filtered using syringe filters.  
In order to purify Histidine-tagged TRIM26 protein, the filtered supernatant was then 
applied to a pre-equilibrated 1 ml HisTrap column. Proteins were separated via affinity 
chromatography using a gradient elution of 5 mM to 500 mM imidazole. The 
chromatography trace is provided (Figure 29, A), with peaks in UV at 260 nm 
representing protein presence. The purity of the chromatography fractions was 
evaluated by 14% SDS-PAGE in addition to Western blotting with TRIM26 specific 
antibodies. Histidine-tagged TRIM26 has a molecular weight of approximately 62.2 
kDa. Using this as a reference, from the SDS-PAGE analysis there was a suggestion 
that TRIM26 was present in chromatography fractions 8-24, peaking in approximately 
fractions 12-14, although not in significant quantities (Figure 29, B). The Western blot 
further confirmed this, although the antibodies appeared to have a greater cross-
reactivity with either the degradation products of TRIM26, or with bacterial protein 
contaminants (Figure 29, C). Due to this, the purest TRIM26 containing fractions 
(fractions 11-16) were selected, pooled and concentrated using 10 kDa centrifugal 
filters for further purification by ion exchange (MonoQ) chromatography. 
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Figure 29. Affinity chromatography purification of recombinant TRIM26 
following bacterial expression of the relevant plasmid. Bacterial cells transformed 
with pET28a-TRIM26 bacterial expression plasmid were cultured into a 400 ml 
expression culture until the OD650nm reached 0.6.  Bacterial expression of recombinant 
TRIM26 was then induced via of isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 
h at 30°C. Bacterial cells were then pelleted and lysed by sonication in the presence 
of protease inhibitors. Recombinant TRIM26 was separated from bacterial proteins 
A 
C     FT    2      4      6     8    10    12    14   16   18    20    22   24 
C    FT    2      4        6     8     10   12    14   16    18    20    22   24 
50 kDa 
37 kDa 
75 kDa  
100 kDa  
150 kDa  
50 kDa 
37 kDa 
75 kDa  
100 kDa  
150 kDa  
TRIM26 
TRIM26 
B 
C Fraction 
Fraction 
 Manual run 3:10_UV  Manual run 3:10_Cond  Manual run 3:10_Fractions  Manual run 3:10_Logbook
 500
1000
1500
mAU
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 ml
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Chromatography fraction 
U
V
 2
6
0
n
m
 
116 
 
via affinity chromatography using a 1 ml HisTrap column and a linear gradient elution 
of 5 mM to 500 mM imidazole. The chromatography trace is provided, with the UV at 
260 nm represented by the blue line, conductivity represented by the brown line and 
the chromatography fractions are shown in red (A). Chromatography fractions were 
collected and purity analysed by 14% SDS-PAGE (B) and Western blotting using 
antibodies specific to TRIM26 (C). Molecular weight markers (kDa) and TRIM26 
presence is indicated.  
 
The chromatography trace following separation of TRIM26-containing protein 
fractions using a 1 ml ion exchange (MonoQ) chromatography column is provided 
(Figure 30, A) with peaks of protein present that were subject to 14 % SDS-PAGE 
separation in addition to Western blotting with TRIM26 specific antibodies. From this, 
it was apparent that protein bands corresponding to the molecular weight of TRIM26 
(62.2 kDa) were most likely present in fractions 11-14 (Figure 30, B). These bands 
were also visible by Western blotting although as in the previous figure, the antibodies 
used are of very poor quality and have a higher cross-reactivity with a likely 
degradation product of TRIM26 at 50 kDa which is significantly less abundant as 
observed following SDS-PAGE analysis (Figure 30, C). Fractions 11-14 were 
selected, pooled and concentrated using 10 kDa centrifugal filters to generate a 
concentrated TRIM26 stock for subsequent assays. To improve preservation of the 
activity of the concentrated stock of the recombinant E3 ubiquitin ligase, it was 
stabilised by the addition of a 50 % glycerol solution (1:1), aliquoted and stored at -
80°C.  
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Figure 30. Ion exchange chromatography purification of recombinant TRIM26. 
Recombinant TRIM26 was expressed using a pET28 bacterial expression plasmid in 
Rosetta2 (DE3) pLysS cells. The recombinant histidine-tagged TRIM26 protein was 
separated from bacterial contaminants using affinity chromatography and select 
fractions pooled and concentrated before being added to a pre-equilibrated 1 ml 
MonoQ ion exchange chromatography column. The chromatography trace is 
provided, with the UV at 260 nm represented by the blue line, conductivity represented 
Chromatography fraction 
U
V
 2
6
0
n
m
 
 Manual run 9:10_UV  Manual run 9:10_Cond  Manual run 9:10_Fractions  Manual run 9:10_Logbook
 200
 400
 600
 800
1000
1200
mAU
0.0 5.0 10.0 15.0 ml
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
A 
B 
C 
118 
 
by the brown line and the chromatography fractions are shown in red (A). Proteins 
were eluted by a linear gradient of 50 mM to 1000 mM KCl. Fractions were collected 
and analysed by 14 % SDS-PAGE (B) followed by Western blotting with TRIM26 
specific antibodies (C). Molecular weight markers (kDa) and TRIM26 presence are 
indicated.  
 
4.4.2.3 Activity of recombinant TRIM26 against NTH1 and E2 dependency 
 
Purification of recombinant TRIM26 enabled further verification that it is indeed the 
active cellular E3 ligase which acts on NTH1. An increasing amount (19 fmol or 26 
fmol) of purified recombinant TRIM26 was used in an in vitro ubiquitylation assay 
containing recombinant NTH1 as the substrate protein, with GST-E1 activating 
enzyme, nine E2 conjugating enzymes and ubiquitin. The reaction was carried out at 
30 °C in a shaking incubator for 1 h at 800 rpm. The completed assay was then 
separated by 10 % SDS-PAGE and analysed by Western blotting using NTH1 specific 
antibodies (Figure 31).  
 
Figure 31. Western blot analysis of an in vitro ubiquitylation assay featuring 
recombinant TRIM26 as the E3 ligase in the presence of NTH1 as the reaction 
substrate. Ubiquitylation assays were performed by combining 0.7 pmol GST-E1 
activating enzyme, 2.5 pmol of nine E2 conjugating enzymes, 0.6 nmol ubiquitin and 
5.8 pmol of histidine-tagged, recombinant NTH1. To this, a titration of recombinant 
TRIM26 (0 fmol, 19 fmol and 26 fmol) was added separately to each ubiquitylation 
assay. The assay reactions were carried out at 30 °C for 1 h in a shaking incubator at 
800 rpm, before completed reactions were separated by 10 % SDS-PAGE and 
analysed via Western blotting using NTH1 specific antibodies. Ubiquitylation of NTH1 
was apparent in reactions containing recombinant TRIM26 only and was not present 
in the control reaction containing no TRIM26 (-). Molecular weight markers (kDa), 
unmodified histidine-tagged NTH1 (NTH1) and ubiquitylated histidine-tagged NTH1 
(NTH1ub) are indicated. 
37 kDa 
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Visualisation of the Western blot analysis shows that in the presence of recombinant 
TRIM26 there is an observable banding pattern demonstrating a shift in molecular 
weight of NTH1 (Figure 30; lanes 2 and 3). This represents that moieties of ubiquitin 
(8 kDa in size) are likely to have been added onto specific lysine residues of NTH1 
via the active E3 ligase. An upward shift in molecular weight of NTH1 is not observed 
in the absence of recombinant TRIM26 (Figure 30; lane 1). Overall, this observation 
confirms that TRIM26 is an active in vitro E3 ligase enzyme that is targeting 
ubiquitylation of recombinant NTH1.  
A final assessment used to verify that TRIM26 is the active E3 ligase specific to NTH1, 
was completion of an E2 dependency screen (Figure 31). It is acknowledged that E3 
ligase enzymes demonstrate dependency on the presence of specific E2 conjugating 
enzymes to effectively ubiquitylate substrate proteins. Based on this, the E2 
dependency of active chromatography fractions purified from HeLa cell extracts from 
the gel filtration stage (Figure 22) of the purification process (Figure 19) was 
compared to the E2 specificity of recombinant TRIM26. For the E2 screen, in vitro 
ubiquitylation assays were performed using recombinant NTH1 as the substrate 
protein combined with GST-E1 activating enzyme and ubiquitin. To each reaction, an 
individual E2 conjugating enzyme was added separately (UbcH2, UbcH3, UbcH5a, 
UbcH5b, UbcH5c UbcH6, UbcH7, UbcH8 or UbcH10). The presence of E3 ligase 
activity was provided in the form of a volume of active gel filtration chromatography 
fraction (Figure 22; fraction 22) or recombinant TRIM26. The assay reactions were 
carried out at 30 °C for 1 h at 800 rpm, before separation by 10 % SDS-PAGE and 
analysis via Western blotting using NTH1 specific antibodies. The Western blots were 
aligned for ease of comparison (Figure 32).  
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Figure 32. Western blot analysis of in vitro ubiquitylation assays examining the 
E2 specificity of the E3 ligase in an active chromatography fraction compared 
to recombinant TRIM26. Ubiquitylation assays were performed by combining 0.7 
pmol GST-E1 activating enzyme, 0.6 nmol ubiquitin and 5.8 pmol of histidine-tagged 
recombinant NTH1 as a substrate. To this, 2.5 pmol of each E2 conjugating enzyme 
(UbcH2, UbcH3, UbcH5a, UbcH5b, UbcH5c UbcH6, UbcH7, UbcH8 or UbcH10) was 
added separately. E3 ligase activity was provided in the form of 2.5 µl of active gel 
filtration chromatography fraction (A) or by the addition of 26 fmol of recombinant 
TRIM26 (B). The ubiquitylation assays were carried out at 30 °C for 1 h at 800 rpm, 
before completed reactions were separated by 10 % SDS-PAGE and analysed via 
Western blotting using NTH1 antibodies. Control reactions included the addition of no 
E2 conjugating enzymes (C-) or the addition of all nine E2 enzymes combined (C+). 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. 
 
In control reactions in the absence of an E3 ligase there is no evidence of NTH1 
ubiquitylation (Figure 32, A and B, lane 1). However as expected, ubiquitylation of 
NTH1 is stimulated by either active purified fraction or TRIM26 in the presence of all 
nine E2 conjugating enzymes (Figure 32, A and B, lane 2). On investigating the E2 
dependency of the E3 ligase acting on NTH1 in vitro, it is apparent that the active E3 
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ligase present within the active purified fraction from HeLa cell extracts is dependent 
on the following E2 conjugating enzymes; UbcH5A, UbcH5B, UbcH5C and UbcH7 
(Figure 32, A). Ubiquitylation of NTH1, represented by an upwards shift in molecular 
weight of approximately 8 kDa, is observed within reactions containing only these E2 
conjugating enzymes. The degree of ubiquitylation appears equivalent to that 
observed when all nine E2 conjugating enzymes are present (Figure 32, A, lane 2). 
In addition, ubiquitylation of NTH1 with TRIM26 as the active E3 ligase also 
demonstrates specificity to the same E2 conjugating enzymes; UbcH5A, UbcH5B, 
UbcH5C and UbcH7. This is once again represented by an upward shift in molecular 
weight of recombinant NTH1. The ubiquitylation appears strongest in the presence of 
UbcH5A, UbcH5B and UbcH5C, and to a lesser extent UbcH7, which appear relatively 
similar to that observed when all E2 conjugating enzymes are present within the 
ubiquitylation reaction (Figure 32, B, lane 2). Overall, the E3 ligase in the active 
chromatography fraction and recombinant TRIM26 both appear mostly dependent on 
the UbcH5 subset of E2 conjugating enzymes. This overlap in E2 specificity further 
improves our confidence that TRIM26 is indeed the E3 ligase that ubiquitylates NTH1 
in vitro. 
4.5. Results I summary  
 
Ubiquitylation is a major PTM utilised by cells to modulate the stability, activity, 
localisation or interactions of cellular proteins. Indeed, ubiquitylation-dependent 
regulation of a number of cellular proteins implicated in DNA repair has already been 
documented. Ubiquitylation is mediated by a cascade of three enzymes; E1 activating 
enzymes, E2 conjugating enzymes and E3 ubiquitin ligases. The substrate specificity 
of the reaction is largely dictated by the E3 ubiquitin ligase enzymes, of which there 
are more than 600 present in human cells. Previous studies have focused on 
identifying the ubiquitylation enzymes specific to the regulation of substrate proteins 
of interest. Colleagues from our laboratory have already successfully endeavoured to 
elucidate the E3 ligase enzymes specific to particular enzymes implicated in the BER 
pathway (25, 47).  
Using a column chromatography approach, combined with an in vitro ubiquitylation 
assay containing recombinant NTH1, I successfully isolated an NTH1 specific 
ubiquitylating activity from HeLa cells which appeared to promote largely 
polyubiquitylation. Surprisingly, mass spectrometry analysis of the final purified active 
fraction revealed the presence of just one protein with known ubiquitylation 
capabilities; TRIM26. Indeed, the maximal level of TRIM26 protein by Western blotting 
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correlated well with the ubiquitylation of NTH1 in the final chromatography fractions. 
Most significantly, when recombinant TRIM26 purified from bacterial overexpression 
was employed in the in vitro ubiquitylation assay, it induced significant ubiquitylation 
of recombinant NTH1 which compared well with that observed with active 
chromatography fractions purified from HeLa cell extracts. Likewise, recombinant 
TRIM26, in ubiquitylating NTH1 also exhibited overlapping dependency on the same 
E2 conjugating enzymes (mainly UbcH5a, UbcH5b and UbcH5c), as purified active 
fractions from HeLa cells. This also correlates with studies screening interactions 
between TRIM proteins and E2 families which demonstrated that TRIM proteins 
generally exhibit dependency on UbcH5a, UbcH5b UbcH5c, UbcH6 and UbcH9 (63). 
Together, these results advocate that TRIM26 is the active, major cellular E3 ligase 
associated with ubiquitylation of NTH1. This correlates with a recent finding within our 
laboratory which also identified TRIM26 as the E3 ligase enzyme acting on another 
BER glycosylase, NEIL1 (46). In this study, the E3 ligase specific to NEIL1 was 
purified using the same approach incorporating column chromatography and in vitro 
ubiquitylation assays. Studies in U2OS cells demonstrated that TRIM26 stabilised 
steady-state NEIL1 levels. Furthermore, stabilisation of NEIL1 following TRIM26 
knockdown contributed to cellular resistance to ionising radiation, highlighting the 
importance of TRIM26 in regulating the cellular DNA damage response (46). Now I 
demonstrate that TRIM26 may in fact have two cellular targets for ubiquitylation-
dependent degradation within the BER pathway, the DNA glycosylases NEIL1 and 
NTH1. It could be hypothesized that TRIM26 may act as a master regulator of 
enzymes implicated in BER. In this instance, TRIM26 may regulate these two specific 
BER proteins due to the redundancy in base damage specificity demonstrated 
between the two glycosylase enzymes, specifically the repair of oxidised pyrimidines 
in DNA. Studies have previously shown that NEIL1 may act as a back-up glycosylase 
for the removal of Tg residues when NTH1 activity is hindered (78, 149). It could be 
speculated that TRIM26 regulates the transition between NTH1 and NEIL1 activity 
when one of the enzymes is rendered inactive or not present in adequate amounts. 
Furthermore, this observation could suggest that BER enzymes regulated by specific 
E3 ligase enzymes may be grouped according to overlapping substrate specificities, 
such as the BER glycosylase enzymes. The reality of this assumption will only be 
realised after more extensive studies regarding the ubiquitylation dependent 
regulation of all of the DNA glycosylase enzymes involved in DNA base excision, in 
addition to the enzymes involved in the other major steps of BER. 
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TRIM26 belongs to a well-conserved subfamily of E3 ligases, termed the TRIM 
ligases, of which there are more than 70 members. Each TRIM enzyme demonstrates 
conserved structures comprising of a RING domain, one or two B-box zinc fingers 
and a coiled coil domain. It is believed that the RING domain confers E3 ligase activity 
of the TRIM family of enzymes and is able to bind to other small molecular proteins 
used to post-translationally modulate proteins, including SUMO proteins (115). It has 
been shown that the coiled coil domain can self-associate to form large protein 
complexes which occupy discrete subcellular compartments (115). This may account 
for the fact that purified TRIM26 from the gel filtration chromatography stage of HeLa 
extract purification was located within fractions of 150-443 kDa; suggesting that the 
62 kDa protein had potentially formed multimers or associates with other proteins as 
part of a larger complex (Figure 22). Emerging roles for TRIM dependent regulation 
of cellular pathways implicated in carcinogenesis including cellular proliferation, DNA 
repair and apoptosis, have been identified (63). Furthermore, TRIM proteins have an 
essential role in the regulation of signalling pathways involved in innate immunity and 
anti-viral response (115, 161). The most abundant RING finger ligase; TRIM28, is 
often deemed a master regulator of the genome due to its association with multiple 
complexes instigated in managing gene expression and in particular, TRIM28 
mediates the turnover of a number of transcription factors (182). This emphasises the 
critical role that TRIM dependent regulation plays within the cellular context.  
 
Alike to the roles of other TRIM proteins reported in the literature, TRIM26 has already 
been shown to play a role in the anti-viral response and tumour suppression (169). 
Low expression levels of TRIM26 have been correlated with worse prognosis in 
hepatocellular carcinoma (168, 169, 188). Bioinformatics revealed that TRIM26 could 
modulate gene sets related to cancer cell metabolism. In addition, silencing of TRIM26 
within cells promoted cell proliferation, migration and invasion (169). A separate study 
showed that TRIM26 acts as a tumour suppressor in non-small-cell lung cancer (188). 
Overexpression of TRIM26 inhibited cell growth and induced apoptosis potentially 
related to downregulation of B-cell lymphoma 2 (Bcl-2), although the molecular 
mechanism underlying this link remains unexplored. It is also unknown if there is a 
correlation between the E3 ligase activity of TRIM26 and its anti-apoptotic properties 
(188). Nevertheless, the E3 ligase activity of TRIM26 has been associated with 
regulation of the antiviral response (168). Viral infection results in the activation of the 
transcription factor, IRF3, which has a number of downstream effects, including the 
production of interferons and clearance of the viral contaminant. Regulation of nuclear 
IRF-3 was shown to be reliant on proteasomal degradation facilitated by K-48 linked 
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polyubiquitylation instigated by TRIM26 (168). Another example of the TRIM26 
regulation of transcription factors is apparent via the TRIM26 induced degradation of 
the transcription factor IID (TFIID) subunit TAF7, in cultured mouse mammary 
epithelial cells. However, the regulation of this particular transcription factor is not 
associated in the regulation of the cellular viral response, but is implicated in the arrest 
of cellular proliferation (109).  
Following my evidence that NTH1 is a target for ubiquitylation by TRIM26, it became 
important to employ the in vitro ubiquitylation assays with other techniques to 
determine which specific lysine residues of NTH1 are ubiquitylated by the E3 ligase. 
Identification of the specific lysine residues of NTH1 that are ubiquitylated by TRIM26 
would further support that TRIM26 is the active E3 ligase which acts on NTH1. 
Furthermore, identification of specific post-translational modification sites is an 
important preliminary step towards understanding the biological role of the covalent 
modification. Due to the diverse functions of ubiquitylation, experiments utilising 
ubiquitylation deficient mutants are increasingly important for understanding the 
molecular impact of ubiquitylation of specific substrates.  
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  CHAPTER 5 - RESULTS II 
 
NTH1 is ubiquitylated by TRIM26 within the N-terminal region  
5.1 Introduction 
 
After confirmation that TRIM26 is the major E3 ligase enzyme, purified from human 
cell extracts, which ubiquitylates NTH1 in vitro, the next objective was to identify the 
lysine residues of NTH1 that are ubiquitylated by the E3 ligase. Not only will this 
further support that TRIM26 ubiquitylates NTH1 in vitro, but it may also enable us to 
primarily assess the molecular role of ubiquitylation. Preliminary structural studies in 
the literature, regarding structural features of NTH1, are largely based on similarities 
to the bacterial homologue. Although, Ikeda et al (1998) used a glutathione S-
transferase fusion polypeptide of recombinant human full-length NTH1 to directly 
identify the catalytic residue of the glycosylase (68). Sequence analysis strategies 
confirmed that Lys-212 was implicated in NTH1 activity. Indeed, replacement of Lys-
212 with a Gln residue inactivated NTH1, plus substitution with an Arg residue 
affected catalytic specificity (68). Despite homology of conserved catalytic residues 
between human NTH1 and its bacterial counterpart, it has been acknowledged that 
human NTH1 exhibits an extended N-terminal tail (90). Kinetic studies have 
demonstrated that the N-terminal residues are not linked to glycolytic activity, but may 
be implicated in putative signals regulating activity or protein-protein interactions (68). 
Controlled proteolysis experiments using truncated versions of NTH1 have suggested 
that the extended N-terminal tail may have an inhibitory effect on NTH1 activity (90). 
The sequence of three isoforms of human NTH1 have been elucidated; M-8, M+1 and 
M+8. The canonical sequence of NTH1 is the M-8 isoform and consists of 312 amino 
acids. The M+1 isoform of NTH1 lacks the first 1-8 N-terminal residues, whereas, the 
M+8 isoform lacks the first 1-15 N-terminal residues. The M+1 isoform is believed to 
represent the translationally active form of human NTH1 (Figure 5.1 and Figure 5.3; 
Full-length NTH1) and is 304 amino acid residues in length. All of the biological 
isoforms of human NTH1 contain a total of 17 lysine residues, which could be subject 
to post-translational modification, via ubiquitylation (Figure 33; red text).   
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Figure 33. The sequence of the human NTH1 isoform M+1.The sequence of the 
major human NTH1 isoform (M+1) is depicted. The M+1 isoform of human NTH1 
differs from the canonical sequence of full length human NTH1, as it lacks the N-
terminal 1-8 residues and begins at residue Met9; which is believed to represent the 
translational start of biologically active NTH1. Full-length human NTH1 consists of 
312 amino acid residues, whereas, the M+1 NTH1 isoform consists of 304 amino acid 
residues. Both forms of NTH1 possess a total of 17 lysine residues (K), which are 
highlighted in yellow. (Protein identifier: P78549-2). 
 
Interestingly, a single nucleotide polymorphism (D239Y) of NTH1 has been revealed 
within 6.2 % of the global population (55). Cellular expression of the D239Y variant 
advocated that individuals with this hereditary polymorphism may be more susceptible 
to genomic instability and cancer. This was due to the fact that cells expressing the 
D239Y exhibited increased chromosomal aberrations, increased foci formation, 
anchorage-independent growth and invasive properties. Similarily, cells expressing 
the variant were more sensitive to genotoxic agents, with increased DNA double 
strand break formation observed (55). Due to the presence of this variant within the 
population, as well as identifying the site of ubiquitylation of NTH1 by TRIM26, I also 
aimed to investigate if the ubiquitylation dependent regulation of the D239Y variant 
differed compared to wild type NTH1. It was of interest to establish if this could 
account for the disrupted cellular phenotype observed in variant expressing cells. 
5.2 Analysis of sites of NTH1 ubiquitylation by tandem mass spectrometry  
To identify the sites within NTH1 that are subject to ubiquitylation by TRIM26, I firstly 
employed a tandem mass spectrometry approach to analyse the products of in vitro 
ubiquitylation reactions. Following separation of an in vitro ubiquitylation reaction 
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containing recombinant His-NTH1 and recombinant His-TRIM26, proteins were 
separated by 10 % SDS-PAGE and stained using Instant Blue (Figure 34, A). From 
the stained gel, the positions of migration of TRIM26 and NTH1 could be identified, 
although it was difficult to visualise bands corresponding to ubiquitylated NTH1, 
largely due to interference from contaminants or degradation products of TRIM26. 
However, using Western blotting analysis, ubiquitylation of NTH1 could clearly be 
observed only in the presence of both TRIM26 and ubiquitin (Figure 34, B; NTH1Ub). 
Therefore, the region corresponding to monoubiquitylated NTH1 was located and 
excised from the stained gel, proteins were then extracted from the gel pieces and 
digested with either trypsin or Arg-C, before being analysed via LC-MS. 
 
Figure 34. Separation of in vitro ubiquitylation assays containing recombinant 
NTH1 for tandem mass spectrometry analysis of potential sites of TRIM26 
dependent ubiquitylation of NTH1. Ubiquitylation assays were performed by 
combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a and 5.8 pmol of 
histidine-tagged, recombinant NTH1. To reaction one, 26 fmol of recombinant 
TRIM26 was also added (+TRIM26 only, lane 1). To the second reaction, 0.6 nmol 
ubiquitin (+Ub only, lane 2) was added. Finally, both 26 fmol of recombinant TRIM26 
and 0.6 nmol ubiquitin was added to the third reaction (+TRIM26 only + Ub, lane 3). 
The assay reactions were carried out at 30 °C for 1 h in a shaking incubator at 800 
rpm. Reactions were terminated by the addition of SDS loading dye and proteins 
separated by 10 % SDS-PAGE and Instant Blue staining (A) and also analysed via 
Western blotting using NTH1 specific antibodies (B). Ubiquitylation of NTH1 was 
apparent in reactions containing both recombinant ubiquitin, in combination with 
recombinant TRIM26 (+TRIM26 + Ub, lane 3), but was not present in the control 
reactions (lane 1 and lane 2). Molecular weight markers (kDa), unmodified histidine-
tagged NTH1 (NTH1) and ubiquitylated histidine-tagged NTH1 (NTH1ub) are 
indicated. The position of bands corresponding to ubiquitylated NTH1 were 
determined by Western blot analysis (B) and were excised from the SDS-PAGE gel 
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(A). Proteins were extracted from gel pieces and digested using either trypsin or Arg-
C, before analysis via LC-MS.  
 
Unfortunately, we could not obtain adequate peptide coverage to enable adequate 
analysis of full-length NT1 protein. For example, digestion with trypsin (cleaving after 
lysine and arginine residues) was 35 %. Similarly, digestion with ArgC (cleaving after 
arginine residues) yielded 30 % coverage of the entire NTH1 protein; which only 
included 3 lysine residues.  
As tandem mass spectrometry analysis of potential sites of TRIM26 dependent 
ubiquitylation of NTH1 was unsuccessful, it was decided that an alternative approach, 
relying on the generation of truncated versions of the DNA glycosylase, would be 
pursued. For this approach, truncated versions of NTH1 would be created via 
manipulation of a bacterial expression plasmid encoding the nth1 gene. Plasmids 
encoding truncated NTH1 proteins would then be transformed and overexpressed in 
E. coli and purified from bacterial contaminants using column chromatography before 
being subject to analysis by in vitro ubiquitylation assays containing recombinant 
TRIM26. It was expected that truncated versions of NTH1 lacking the lysine residues 
that are specifically ubiquitylated by TRIM26 would not exhibit the characteristic 
banding pattern representative of ubiquitylation following SDS-PAGE and Western 
blotting analysis. 
5.3. Generation of truncated versions of NTH1 by PCR and LIC cloning  
 
To more successfully examine the region of NTH1 containing the lysine residues that 
are subject to TRIM26 dependent ubiquitylation, truncated versions of NTH1 were 
generated for assessment via in vitro ubiquitylation assays, using recombinant 
TRIM26. It was anticipated that a truncated version of NTH1 containing the lysine 
residues that are subject to ubiquitylation would exhibit an observable 8 kDa shift in 
molecular weight following incubation with TRIM26. A summary of the truncations 
generated is provided (Figure 35). Whereas, truncated versions of NTH1 lacking the 
necessary ubiquitylated lysine residues, would not demonstrate this characteristic 
shift in molecular weight.  
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Figure 35. Schematic representation of the structural features of NTH1 and the 
truncated versions of NTH1 created to assess potential sites of TRIM26 
dependent ubiquitylation in vitro. The N-terminal region of NTH1 contains nuclear 
localisation regions (represented in blue). The C-terminal region of NTH1 contains a 
helix-hairpin-helix domain (in yellow) and an iron-sulphur 4[Fe-4S] cluster loop (in 
green), which have been linked to DNA binding functionalities. To assess potential 
sites of TRIM26 dependent ubiquitylation of NTH1, truncated versions of full-length 
NTH1 were generated using a LIC cloning approach to generate pET28 bacterial 
expression plasmids which would express NTH1 variants. Overall, two C-terminal 
truncations were created; NTH1 99-304 and NTH1 185-304 alongside two N-terminal 
truncated variants; NTH1 9-93 and NTH1 9-174.  
 
Truncated versions of NTH1 were created using a LIC cloning approach, whereby 
firstly an empty pET28a bacterial expression vector was PCR amplified. The size of 
an empty pET28 plasmid is 5369 bp (Figure 16). Following agarose gel analysis of 
four PCR amplification reactions, generation of the pET28 construct was generally 
successful across all reactions (Figure 36, A, lanes 1-4), with similar yields of empty 
pET28 vector obtained in each reaction. Reactions 1-4 were completed in the 
presence of different reaction buffers: reaction 1 contained HF buffer, reaction 2 
contained HF buffer with DMSO, whereas, reaction 3 was completed in the presence 
of GC buffer, with reaction 4 containing GC buffer with DMSO. As similar yields of 
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empty pET28 vector obtained in each reaction, all four reactions were selected, 
pooled and purified from the PCR reactions for subsequent stages. Alongside this, 
inserts encoding truncations of the nth1 gene were PCR amplified using specifically 
designed primers which were used in combination with the pET28NTH1 plasmid 
(obtained from Dr. Allinson) encoding the full-length gene. Firstly, inserts 
corresponding to C-terminal truncated versions of NTH1; NTH1 99-305 and NTH1 
185-305, were amplified (Figure 36, B and C). The size of the insert corresponding 
to NTH1 99-305 is approximately 663 bp. After completing a number of PCR 
amplification reactions, it was apparent that all four reactions had yielded amplified 
NTH1 99-305, represented by DNA bands of the appropriate size following agarose 
gel analysis (Figure 36, B, lanes 1-4). To note, the reaction conditions for all of the 
plasmid inserts match those for the amplification of the vector DNA; reaction 1 
contained HF buffer, reaction 2 contained HF buffer with DMSO, whereas, reaction 3 
was completed in the presence of GC buffer, with reaction 4 containing GC buffer with 
DMSO. The levels of NTH1 99-305 insert DNA produced was variable across each 
reaction, represented by the varying intensity of the agarose gel bands. Due to this, 
reaction 1 (Figure 36, B, lane 1) was selected and purified from the PCR reactions 
for subsequent stages. The size of the PCR product of NTH1 185-305 is 405 bp and 
following analysis of four PCR reactions using agarose gel analysis, it was apparent 
that a similar yield of bands corresponding to the relevant sized products had been 
obtained across all four lanes (Figure 36, C, lanes 1-4). All four reaction products 
were selected, pooled and purified from the PCR reactions for later LIC cloning 
stages. Aside to this, inserts corresponding to N-terminal truncated versions of NTH1; 
NTH1 9-174 and NTH1 9-93, were similarly generated using primers incubated with 
the pET28aNTH1 plasmid encoding the full-length gene (Figure 36, D). The size of 
the PCR product for NTH1 9-93 was 313 bp. Once again, four amplification reactions 
were established and similar levels and purify of the DNA product were obtained in all 
four lanes (Figure 36, D, 1-4). Therefore, these were pooled and subject to PCR 
purification. Likewise, four amplification reactions were set-up to generate NTH1 9-
174; the product size of which was expected to be 556 bp. Yet again, all amplification 
reactions yielded similar PCR product levels, so they were pooled and purified from 
the PCR reactions (Figure 36, D, 5-8). 
Following generation of the empty pET28 vector and a number of inserts encoding 
the NTH1 truncations, a LIC cloning strategy was employed to anneal the two different 
components together by incubating different ratios of the vector to nth1 gene insert 
DNA.  
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Figure 36. PCR amplification of the products required to generate the bacterial 
expression plasmids for truncated versions of NTH1. DNA corresponding to an 
empty pET28a bacterial expression vector was PCR amplified using custom 
oligonucleotides with LIC overhangs (A), alongside inserts corresponding to C-
terminal truncations of NTH1; 99-305 (B) and 185-305 (C) or N-terminal truncations 
of NTH1; 9-93 and 9-174 (D), using custom oligonucleotides with complementary LIC 
overhangs incubated with a pET28NTH1 bacterial expression plasmid. Lanes 1-4 
were completed in the presence of different reaction buffers (1: HF buffer, 2: HF buffer 
with DMSO, 3: GC buffer, 4: GC buffer with DMSO). The size of the PCR products 
was analysed using 1 % agarose gels in 1x TAE. The expected sizes of each PCR 
product in base pairs are featured in brackets.  
 
Individual LIC reactions were transformed into E. coli and plasmid DNA purified from 
overnight bacterial cultures. Initially, the correct sequences of the bacterial expression 
plasmids generated to create truncated versions of NTH1 were confirmed via a Van9I 
restriction digest. The sizes of the digestion products were visualised using agarose 
gel electrophoresis analysis (Figure 37). For the pET28NTH1 9-93 plasmid construct 
digestion products of the expected sizes, 3984 bp, 1242 bp and 430 bp were observed 
(Figure 37; Lane 1). Similarly, products of the expected sizes; 3984 bp, 1485 bp and 
430 bp, were confirmed following digestion of the pET28NTH1 9-174 plasmid 
construct (Figure 37; Lane 2). Likewise, digestion products of the expected sizes; 
3984 bp, 1260 bp and 430 bp, were apparent following digestion of the pET28NTH1 
99-305 bacterial expression plasmid (Figure 37; Lane 3). Finally, products of the 
expected sizes; 3984 bp, 1518 bp and 430 bp, could be seen following Van91I 
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digestion of the pET28NTH1 185-305 bacterial expression plasmid (Figure 37; Lane 
4). Observation of restriction digest products of the expected sizes suggested that the 
composition of the bacterial expression plasmids for each NTH1 truncation were 
correct. To confirm this, each plasmid was also analysed by gene sequencing 
provided by the Source Bioscience Sanger Sequencing service (see Appendix).   
 
 
Figure 37. Preliminary analysis of the sequences of PCR constructs for NTH1 
truncations using restriction digests. The sequences of plasmids for bacterial 
expression of truncated versions of NTH1 (9-93, 9-174, 185-305 and 99-305) 
generated using a LIC technique, were initially assessed via a restriction digest, using 
Van91. The sizes of the PCR fragments after the restriction digest were analysed 
using 1 % agarose gels in 1x TAE. Expected sizes of the DNA digests are provided.  
 
Following confirmation of the correct DNA sequences of the bacterial expression 
plasmids encoding the nth1 truncated gene inserts, the constructs were transformed 
into Rosetta 2(DE3) pLysS cells, cultures were grown and NTH1 truncated proteins 
overexpressed using IPTG induction. The bacterial cells were pelleted by 
centrifugation, and each NTH1 truncated protein was purified by His-trap affinity 
chromatography using an AKTA-purifier FPLC.  
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5.3.1 Affinity chromatography purification of NTH1 9-93 
Bacterial cells expressing the N-terminal truncation of NTH1 consisting of residues 9-
93, were re-suspended in lysis buffer containing protease inhibitors and lysed via 
incubation with lysozyme followed by bursts of sonication. The histidine-tagged NTH1 
9-93 truncation was then separated from bacterial protein contaminants by affinity 
chromatography with an AKTA purifier FPLC. The cell lysate was loaded onto a 1 ml 
HisTrap chromatography column pre-equilibrated in lysis buffer containing PMSF. 
Bound proteins were collected by a 20 ml gradient elution using elution buffer 
containing 500 mM imidazole. The chromatography trace is provided, with peaks in 
UV representing peaks in protein expression (Figure 38, A, blue line). Fractions were 
subject to analysis by SDS-PAGE analysis and Instant blue staining (Figure 38, B) 
and also by Western blotting with anti-histidine antibodies to select fractions 
containing purified his-tagged NTH1 9-93 (Figure 38, C). The approximate molecular 
weight of the truncated version of NTH1 comprising of residues 9-93 is 13.5 kDa. 
From SDS-PAGE and staining analysis of the chromatography fractions, it was 
apparent that protein bands of this molecular weight were present largely in fractions 
18-28 (Figure 38, B and C). In addition, protein bands at this position demonstrated 
cross-reactivity with anti-histidine antibodies, further advocating that these bands 
represent truncated NTH1 9-93 (Figure 38, C). For this reason, fractions 19-28 were 
selected containing the purest NTH1 protein, pooled and concentrated using Amicon 
Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in a swinging bucket rotor at 
4000 x g to generate a concentrated stock of NTH1 9-93 protein.  
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Figure 38. Analysis of affinity chromatography purification of the N-terminal 
truncation of NTH1 9-93 by SDS-PAGE and Western blotting with anti-histidine 
antibodies. Bacterial cells transformed with pET28a-NTH1 9-93 bacterial expression 
plasmid were cultured into a 400 ml expression culture until the OD650nm reached 0.6. 
Bacterial expression of recombinant NTH1 9-93 was then induced via of isopropyl β-
D-1-thiogalactopyranoside (IPTG) for 3 h at 30°C. Bacterial cells were then pelleted 
and lysed by sonication in the presence of protease inhibitors. Recombinant NTH1 9-
93 was separated from bacterial proteins via affinity chromatography using a 1 ml 
HisTrap column and a linear gradient elution of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV at 260 nm represented by the blue 
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line, conductivity represented by the brown line and the chromatography fractions are 
shown in red (A). Chromatography fractions were collected and purity analysed by 16 
% SDS-PAGE (B) and Western blotting using antibodies specific to the histidine tag 
featured on recombinant NTH1 (C). Molecular weight markers (kDa) and NTH1 9-93 
presence is indicated.  
5.3.2 Affinity chromatography purification of NTH1 9-174 
Bacterial cells expressing the N-terminal truncation of NTH1 consisting of residues 9-
174 were lysed via incubation with lysozyme, followed by bursts of sonication. The 
histidine-tagged NTH1 9-174 truncation was then separated from bacterial protein 
contaminants by affinity chromatography with an AKTA purifier FPLC. The cell lysate 
was loaded onto a 1 ml HisTrap chromatography column pre-equilibrated in lysis 
buffer containing PMSF. Bound proteins were collected by a 20 ml gradient elution 
using elution buffer containing 500 mM imidazole. The chromatography trace is 
provided, with peaks in UV representing peaks in protein expression (Figure 39, A). 
Fractions were subject to analysis by SDS-PAGE and Instant blue staining (Figure 
39, B) and also by Western blotting with anti-histidine antibodies to select fractions 
with purified his-tagged NTH1 9-174 (Figure 39, C). The approximate molecular 
weight of the truncated version of NTH1 comprising of residues 9-174 is 22.5 kDa. 
From SDS-PAGE and staining analysis, it was apparent that protein bands of this 
molecular weight were present in fractions 16-24 (Figure 39, B). However, evidence 
of a substantial amount of protein degradation was observed; represented by a more 
intense protein band at ~15 kDa within these fractions. This was further confirmed by 
analysis of fractions by Western blotting analysis whereby little full length truncated 
NTH1 9-174 protein was observed (Figure 39; C, protein degradation bands). To 
resolve this protein degradation, bacterial expression of NTH1 9-174 was repeated 
and the affinity chromatography purification stage was completed in the presence of 
increased concentrations of each protease inhibitor to the affinity chromatography 
buffers in an attempt to stabilise the NTH1 truncated protein. The proteins present in 
each chromatography fraction (Figure 40, A) were analysed separately via SDS-
PAGE and Instant blue staining (Figure 40, B) and by Western blotting with anti-
histidine antibodies (Figure 40, C). Unfortunately, a similar level of degradation of the 
NTH1 9-174 truncated protein was observed despite the attempts made to stabilise 
the expression product and largely a 15 kDa protein product was observable partially 
by Western blotting analysis (Figure 40, C, protein degradation bands). It was 
decided that analysis of this particular truncation of NTH1 via the in vitro ubiquitylation 
assay would be unlikely to yield conclusive evidence regarding elucidating the site of 
TRIM26 dependent ubiquitylation. For this reason, this truncation product was omitted 
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from subsequent analysis via the in vitro ubiquitylation assay. It was anticipated that 
adequate information regarding the position of ubiquitylation of NTH1 could be 
obtained through analysis of the other truncations generated in this particular 
approach (Figure 35).  
 
Figure 39. Analysis of affinity chromatography purification of the N-terminal 
truncation of NTH1 9-174 by SDS-PAGE and Western blotting with anti-histidine 
antibodies. Bacterial cells transformed with pET28a-NTH1 9-174 bacterial 
expression plasmid were cultured into a 400 ml expression culture until the OD650nm 
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reached 0.6. Bacterial expression of recombinant NTH1 9-174 was then induced via 
of isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 30°C. Bacterial cells were 
then pelleted and lysed by sonication in the presence of protease inhibitors. 
Recombinant NTH1 9-174 was separated from bacterial proteins via affinity 
chromatography using a 1 ml HisTrap column and a linear gradient elution of 5 mM 
to 500 mM imidazole. The chromatography trace is provided, with the UV260nm 
represented by the blue line, conductivity represented by the brown line and the 
chromatography fractions are shown in red (A). Chromatography fractions were 
collected and purity analysed by 16 % SDS-PAGE (B) and Western blotting using 
antibodies specific to the histidine tag featured on recombinant NTH1 (C). Molecular 
weight markers (kDa) and NTH1 9-174 presence is indicated.  
 
 
 
Figure 40. Repeat analysis of affinity chromatography purification of the N-
terminal truncation of NTH1 9-174 by SDS-PAGE and Western blotting with anti-
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histidine antibodies. Bacterial cells transformed with pET28a-NTH1 9-174 bacterial 
expression plasmid were cultured into a 400 ml expression culture until the OD650nm 
reached 0.6. Bacterial expression of recombinant NTH1 9-174 was then induced via 
of isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 30°C. Bacterial cells were 
then pelleted and lysed by sonication in the presence of protease inhibitors. 
Recombinant NTH1 9-174 was separated from bacterial proteins via affinity 
chromatography using a 1 ml HisTrap column and a linear gradient elution of 5 mM 
to 500 mM imidazole. Chromatography fractions were collected and purity analysed 
by 16 % SDS-PAGE (A) and Western blotting using antibodies specific to the histidine 
tag featured on recombinant NTH1 (B). Molecular weight markers (kDa) and NTH1 9-
174 presence is indicated. 
 
5.3.3 Affinity chromatography purification of NTH1 99-305 
Bacterial cells expressing the C-terminal truncation of NTH1 consisting of residues 
99-305 were lysed via incubation with lysozyme, followed by bursts of sonication. The 
histidine-tagged NTH1 99-305 truncation was then separated from bacterial protein 
contaminants by affinity chromatography with an AKTA purifier FPLC. The cell lysate 
was loaded onto a 1 ml HisTrap chromatography column pre-equilibrated in lysis 
buffer containing PMSF. Bound proteins were collected by a 20 ml gradient elution 
using elution buffer containing 500 mM imidazole. The chromatography trace is 
provided, with peaks in UV representing peaks in protein expression (Figure 41, A). 
Fractions were subject to analysis by SDS-PAGE and Instant blue staining (Figure 
41, B) and also Western blotting with anti-histidine antibodies to select fractions with 
purified his-tagged NTH1 99-305 (Figure 41, C). The approximate molecular weight 
of the truncated version of NTH1 comprising of residues 99-305 is 25.4 kDa. From 
SDS-PAGE and staining analysis, it was apparent that protein bands of this molecular 
weight were present in fractions 8-20, although several other protein bands appeared 
in this region but also at a lower molecular weight (Figure 41, B). In addition, a protein 
band at ~25 kDa demonstrated cross-reactivity with anti-histidine antibodies; 
suggesting that this band represents truncated NTH1 99-305 protein (Figure 41, C).  
However, due to consideration of protein purity, fractions 11-20 were selected, pooled 
and concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) 
in a swinging bucket rotor at 4000 x g to generate a concentrated stock of NTH1 99-
305 protein.  
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Figure 41. Affinity chromatography purification of the C-terminal truncation of 
NTH1 99-305 by SDS-PAGE and Western blotting with anti-histidine antibodies. 
Bacterial cells transformed with pET28a-NTH1 99-305 bacterial expression plasmid 
were cultured into a 400 ml expression culture until the OD650nm reached 0.6. Bacterial 
expression of recombinant NTH1 99-305 was then induced via of isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 3 h at 30°C. Bacterial cells were then pelleted and 
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lysed by sonication in the presence of protease inhibitors. Recombinant NTH1 99-305 
was separated from bacterial proteins via affinity chromatography using a 1 ml 
HisTrap column and a linear gradient elution of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV260nm represented by the blue line, 
conductivity represented by the brown line and the chromatography fractions are 
shown in red (A). Chromatography fractions were collected and purity analysed by 16 
% SDS-PAGE (B) and Western blotting using antibodies specific to the histidine tag 
featured on recombinant NTH1 (C). Molecular weight markers (kDa) and NTH1 99-
305 presence is indicated.  
 
Due to concerns related to potential bacterial contaminants impacting the 
ubiquitylation capacity of the NTH1 99-305 truncation, the recombinant protein was 
further separated via gel filtration chromatography using a Superdex 75 
chromatography 10/300GL column (GE Healthcare, Little Chafont, UK) equilibrated 
in gel filtration buffer (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, 5 % glycerol with 
1 mM DTT and 1 mM PMSF) using an AKTA-purifier FPLC at 4°C. The 
chromatography trace is provided, with peaks in UV representing peaks in protein 
expression (Figure 42, A). Collected fractions were analysed via SDS-PAGE and 
Instant blue staining (Figure 42, B) and by Western blotting analysis with anti-histidine 
antibodies (Figure 42, C). From SDS-PAGE and staining analysis, a protein 
corresponding to the molecular weight of NTH1 99-305 at 25 kDa appears to be 
present largely in fractions 21-25 (Figure 42, B). Additionally, from Western blotting 
analysis, it was observed that protein bands of approximately 25.4 kDa were apparent 
largely in two peaks of fractions 15-19 and 23-29 (Figure 42, C). However, SDS-
PAGE and staining analysis in combination with Western blotting analysis enabled us 
to refine the presence of fractions containing the least bacterial contaminants and the 
maximal levels of the NTH1 99-305 truncation. Due to this, it was decided that 
fractions 21-25 would be selected, pooled and concentrated using Amicon Ultra 15 
ml centrifugal concentrators (10 kDa MWCO) in a swinging bucket rotor at 4000 x g 
to generate a concentrated stock of NTH1 99-305 protein of refined purity.  
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Figure 42. Size exclusion chromatography purification of the C-terminal 
truncation of NTH1 99-305 by SDS-PAGE and Western blotting with anti-
histidine antibodies. Affinity chromatography fractions containing NTH1 99-305 
were selected, pooled and concentrated using Amicon Ultra 15 ml centrifugal 
concentrators (10 kDa MWCO) to approximately 500 µl before being loaded onto a 
size exclusion Superdex 75 chromatography column, pre-equilibrated with gel 
filtration buffer (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, 5 % glycerol with 1 mM 
DTT and 1 mM PMSF) using an AKTA-purifier FPLC in a cold cabinet at 4°C, 
collecting 0.5 ml fractions. The chromatography trace is provided, with the UV260nm 
represented by the blue line, conductivity represented by the brown line and the 
chromatography fractions are shown in red (A). Fractions were analysed via 16 % 
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SDS-PAGE (B) and Western blotting with anti-histidine antibodies (C). Molecular 
weight markers (kDa) and NTH1 99-305 presence is indicated.  
 
5.3.4 Affinity chromatography purification of NTH1 185-305 
Bacterial cells expressing the C-terminal truncation of NTH1 consisting of residues 
185-305 were lysed via incubation with lysozyme, followed by bursts of sonication. 
The histidine-tagged NTH1 185-305 was then separated from bacterial protein 
contaminants by affinity chromatography with an AKTA purifier FPLC. The cell lysate 
was loaded onto a 1 ml HisTrap chromatography column pre-equilibrated in lysis 
buffer containing PMSF. Bound proteins were collected by 20 ml gradient elution 
using elution buffer containing 500 mM imidazole. The chromatography trace is 
provided, with peaks in UV representing peaks in protein expression (Figure 43, A). 
Fractions were subject to analysis by SDS-PAGE and Instant Blue staining (Figure 
43, B) and by Western blotting with anti-histidine antibodies to select fractions with 
purified his-tagged NTH1 185-305 (Figure 43, C). The approximate molecular weight 
of the truncated version of NTH1 comprising of residues 185-305 is 13.2 kDa. From 
SDS-PAGE and staining analysis, a protein of molecular weight of ~13 kDa was 
present in fractions 14-20 although these also contained other higher molecular 
weight proteins (Figure 43, B). However Western blotting analysis revealed the 
presence of a protein band of this molecular weight present in fractions 10-20 as 
demonstrated by cross-reactivity with anti-histidine antibodies (Figure 43; C); 
suggesting that this band represents truncated NTH1 185-305. However, due to 
consideration of protein purity, fractions 16-20 were selected, pooled and 
concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in 
a swinging bucket rotor at 4000 x g to generate a concentrated stock of NTH1 185-
305 protein. 
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Figure 43. Affinity chromatography purification of the C-terminal truncation of 
NTH1 185-305 by SDS-PAGE and Western blotting with anti-histidine 
antibodies. Bacterial cells transformed with pET28a-NTH1 185-305 bacterial 
expression plasmid were cultured into a 400 ml expression culture until the OD650nm 
reached 0.6. Bacterial expression of recombinant NTH1 185-305 was then induced 
via of isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 30°C. Bacterial cells 
were then pelleted and lysed by sonication in the presence of protease inhibitors. 
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Recombinant NTH1 185-305 was separated from bacterial proteins via affinity 
chromatography using a 1 ml HisTrap column and a linear gradient elution of 5 mM 
to 500 mM imidazole. The chromatography trace is provided, with the UV260nm 
represented by the blue line, conductivity represented by the brown line and the 
chromatography fractions are shown in red (A). Chromatography fractions were 
collected and purity analysed by 16 % SDS-PAGE (B) and Western blotting using 
antibodies specific to NTH1 (C). Molecular weight markers (kDa) and NTH1 185-305 
presence is indicated.  
 
To further improve the purity of the NTH1 185-305 protein, it was decided to further 
separate proteins within these fractions based on size exclusion chromatography. For 
this, concentrated affinity chromatography fractions were loaded onto a Superdex 75 
gel filtration chromatography column pre-equilibrated in gel filtration buffer using an 
AKTA-purifier FPLC at 4°C. The chromatography trace is provided, with peaks in UV 
representing peaks in protein expression (Figure 44, A). Fractions were collected and 
analysed via SDS-PAGE and Instant Blue (Figure 44, B) and by Western blotting with 
anti-histidine antibodies (Figure 44, C). SDS-PAGE staining analysis showed that the 
gel filtration fractions, 16-20 contained a protein of the expected molecular weight of 
13.2 kDa (Figure 44, B). Moreover, this protein demonstrated cross-reactivity with 
NTH1 antibodies; further advocating that this banding pattern corresponds to the 
presence of histidine tagged, recombinant NTH1 185-305 (Figure 44, C). Therefore, 
gel filtration chromatography fractions 16-20 were selected, pooled and concentrated 
using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in a swinging 
bucket rotor at 4000 x g to generate a concentrated stock of relatively pure NTH1 185-
305 protein.  
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Figure 44. Size exclusion chromatography purification of the C-terminal 
truncation of NTH1 185-305 by SDS-PAGE and Western blotting with anti-
histidine antibodies. Affinity chromatography fractions containing NTH1 185-305 
were selected, pooled and concentrated using Amicon Ultra 15 ml centrifugal 
concentrators (10 kDa MWCO) to approximately 500 µl before being loaded onto a 
size exclusion Superdex 75 chromatography column, pre-equilibrated with gel 
filtration buffer (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, 5 % glycerol with 1 mM 
DTT and 1 µM PMSF) using an AKTA-purifier FPLC in a cold cabinet at 4°C, collecting 
0.5 ml fractions. The chromatography trace is provided, with the UV260nm 
represented by the blue line, conductivity represented by the brown line and the 
chromatography fractions are shown in red (A). Fractions were analysed via 16 % 
SDS-PAGE (B) and Western blotting with NTH1 antibodies (C). Molecular weight 
markers (kDa) and NTH1 185-305 presence is indicated.  
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5.3.5 Analysis of NTH1 truncations via in vitro ubiquitylation by TRIM26  
After expressing and purifying truncated versions of NTH1, I analysed which truncated 
proteins contained the lysine residues that are subject to TRIM26 dependent 
ubiquitylation. To do this, equimolar amounts of each NTH1 truncation was subject to 
an in vitro ubiquitylation assay in the absence (-) of recombinant TRIM26, or with the 
addition of 19 fmol of recombinant TRIM26 (+) or 26 fmol recombinant TRIM26 (++). 
Completed reactions were analysed via SDS-PAGE in combination with Western blot 
analysis using antibodies recognising either the NTH1 specific antibodies (Figure 45).  
 
Figure 45. Western blotting analysis of truncated versions of NTH1 following in 
vitro ubiquitylation with recombinant TRIM26. Ubiquitylation assays were 
performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes and 0.6 nmol ubiquitin with either 5.8 pmol of wild type histidine-
tagged, recombinant NTH1 (WT) or histidine-tagged, recombinant versions of each 
NTH1 truncation; NTH1 9-93, NTH1 99-305 or NTH1 185-305. For each version of 
NTH1 being analysed, a titration of recombinant TRIM26; 0 fmol (-), 19 fmol (+) and 
26 fmol (++) was added to distinct ubiquitylation assays. The assay reactions were 
carried out at 30 °C for 1 h in a shaking incubator at 800 rpm, before completed 
reactions were separated by 10 % SDS-PAGE and analysed via Western blotting 
using NTH1 specific antibodies (B). Molecular weight markers (kDa), are indicated.  
 
Despite extensive effort, it was apparent that determination of ubiquitylated sites of 
NTH1 using truncated versions of the glycosylase was somewhat initially 
inconclusive. Truncations of NTH1 from the N-terminal end of the protein appeared to 
significantly impede the level of ubiquitylation observed in the presence of either 
titrated concentration of TRIM26 (Figure 45; lanes 8-9 and 11-12). It was anticipated 
therefore that the N-terminus of NTH1 containing the lysine residues that are subject 
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to TRIM26 dependent ubiquitylation would still exhibit the banding pattern associated 
with ubiquitylation following the in vitro assay. However, this was not observed 
(Figure 45; lanes 5-6) despite the observation that the full length NTH1 protein in the 
presence of TRIM26 was still efficiently ubiquitylated (Figure 45; lanes 2-3). There is 
some suggestion that only in the presence of TRIM26, NTH1 99-305 demonstrates 
an upward shift of bands at 33 kDa representative of ubiquitylation (Figure 45, lanes 
8 and 9), however, it could be concluded that these bands may in fact represent other 
protein contaminants associated with the addition of recombinant TRIM26. This is 
supported by the presence of protein bands at a similar molecular weight following in 
vitro ubiquitylation of other NTH1 truncations (Figure 45, lanes 5 and 6, 11 and 12).  
The fact that no significant ubiquitylation of the NTH1 9-93 protein was observed 
would suggest that either this truncation does not contain the lysine residues for 
TRIM26-dependent ubiquitylation, or that the protein does not contain the domains 
that promote TRIM26 binding. Overall, it would appear that significantly disrupting the 
structure of the full-length NTH1 protein via creating truncated versions may in fact 
significantly inhibit any potential ubiquitylation via TRIM26.  
In an attempt to further clarify if any specific domains of NTH1 demonstrated evidence 
of TRIM26 dependent ubiquitylation, I repeated the in vitro ubiquitylation assay once 
more. In this experiment, I decided to focus on the N-terminal truncated NTH1 
products (99-305 and 185-305) in this additional assay (Figure 46). Once more, no 
obvious signs of ubiquitylation of these truncated proteins (Figure 46; lanes 5-6 and 
8-9) was apparent, in comparison to the full-length protein which demonstrated 
significant TRIM26-dependent ubiquitylation (Figure 46; lanes 2 and 3). The 
appearance of bands of increased molecular weights, observed only in the presence 
of TRIM26, could be believed to represent ubiquitylation of the 99-305 and 185-305 
truncated proteins (Figure 5.46; lanes 5, 6, 8 and 9). However, protein bands of 
similar molecular weights can also be observed in alternative reactions, even lacking 
TRIM26 (Figure 46; lane 4 and 7). It was concluded that these banding patterns may 
in fact signify protein impurities associated with the ubiquitylation assay itself and that 
truncated versions of NTH1, proved to provide little clarification regarding which 
specific lysine residues are subject to TRIM26-dependent modification. However, 
given that depletion of even the first 98 amino acids of NTH1 (in 99-305 truncation) 
appeared to completely supress ubiquitylation of the protein by TRIM26, this at least 
indicated that ubiquitylation was potentially within the N-terminus of the protein. 
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Figure 46. Repeat Western blotting analysis of truncated versions of NTH1 
following in vitro ubiquitylation with recombinant TRIM26. Ubiquitylation assays 
were performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes and 0.6 nmol ubiquitin with either 5.8 pmol of wild type histidine-
tagged, recombinant NTH1 (WT) or histidine-tagged, recombinant versions of each 
NTH1 truncation; NTH1 99-305 or NTH1 185-305. For each version of NTH1 being 
analysed, a titration of recombinant TRIM26; 0 fmol (-), 19 fmol (+) and 26 fmol (++) 
was added to distinct ubiquitylation assays. The assay reactions were carried out at 
30 °C for 1 h in a shaking incubator at 800 rpm, before completed reactions were 
separated by 10 % SDS-PAGE and analysed via Western blotting using NTH1 
specific antibodies (B). Molecular weight markers (kDa), are indicated.  
 
5.4 Analysis of ubiquitylation of site specific mutants of NTH1 by TRIM26 
 
Since identification of TRIM26 dependent ubiquitylation of NTH1 remained 
inconclusive using truncated versions of the glycosylase, it was decided that a site-
directed mutagenesis approach should be adopted. Not only would this allow us to 
identify more specifically certain NTH1 lysine residues that are subject to 
ubiquitylation, but it also minimised the disruption of the structure of the full-length 
enzyme which would hopefully minimise the instability of the NTH1 mutants. In 
addition this approach would limit any reduction in binding of TRIM26 via specific 
domains, and thus improve the chances of identifying NTH1 ubiquitylation sites. For 
this strategy, conservative substitution of certain lysine residues to arginine residues 
was performed. It was anticipated that conservatively substituting lysine residues with 
an amino acid demonstrating similar biochemical characteristics and charge would 
cause the least disruption of the overall structure of the glycosylase enzyme and 
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would enable to discover which substitution caused the greatest reduction in TRIM26-
dependent ubiquitylation capacity. Therefore, as part of this strategy I began to mutate 
each lysine residue sequentially from each terminal end of the NTH1 enzyme, 
however, due to reports in the literature, it was decided that our main emphasis would 
initially focus on mutation of the lysine residues situated at the N-terminal end of 
NTH1. For instance, it is known that human NTH1 possesses an extended N-terminal 
section compared to its bacterial homologues (90). Kinetic studies have suggested 
this extended N-terminal region is not associated with the glycolytic activity of the 
enzyme but could be implicated in regulation (68). In addition, it has been shown that 
the extended N-terminal region could inhibit NTH1 activity (90). As described in the 
previous section, deletion of the immediate N-terminus of NTH1 (first 98 amino acids) 
was sufficient to inhibit ubiquitylation of the remainder of the protein by TRIM26. 
Cumulatively, these results tentatively advocate that the N-terminal region of human 
NTH1 could be regulated by signalling modifications, such as ubiquitylation, which 
may act to control NTH1 activity but also stability.  
For this reason, the following point mutations were created (Table 8); with site 
directed mutagenesis of N-terminal residues being the initial primary focus. However 
additionally, a C-terminal lysine mutant of NTH1 was also created, whereby, two 
proximal lysine residues (245 and 246, were substituted together) (Table 8). The 
intention was that if no conclusive effects on NTH1 ubiquitylation were observed 
following site directed mutagenesis of these specific residues, then I would continue 
substituting each lysine residue simultaneously from each terminal end of NTH1.  
Table 8. The custom oligonucleotides which were used to generate NTH1 point 
mutants to analyse the site of TRIM26 dependent ubiquitylation. For each site 
directed mutagenesis reaction 0.3 µM of forward oligonucleotide and 0.3 µM reverse 
oligonucleotides were incubated with 0.02 U/ µl of High Fidelity Phusion Polymerase, 
1x Phusion HF buffer, 200 µM dNTPS and 250 pg/µl pET28NTH1 plasmid in a final 
reaction volume of 50 µl (made up with deionised water). The PCR reactions were 
performed by one cycle of denaturation at 98°C for 2 min, followed by 18 cycles of; 
98°C for 30 s, 55°C for 1 min and 72°C for 5 min, followed by a final extension stage 
at 72°C for 20 min.  
Mutant Forward oligonucleotide sequence (5’-3’) Reverse oligonucleotide sequence (5’-3’) 
K42R CAG-AAG-CGA-GGA-GAA-GCC-ACA-GCC-CC 
GGG-GCT-GTG-GCT-TCT-CCT-CGC-TTC-
TGC 
K48R ACA-GCC-CCG-TGA-GGC-GTC-CGC-GG CCG-CGG-ACG-CCT-CAC-GGG-GC 
K52R GCG-TCC-GCG-GAG-AGC-ACA-GAG-ACT-GC 
GCA-GTC-TCT-GTG-CTC-TCC-GCG-GAC-
GC 
K48, 52R 
GCC-CCG-TGA-GGC-GTC-CGC-GGA-GAG-
CAC-AG 
CTG-TGC-TCT-CCG-CGG-ACG-CCT-CAC-
GGG-G 
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K67R 
GGG-CTC-GGA-CAG-TGA-GAG-AGG-TGA-
GGG 
CCC-TCA-CCT-CTC-TCA-CTG-TCC-GAG-
CCC 
K245, 
246R 
CTG-AGG-TGG-ACC-AGG-AGG-GCA-ACC-
AAG-TCC-C 
GAC-TTG-GTT-GCC-CTC-CTG-GTC-CAC-
CTC-AGC-C 
 
5.4.1 Generation of site specific mutants of NTH1 by PCR 
 
In order to achieve site specific lysine mutants of NTH1, specific oligonucleotide 
primers were designed to confer a desired lysine to arginine mutation in the 
pET28NTH1 plasmid (kindly provided by Dr. Allinson, University of Lancaster). The 
custom primers were incubated with the target plasmid in the presence of Phusion 
High-Fidelity DNA polymerase (ThermoFisher Scientific, UK) and amplified by PCR.  
The custom oligonucleotides used to generate each NTH1 mutation are provided 
(Table 8). The ability of the reaction to generate the correct sized PCR product was 
assessed on a 1 % agarose gel (Figure 47). The expected size of each pET28a 
expression plasmid containing an insert encoding the mutated nth1 gene was 6,239 
bp. Evaluation of the PCR reactions, verified that plasmids of this approximate size 
had been generated each containing the required mutations (Figure 47).  
 
Figure 47. PCR products following site directed mutagenesis of the pET28NTH1 
bacterial expression plasmid. Per PCR reaction 250 pg/µl of pET28NTH1 bacterial 
expression plasmid was incubated with 0.02 U/µl high fidelity Phusion polymerase, 
200 µM dNTPs, 0.3 µM custom forward primer, 0.3 µM custom reverse primer and 1 
x Phusion HF buffer (h) or GC buffer (g) with/without DMSO (+). A: pET28NTH1K42R, 
B: pET28NTH1K245,246R, C: pET28NTH1K52R, D: pET28NTH1K48R, E: 
pET28NTH1K67R, F: pET28NTH1K48,52R The size of the PCR products was 
analysed using 1 % agarose gels in 1x TAE. The expected sizes of each PCR product 
in base pairs are featured. 
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Noticeably, this analysis could not confirm whether the nth1 gene contained the 
required point mutation. Therefore, plasmids of pET28NTH1 containing the desired 
lysine to arginine point mutation were subject to treatment with DpnI to remove 
methylated DNA corresponding to the template DNA containing the wild type nth1 
gene sequence, before being transformed into library efficient bacterial DH5α cells 
grown on selective agar containing kanamycin. Successfully grown colonies were 
then grown in overnight cultures and plasmid DNA was isolated via the QIAprep Spin 
Miniprep Kit (QIAGEN). The success of each site-directed mutagenesis reaction was 
analysed by DNA sequencing each plasmid using the Sanger Sequencing Service 
(see Appendix). 
5.4.2 Purification of site specific mutants of NTH1 
All of the plasmids containing the appropriate point mutations (K42R, K48R, K52R, 
K48,52R, K67R, K245,246R) were transformed into Rosetta 2(DE3) pLysS cells, 
cultures were grown and protein expression was induced using IPTG. Cell lysates 
were generated and each mutant NTH1 protein was purified separately by affinity 
chromatography using separate 1 ml HisTrap affinity chromatography columns 
attached to an AKTApurifier chromatography system at 4°C. Proteins were eluted 
using a 20 ml gradient of 5 mM to 500 mM imidazole.  
5.4.2.1 Affinity chromatography purification of K42R 
The bacterial expression plasmid encoding pET28NTH1K42R was transformed into 
Rosetta 2(DE3) pLysS cells which were cultured to 400 ml before recombinant protein 
expression was induced via IPTG addition. Following this, cells were pelleted and re-
suspended in lysis buffer containing protease inhibitors before being lysed via 
incubation with lysozyme in combination with bursts of sonication. Cell debris was 
removed by centrifugation and cell lysates were syringe filtered before being applied 
to a 1 ml HisTrap column attached to an AKTA purifier FPLC. Bound proteins were 
eluted via a 20 ml gradient elution of 5 mM to 500 mM imidazole, collecting 0.5 ml 
fractions. The chromatography trace is provided, with peaks in UV representing peaks 
in protein expression (Figure 48, A). The protein content of the chromatography 
fractions collected was assessed via 10 % SDS-PAGE and Instant Blue staining 
(Figure 48, B) and also by Western blotting analysis using NTH1 specific antibodies 
(Figure 48, C).  
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Figure 48. Affinity chromatography of NTH1 point mutation at lysine residue 42 
(K42R). Point mutations of NTH1 lysine residues (K) to arginine (R) residues were 
created via site-directed mutagenesis of a pET28NTH1 plasmid using custom 
oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid constructs were 
transformed into Rosetta 2(DE3) pLysS cells and protein expression induced via 1 
mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial suspension was 
pelleted by centrifugation and supernatant removed. The Rosetta 2(DE3) pLysS cells 
were re-suspended in lysis buffer with protease inhibitors before the cells were lysed 
open via incubation with lysozyme followed by sonication. Cells were pelleted by 
centrifugation and the supernatant filtered through syringe filters. Filtered supernatant 
was applied to a pre-equilibrated 1 ml His-trap affinity chromatography column. 
Proteins were eluted via a gradient of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV260nm represented by the blue line, 
conductivity represented by the brown line and the chromatography fractions are 
shown in red (A). The contents of select chromatography fractions were analysed via 
10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Molecular weight markers (kDa) are indicated as well as fraction numbers and the 
presence of the NTH1 mutation.   
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Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 18-26 contained protein bands of the expected molecular 
weight of NTH1 (Figure 48, A and B; 34.4 kDa), and that these proteins also 
demonstrated cross-reactivity to the anti-NTH1 antibodies utilised (Figure 48, C). For 
this reason, these fractions were believed to contain NTH1 K42R and consequently 
fractions 20-26 containing relatively pure protein were selected, pooled and 
concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) in 
a swinging bucket rotor at 4000 x g until the volume reached approximately 500 µl. 
This volume was then made up to 1 mL in JPDB buffer (50 mM Tris HCl pH 8, 50 mM 
KCl, 1 mM EDTA, 10 % glycerol) and concentrated once more at 4000 x g. This 
process was repeated twice more to buffer exchange the fractions. 
 
5.6.3.2 Affinity chromatography purification of K52R 
The bacterial expression plasmid encoding pET28NTH1K52R was transformed into 
Rosetta 2(DE3) pLysS cells and a 400 ml culture was grown and recombinant protein 
expression was induced via the addition of IPTG. Cells were pelleted, re-suspended 
in lysis buffer containing protease inhibitors, before being lysed using lysozyme and 
sonication. Bacterial cell debris was removed by centrifugation and the cell lysate was 
syringe filtered before being applied to a 1 ml HisTrap column attached to an AKTA 
purifier FPLC. Bound proteins were eluted via 20 ml gradient elution of 5 mM to 500 
mM imidazole, collecting 0.5 ml fractions. The chromatography trace is provided, with 
peaks in UV representing peaks in protein expression (Figure 49, A). Collected 
chromatography fractions were assessed via 10 % SDS-PAGE and Instant Blue 
staining (Figure 49, B) and also by Western blotting analysis using NTH1 specific 
antibodies (Figure 49, C).  
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Figure 49. Affinity chromatography of NTH1 point mutation at lysine residue 52 
(K52R). Point mutations of NTH1 lysine residues (K) to arginine (R) residues were 
created via site-directed mutagenesis of a pET28NTH1 plasmid using custom 
oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid constructs were 
transformed into Rosetta 2(DE3) pLysS cells and protein expression induced via 1 
mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial suspension was 
pelleted by centrifugation and supernatant removed. The Rosetta 2(DE3) pLysS cells 
were re-suspended in lysis buffer with protease inhibitors before the cells were lysed 
open via incubation with lysozyme followed by sonication. Cells were pelleted by 
centrifugation and the supernatant filtered through syringe filters. Filtered supernatant 
was applied to a pre-equilibrated 1 ml His-trap affinity chromatography column. 
Proteins were eluted via a gradient of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV260nm represented by the blue line, 
conductivity represented by the brown line and the chromatography fractions are 
shown in red (A). The contents of select chromatography fractions were analysed via 
10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Molecular weight markers (kDa) are indicated as well as fraction numbers and the 
presence of the NTH1 mutation.   
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Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 18-24 contained protein bands of the expected molecular 
weight for NTH1 K52R, which cross-reacted with anti-NTH1 antibodies (Figure 49, A 
and B; 34.4 kDa). These fractions were selected, pooled and concentrated using 
Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) until the final volume 
reached approximately 500 µl. This volume was then made up to 1 mL in JPDB buffer 
(50 mM Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated 
once more at 4000 x g. This process was repeated twice more to buffer exchange the 
fractions. 
 
5.4.2.3 Affinity chromatography purification of K48R 
The bacterial expression plasmid encoding pET28NTH1K48R was transformed into 
Rosetta 2(DE3) pLysS cells, a culture of 400 ml was grown and protein expression 
induced by IPTG. Cells were pelleted, re-suspended in lysis buffer containing 
protease inhibitors and lysed. Bacterial cell contaminants were removed by 
centrifugation, a cell lysate prepared and applied to a 1 ml HisTrap column attached 
to an AKTA purifier FPLC. Bound proteins were eluted via 20 ml gradient elution of 5 
mM to 500 mM imidazole, collecting 0.5 ml fractions. The chromatography trace is 
provided, with peaks in UV representing peaks in protein expression (Figure 50, A). 
Collected fractions were assessed via 10 % SDS-PAGE and Instant Blue staining 
(Figure 50, B) and also by Western blotting analysis using NTH1 specific antibodies 
(Figure 50, C).  
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Figure 50. Affinity chromatography of NTH1 point mutation at lysine residue 48 
(K48R). Point mutations of NTH1 lysine residues (K) to arginine (R) residues were 
created via site-directed mutagenesis of a pET28NTH1 plasmid using custom 
oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid constructs were 
transformed into Rosetta 2(DE3) pLysS cells and protein expression induced via 1 
mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial suspension was 
pelleted by centrifugation and supernatant removed. The Rosetta 2(DE3) pLysS cells 
were re-suspended in lysis buffer with protease inhibitors before the cells were lysed 
open via incubation with lysozyme followed by sonication. Cells were pelleted by 
centrifugation and the supernatant filtered through syringe filters. Filtered supernatant 
was applied to a pre-equilibrated 1 ml His-trap affinity chromatography column. 
Proteins were eluted via a gradient of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV260nm represented by the blue line, 
conductivity represented by the brown line and the chromatography fractions are 
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shown in red (A). The contents of select chromatography fractions were analysed via 
10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Molecular weight markers (kDa) are indicated, as well as fraction numbers and the 
presence of the NTH1 mutation.   
 
Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 16-26 contained protein bands corresponding to NTH1 K48R 
and this was further confirmed by Western blotting analysis using NTH1-specific 
antibodies (Figure 50; A and B; 34.4 kDa). These fractions were selected, pooled 
and concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) 
until 500 µl in volume. This volume was then made up to 1 mL in JPDB buffer (50 mM 
Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated once more 
at 4000 x g. This process was repeated twice more to buffer exchange the fractions. 
 
5.4.2.4 Affinity chromatography purification of K67R 
The bacterial expression plasmid encoding pET28NTH1K67R transformed into 
Rosetta 2(DE3) pLysS cells, a 400 ml cell culture was grown and IPTG used to induce 
protein expression. Cells were pelleted, re-suspended in lysis buffer containing 
protease inhibitors and lysed. Bacterial cell contaminants were removed by 
centrifugation, the cell lysate was filtered and applied to a 1 ml HisTrap column 
attached to an AKTA purifier FPLC. Bound proteins were eluted via 20 ml gradient 
elution of 5 mM to 500 mM imidazole, collecting 0.5 ml fractions. The chromatography 
trace is provided, with peaks in UV representing peaks in protein expression (Figure 
51, A). Collected fractions were assessed via 10 % SDS-PAGE and Instant Blue 
staining (Figure 51, B) and also by Western blotting analysis using NTH1 specific 
antibodies (Figure 51, C).  
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Figure 51. Affinity chromatography of NTH1 point mutation at lysine residue 67 
(K67R). Point mutations of NTH1 lysine residues (K) to arginine (R) residues were 
created via site-directed mutagenesis of a pET28NTH1 plasmid using custom 
oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid constructs were 
transformed into Rosetta 2(DE3) pLysS cells and protein expression induced via 1 
mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial suspension was 
pelleted by centrifugation and supernatant removed. The Rosetta 2(DE3) pLysS cells 
were re-suspended in lysis buffer with protease inhibitors before the cells were lysed 
open via incubation with lysozyme followed by sonication. Cells were pelleted by 
centrifugation and the supernatant filtered through syringe filters. Filtered supernatant 
was applied to a pre-equilibrated 1 ml His-trap affinity chromatography column. 
Proteins were eluted via a gradient of 5 mM to 500 mM imidazole. The 
chromatography trace is provided, with the UV260nm represented by the blue line, 
conductivity represented by the brown line and the chromatography fractions are 
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shown in red (A). The contents of select chromatography fractions were analysed via 
10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Molecular weight markers (kDa) are indicated as well as fraction numbers and the 
presence of the NTH1 mutation.   
 
Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 18-24 largely contained protein bands corresponding to NTH1 
K67R (Figure 5.19A; 34.4 kDa). This was supported by Western blotting analysis 
which similarly demonstrated that fractions 18-24 contained protein that cross-reacted 
with NTH1-specific antibodies. These fractions were selected, pooled and 
concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) 
until 500 µl in volume. This volume was then made up to 1 mL in JPDB buffer (50 mM 
Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated once more 
at 4000 x g. This process was repeated twice more to buffer exchange the fractions. 
 
5.4.2.5 Affinity chromatography purification of K48,52R 
The bacterial expression plasmid encoding pET28NTH1K48,52R was transformed 
into Rosetta 2(DE3) pLysS cells, a 400 ml culture was grown and IPTG added to 
induce protein expression. Cells were pelleted by centrifugation, re-suspended in lysis 
buffer containing protease inhibitors and lysed. Bacterial cell contaminants were 
removed by centrifugation, a cell lysate was prepared and applied to a 1 ml HisTrap 
column attached to an AKTA purifier FPLC. Bound proteins were eluted via 20 ml 
gradient elution of 5 mM to 500 mM imidazole, collecting 0.5 ml fractions. The 
chromatography trace is provided, with peaks in UV representing peaks in protein 
expression (Figure 52, A). Collected fractions were assessed via 10 % SDS-PAGE 
and Instant Blue staining (Figure 52, B) and also by Western blotting analysis using 
NTH1 specific antibodies (Figure 52, C).  
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Figure 52. Affinity chromatography of NTH1 point mutation at lysine residues 
48 and 52 (K48, 52R). Point mutations of NTH1 lysine residues (K) to arginine (R) 
residues were created via site-directed mutagenesis of a pET28NTH1 plasmid using 
custom oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid 
constructs were transformed into Rosetta 2(DE3) pLysS cells and protein expression 
induced via 1 mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial 
suspension was pelleted by centrifugation and supernatant removed. The Rosetta 
2(DE3) pLysS cells were re-suspended in lysis buffer with protease inhibitors before 
the cells were lysed open via incubation with lysozyme followed by sonication. Cells 
were pelleted by centrifugation and the supernatant filtered through syringe filters. 
Filtered supernatant was applied to a pre-equilibrated 1 ml His-trap affinity 
chromatography column. Proteins were eluted via a gradient of 5 mM to 500 mM 
imidazole. The chromatography trace is provided, with the UV260nm represented by 
the blue line, conductivity represented by the brown line and the chromatography 
fractions are shown in red (A). The contents of select chromatography fractions were 
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analysed via 10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies 
(C). Molecular weight markers (kDa) are indicated as well as fraction numbers and 
the presence of the NTH1 mutation.   
Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 18-26 contained protein bands corresponding to NTH1 K48, 
52R and which was confirmed utilising Western blotting containing NTH1-specific 
antibodies (Figure 52, A and B; 34.4 kDa). These fractions were selected, pooled 
and concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) 
until 500 µl in volume. This volume was then made up to 1 mL in JPDB buffer (50 mM 
Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated once more 
at 4000 x g. This process was repeated twice more to buffer exchange the fractions. 
 
5.4.2.6 Affinity chromatography purification of K245,246R 
The bacterial expression plasmid encoding pET28NTH1K245,246R was transformed 
into Rosetta 2(DE3) pLysS cells, a 400 ml culture was grown and protein expression 
induced with IPTG. Cells were pelleted by centrifugation, re-suspended in lysis buffer 
containing protease inhibitors and lysed. Bacterial cell contaminants were removed 
by centrifugation, a cell lysate was prepared and applied to a 1 ml HisTrap column 
attached to an AKTA purifier FPLC. Bound proteins were eluted via 20 ml gradient 
elution of 5 mM to 500 mM imidazole, collecting 0.5 ml fractions. The chromatography 
trace is provided, with peaks in UV representing peaks in protein expression (Figure 
53, A). Collected fractions were assessed via 10 % SDS-PAGE and Instant Blue 
staining (Figure 53, B) and by Western blotting analysis using NTH1 specific 
antibodies (Figure 53, C). 
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Figure 53. Affinity chromatography of NTH1 point mutation at lysine residues 
245 and 246 (K245, 246R). Point mutations of NTH1 lysine residues (K) to arginine 
(R) residues were created via site-directed mutagenesis of a pET28NTH1 plasmid 
using custom oligonucleotides with Phusion High-fidelity DNA polymerase. Plasmid 
constructs were transformed into Rosetta 2(DE3) pLysS cells and protein expression 
induced via 1 mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The bacterial 
suspension was pelleted by centrifugation and supernatant removed. The Rosetta 
2(DE3) pLysS cells were re-suspended in lysis buffer with protease inhibitors before 
the cells were lysed open via incubation with lysozyme followed by sonication. Cells 
were pelleted by centrifugation and the supernatant filtered through syringe filters. 
Filtered supernatant was applied to a pre-equilibrated 1 ml His-trap affinity 
chromatography column. Proteins were eluted via a gradient of 5 mM to 500 mM 
imidazole. The chromatography trace is provided, with the UV260nm represented by 
the blue line, conductivity represented by the brown line and the chromatography 
fractions are shown in red (A). The contents of select chromatography fractions were 
analysed via 10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies 
(C). Molecular weight markers (kDa) are indicated as well as fraction numbers and 
the presence of the NTH1 mutation.   
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Following SDS-PAGE protein analysis of the chromatography fractions, it was 
apparent that fractions 18-26 largely contained protein bands corresponding to NTH1 
K245,246R and these bands also cross-reacted with NTH1-specific antibodies by 
Western blotting (Figure 53, A and B; 34.4 kDa). These fractions were selected, 
pooled and concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa 
MWCO) until 500 µl in volume. This volume was then made up to 1 mL in JPDB buffer 
(50 mM Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated 
once more at 4000 x g. This process was repeated twice more to buffer exchange the 
fractions. 
5.4.2.7 Affinity chromatography purification of K42,48,52,67R 
The bacterial expression plasmid encoding pET28NTH1K42,48,52,67R was 
transformed into Rosetta 2(DE3) pLysS cells, a 400 ml culture was grown and protein 
expression induced with IPTG. Cells were pelleted by centrifugation, re-suspended in 
lysis buffer containing protease inhibitors and lysed. Bacterial cell contaminants were 
removed by centrifugation, a cell lysate was prepared and applied to a 1 ml HisTrap 
column attached to an AKTA purifier FPLC. Bound proteins were eluted via 20 ml 
gradient elution of 5 mM to 500 mM imidazole, collecting 0.5 ml fractions. The 
chromatography trace is provided, with peaks in UV representing peaks in protein 
expression (Figure 54, A). Collected fractions were assessed via 10 % SDS-PAGE 
and Instant Blue staining (Figure 54, B) and by Western blotting analysis using NTH1 
specific antibodies (Figure 54, C). 
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Figure 54. Affinity chromatography of NTH1 point mutation at lysine residues 
42, 48, 52, 67 (K42, 48, 52, 67 R). Point mutations of NTH1 lysine residues (K) to 
arginine (R) residues were created via site-directed mutagenesis of a pET28NTH1 
plasmid using custom oligonucleotides with Phusion High-fidelity DNA polymerase. 
Plasmid constructs were transformed into Rosetta 2(DE3) pLysS cells and protein 
expression induced via 1 mM IPTG in a 400 ml culture for 3 h at 37°C, 250 rpm. The 
bacterial suspension was pelleted by centrifugation and supernatant removed. The 
Rosetta 2(DE3) pLysS cells were re-suspended in lysis buffer with protease inhibitors 
before the cells were lysed open via incubation with lysozyme followed by sonication. 
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Cells were pelleted by centrifugation and the supernatant filtered through syringe 
filters. Filtered supernatant was applied to a pre-equilibrated 1 ml His-trap affinity 
chromatography column. Proteins were eluted via a gradient of 5 mM to 500 mM 
imidazole. The chromatography trace is provided, with the UV260nm represented by 
the blue line, conductivity represented by the brown line and the chromatography 
fractions are shown in red (A). The contents of select chromatography fractions were 
analysed via SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Molecular weight markers (kDa) are indicated as well as fraction numbers and the 
presence of the NTH1 mutation.   
 
5.4.2.8 Activity of TRIM26 on site specific mutants of NTH1 
Purified wild-type full-length NTH1 and site-specific mutants of NTH1 (K42R, K48R, 
K52R and K67R containing single mutations; K48,52R, K245,246R containing double 
mutations) were subsequently subject to the in vitro ubiquitylation assay, with 
increasing concentrations of recombinant TRIM26. Completed reactions were 
separated by SDS-PAGE and analysed by Western blotting using NTH1 specific 
antibodies (Figures 55, 56 and 57). It was expected that replacement of the lysine 
residues of NTH1 that are subject to TRIM26 dependent ubiquitylation, would 
significantly impede the upward shift in molecular weight of NTH1 observed via 
Western blotting analysis, thus representing reduced ubiquitylation capacity. 
It was apparent that TRIM26 dependent ubiquitylation was impeded when lysine 
residues located within the N-terminal region were substituted for arginine residues 
(Figure 45). Mutation of single lysine residues at positions 42 or 52 caused the most 
obvious reduction in the levels of ubiquitylated NTH1 (Figure 55, A). When quantified, 
the K42R and K52R mutations induced nearly a 50 % decrease in NTH1Ub ratio when 
normalised to WT NTH1 (Figure 55, B). This is in contrast to mutation of two lysine 
residues, 245 and 246 located at the C-terminal end of NTH1. Substitution of these 
two lysine residues induced only an approximate 30 % reduction in the level of NTH1ub 
compared to WT NTH1. (Figure 55).  
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Figure 55. Western blotting analysis of in vitro ubiquitylation assays using 
recombinant TRIM26 with a range of NTH1 lysine mutants. Ubiquitylation assays 
were performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes, 0.6 nmol ubiquitin and 5.8 pmol of histidine-tagged, 
recombinant NTH1 lysine mutants; K42R, K52R, or K245 246R. To this, a titration of 
recombinant TRIM26; 0 fmol (-), 19 fmol (+) and 26 fmol (++) was added separately 
to each ubiquitylation assay. The assay reactions were carried out at 30 °C for 1 h in 
a shaking incubator at 800 rpm, before completed reactions were separated by 10 % 
SDS-PAGE and analysed via Western blotting using NTH1 specific antibodies. 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. Bands representing an 
upward shift in molecular weight of NTH1, with the addition of 26 fmol of TRIM26, 
were quantified using the Image Studio Lite Licor software. The ratio of NTH1 and 
NTH1ub was calculated and normalised against WT NTH1/NTH1ub ratio, which was set 
to 1 (B). 
Following this observation, I continued to generate and analyse the effects alternative 
N-terminal lysine mutants had on the ubiquitylation on NTH1. Interestingly, 
substitution of two lysine residues at positions 48 and 52 resulted in very little 
difference in NTH1 ubiquitylation compared to the wild type protein (Figure 56, A), 
causing an approximate 10 % reduction in NTH1ub in the presence of 26 fmol of 
TRIM26 when compared to WT NTH1 (Figure 56, B). The K48R substitution alone 
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resulted in a slightly more substantial reduction in NTH1ub (Figure 56, A) of 
approximately 30 % in the presence of 26 fmol of TRIM26 (Figure 56, B).  
However, the most obvious reduction of NTH1ub was observed when the lysine 
residue at position 67 was mutated (Figure 56, A).  Substitution of this residue caused 
over a 70 % reduction in ubiquitylation bands in the presence of 26 fmol TRIM26 
(Figure 56, B). Although, it is worth noting that the efficiency of the quantified reaction 
(Figure 56, A, lane 12) may not be completely effective as the level of ubiquitylation 
in the presence of the lower quantity of TRIM26 seems slightly increased, whereas it 
would be expected that the higher amount of the E3 ligase would induce the higher 
level of ubiquitylation of NTH1 even when impeded by a specific lysine substitution. 
Despite this, it is still apparent that across both reactions containing TRIM26, the 
K67R substitution causes the most substantial reduction in NTH1ub (Figure 56, A). 
Cumulatively these data suggest that the lysine residues within the N-terminus of 
NTH1 are critical for ubiquitylation, although specifically that K67 may be the major 
residue which is ubiquitylated by TRIM26. To explore this concept further, it was 
decided that a quadruple mutant with multiple N-terminal lysine residues replaced with 
arginine residues; K42,48,52,67R, would be created (Figure 54). This was then 
subject to an in vitro ubiquitylation assay alongside the wild type and the K67R NTH1 
single lysine mutant with recombinant TRIM26 (Figure 57, A).  
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Figure 56. Western blotting analysis of in vitro ubiquitylation assays using 
recombinant TRIM26 with a range of NTH1 lysine mutants. Ubiquitylation assays 
were performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes, 0.6 nmol ubiquitin and 5.8 pmol of histidine-tagged, 
recombinant NTH1 lysine mutants; K48R, K67R or K48 52R. To this, a titration of 
recombinant TRIM26; 0 fmol (-), 19 fmol (+) and 26 fmol (++) was added separately 
to each ubiquitylation assay. The assay reactions were carried out at 30 °C for 1 h in 
a shaking incubator at 800 rpm, before completed reactions were separated by 10 % 
SDS-PAGE and analysed via Western blotting using NTH1 specific antibodies (A). 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. Bands representing an 
upward shift in molecular weight of NTH1, with the addition of 26 fmol of TRIM26, 
were quantified using the Image Studio Lite Licor software. The ratio of NTH1 and 
NTH1ub was calculated and normalised against WT NTH1/NTH1ub ratio, which was set 
to 1 (B).  
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Figure 57. Western blotting analysis of in vitro ubiquitylation assays using 
recombinant TRIM26 with a range of NTH1 lysine mutants. Ubiquitylation assays 
were performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes, 0.6 nmol ubiquitin and 5.8 pmol of histidine-tagged, 
recombinant NTH1 lysine mutants; K67R and a quadruple mutant consisting of 
K42,48,52,67R. To this, 19 fmol of recombinant TRIM26 was added separately to 
each ubiquitylation assay. The assay reactions were carried out at 30 °C for 1 h in a 
shaking incubator at 800 rpm, before completed reactions were separated by 10 % 
SDS-PAGE and analysed via Western blotting using NTH1 specific antibodies (A). 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. Bands representing an 
upward shift in molecular weight of NTH1, with the addition of 26 fmol of TRIM26, 
were quantified using the Image Studio Lite Licor software. The ratio of NTH1 and 
NTH1ub was calculated and normalised against WT NTH1/NTH1ub ratio, which was set 
to 1 (B). 
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Following further investigation regarding the site of NTH1 ubiquitylation, it is apparent 
that both the K67R NTH1 and quadruple mutant (K42,48,52,67R) also containing this 
particularly lysine substitution have significantly reduced levels of TRIM26 dependent 
ubiquitylation (Figure 57, A) of around 50 %. However, it is worth noting that the 
efficiency of the in vitro ubiquitylation assays for this particular set of reactions was 
not completely efficient, as even with the addition of WT NTH1 and TRIM26 the level 
of NTH1ub  bands was not as intense as previously observed throughout the project. 
Reasons for this could be due to a loss of activity of the E3 ligase enzyme, following 
multiple freeze-thaw cycles during each use. This theory is likely since these 
ubiquitylation reactions were completed near to the final stages of the project. Despite 
the inefficient ubiquitylation reactions, a reduction in NTH1 ubiquitylation was 
consistently observed with the mutation of just K67R alone; which is consistent with 
the previous result and further advocates that this residue is the major site specifically 
ubiquitylated by TRIM26. This suggests that ubiquitylation of NTH1 has been 
significantly hindered by the loss of this specific lysine residue present within the N-
terminus of the protein. Cumulatively this provides evidence that lysine 67 is the major 
ubiquitylation site by TRIM26, with lysines 42, 48 and 52 acting as more minor sites 
that are modified by TRIM26. 
5.4.2.9 Activity of TRIM26 versus D239Y NTH1 
In addition to investigating the impact of disrupting the major site of NTH1 
ubiquitylation in cells, I also employed a site-directed mutagenesis approach to 
examine the D239Y variant of NTH1 described in the literature (55). This variant is 
reportedly present in 6.2 % of the global population and is associated with increased 
genome instability. Using custom primers in a PCR reaction with high fidelity Phusion 
DNA polymerase, the expression vector for the D239Y variant was generated from a 
pET28NTH1 plasmid and subsequently transformed into DH5α cells (Figure 58). 
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Figure 58. PCR product following site directed mutagenesis of the pET28NTH1 
bacterial expression plasmid to generate the D239Y variant. Per PCR reaction 
250 pg/µl of pET28NTH1 bacterial expression plasmid was incubated with 0.02 U/µl 
high fidelity Phusion polymerase, 200 µM dNTPs, 0.3 µM custom forward primer, 0.3 
µM custom reverse primer and 1 x Phusion GC buffer (g) with/without DMSO (+) to 
generate pET28NTH1D239Y. The size of the PCR product was analysed using a 1 
% agarose gel in 1x TAE. The expected size of the PCR product in base pairs is 
featured. 
Overnight bacterial cultures were grown and plasmid DNA was extracted and 
sequenced using the Sanger Sequencing Service (Source Bioscience Sequencing, 
Nottingham, UK) (see Appendix). Confirmed plasmids encoding the D239Y point 
mutation were transformed into Rosetta 2(DE3) pLysS cells, a 400 ml culture was 
grown and protein expression induced using IPTG. Following preparation of a lysate 
from the bacterial cell pellet generated by centrifugation, the NTH1 D239Y protein 
was purified by His-trap affinity chromatography using a 20 ml gradient elution of 
imidazole from 5 to 500 mM (Figure 58, A). Chromatography fractions were analysed 
via 10 % SDS-PAGE and Instant Blue staining (Figure 58, B) and also by Western 
blotting (Figure 58, C). From this, it was apparent that a protein band of the expected 
34.4 kDa molecular weight which also cross-reacted with NTH1-specific antibodies 
was located in fractions 16-26 (Figure 58, B and C). For the purposes of reducing 
the presence of other protein contaminants, fractions 18-26 were selected, pooled 
and concentrated using Amicon Ultra 15 ml centrifugal concentrators (10 kDa MWCO) 
until 500 µl in volume. This volume was then made up to 1 mL in JPDB buffer (50 mM 
Tris HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) and concentrated once more 
at 4000 x g. This process was repeated twice more to buffer exchange the fractions. 
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Figure 59. Analysis of HisTrap chromatography of the NTH1 point mutation, 
D239Y. The mutant version of NTH1 D239Y was created via site-directed 
mutagenesis of a pET28NTH1 plasmid using custom oligonucleotides with Phusion 
High-fidelity DNA polymerase. Plasmid constructs were transformed into Rosetta 
2(DE3) pLysS cells and protein expression induced via 1 mM IPTG in a 400 ml culture 
for 3 h at 37°C, 250 rpm. The bacterial suspension was pelleted by centrifugation and 
supernatant removed. The Rosetta 2(DE3) pLysS cells were resuspended in lysis 
buffer with protease inhibitors before the cells were lysed open via incubation with 
lysozyme followed by sonication. Cells were pelleted by centrifugation and the 
supernatant filtered through syringe filters. Filtered supernatant was applied to a pre-
equilibrated 1 ml His-trap affinity chromatography column. Proteins were eluted via a 
gradient of 5 mM to 500 mM imidazole. The contents of each fraction were analysed 
via 10 % SDS-PAGE (B) and Western blotting with NTH1 specific antibodies (C). 
Protein bands corresponding to D239Y NTH1 protein expression were most apparent 
in fractions 18-26. These fractions were pooled and concentrated.  
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The concentrated stock of NTH1 D239Y was then subject to an in vitro ubiquitylation 
assay, alongside wild-type NTH1, in the presence of titrated amounts of TRIM26. 
Completed reactions were analysed by 10 % SDS-PAGE and Western blotting with 
NTH1 specific antibodies (Figure 60). 
Interestingly, it was discovered that ubiquitylation of NTH1 by TRIM26 appeared 
significantly impeded by the D239Y substitution (Figure 60, A; lanes 5 and 6). The 
upward shift in molecular weight of NTH1, associated with the addition of ubiquitin 
moieties, is almost completely supressed by the presence of the D239Y substitution, 
since ubiquitylation is reduced by more than 80 % (Figure 60, B). This is especially 
obvious when directly comparing reactions containing wild-type NTH1 (Figure 60, A; 
lanes 2 and 3) to reactions containing the D239Y variant (Figure 60, A; lanes 5 and 
6). This result suggests that the aspartate residue in position 239 could potentially 
affect the ubiquitylation dependent regulation of NTH1 via TRIM26. It is likely that 
substitution of the aspartic acid residue at this position impacts the tertiary structure 
of NTH1, thus influencing its ability to interact with TRIM26. In the wider context, the 
inability of NTH1 to be regulated appropriately due to a change in tertiary structure, 
instigated by the D239Y substitution, could potentially contribute to the genomic 
instability and cellular transformation exhibited by cells expressing the D239Y variant 
(55). 
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Figure 60. Western blotting analysis of in vitro ubiquitylation assays using 
recombinant TRIM26 with a NTH1 D239Y mutant. Ubiquitylation assays were 
performed by combining 0.7 pmol GST-E1 activating enzyme, 5 pmol of UbcH5a 
conjugating enzymes, 0.6 nmol ubiquitin and 5.8 pmol of histidine-tagged, 
recombinant NTH1 (WT) or a mutant version of NTH1 (D239Y NTH1). To this, 0 fmol 
(-), 19 fmol (+), or 26 fmol (++) of recombinant TRIM26 was added separately to each 
ubiquitylation assay. The assay reactions were carried out at 30 °C for 1 h in a shaking 
incubator at 800 rpm, before completed reactions were separated by 10 % SDS-
PAGE and analysed via Western blotting using NTH1 specific antibodies (A). 
Molecular weight markers (kDa), unmodified histidine-tagged NTH1 (NTH1) and 
ubiquitylated histidine-tagged NTH1 (NTH1ub) are indicated. Bands representing an 
upward shift in molecular weight of NTH1, with the addition of 26 fmol of TRIM26, 
were quantified using the Image Studio Lite Licor software. The ratio of NTH1 and 
NTH1ub was calculated and normalised against WT NTH1/NTH1ub ratio, which was 
set to 1 (B). 
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5.5. Results Summary 
NTH1 contains a total of 17 lysine residues, which are potential targets for TRIM26 
dependent ubiquitylation (Figure 33). To elucidate which sites within NTH1 are 
subject to ubiquitylation, I first adopted a mass spectrometry approach to analyse the 
products of in vitro ubiquitylation reactions. However, despite digestions with either 
trypsin or ArgC, full coverage of the peptides within NTH1 was not obtained and so 
could not fully determine any specific lysine residues as sites of ubiquitylation. 
Therefore, I created truncation mutants of NTH1 and assessed which section of the 
protein was subject to TRIM26 dependent ubiquitylation. Results from this appeared 
somewhat inconclusive, although it was observed that deletion of the first 98 amino 
acids of NTH1 caused a suppression of ubiquitylation by TRIM26, suggesting that this 
region contains the major sites of ubiquitylation (Figure 45). However, I was unable 
to show that a truncation containing the immediate N-terminus (9-99) of NTH1 was a 
substrate for ubiquitylation by TRIM26. Arguably, this could be because the protein is 
not of sufficient size, therefore, does not structurally resemble the full-length protein 
which may prevent TRIM26 protein binding. 
Following this, it was decided that a site directed mutagenesis approach of each 
separate lysine residue would be more informative. Reports in the literature suggest 
that the extended N-terminal region of human NTH1 could be subject to post-
translational modifications, including ubiquitylation (68, 90). Furthermore, and as 
mentioned above, deletion of the first 98 amino acids of NTH1 inhibited the 
ubiquitylation of the truncated NTH1 99-305 protein (Figure 45). Therefore, my 
primary focus regarding site-directed mutagenesis was mainly targeted towards the 
N-terminal lysine residues within this region (positions 42, 48, 52 and 67). I also 
generated a C-terminal point mutation (positions 245 and 246) for comparison. It was 
anticipated that if disruption of ubiquitylation was not observed following mutation of 
these individual specific lysine residues, then I would continue to mutate each lysine 
residue sequentially from each terminal end of the glycosylase; with a specific focus 
on the N-terminus. Overall, I discovered that conservative subsitution of lysine 42, 48  
or 52 to arginine, or a double mutant at lysines 48 and 52, had a minor impact on the 
degree of ubiquitylation of NTH1 via TRIM26 (Figure 55). However, mutation of lysine 
67 to arginine caused a noteable reduction in NTH1 ubiquitylation, suggesting that 
this is the main target for TRIM26 dependent regulation in vitro (Figure 56). Deletion 
of all four lysine residues  (42, 48, 52 and 67) on the N-terminus of NTH1 appeared 
to completely supress ubiquitylation of the protein by TRIM26 in vitro (Figure 57), 
reinforcing the truncation analysis data that the lysine residues present in this region 
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are the major targets for TRIM26-dependent ubiquitylation. However, I conclude that 
lysine 67 in NTH1 is the major critical target for TRIM26, with lysines 42, 48 and 52 
acting as minor ubiquitylation sites. 
In addtion to this, I also investigated the ubiquitylation dependent regulation of the 
D239Y NTH1 variant which has been shown to be present in 6.2 % of the global 
population and to be inactive as a DNA glycosylase (55).  This protein has also been 
suggested to cause genomic instability and be associated with cancer development. 
I demonstrated that the D239Y variant is not an efficient target for ubiquitylation by 
TRIM26 in vitro (Figure 58), suggesting that this mutant may not be sufficiently 
regulated by the UPP in cells. Therefore as well as the D239Y variant being inactive 
as a DNA glycosylase, I also predict that this protein may accumuate in cells as a 
result of the lack of recognition of the protein by TRIM26-dependent ubiquitylation and 
subsequent proteasomal degradation. 
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 CHAPTER 6 - RESULTS III 
 
The cellular regulation of NTH1 by ubiquitylation  
6.1 Introduction 
 
The BER pathway is one of the major DNA repair pathways employed by cells to 
manage minor DNA insults, including individual base lesions. NTH1 is one of the 
major DNA glycosylases which excises oxidised pyrimidines (including 5-
hydroxycytosine, 5-hydroxyuracil and Tg), during the initial stages of BER. 
Attributable to this critical cellular role, reduced expression of NTH1 protein has been 
observed in gastric, liver and prostate cancer, suggesting that accumulation of DNA 
damage, repaired by NTH1 could be a contributor to the promotion of these cancers. 
Together, this highlights the importance of preserving cellular NTH1 protein levels in 
maintaining genome stability and preventing the development of cancer.  
A number of BER proteins have already been shown to be regulated by the PTM, 
ubiquitylation. The specific enzymes involved in the enzymatic cascade, facilitating 
ubiquitin attachment to each BER enzyme, particularly the E3 ubiquitin ligases, have 
started to be elucidated (25, 48). From this, it is apparent that the effects of 
ubiquitylation vary considerable depending on the substrate protein. For instance, 
polyubiquitylation of APE1 has been shown to be regulated via the E3 ligase, UBR3 
that controls the steady state levels of the protein (102). This is also apparent for 
PNKP; a Cul4A-DDB1-Roc1 complex is the major E3 ligase shown to ubiquitylate and 
regulate PNKP (124). This process was demonstrated to be dependent on the adaptor 
protein, STRAP (124). Furthermore, CHIP was identified as the major E3 ligase which 
polyubiquitylates Pol β for proteasomal degradation (125). Another E3 ligase, Mule 
monoubiquitylates Pol β at multiple sites, causing its retention in the cytoplasm (126). 
It is important to consider the dynamic ways in which multiple E3 ligase enzymes may 
inflict different biological effects on substrate BER proteins, via manipulation of the 
diverse UPP code. 
Gathering detailed knowledge regarding the regulation of BER proteins may improve 
our understanding of the cellular response to DNA damage, which could ultimately 
aid the development of novel drug targets for the prevention or treatment of human 
diseases. In the treatment of cancer, particularly those associated with elevated NTH1 
levels, therapeutic strategies could be developed to specifically reduce the levels of 
the glycosylase. This approach could be combined with current strategies (such as 
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radiotherapy and chemotherapy) to improve patient sensitivity to treatment options, 
which target the cancer by influencing DNA damage. Consequently, these options 
could improve patient response rates and decrease mortality.  
For this reason, it is important to explore the effects of ubiquitylation dependent 
regulation of NTH1 in the cellular context. In previous chapters, I have identified 
TRIM26, as the major E3 ligase involved in the enzymatic cascade facilitating ubiquitin 
attachment to NTH1 in vitro. I have also identified that the N-terminal region of NTH1 
(particularly lysine 67) is subject to regulation via polyubiquitylation by TRIM26, 
suggesting that the protein may be targeted for proteasomal degradation. The 
following chapter aims to explore the mechanisms of TRIM26 dependent regulation 
of NTH1 in cells, with a specific focus on examining the role of TRIM26 in regulating 
NTH1 protein stability. Furthermore, the importance of this mechanism in the cellular 
response to DNA damage will be examined.  
6.2 NTH1 is regulated by the UPP in cells  
 
Initially, to assess if NTH1 is a target for ubiquitylation-dependent proteasomal 
degradation in cells, levels of NTH1 in whole cell extract were assessed before and 
after exposure to MG-132. MG-132 is a potent inhibitor of the cellular proteasome that 
acts as a peptide aldehyde which blocks the proteolytic capacity of the β subunit in 
the 26S proteasome complex. It is anticipated that levels of proteins regulated by 
ubiquitylation-dependent degradation through the UPP will accumulate following MG-
132 exposure.  
For the purpose of this study (and subsequent cellular studies), HCT116p53+/+ were 
used. Not only are these cells well characterised in culture, but it was also hoped that 
since a homozygous loss-of-function germline mutation in the NTH1 gene 
predisposes to a new subtype of BER-associated adenomatous polyposis and 
colorectal cancer (175), understanding the mechanism of regulation of NTH1 in 
HCT116p53+/+ cells could be clinically relevant in the eventual treatment of this disease.  
HCT116p53+/+ cells were cultured in 10 cm dishes until approximately 80 % confluency 
was achieved. Cells were then treated with 10 µM of MG-132 (or DMSO only as a 
control), in serum-containing media and incubated at 37°C for 8 h, to allow protein 
levels to accumulate as a consequence of proteasomal inhibition. Following this, the 
media was removed and cells harvested in cold PBS. Whole cell extract was then 
prepared and NTH1 levels assessed by separation of proteins by 10 % SDS-PAGE 
followed by Western blotting using NTH1 specific antibodies (Figure 61, A). Western 
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blots were further probed with tubulin specific antibodies to act as a loading control to 
enable quantification of changes of NTH1 irrespective of loading discrepancies. Three 
biological replicates of the experiment were performed and the average values 
compared (Figure 61, B).  
 
Figure 61. Accumulation of NTH1 levels normalised to tubulin in human colon 
carcinoma (HCT116p53+/+) cells following treatment with the proteasomal 
inhibitor MG-132 for 8 h.  HCT116p53+/+ cells were cultured in serum-containing 
medium until approximately 80 % confluent. Cells were then treated with either 10 µM 
DMSO control (-) or 10 µM MG-132 proteasomal inhibitor (+) for 8 h in serum-
containing media. Cells were harvested and extracts prepared using the Tanaka 
method. Cell extract proteins were separated by 10 % SDS-PAGE and NTH1 levels 
analysed by Western blotting using NTH1 specific antibodies. Tubulin specific 
antibodies were also used to probe the same Western blot analysis to act as a loading 
control (A). Levels of NTH1 expression were quantified relative to tubulin expression 
using an Odyssey imaging system. Three biological replicates were completed (B). 
*p<0.05 as analysed by a two-sample t-test. 
 
Treatment of cells with the potent proteasome inhibitor MG-132, resulted in the 
accumulation of the protein levels of NTH1 (Figure 61, B). In the presence of MG-
132, average NTH1 protein levels increased by approximately 1.6-fold. This 
difference was statistically significant using a two-sample t-test (p<0.05), suggesting 
that NTH1 levels are regulated by ubiquitylation dependent degradation in cells. This 
finding correlates with proteomic screens which have identified that NTH1 is subject 
to ubiquitylation, but the enzymes involved have yet to be elucidated (34). This finding 
therefore further suggests that the stability of NTH1 is ubiquitylation dependent, so 
- 
NTH1 
Tubulin 
+ MG-132 
A 
B 
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the next logical stage was to confirm the role of TRIM26 in this process and establish 
if ubiquitylation dependent regulation of NTH1 is TRIM26 dependent in cells.  
 
6.3 TRIM26 regulates NTH1 dependent ubiquitylation in cells  
 
After discovering that NTH1 is ubiquitylated and degraded by the proteasome, the 
next obvious experimental step was to assess if NTH1 is ubiquitylated in cells, 
specifically by TRIM26. To achieve this, I analysed the effect of combined 
overexpression of HA-tagged TRIM26 (kindly provided by Prof A. Garcia-Sastre, 
The Icahn School of Medicine at Mount Sinai, USA) and Flag-tagged NTH1 in the 
presence of HA-tagged ubiquitin (HA-Ub) in HCT116p53+/+ cells. In order to complete 
this experimentation, the flag-tagged mammalian expression plasmid encoding the 
nth1 gene was cloned from the pET28aNTH1 plasmid. The mammalian expression 
plasmid for NTH1, pCMV-3Tag-NTH1 was generated using a LIC cloning strategy 
(Section 5.4.2.9, Figure 58).  
Initially, a test expression of both of these plasmids was conducted in HCT116p53+/+ 
cells to assess the optimal concentration of plasmid needed to attain suitable 
overexpression of both proteins of interest (Figure 62). Expression of either protein 
of interest was confirmed via comparison to a Lipofectamine 2000 control, containing 
transfection reagent alone. Following transfection, cells were incubated at 37°C in a 
humidified cell culture incubator for 24 h. Cells were then harvested in cold PBS, 
pelleted by centrifugation and proteins extracted. Cell extracts were analysed by 10 
% SDS-PAGE and Western blotting. From this preliminary test, it was understood that 
transfection of 110 fmol of pCMV-3Tag3a-HA-tagged-TRIM26 yielded sufficient 
overexpression of the E3 ligase (Figure 62, A). Furthermore, transfection of 150 fmol 
of pCMV-3Tag-FLAG-tagged-NTH1 induced good expression of NTH1 (Figure 62, 
B).  
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Figure 62. Protein expression levels of TRIM26 (A) and NTH1 (B) following the 
transfection of titrated amounts of corresponding mammalian expression 
plasmids. HCT116p53+/+ cells were cultured in 10 cm dishes in serum-containing 
media until 80% confluent. For test expression of the of pCMV-3Tag3a-TRIM26 
mammalian expression vector (A) cells were transfected with 10 µl Lipofectamine 
2000 (- control), or either 55 fmol or 110 fmol of pCMV-3Tag3a-TRIM26 mammalian 
expression vector. For test expression of the pCMV-3Tag3a-NTH1 mammalian 
expression plasmid (B) cells were transfected with 10 µl Lipofectamine 2000 (- 
control), or either 30 fmol or 150 fmol of pCMV-3Tag3a-TRIM26 mammalian 
expression vector. Transfected cellular cultures were incubated for 24 h at 37°C in a 
humidified cell incubator. Cells were then harvested in cold PBS, pelleted and cellular 
protein extracted via the Tanaka method. Protein expression was analysed by 10 % 
SDS-PAGE and Western blotting using antibodies specific to TRIM26 (A) or FLAG-
TAG (B). From this, it was evident that 110 fmol of pCMV-3Tag3a-TRIM26 and 150 
fmol of pCMV-3Tag3a-NTH1 are required for overexpression of each protein.  
 
Previous studies within the laboratory dictated an appropriate concentration of 
mammalian vector PMT123 HA-Ub (270 fmol) to use in HCT116p53+/+ cells (46). These 
concentrations of plasmids were then utilised to examine levels of ubiquitylated NTH1 
in cells using immunoprecipitation.  
A plasmid expressing HA-tagged ubiquitin alone, or in combination with Flag-tagged 
NTH1 and HA-tagged TRIM26, was transfected into HCT116p53+/+ cells, and after 24 
h, cells were treated with MG-132 to allow accumulation of ubiquitylated proteins. 
Cells were then harvested in cold PBS, pelleted by centrifugation and proteins 
extracted and used for immunoprecipitation of NTH1. Using a Flag pulldown of NTH1 
in the absence of TRIM26, I show evidence of moderate levels of NTH1 
polyubiquitylation as indicated by a smear of protein cross-reacting with the HA 
antibodies above 50 kDa (Flag-NTH1ub), which is absent in cells expressing HA-
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tagged ubiquitin only as a control (Figure 63, A, compare lanes 1 and 2). This 
demonstrates specific ubiquitylation of NTH1 by an E3 ligase present within the 
HCT116p53+/+ cells. Cellular ubiquitylation of Flag-tagged NTH1 was further enhanced 
by co-expression with HA-tagged TRIM26 (Figure 63, A, compare lanes 2 and 3), 
demonstrating clear evidence that NTH1 is a target for ubiquitylation specifically by 
TRIM26 in cultured cells. 
 
Figure 63. Examination of the ubiquitylation of NTH1 in cells by TRIM26.  
HCT116+/+ cells were cultured in serum-containing media until approximately 80 % 
confluent. Cells were then treated with 270 fmol of PMT-HA-Ub only, or 270 fmol of 
PMT-HA-Ub plus 150 fmol pCMV-3Tag3a-NTH1 and 110 fmol of pCMV-3Tag3a-
TRIM26 or 270 fmol of PMT-HA-Ub with 110 fmol of pCMV-3Tag3a-TRIM26. Cells 
were cultured 24 h in serum-containing media at 37°C in a humidified cell incubator 
then treated with 10 µM of MG-132 for 6 h. Cell extracts were prepared using the 
Tanaka method. For immunoprecipitation 10 µl of Anti-FLAG M2 magnetic beads with 
equal concentrations of cellular protein extract from each treatment were mixed for 2 
h on a rotor at 4°C. Magnetic beads were washed in buffer containing 150 mM KCl to 
eliminate unbound proteins before levels of ubiquitylated NTH1 bound to the Anti-
FLAG M2 magnetic beads were analysed by Western blotting.  
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6.4 Effect of lysine 67 on the stability of NTH1  
Since discovering that NTH1 is a target for TRIM26 ubiquitylation in cultured cells, it 
was considered interesting to establish if disruption of the major site of TRIM26 
dependent ubiquitylation of NTH1, lysine 67 (previously identified by in vitro studies), 
affected NTH1 stability in cells. This would be achieved by overexpressing wild type 
NTH1 and the K67R NTH1 variant in cells and examining their stability. To investigate 
this, mammalian expression plasmids for both proteins were generated. The 
mammalian expression plasmid for NTH1, pCMV-3Tag-NTH1, was generated using 
a LIC cloning strategy whereby the nth1 gene was cloned from the pET28aNTH1 
bacterial expression plasmid. Once generated, this was then subject to site directed 
mutagenesis using the appropriate primers to yield the pCMV-3Tag-NTH1-K67R 
expression plasmid.  
The empty pCMV-3Tag vector and the insert for wild type NTH1 variant were amplified 
separately (Figure 64). The size of the PCR products obtained were analysed on a 1 
% agarose gel; a PCR product related to the approximate size of the pCMV-3Tag 
vector of 4214 bp was obtained (Figure 64, A), plus a PCR product related to the 
approximate size of the NTH1 insert of 1824 bp was also obtained (Figure 64, B).  
 
Figure 64. PCR amplification of a pCMV-3TAG vector (A) and an insert for NTH1 
mammalian expression (B) for use in a ligase independent cloning (LIC) 
strategy. An empty pCMV-3TAG vector was PCR amplified using relevant 
oligonucleotides flanked by corresponding LIC sequences. The reaction was 
completed in the presence of GC buffer only. The size of each reaction product was 
confirmed using a 1 % agarose gel (A). As bands corresponding to the correct size 
(4214 bp), this was subject to DpnI treatment and pooled during PCR purification. 
Similarly, an insert for NTH1 expression was also PCR amplified using relevant 
oligonucleotides flanked by corresponding LIC sequences and the size of the reaction 
products analysed on a 1 % agarose gel (B). The NTH1 insert reaction was performed 
in the presence of GC buffer. From this it was apparent that the reaction yielded PCR 
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products displaying DNA bands corresponding to products of the expected size (1824 
bp). The reaction was therefore subject to DpnI treatment before being pooled during 
PCR purification. 
Following this, the PCR products were subject to incubation with DpnI, to remove 
methylated, template DNAand the plasmid DNA was purified using a PCR purification 
kit. Afterwards, complementary overhangs were formed using the exonuclease 
activity of T4 DNA polymerase with only one dNTP in each respective reaction mix. 
The complementary overhangs were then annealed together by incubating insert and 
vector at a ratio of 1:1. Constructs were amplified by transformation into library 
efficient DH5α bacterial cells and grown on selective media. Successful colonies were 
inoculated into a 5 ml culture of LB media containing selective antibiotic. Amplified 
plasmid DNA was then purified from bacterial contaminants using the QIAprep Spin 
Miniprep Kit. A diagnostic digest using an appropriate restriction enzyme, ArvII, was 
then performed as a preliminary method to assess the identity of each plasmid. 
Products of the restriction digest were analysed on a 1 % agarose gel (Figure 65). 
From this, it was apparent that the correct sized products (2654, 1487, 1015 bp) were 
obtained following digestion of the generated plasmid (Figure 65, lane 2). To confirm 
this, the plasmid was also sequenced using the Sanger Sequencing Service (Source 
Bioscience Sequencing, Nottingham, UK) which further proved that the pCMV-3Tag-
NTH1 vector had been created.  
 
 
Figure 65. Restriction digest to determine the successful generation of an insert 
corresponding to NTH1 ligated into a pCMV-3TAG expression plasmid via a 
ligase independent cloning (LIC) strategy. An empty pCMV-3TAG vector was PCR 
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amplified using relevant oligonucleotides flanked by corresponding LIC sequences. 
Separately, an insert for NTH1 expression was also PCR amplified using relevant 
oligonucleotides flanked by corresponding LIC sequences. The size of both PCR 
products was confirmed on a 1% agarose gel before being subject to DpnI treatment 
and PCR purification. A ratio of vector and insert were then incubated (1:1) for 10 min 
at 22°C. Plasmid constructs were transformed into library efficient DH5α bacterial 
cells grown on selective agar. A 5 ml overnight culture of successful colonies was 
generated in the presence of selective antibiotics before plasmid DNA was purified 
via the QIAprep Spin Miniprep Kit (QIAGEN). A restriction digest of plasmid DNA 
using ArvII was then performed to preliminary assess if the correct construct has been 
formed. Products of the restriction digest were analysed on a 0.8 % agarose gel. The 
lanes (I and II) represent two different plasmids being assessed. Lane I is the control 
empty pCMV-3TAG vector, from this it was apparent that the correct digest sizes 
(3199 bp and 1015 bp) were produced via digestion of the plasmid. Lane II is pCMV-
3TAG-NTH1 vector. From this it was apparent that the correct digest sizes (2654, 
1487, 1015 bp) were produced via digestion of the plasmids. Note that the presence 
of bands above these expected sizes were believed to represent supercoiled DNA. 
This plasmid was then sequenced via the Sanger Sequencing Service to further 
confirm the correct sequence.  
 
Following the successful generation of the pCMV-3Tag-NTH1 vector, the mammalian 
expression plasmid for the K67R mutant was generated from this using a site-directed 
mutagenesis approach (Figure 66). The size of the PCR product was analysed using 
a 1 % agarose gel, however, this could not prove that the base substitution had been 
incorporated. Therefore, the plasmid was subject to sequencing using the Sanger 
Sequencing Service (Source Bioscience Sequencing, Nottingham, UK) to confirm this 
(see supplementary for sequencing data). 
 
Figure 66. PCR product following site directed mutagenesis of the pCMV-3Tag-
NTH1 vector bacterial expression plasmid to generate the NTH1 K67R variant. 
Per PCR reaction 250 pg/µl of pCMV-3Tag-NTH1 bacterial expression plasmid was 
incubated with 0.02 U/µl high fidelity Phusion polymerase, 200 µM dNTPs, 0.3 µM 
custom forward primer, 0.3 µM custom reverse primer and 1 x Phusion GC buffer with 
DMSO to generate pCMV-3Tag-NTH1-K67R plasmid. The size of the PCR product 
5174 bp 
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was analysed using a 1 % agarose gel in 1x TAE. The expected size of the PCR 
product in base pairs (5174 bp) is highlighted. 
 
Following this, equal amounts of wild type pCMV-3Tag-NTH1 and pCMV-3Tag-K67R-
NTH1 mammalian expression plasmids were transfected into HCT116p53+/+ cells with 
Lipofectamine 2000 transfection reagent. Following transfection, cells were incubated 
at 37°C in a humidified cell culture incubator for 24 h. Cells were then harvested in 
cold PBS, pelleted by centrifugation and proteins extracted. Cell extracts were 
analysed by 10 % SDS-PAGE and Western blotting using NTH1 specific antibodies. 
Western blots were also probed with tubulin specific antibodies, which acted as a 
loading control (Figure 67, A). Protein stability was quantified relative to the tubulin 
loading control following the transfection of 25 fmol of both NTH1 variants. Three 
biological replicates were performed to ensure reproducibility (Figure 67, B).  
 
 
Figure 67. Protein expression levels of wild type NTH1 (WT NTH1) and lysine 67 
NTH1 variant (K67R NTH1) following the transfection of titrated amounts of 
corresponding mammalian expression plasmids. HCT116+/+ cells were cultured 
in 10 cm dishes in serum-containing media until 80 % confluent. Cells were 
transfected with 25 fmol of pCMV-3Tag3a-NTH1 or 25 fmol of pCMV-3Tag3a-K67R-
NTH1 using Lipofectamine 2000 transfection reagent. Transfected cellular cultures 
were incubated for 24 h at 37°C in a humidified cell incubator. Cells were then 
harvested in cold PBS, pelleted and cellular protein extracted via the Tanaka method. 
Protein expression was analysed by 10 % SDS-PAGE and Western blotting using 
antibodies specific to NTH1 and tubulin loading control (A). Included is the mean 
NTH1/tubulin ratio across three biological replicates, with standard errors normalised 
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to the untreated control which was set to 1.0. *p<0.0005 as analysed by a one sample 
t-test (B).  
 
Remarkably, results demonstrated that the substitution of lysine 67 to arginine of 
NTH1 caused a statistically significant increase in the stability of the glycosylase (by 
approximately 1.6 fold) when compared to the wild type protein (Figure 67, B). 
Overall, this provides further evidence that lysine 67 is a major site of NTH1 
ubiquitylation in the cellular context. This data suggests that the stability of newly 
synthesised NTH1 protein may be dependent on lysine 67, which is a target site for 
TRIM26 dependent ubiquitylation and is associated with regulating protein stability. 
6.5 Quantification of siRNA dependent TRIM26 knockdown 
 
To further study the cellular impact of NTH1 ubiquitylation by TRIM26, I aimed to 
examine the effects of siRNA-mediated depletion of TRIM26 in cultured HCT116p53+/+ 
cells. Firstly, to demonstrate that siRNA sequences targeting TRIM26 are effective in 
reducing trim26 gene expression, quantitative PCR (qPCR) was performed using 
RNA extracted from cells. HCT116p53+/+ cells were cultured in serum-containing media 
in 10 cm dishes until 30-50 % confluent. Then they were transfected with 
Lipofectamine RNAiMAX only as a control, or 70 nM TRIM26 siRNA sequence 1 (5'-
CCGGAGAAUUCUCAGAUAA-3'), or 70 nm TRIM26 siRNA sequence 2 (5'-
GAGUCACAGGAACUCAUCU-3'), or 70 nm of both TRIM26 siRNA sequences 
combined for 72 h at 37°C in a humidified CO2 incubator. Cells were harvested in cold 
PBS, pelleted by centrifugation and RNA extracted. RNA was converted to cDNA by 
reverse transcription using oligo(dT) and then subject to qPCR analysis. Overall, 
qPCR analysis confirmed that both TRIM26 siRNA sequences were able to reduce 
trim26 expression, with sequence 1 being ~50 % efficient and sequence 2 being ~70 
% efficient. However, a superior knockdown (~80%) was achieved when a 
combination of both TRIM26 siRNA sequences were used (Figure 68). Due to this, 
knockdown of TRIM26 in subsequent studies in HCT116p53+/+ cells was achieved via 
a combination of 70 nM of each siRNA sequence.  
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Figure 68. Efficiency of TRIM26 knockdown using siTRIM26_1 or siTRIM26_2 or 
both combined over 72 h. Cells were grown in 10 cm dishes until 30-50 % confluent 
and treated with 10 µl Lipofectamine RNAiMAX transfection reagent (Mock), or 70 nM 
TRIM26 siRNA_1 (5'-CCGGAGAAUUCUCAGAUAA-3'), or 70 nM TRIM26 siRNA_2 
(5'-GAGUCACAGGAACUCAUCU-3'), or both TRIM26 siRNA sequences combined 
for 72 h. Following this, cDNA was created from harvested cell pellets and subject to 
qPCR analysis which confirms that a superior knockdown (~80 %) is achieved when 
both siRNA sequences are present. The percentage knockdown for each siRNA was 
quantitated by RT-PCR and the gene levels of mRNA (RQ value) calculated from the 
CT value for the RT-PCR run. Bar chart shows the mock (lipofectamine only) 
normalised to 1 and the relative gene levels after siRNA knockdown. A non-template 
control (just primers, no cDNA) was also run for each primer to check for any 
contamination which could alter results. 
 
6.6 TRIM26 does not regulate cellular steady state levels of NTH1  
 
To investigate if TRIM26 directly influences the steady state levels of NTH1in cells, 
particularly since TRIM26 promotes polyubiquitylation of NTH1 in cells, levels of NTH1 
in whole cell extracts from HCT116p53+/+ cells following TRIM26 depletion were 
investigated. Further to this, the suitability of two non-targeting (NT) controls from two 
different sources (Qiagen and Eurogentec) were assessed in comparison to 
Lipofectamine RNAiMAX only treated cells, as the transfection reagent only. It was 
anticipated that the NT control siRNA sequences should not influence NTH1 protein 
levels.   
HCT116p53+/+ cells were cultured in 35 mm dishes until 30-50 % confluent before being 
transfected with either Lipofectamine RNAiMAX only, TRIM26 siRNA (combining two 
separate TRIM26 siRNAs as in Figure 68), Qiagen NT control siRNA, or Eurogentec 
NT control siRNA and incubated for 72 h at 37°C in a humidified CO2 incubator. 
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Following this, cells were harvested in cold PBS, pelleted by centrifugation and 
proteins extracted. Cell extracts were separated by 10 % SDS-PAGE and analysed 
by Western blotting using antibodies specific to NTH1 (Figure 69, A). In addition to 
this, tubulin antibodies were utilised as a loading control to quantify NTH1 protein 
levels taking into account loading discrepancies. Levels of NTH1 protein expression 
were normalised to the level in the Lipofectamine RNAiMAX only treated cells, which 
was given a value of 1 (Figure 69, B). Three independent replicates of each treatment 
were completed and average NTH1 protein expression was compared (Figure 69, 
B).  
 
Figure 69. Cellular steady state NTH1 protein levels in HCT116p53+/+ whole cell 
extract, following treatment with; Lipofectamine RNAiMAX only, 140 nM non-
targeting (NT) controls (QIAGEN or Eurogentec), or 140 nM TRIM26 siRNA for 
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72 h. HCT116p53+/+ cells were grown in 35 mm dishes for 24 h until 30-50 % confluent 
and then treated with 2.5 µl Lipofectamine RNAiMAX transfection reagent only, or in 
the presence of 140 nM Qiagen non-targeting (NT) control siRNA, or 140 nM 
Eurogentec NT control siRNA or 140 nM TRIM26 siRNA for 72 h. Whole cell extracts 
were prepared via the Tanaka method and analysed by 10 % SDS-PAGE followed by 
Western blotting. The presence of NTH1 was observed via immunoblotting using 
NTH1 antibodies, with tubulin antibodies acting as a loading control (A). Levels of 
NTH1 were quantified relative to tubulin antibodies from at least three independent 
experiments. The mean NTH1/tubulin ratio was normalised to the Lipofectamine 
RNAiMAX only control, which was set to 1 (B). Statistical significance via independent 
t-tests compared Lipofectamine RNAiMAX only to each treatment (*p <0.05).  
 
Transfection of cells with NT control siRNA derived from Qiagen appeared to cause 
no dramatic change in NTH1 expression relative to Lipofectamine RNAiMAX only 
treated cells (Figure 69, A and B). However, transfection with NT control siRNA 
obtained from Eurogentec NT siRNA appeared to result in a significant reduction in 
NTH1 protein levels (p=0.041) (Figure 69, A and B).  This suggests that this specific 
NT control siRNA may in fact be causing non-specific effects within the cell and will 
not be a suitable siRNA control in subsequent studies. Following TRIM26 siRNA, 
quantification of NTH1 protein expression levels in whole cell extracts suggests that 
a depletion of TRIM26 protein expression does not significantly stabilise NTH1 steady 
state levels relative to tubulin across three independent replicates, compared to 
Lipofectamine RNAiMAX only treated cells or the Qiagen NT control siRNA (Figure 
69, A and B). This was surprising given the strong biochemical data acquired in vitro 
demonstrating that TRIM26 can catalyse polyubiquitylation of NTH1. However, these 
data indicated that TRIM26 does not play a significant role in controlling cellular 
protein levels of NTH1 in unstressed HCT116p53+/+ cells. 
6.7 NTH1 localisation is unaffected by TRIM26 depletion 
 
The literature has described that NTH1 is largely localised to the nucleus, with some 
levels of cytoplasmic NTH1 identified in the mitochondria (69, 95). To clarify this, I 
investigated the localisation of NTH1 in HCT116p53+/+ cells (Figure 70). I also aimed 
to explore if TRIM26 influences the cellular distribution of NTH1 via ubiquitylation by 
investigating the effects of siRNA induced knockdown of TRIM26 on the localisation 
of NTH1 protein.  
HCT116p53+/+ cells were grown in 10 cm dishes and transfected with either 
Lipofectamine RNAiMAX alone, Qiagen NT control siRNA, or TRIM26 siRNA and 
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incubated in a humidified CO2  incubator at 37°C for 72 h. Cells were then harvested 
in cold PBS, pelleted by centrifugation before being resuspended and incubated in 
two sequential cell fractionation buffers to generate a soluble cytoplasmic protein 
fraction, and a chromatin bound protein fraction with a centrifugation step used to 
generate the two fractions. The protein concentration of each fraction was evaluated 
by a Bradford assay to enable the separation of equal concentrations of each sample 
by 10 % SDS-PAGE followed by Western blotting with NTH1 specific antibodies 
(Figure 70, A). In addition, Western blots were immunoblotted with Lamin specific 
antibodies to act as a loading control for the chromatin bound fraction. Levels of NTH1 
protein expression relative to Lamin (at 69 kDa) were then quantified. This was 
repeated across three independent biological replicates. The average NTH1 protein 
levels were normalised to NTH1 expression in Lipofectamine RNAiMAX only levels, 
which was given a value of 1 (Figure 70, B).  
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Figure 70. Nuclear expression levels of NTH1 protein in HCT116p53+/+ cells 
following treatment with Lipofectamine RNAiMAX only, 140 nM Qiagen non-
targeting (NT) control or 140 nM TRIM26 siRNA. HCT116p53+/+ cells were grown in 
10 cm dishes until 30-50 % confluent and then treated with 10 µl Lipofectamine 
RNAiMAX transfection reagent only or with 140 nM Qiagen non-targeting (NT) control 
or 140 nM TRIM26 siRNA for 72 h. Cells were harvested and fractionated extracts 
prepared via incubation with fractionation buffer I/II in the presence of protease 
inhibitors to obtain a soluble cytoplasmic protein fraction and an insoluble nuclear 
protein fraction. The concentration of each extract was measured via Bradford assay 
and equal amounts of loaded onto a 10 % SDS-PAGE gel. Levels of NTH1 were 
analysed by SDS-PAGE followed by Western blotting with NTH1 specific antibodies 
in addition to Lamin specific antibodies as a loading control (A). Three independent 
repeats were completed and the mean NTH1/lamin ratio normalised to the 
Lipofectamine RNAiMAX only control, which was set to 1 (B). Statistical significance 
via independent t-tests compared Lipofectamine RNAiMAX only to each treatment (*p 
<0.05) but no significance was detected.  
 
As predicted, analysis of fractionated extracts demonstrated that NTH1 is almost 
entirely localised within the chromatin bound protein fraction (Figure 70, A, compare 
lanes 1 and 2). A very slight decrease in NTH1 levels was caused by treatment with 
Qiagen NT control siRNA although this was within experimental error and was not 
statistically significant demonstrating that this control siRNA had no dramatic impact 
on NTH1 protein cellular localisation (Figure 70, A, compare lanes 2 and 4). As 
observed with studies of NTH1 levels in whole cell extracts (Figure 69), a knockdown 
of TRIM26 mediated by siRNA does not result in a significant stabilisation of NTH1 
levels, but this experiment now demonstrates that the levels of NTH1 on chromatin 
are also unaltered (Figure 70, A, compare lanes 2 and 6). In fact, a reduction of 
TRIM26 expression caused a partial decrease in NTH1 protein levels. Furthermore, 
there was also no redistribution of NTH1 into the soluble fraction as a consequence 
of TRIM26 siRNA suggesting that an absence of TRIM26, and therefore of NTH1 
ubiquitylation, does not appear to impact on cellular localisation and on association of 
NTH1 with chromatin.  
Following this, I aimed to investigate in more detail if NTH1 was further 
compartmentalised within the nucleus itself and the potential dependence of this on 
the presence of TRIM26. For this, I amended the original fractionation protocol to 
generate a soluble nuclear protein fraction in addition to the chromatin bound protein 
fraction, by the incorporation of an additional step utilising a separate buffer. The 
localisation of NTH1 was evaluated by protein separation via 10 % SDS PAGE 
followed by Western blotting with NTH1 specific antibodies. Once again, Lamin 
antibodies were employed as a loading control for the chromatin bound fraction. 
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Levels of NTH1 were quantified and normalised against Lamin expression (Figure 
71).  
 
 
Figure 71. Cytoplasmic (C), soluble nuclear (SN) or chromatin bound (CB) 
localisation of NTH1 protein in HCT116 cells following treatment with 
Lipofectamine RNAiMAX only, or 140 nM TRIM26 siRNA. HCT116p53+/+ cells were 
grown in 10 cm dishes until 30-50 % confluent and then treated with 10 µl 
Lipofectamine RNAiMAX transfection reagent or 140 nm TRIM26 siRNA for 72 h. 
Cells were harvested then fractionated extracts were prepared via incubation with 
fractionation buffer I/II in the presence of protease inhibitors combined with a series 
of centrifugation steps to yield a cytoplasmic protein fraction (C), a soluble nuclear 
protein fraction (SN) and a chromatin bound protein extract fraction (CB). The 
concentration of each extract was measured via Bradford assay and equal amounts 
loaded onto a 10 % SDS-PAGE gel. Levels of NTH1 were analysed by Western 
blotting with NTH1 specific antibodies and antibodies specific to Lamin were used as 
a loading control (A). NTH1 levels were quantified relative to Lamin (at 69 kDa) across 
three independent repeats. The mean NTH1/lamin ratio was normalised to the 
Lipofectamine RNAiMAX only control, which was set to 1 (B). Statistical significance 
via independent t-tests compared Lipofectamine RNAiMAX only to TRIM26 siRNA (*p 
<0.05), but no significance was detected. 
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From this modified fractionation protocol of cellular extracts, it was concluded that 
NTH1 was still consistently largely found within the chromatin bound protein extract, 
although a trace amount of protein was visible in the soluble nuclear fraction (Figure 
71, A, lanes 2 and 5). Alike to the other cellular extract studies described previously, 
the siRNA dependent knockdown of the E3 ligase, TRIM26, did not substantially 
stabilise NTH1 levels (Figure 71). In fact a TRIM26 siRNA induced knockdown 
resulted in a mild (~10 %) increase in NTH1 protein expression, relative to the Lamin 
loading control (Figure 71, B). Statistical analysis reported that changes in NTH1 
expression levels (normalised to Lamin) in the chromatin bound fraction was not 
significantly different between the two treatment groups (p=0.58). Furthermore, an 
absence of TRIM26 did not impact significantly on the localisation of NTH1 in the 
chromatin bound fraction and particularly there was no relocalisation of NTH1 into the 
soluble nuclear fraction (Figure 71, A). This suggests that ubiquitylation dependent 
regulation of the steady state levels of NTH1 may not be directly TRIM26 dependent, 
or that the turnover rate of the protein in these cells is low under normal conditions. 
Additionally, this would also suggest that NTH1 is extremely stable when bound to 
chromatin and is not targeted directly for ubiquitylation by TRIM26.  
6.8 DNA damage induction of NTH1  
 
The above results suggest that TRIM26 does not play a substantial role in regulating 
the cellular steady state levels of NTH1, therefore I hypothesised that NTH1 protein 
levels are altered under conditions of oxidative stress and particularly following DNA 
damage. Therefore, I investigated whether TRIM26 regulates DNA damage 
responsive levels of the DNA glycosylase. For the purpose of inducing DNA damage 
via oxidative stress, it was decided that hydrogen peroxide exposure would be most 
appropriate. Hydrogen peroxide was deemed more superior, compared to inducing 
DNA damage via other methods such as ionising radiation, in more readily causing 
oxidative DNA damage which would be more applicable to repair by NTH1 (184). 
Therefore, the first step was to examine whether NTH1 protein is induced following 
DNA damage induced by hydrogen peroxide. Secondly, to examine if TRIM26 is 
implicated in regulation of NTH1 in response to hydrogen peroxide exposure, the 
effects of TRIM26 depletion via a siRNA mediated knockdown was assessed.  
HCT116p53+/+ cells were cultured in 10 cm dishes until 30-50 % confluent before being 
transfected with either Qiagen non-targeting (NT) control siRNA, or TRIM26 siRNA in 
a 37°C humidified CO2 incubator for 72 h. Following this, DNA damage was induced 
via exposure to hydrogen peroxide (150 µM) at 37°C in a humidified CO2 incubator 
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for 15 min. Untreated cells were subject to treatment with supplemented media only 
for 15 min as a control. After 15 min, the media only or hydrogen peroxide solutions 
were aspirated and replaced with fresh, serum-containing media and cells were 
returned to the 37°C humidified CO2 incubator and allowed to repair for specified time 
intervals (0-8 h). At the designated times, cells were harvested in cold PBS, pelleted 
by centrifugation and extracts prepared. Protein concentrations were assessed using 
a Bradford assay before equal amounts of each sample were separated by 10 % 
SDS-PAGE followed by analysis by Western blotting (Figure 72). Antibodies specific 
to NTH1 were used to evaluate NTH1 protein expression over time, with tubulin 
specific antibodies employed as a loading control. Levels of NTH1 expression were 
quantified relative to levels of tubulin which was then normalised to levels of NTH1 
protein expression observed in untreated cell cultures, which was set to 1 (Figure 
73). 
 
 
Figure 72. Western blotting analysis of fluctuations in NTH1 protein expression 
relative to tubulin over time following exposure to hydrogen peroxide following 
treatment with non-targeting siRNA or TRIM26 siRNA. HCT116p53+/+ cells were 
cultured in 10 cm dishes until 30-50 % confluent before being transfected with (A) 140 
nM Qiagen non-targeting (NT) control siRNA, or (B) 140 nM TRIM26 siRNA in a 37°C 
humidified cell culture incubator for 72 h. Afterwards, cells were exposed to 150 µM 
of hydrogen peroxide at 37°C in a humidified cell culture incubator for 15 min. The 
media was then removed before cells were washed in PBS and immersed in fresh 
serum-containing media. They were then returned to a 37°C humidified cell culture 
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incubator and allowed to repair for specified time intervals (0, 0.5, 1, 2, 4, 6, 8 h). At 
designated times cells were harvested and cell extracts were prepared via the Tanaka 
method. Protein concentrations were assessed via Bradford assays and equal 
amounts of extract were analysed by Western blotting. Antibodies specific to NTH1 
were used to quantify NTH1 protein expression over time relative to tubulin expression 
visualised using tubulin specific antibodies. 
 
Figure 73. Quantification of immunoblotting analysis of fluctuations in NTH1 
protein expression relative to tubulin over time following exposure to hydrogen 
peroxide following treatment with non-targeting (NT) siRNA or TRIM26 siRNA. 
HCT116p53+/+ cells were cultured in 10 cm dishes until 30-50 % confluent before being 
transfected with 140 nM Qiagen non-targeting (NT) control siRNA, or 140 nM TRIM26 
siRNA in a 37°C humidified cell culture incubator for 72 h. Afterwards, cells were 
exposed to 150 µM of hydrogen peroxide at 37°C in a humidified cell culture incubator 
for 15 mins. The media was then removed before cells were washed in PBS and 
immersed in fresh serum-containing media. Cells were then returned to a 37°C 
humidified cell culture incubator and allowed to repair for specified time intervals (0, 
0.5, 1, 2, 4, 6, 8 h). At designated times, cells were harvested and cell extracts were 
prepared via the Tanaka method. Protein concentrations were assessed via Bradford 
assays and equal amounts of extract were analysed by Western blotting. Antibodies 
specific to NTH1 were used to quantify NTH1 protein expression over time relative to 
tubulin expression visualised using tubulin specific antibodies. Levels of NTH1 protein 
relative to tubulin were quantified from at least three independent experiments. Shown 
is the mean NTH1/tubulin ratio with standard errors normalised to the untreated 
control which was set to 1.0. *p<0.05, **p<0.02 as analysed by a one sample t-test of 
ratios at the respective time points comparing NT control siRNA and TRIM26 siRNA 
treated cells. 
From the time dependent DNA damage response assay, it is apparent that NTH1 
protein expression levels in the presence of a NT control siRNA increase by ~1.3-fold 
from 0.5 h post-treatment, and continue to remain at this level for up to 4 h before 
returning to the levels seen in the untreated controls after 6-8 h post-treatment with 
hydrogen peroxide (Figure 72A and Figure 73). Following the depletion of TRIM26 
RNA (using siRNA) there is a modest, but statistically significant increase in NTH1 
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protein levels above those seen with the NT siRNA control particularly at 0.5-2 h post-
treatment (Figure 72B and Figure 73). It is important to acknowledge that we were 
only able to deplete ~75 % of TRIM26 RNA (using siRNA), and that cells still contained 
~25 % of TRIM26 RNA, which may be supressing the level of induction of NTH1 
observed following treatment with hydrogen peroxide. It is worth noting that we 
attempted to study TRIM26 protein levels in cells, following siRNA medicated 
depletion, but our observations were limited by the specificity of the TRIM26 
antibodies available.  
Despite this, the results from this assay advocates that induction of NTH1 in response 
to cellular DNA damage may be regulated in a TRIM26 dependent manner. It appears 
that the E3 ligase may play a role in carefully controlling the induction of NTH1 protein 
levels in response to DNA damage induced by oxidative stress. Due to the 
bifunctionality of NTH1, uncontrolled over amplification of the glycosylase may result 
in the excess formation of abasic sites or DNA single strand breaks which would be 
counteractive to DNA restoration and maintaining genome stability. It is however 
notable that the protein levels of NTH1 do eventually return to untreated control levels 
even in the absence of TRIM26, suggesting an alternative mechanism by which NTH1 
protein levels are degraded. However, it is possible that the residual RNA levels (~25 
%) of TRIM26 may be responsible for this effect. Nevertheless, this supports an 
important role for TRIM26 in controlling NTH1 protein following DNA damage. 
6.9 Cell survival in response to NTH1 regulation 
 
Following the demonstration that regulation of NTH1 protein induction via TRIM26 
occurs in response to hydrogen peroxide-induced DNA damage (Figure 73) I next 
aimed to explore whether this influenced the ability of cells to survive post-treatment. 
Predictably, a further elevation in the protein levels of NTH1 in the absence of TRIM26 
(Figure 73) should increase resistance of cells to oxidative stress. To assess this, I 
utilised the clonogenic assay to examine the ability of a single cell to form a defined 
colony following treatment with hydrogen peroxide (53), and the dependence of this 
on TRIM26 protein.  
Initially, the appropriate concentration of hydrogen peroxide to use was evaluated via 
a titration assay. HCT116p53+/+ cells were cultured in 10 cm dishes until between 30-
50 % confluent, before being treated with either Lipofectamine RNAiMAX only or 
TRIM26 siRNA for 72 h. Following this, cells were treated with increasing 
concentrations of hydrogen peroxide (0-300 µM) for 15 min at 37 °C. Then cells were 
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trypsinised and a defined number seeded into 6 well plates before being incubated 
for up to 2 weeks at 37 °C in a humidified CO2 incubator. Cells were fixed with 
glutaraldehyde and stained with crystal violet. Cell survival was determined by 
counting the fraction of cells which retained the ability to produce colonies, normalised 
to the untreated control which was set to 1.0. From this single preliminary experiment, 
it was established that a dose of 0-400 µM hydrogen peroxide was sufficient to 
produce a suitable survival curve using HCT116p53+/+ cells (Figure 74). However, it 
was noticeable even from this preliminary experiment, that cells lacking TRIM26 
through siRNA depletion appeared to be more resistant to the cell killing effects of 
hydrogen peroxide. 
 
Figure 74. HCT116p53+/+ clonogenic cell survival in response to increasing 
concentrations of hydrogen peroxide with or without TRIM26 depletion. 
HCT116p53+/+ cells were cultured in 10 cm dishes until 30-50 % confluent before being 
transfected with 10 µl of Lipofectamine RNAiMAX only (Mock, solid line) or 140 nM of 
TRIM26 siRNA (dashed line) for 72 h. Following this, cells were treated with hydrogen 
peroxide (0 - 800 μM) for 15 min at 37 °C in a humidified cell incubator. Subsequently, 
cells were washed in PBS, trypsinised, counted and a defined number seeded into a 
6-well plate before being incubated at 37 °C in a humidified cell incubator for up to 2 
weeks. Colonies were then fixed and stained with 6 % glutaraldehyde, 0.5 % crystal 
violet for 30 min. Plates were washed, left to air dry overnight and colonies counted 
using the GelCount colony analyser (Oxford Optronics, Oxford, UK). Relative colony 
formation (surviving fraction) was expressed as colonies per treatment level versus 
colonies that appeared in the untreated control. 
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In order to avoid potential off target effects induced by NT control siRNA sequences, 
I then compared the clonogenic cell survival curves following treatment with two 
different NT control siRNA sequences obtained from two different sources, to a 
Lipofectamine RNAiMAX only control (Figure 74). Once again, HCT116p53+/+ cells 
were cultured in 10 cm dishes until 30-50 % confluent before being transfected with 
either Lipofectamine RNAiMAX only, Qiagen NT siRNA, or Eurogentec NT siRNA for 
72 h. Following this, cells were treated with increasing concentrations of hydrogen 
peroxide (0-800 μM) for 15 min. Then a defined number of cells were seeded into 6 
well plates in triplicate and incubated for up to 2 weeks at 37 °C in a humidified CO2 
incubator (Figure 75).  
Figure 75. HCT116 clonogenic cell survival in response to increasing 
concentrations of hydrogen peroxide with Lipofectamine only, Eurogentec NT 
siRNA or Qiagen NT siRNA. HCT116 cells were cultured in 10 cm dishes until 30-
50 % confluent before being transfected with 10 µl of Lipofectamine RNAiMAX only 
(Mock, solid line), or 140 nM Eurogentec NTC siRNA (grey line), or 140 nM Qiagen 
NTC siRNA (dashed line) for 72 h.  Following this, cells were treated with hydrogen 
peroxide (0 – 400 µM) for 15 min at 37 °C in a humidified cell incubator. Subsequently, 
cells were washed in PBS, trypsinised, counted and a defined number seeded into a 
6-well plate before being incubated at 37 °C in a humidified cell incubator for up to 2 
weeks. Colonies were then fixed and stained with 6 % glutaraldehyde, 0.5 % crystal 
violet for 30 min. Plates were washed, left to air dry overnight and colonies counted 
using the GelCount colony analyser (Oxford Optronics, Oxford, UK). Relative colony 
formation (surviving fraction) was expressed as colonies per treatment level versus 
colonies that appeared in the untreated control. 
From this second preliminary study, it was apparent that the survival curve induced 
by the NT control siRNA sequences obtained from Qiagen was most similar to the cell 
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survival observed by treatment with Lipofectamine RNAiMAX only (Figure 75). In 
contrast, the Eurogentec NT control siRNA caused significantly increased cellular 
resistance to increasing hydrogen peroxide concentration. Based on this, and on the 
previous Western blotting data where the Qiagen NT control siRNA had no significant 
impact on NTH1 protein levels (Figure 69), this was deemed as the most suitable 
control siRNA to utilise in subsequent clonogenic survival assays.  
After these preliminary experiments, the influence of TRIM26 depletion on survival of 
cells in response to hydrogen peroxide was thoroughly examined, in comparison to 
the Qiagen NT control siRNA, utilising three independent experiments. As expected, 
with exposure to increasing concentrations of hydrogen peroxide, HCT116p53+/+ cell 
survival decreased across all treatments in a dose dependent manner (Figure 76). 
However following depletion of TRIM26 via siRNA, I found that this caused a 
statistically significant resistance (p<0.0001) to hydrogen peroxide-induced cell killing 
in comparison to the NT control siRNA treated cells. This is represented by an upward 
shift of the survival curve compared to the NT control siRNA treated cells. This 
observable resistance is predictably due to an increased DNA damage response due 
to induction of NTH1 protein levels that are further stabilised in the absence of TRIM26 
protein expression (Figure 73). This change in surviving fraction is particularly 
impressive, especially considering that only a knockdown efficiency of approximately 
80 % was achieved using a combination of two siRNA sequences.  Nevertheless, this 
demonstrates that the levels of TRIM26 are important in regulating the cellular 
response to DNA damage induced by oxidative stress. To additionally support that 
increased resistance of cells to hydrogen peroxide in the absence of TRIM26 is 
caused by NTH1 protein accumulation, I overexpressed NTH1 using a mammalian 
expression plasmid (Figure 63) in HCT116p53+/+ cells to mimic the conditions of 
TRIM26 depletion. 
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Figure 76. HCT116 clonogenic cell survival in response to increasing 
concentrations of hydrogen peroxide with 140 nM TRIM26 siRNA, or 140 nM 
Qiagen NT siRNA, or partial NTH1 overexpression. HCT116 cells were cultured in 
10 cm dishes until 30-50 % confluent before being transfected with 10 ul of 
Lipofectamine RNAiMAX only (blue line), or 140 nM Qiagen NTC siRNA (dashed line), 
or 140 nM TRIM26 siRNA (black line) for 72 h, or a partial overexpression of 60 ng 
pCMVNTH1 mammalian plasmid (grey line) for 24 h. Following this, cells were treated 
with hydrogen peroxide (0 - 300 µM) for 15 min at 37 °C in a humidified cell incubator. 
Subsequently, cells were washed in PBS, trypsinised, counted and a defined number 
seeded into a 6-well plate before being incubated at 37 °C in a humidified cell 
incubator for up to 2 weeks. Colonies were then fixed and stained with 6 % 
glutaraldehyde, 0.5 % crystal violet for 30 min. Plates were washed, left to air dry 
overnight and colonies counted using the GelCount colony analyser (Oxford 
Optronics, Oxford, UK). Relative colony formation (surviving fraction) was expressed 
as colonies per treatment level versus colonies that appeared in the untreated control. 
Statistical analysis was performed using the CFAssay for R package (18).  
Exogenous NTH1 expression appeared able to recapitulate cellular resistance to 
hydrogen peroxide. This was statistically significant (p<0.0001) when compared to the 
NT siRNA control treated cells (Figure 76), and the level of resistance was similar to 
that achieved following treatment of cells with TRIM26 siRNA. This is consistent with 
the observation that depletion of TRIM26 induces increased cell survival directly by 
causing an elevation in NTH1 protein levels following conditions of cellular oxidative 
DNA damage.  
0.01
0.1
1
0 50 100 200 300
Su
rv
iv
in
g 
fr
ac
ti
o
n
Hydrogen peroxide (nM)
TRIM26 siRNA Qiagen NTC NTH1 overexpression
202 
 
6.10 DNA damage repair kinetics and dependence on TRIM26 
 
Since I effectively demonstrated that depletion of TRIM26 protein expression levels 
modulates cellular sensitivity to hydrogen peroxide by regulating NTH1 protein 
induction, I next aimed to examine the impact on cellular DNA damage repair kinetics. 
Since I had shown that cellular survival is increased following TRIM26 siRNA, which 
can be mimicked by NTH1 overexpression, then predictably this is due to increased 
capacity for oxidative DNA damage repair due to increased NTH1 protein levels. 
Originally developed in 1984, the single cell gel electrophoresis (comet) assay is a 
widely used technique used to visualise and quantify DNA damage within individual 
cells (114). More specifically, I aimed to utilise the alkaline comet assay to analyse 
the repair of hydrogen peroxide induced DNA strand breaks and alkali-labile sites, 
which are generated directly or as intermediates of DNA base damage repair (145). 
The goal was then to establish if TRIM26 had any effect on DNA damage repair 
kinetics when protein expression levels of the E3 ligase were depleted using siRNA, 
and the contribution of NTH1 protein specifically to this effect.  
HCT116p53+/+ cells were therefore seeded into 35 mm dishes and cultured until at least 
80 % confluency was achieved. After this, exponentially growing cells in each culture 
were trypsinised and cells in suspension were transferred into a 24-well plate. DNA 
damage was induced by treating cells in suspension with hydrogen peroxide. 
Previous work within our group had determined treating cells in suspension with a 
genotoxin before embedding them within agarose is superior in terms of analysing 
DNA damage repair kinetics compared to treating cultured cells as a monolayer with 
a genotoxic insult (112). Following hydrogen peroxide treatment of cells in suspension 
in media for 5 min, cells were diluted in molten low melting point agarose and 
immediately added onto a glass microscope slide pre-coated in normal melting point 
agarose. The cell/agarose suspension was covered with a glass coverslip and 
transferred to a metal tray on ice to encourage the agarose to set. At this point the 
slides containing cells were placed in a humidified chamber for certain time points 
(10-120 min) to promote cellular DNA damage repair. After this, the cover slip was 
removed and cells lysed in cold lysis buffer before subsequent DNA unwinding, 
electrophoresis and staining of the DNA.  
Initially, for the purpose of identifying a suitable hydrogen peroxide concentration to 
induce an appropriate level of DNA damage of cells in suspension, a titration assay 
was performed which tested a range of concentrations (0 – 40 µM). From previous 
experience within our laboratory, the ideal level of detectable DNA damage that 
203 
 
migrates during electrophoresis to form the comet tail (% tail DNA) should be ~40 %, 
which is also at a point where the cells are able to repair the DNA damage efficiently 
without going into apoptosis (112).  
 
 
Figure 77. DNA damage repair kinetics as measured by the single cell gel 
electrophoresis (comet) assay following a titration of increasing concentrations 
of hydrogen peroxide. HCT116p53+/+ cells were cultured in 35 mm dishes until 80 % 
confluent at 37 °C in a humidified cell incubator. After this, cells were trypsinised, 
counted and a defined number transferred into a 24-well plate in suspension in media. 
DNA damage was induced by treating cells with 0-40 µM of hydrogen peroxide for 5 
min on ice. Cells are the mixed with molten low melting point agarose (at ~35 °C) 
before being transferred to a microscope slide pre-coated with normal melting point 
agarose. A cover slip is then placed over the cell/agarose mixture then the agarose is 
set by placing on a metal tray on ice for ~ 2 min. The cover slip was then removed 
and repair halted by placing slides in cold lysis buffer for at least 1 h. The slides were 
then placed in electrophoresis buffer and DNA allowed to unwind for 30 min before 
subsequent electrophoresis followed by staining stages. DNA damage was then 
analysed using Komet 5.5 (Andor Technology, Belfast, UK) measuring 50 cells per 
slide and >2 slides per time interval. Three independent replicates of the alkaline 
comet assay were performed to ensure reproducibility and the % tail DNA values are 
shown.  
 
From the titration assay using increasing concentrations of hydrogen peroxide 
treatment (Figure 77), it was apparent that an optimum level of ~40 % of DNA damage 
(% tail DNA) was induced using between 5-10 µM of hydrogen peroxide incubated at 
5 min at 37 °C in a humidified CO2 incubator. Below 5 µM of hydrogen peroxide, it is 
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likely that the level of DNA damage is not sufficient to allow detailed kinetics of DNA 
damage repair and may affect our observations regarding the impact of TRIM26 
depletion. Similarly, beyond 10 µM the level of quantified DNA damage is between 
70-90 %. At this level, it is likely that cells will not be able to repair the excessive DNA 
damage and will probably undergo apoptosis. Therefore, this preliminary study 
dictated that for subsequent repair studies, a hydrogen peroxide concentration of 7.5 
µM would be most appropriate.  
For the purpose of investigating the impact of TRIM26 depletion on DNA damage 
repair kinetics via the alkaline comet assay, HCT116p53+/+ cells were cultured in 35 
mm dishes until 50 % confluent. Cells were transfected with either Qiagen NT control 
siRNA or 140 nM TRIM26 siRNA and incubated at 37 °C in a humidified CO2 incubator 
for 72 h. Additionally to study the impact of partial overexpression of NTH1, and thus 
mimicking the effects of TRIM26 depletion, HCT116p53+/+ cells were cultured in 35 mm 
dishes until approximately 80 % confluent before being transfected with pCMV-NTH1 
mammalian expression plasmid for 24 h at 37 °C in a humidified CO2 incubator. After 
this, all of the treated cells were trypsinised, counted and diluted to 1x105 cells/ml and 
transferred into a 24-well plate in suspension in media. DNA damage was induced by 
treating cells in suspension with 7.5 µM of hydrogen peroxide for 5 min on ice. Cells 
were mixed with molten low melting point agarose (at ~35 °C) before being transferred 
to a microscope slide pre-coated with normal melting point agarose. A cover slip was 
then placed over the cell/agarose mixture, then the agarose was set by placing on a 
metal tray on ice for ~ 2 min. For DNA damage repair kinetic studies, the slides were 
transferred to a humidified chamber pre-warmed at 37 °C and allowed to undergo 
DNA damage repair for the allocated time intervals (0-120 min). The cover slip was 
then removed and repair halted by placing slides in cold lysis buffer containing high 
salt and detergent for at least 1 h. The slides were then placed in electrophoresis 
buffer and DNA allowed to unwind for 30 min before subsequent electrophoresis. The 
DNA was stained using SYBR Gold and the levels of DNA single strand breaks and 
alkali-labile sites was then analysed using Komet 5.5 software (Andor Technology, 
Belfast, UK) measuring 50 cells per slide and >2 slides per time interval. Overall, three 
independent replicates of the alkaline comet assay were performed to ensure 
reproducibility (Figure 78). The % tail DNA measured at each time interval was 
normalised to the % tail DNA measured at the 0 min time interval which is set to 100 
%, to allow an assessment of the kinetics of DNA damage repair.  
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Figure 78. The implication of depleted TRIM26 or partially overexpressed NTH1 
protein expression levels on DNA damage repair kinetics as measured by the 
single cell gel electrophoresis (comet) assay. HCT116p53+/+ cells were cultured in 
35 mm dishes until 30-50 % confluent before being transfected with either 140 nM 
Qiagen NT control siRNA or 140 nM TRIM26 siRNA and incubated at 37 °C in a 
humidified cell incubator for 72 h. Alternatively, for the partial overexpression of NTH1, 
HCT116p53+/+ cells were cultured in 35 mm dishes until 80 % confluent before being 
transfected with 60 ng of pCMVNTH1 mammalian expression plasmid and incubated 
at 37 °C in a humidified cell incubator for 24 h. After this, cells were trypsinised, 
counted and a defined number transferred into a 24-well plate in suspension in media. 
DNA damage was induced by treating cells with 7.5 µM of hydrogen peroxide for 5 
min on ice. Cells were mixed with molten low melting point agarose (at ~35 °C) before 
being transferred to a microscope slide pre-coated with normal melting point agarose. 
A cover slip was then placed over the cell/agarose mixture, then the agarose was set 
by placing on a metal tray on ice for ~ 2 min. For DNA damage repair kinetic studies, 
the slides were transferred to a humidified chamber pre-warmed at 37 °C and allowed 
to undergo DNA repair for the allocated time intervals. The cover slip was then 
removed and repair halted by placing slides in cold lysis buffer for at least 1 h. The 
slides were then placed in electrophoresis buffer and DNA allowed to unwind for 30 
min before subsequent electrophoresis followed by staining stages. DNA damage 
was then analysed using Komet 5.5 (Andor Technology, Belfast, UK) measuring 50 
cells per slide and >2 slides per time interval. Three independent replicates of the 
alkaline comet assay were performed to ensure reproducibility. The % tail DNA 
damage measured was normalised to the % tail DNA at the 0 min interval which was 
set to 100 %. A t-test was performed at each time interval comparing Qiagen NTC 
treated cells with either TRIM26 siRNA treated cells or following a partial 
overexpression of NTH1 *p < 0.05, **p < 0.02, ***p < 0.01. 
 
Performing the alkaline comet assay with a range of repair times following hydrogen 
peroxide induced DNA damage, enabled me to investigate differences in repair 
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kinetics between each treatment. As expected over time, the % tail DNA measured 
decreased and across all treatments gradually from 0-120 min, and particularly at 120 
min the % tail DNA is generally equivalent to that of untreated cells, showing that most 
of the genomic damage had been repaired and DNA integrity restored. In NT control 
siRNA treated cells, after 10 min the % tail DNA increases slightly beyond the 
normalised level at 0 min. This most likely represents the formation of single strand 
breaks following incision of the DNA backbone after the removal of damaged, oxidised 
DNA bases (Figure 78). However, between 20-60 min following treatment with 
hydrogen peroxide, the % tail DNA decreases significantly which is consistent with 
the kinetics of repair of DNA single strand breaks and base damage through the BER 
pathway. 
In comparison to Qiagen NT control siRNA treated cells, it is noticeable that improved 
DNA damage repair kinetics are observed with an siRNA induced depletion of TRIM26 
protein expression levels represented by the average % tail DNA measured being 
consistently decreased compared to the average % tail DNA of NT control siRNA cells 
across each of the time intervals (Figure 78). This difference is statistically significant 
at 10-60 min post-treatment (*p < 0.05, **p<0.02) and reflects the increased capacity 
of TRIM26 depleted cells to perform repair of DNA damage induced by hydrogen 
peroxide. Furthermore, a partial overexpression of NTH1 also induces faster DNA 
damage repair kinetics, mimicking the effects of TRIM26 depletion (Figure 78). In fact 
the difference in % tail DNA is statistically significant in NTH1 overexpressing cells 
compared to Qiagen NT control siRNA treated cells at 10-120 min post-treatment 
(*p<0.05, **p<0.02, ***p<0.01), demonstrating increased DNA repair capacity of 
NTH1 overexpressing cells.  Therefore I have clearly demonstrated that a partial 
overexpression of NTH1 mimics the effects of depletion of TRIM26 protein expression 
levels by improving DNA damage repair kinetics in response to hydrogen peroxide 
tretament of HCT116p53+/+ cells. An overexpression of NTH1 results in an increased 
presence of the BER glycosylase, meaning that oxidised DNA base lesions induced 
by hydrogen peroxide exposure may be more readily excised and repaired. Likewise, 
a depletion of TRIM26 levels may induce faster DNA repair kinetics by directly 
influencing damage responsive NTH1 protein levels, alike to those observed during 
the time course assay (Figure 73).  
6.11 Results III summary  
 
Overall, the main aim of this chapter was to examine the ubiquitylation dependent 
regulation of NTH1 in a cellular context. In previous Chapters, I identified TRIM26 as 
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the major E3 ligase involved in the enzymatic cascade which facilitates ubiquitin 
attachment to recombinant NTH1 during in vitro ubiquitylation assays. I also clarified 
that the N-terminal region of NTH1 is subject to regulation via polyubiquitylation, 
specifically lysine 67, suggesting that this is the target within the NTH1 protein that is 
ubiquitylated by TRIM26 for proteasomal degradation. The main purpose of the wirk 
detailed in this final chapter was to explore the mechanisms of TRIM26 dependent 
regulation of NTH1 within cells, with a focus on examining the role of TRIM26 in 
regulating NTH1 protein stability, plus the importance of this mechanism in the cellular 
response to DNA damage. 
In summary, studies in HCT116p53+/+ cells confirmed that NTH1 is undoubtedly subject 
to ubiquitylation dependent regulation in cells. In particular, the accumulation of NTH1 
following inhibition of the proteasome by MG-132 suggests that ubiquitylation may 
influence stabilisation of the protein levels of NTH1. Immunoprecipitation studies 
following overexpression of TRIM26 in HCT116p53+/+ cells provided evidence that this 
is an E3 ligase enzyme implicated in the ubiquitylation-dependent regulation of NTH1 
within cells. Indeed, an increased smearing pattern representative of increased 
polyubiquitylation was observed following overexpression of TRIM26, suggesting that 
the protein is eventually targeted for degradation by the proteasome. Data using site-
directed of the mammalian expression plasmid for NTH1, suggests that the stability 
of newly synthesised NTH1 protein may be dependent on lysine 67, which is a target 
site for TRIM26 dependent ubiquitylation and is associated with regulating protein 
stability. 
By supressing TRIM26 protein expression levels using an siRNA induced knockdown, 
surprisingly it became increasingly apparent that TRIM26 dependent ubiquitylation 
was not implicated in the regulation of the steady state protein levels of NTH1. In fact, 
this was observed in whole cell extract and fractionated cellular extracts which 
confirmed that NTH1 is largely localised to the nucleus, and mostly chromatin bound.  
Although, TRIM26 has no impact on either the accumulation of NTH1 on chromatin in 
unstressed cells, or on the localisation of NTH1 into the cytoplasmic or soluble nuclear 
compartments of the cell. I demonstrate that TRIM26 in fact regulates DNA damage 
responsive levels of NTH1 protein. This was supported by analysis of whole cell 
extract protein expression from HCT116p53+/+ cells following different repair times after 
hydrogen peroxide exposure. Indeed, I firstly demonstrate that NTH1 protein is 
induced in response to oxidative stress following hydrogen peroxide treatment of cells 
at time points where BER is most active (0.5-2 h), and that depletion of TRIM26 
instigated an enhanced elevation of NTH1 levels in response to the genotoxic 
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treatment. Heightened stabilisation of NTH1 protein expression in response to 
TRIM26 suppression may facilitate the ability of cells to survive excessive DNA 
damage insult, which was demonstrated using the clonogenic survival assay. 
Increased cellular resistance to hydrogen peroxide following TRIM26 siRNA was 
observed. Recapitulation of increased cellular survival following TRIM26 depletion 
was achieved via a partial overexpression of NTH1, resulting in a similar survival 
curve, as that observed with TRIM26 siRNA mediated knockdown. This supported the 
hypothesis that the ubiquitylation dependent regulation of NTH1, via TRIM26, may 
impact on the cellular ability to withstand oxidative stress and genotoxic insults. 
Related to this, TRIM26 depletion also resulted in faster DNA damage repair kinetics; 
measured via the alkaline comet assay. Similar repair rates were also observed with 
partial NTH1 overexpression. Therefore, the alkaline comet assay further advocates 
that TRIM26 carefully regulates NTH1 protein levels in response to oxidative DNA 
damage. This interaction influences rates of DNA damage repair and overall survival.  
Overall, I have gained additional evidence relating to in vitro studies demonstrating 
that TRIM26 can target NTH1 for polyubiquitylation, and now further provide evidence 
that this mechanism is important in a cellular context, particular under conditions of 
oxidative stress. Whilst the literature specifically relating to this is quite sparse, some 
of the data compare well to reports in the literature. For instance, other groups have 
documented that NTH1 is predominantly localised to the nucleus (69, 95). Likewise, I 
also identified that NTH1 is mainly nuclear although predominantly associated with 
chromatin. This observation is also in agreement with reports in the literature that 
have recognised that NTH1 may play an important role in the repair of DNA base 
lesions which are occluded within histone octamers (130). With regards to the 
ubiquitylation dependent regulation of NTH1, my studies following treatment of cells 
with a potent proteasomal inhibitor (MG-132) advocate that the glycosylase is subject 
to ubiquitylation in cells. This observation is supported by a proteomic screen which 
identified that NTH1 is ubiquitylated, although the enzymes involved in the 
ubiquitylation process were not elucidated (34). However I now provide evidence that 
TRIM26 is the major E3 ligase in cells that catalyses ubiquitylation, and subsequent 
proteasomal degradation, of NTH1. Furthermore I have clearly demonstrated that 
ubiquitylation-dependent regulation of NTH1 by TRIM26 is a crucial mechanism for 
controlling the cellular NTH1 protein levels in response to oxidative stress, and 
therefore is a vital process for maintaining genome stability.   
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Chapter 7 - Discussion 
7.1 Overview 
NTH1 is an important biological enzyme implicated in the repair of oxidised pyrimidine 
DNA nucleobases; such as 5-hydroxyuracil or 5-hydrocytosine, during the BER 
pathway. Crucially, NTH1 is involved in the excision and repair of the highly mutagenic 
DNA base lesion, Tg (42, 76, 165). Although nth1 knockout mouse models display no 
overt phenotype, due to redundancy between the BER glycosylases (149), nth1 
depleted cells exhibit hypersensitivity to DNA damaging agents (184) and reduced 
repair capacity of oxidative DNA base lesions (51, 123). Furthermore, double 
knockout models of nth1 and neil1 demonstrate increased tumour incidence (26). 
More specifically, altered NTH1 expression has been implicated in a number of human 
cancers; including colorectal cancer (175), prostate cancer (156) and gastric cancer 
(58). In addition, expression of a single nucleotide polymorphism of NTH1, present in 
6.2 % of the global population, results in the accumulation of chromosomal 
aberrations and cellular transformation (55). Collectively, these observations highlight 
the importance of NTH1 in the preservation of genomic stability and suggest an anti-
tumorigenic role of the glycosylase. Despite this importance, the molecular 
mechanisms underlying the regulation of cellular NTH1 remain understudied.  
Notably, a number of studies have demonstrated that enzymes involved in the BER 
pathway are regulated by PTMs (25, 48), including ubiquitylation. Indeed, APE1 (102), 
Pol β (125) and PNKP (124), have all been shown to be regulated by ubiquitylation. 
Ubiquitylation is a process during which single or multiple ubiquitin moieties are added 
onto specific lysine residues of substrate proteins, via a cascade of ubiquitylation 
enzymes. The final stage of ubiquitylation is dependent on the action of E3 ubiquitin 
ligase enzymes. It is estimated that there are over 600 E3 ligase enzymes, which 
define the specificity of the ubiquitin attachment to specific substrate proteins. The 
ubiquitylation dependent regulation of some BER enzymes has already been 
confirmed, plus the specific E3 ligase enzymes involved have been identified. For 
instance, the E3 ligase enzymes implicated in the regulation of APE1, Pol β and PNKP 
have been characterised as UBR3, CHIP and Mule, and Cul-4A-DDB1-STRAP, 
respectively (102, 124-126). In fact, recent studies within our laboratory, discovered 
that TRIM26 is the major E3 ligase responsible for the ubiquitylation dependent 
regulation of the BER glycosylase, NEIL1 (46). Previous studies within the literature 
have focused on enzymes involved further downstream in the BER pathway (25, 48), 
particularly, in the DNA polymerase and DNA ligase steps of BER. However, the most 
recent study in our laboratory (46), highlights that more emphasis should focus on 
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understanding the regulation of enzymes involved in the initial stages of the BER 
pathway. In fact, proteomic screens have suggested that numerous DNA glycosylase 
enzymes are subject to ubiquitylation; including NTH1, MDB4, TDG and NEIL2 (34), 
but the UPP enzymes involved and the biological impact of this regulation is not fully 
understood. Furthermore, the limitations of proteome wide studies could even mean 
that the ubiquitylation dependent regulation of certain proteins remains undetected 
(34).  
Despite the potential limitations of proteomic screens, it was still reasonable to 
hypothesise that NTH1 was subject to ubiquitylation dependent regulation, catalysed 
by specific E3 ligase enzymes. Therefore, the overarching aim of this project was to 
understand the molecular mechanisms employed by human cells to regulate the 
steady-state and DNA damage induced levels of NTH1 via ubiquitylation, with specific 
emphasis on discovering the E3 ligase enzymes involved. 
7.2 Identification of TRIM26 as the major E3 ligase for NTH1 
A well refined, unbiased protein purification technique, previously utilised in our 
laboratory was employed to identify candidate E3 ligase enzymes. Fractionated 
human cell extracts are generated using a series of column chromatography columns, 
then examined for E3 ligase activity via in vitro ubiquitylation assays containing the 
substrate NTH1 protein (46, 125, 126). Using this technique, the major E3 ligase in 
human cell extracts that catalysed the in vitro ubiquitylation of NTH1 was confined to 
one chromatography fraction. Mass spectrometry analysis identified that TRIM26 was 
the only candidate E3 ligase present in this ubiquitylated fraction. I further 
strengthened this finding by repeating in vitro NTH1 ubiquitylation assays using 
recombinant TRIM26, expressed and purified from bacterial cells. Together, these 
findings identify TRIM26 as the major E3 in human cell extracts that catalyses the 
ubiquitylation of NTH1.  
During isolation and identification of TRIM26 as the major E3 ligase involved in the 
ubiquitylation of NTH1 in vitro, a separate ubiquitylation activity was observed, 
suggesting the presence of another minor E3 ligase with NTH1 specificity. 
Unfortunately, the enzyme related to this activity proved unstable and difficult to 
isolate due to consistent protein degradation. Therefore, potential ongoing 
investigations within our laboratory to attempt to isolate and identify this additional E3 
ligase enzyme may prove interesting. It is probable that NTH1 could be subject to 
ubiquitylation dependent regulation by multiple E3 ligase enzymes; alike to the 
regulation of Pol β by CHIP (125) and Mule (126). Due to observations related to 
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NTH1 increasing in molecular weight by multiples of 8 kDa ,representing the addition 
of multiple ubiquitin moieties, I proposed that TRIM26 stimulates polyubiquitylation. In 
contrast, the E3 ligase activity, which I was unable to purify induced largely 
monoubiquitylation of NTH1 in vitro. It is worth noting that the intensity of the protein 
banding pattern decreased at the latter stages of the purification scheme, presumably 
due to loss of enzymatic activity induced by multiple incidences of freeze-thaw cycles. 
However, it could be that the purification scheme led to dissociation of TRIM26 from 
additional protein binding partners or factors that promote NTH1 polyubiquitylation. 
The fact that TRIM26 was purified from gel filtration fractions with an estimated 
molecular weight of between 200-443 kDa further advocates that the protein is 
multimeric or stably bound to other (unidentified) proteins that may influence its 
activity. Remarkably, our group has recently demonstrated that another DNA 
glycosylase, NEIL1, is also subject to ubiquitylation via TRIM26, in addition to another 
E3 ligase; termed Mule (46). This study utilised the same well-characterised 
purification technique relying on a series of chromatography columns, in combination 
with in vitro ubiquitylation assays, to purify TRIM26 as one of the major E3 ubiquitin 
ligases from human cells, responsible for ubiquitylation of NEIL1. 
The tripartite motif (TRIM) superfamily of proteins are defined by the presence of 
conserved domains; including a RING domain, one or two B-box domains and an 
associated coiled-coil domain in the N-terminal region (63). The RING domain is 
implicated in the conjugation of proteins with ubiquitin related modifiers; including 
ubiquitin, SUMO and other ubiquitin-like molecules (63, 115). The RING domain 
facilitates the biological flexibility of TRIM proteins and may enable involvement in 
numerous biological pathways. Investigations related to elucidating the role of 
members of the TRIM superfamily are in preliminary stages. However, TRIM proteins 
have been shown to be involved in a broad range of processes related to genetic 
disorders, neurological disorders and cellular transformation (115). For example, 
recent exome sequencing analysis, revealed an intronic single nucleotide 
polymorphism in the TRIM26 gene associated with schizophrenia patients (1). Many 
TRIM proteins have been associated with carcinogenesis, with individual TRIM 
proteins either being underexpressed or overexpressed and exerting their cancerous 
effects in individual ways. Certainly, some TRIM proteins are implicated in 
carcinogenesis through regulation of the abundance or activity of the important 
tumour suppressor protein, p53. Indeed, TRIM21, TRIM25, TRIM28 and TRIM29 all 
reduce p53 activity via different mechanisms. As an example, TRIM25 indirectly 
reduces p53 activity by downregulating a histone acetyltransferase (p300), which 
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acetylates p53. Acetylation of p53 is required for transcriptional activation of 
numerous p53 target genes (50). Conversely, there are other TRIM proteins which 
enhance p53 activity; including, TRIM8, TRIM13 and TRIM19 (50). Another important 
cellular component that is controlled by TRIM proteins and associated with 
carcinogenesis is the transcription factor, nuclear factor kappa B (NF-κB). The NF-κB 
protein also regulates cellular proliferation, apoptosis, immunological process and 
inflammation (50). Despite studies identifying the diverse cellular roles of TRIM 
proteins being relatively preliminary, it is becoming increasingly apparent that TRIM 
proteins play an important function in the regulation of innate immunity. In fact, the 
most extensive studies regarding the functioning of TRIM proteins has been 
conducted in relation to human immunodeficiency virus (HIV) infection (115). These 
investigations have revealed several TRIM family members that interfere with the life 
cycle of the HIV infection pathway. For instance, TRIM11, TRIM32 and to a lesser 
extent TRIM22 have been suggested to repress viral gene expression. Likewise, 
TRIM22 and TRIM15 are believed to inhibit HIV assembly. Although, the precise 
mechanisms of these interference steps have yet to be resolved, these observations 
should be approached with caution as it has also been shown that other TRIM proteins 
can facilitate HIV infection (115). These studies may also have limited relation to 
regular context, as they are often completed using specific cell lineages, thus TRIM 
related interference may differ depending on the cell lineage, differentiation status or 
presence of PTMs. In addition to this, more convincing studies have shown that TRIM 
proteins are involved in regulation of innate immunity via the action of interferons (IFN) 
(63). Critically, stimulation of human monocytes and macrophages by IFNγ resulted 
in the increased expression of up to 26 TRIM genes (out of 44 studied) (115). TRIM8 
is one of the proteins that is induced by IFNγ in many cells and it was identified that 
TRIM8 was implicated in the downregulation of the suppressor of cytokine signalling 
1 (SOCS1), which is known to interfere with a well-known inflammatory pathway 
(JAK/STAT) to downregulate IFN-activated gene expression. Although the precise 
mechanism through which TRIM8 achieves this has yet to be completely realised, co-
expression of TRIM8 with SOCS1 promoted SOCS1 degradation suggesting that 
TRIM8 could be destabilising SOCS1 potentially by a ubiquitylation dependent 
mechanism. 
TRIM26 has been shown to negatively regulate IFNβ production and an antiviral 
response by promoting the ubiquitylation dependent degradation of the transcription 
factor, IRF3 (167). When bound to IRF3, TRIM26 promoted the K48-linked 
polyubiquitylation dependent degradation and subsequent termination of the 
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transcription factor (167). Likewise, it is acknowledged that TBK1 is an essential 
kinase engaged downstream of multiple receptors that mediates IRF3 
phosphorylation and activation. A separate study demonstrated that upon viral 
infection, TRIM26 underwent autoubiquitylation to promote association with NEMO. 
This association bridged TBK1 to NEMO, enabling the activation of TBK1 (133). 
These observations highlight the cross-talk between the UPP and regulation of other 
pathways implicated in innate immunity and survival. Most recently, a separate study 
identified the involvement of TRIM26 dependent ubiquitylation in the regulation of 
cellular proliferation in response to transforming growth factor β (TGF-β) stimulation. 
Following treatment of cells with TGF-β, there was increased expression of TRIM26, 
which stimulated the polyubiquitylation of the protein TAF7, thereby targeting it for 
proteasomal degradation (109). The protein TAF7 is an important subunit of the 
general transcription factor IID (TFIID) complex, which plays a passive role in 
mediating the regulation of the expression of a number of gene promoters by RNA 
polymerase II. Degradation of the TAF7 subunit was needed to mediate proliferative 
arrest. This study demonstrated the key involvement of TRIM26 in this process and 
in the regulation of gene expression or the cell cycle (109). In addition to this, it has 
been proposed that TRIM26 regulates cellular apoptosis in non-small-cell lung 
cancer, via observations of reduced TRIM26 expression in patient samples. Further 
studies identified that overexpression of TRIM26 inhibited cell growth, plus induced 
cellular apoptosis, through downregulation of B-cell lymphoma 2 (BCL-2) (188). This 
was uncovered by simultaneous overexpression of BCL-2, which partially reversed 
TRIM26-mediated apoptosis in non-small-cell lung cancer cells (188). However, 
further work is required to elucidate the precise molecular mechanism and role of 
ubiquitylation in BCL-2 dependent regulation of apoptosis. 
Collectively, reports in the literature suggest an increasingly versatile role of TRIM 
proteins within the cellular context. This would not be completely surprising given the 
diversity of the superfamily of TRIM proteins; owing to variable arrangement of protein 
domains, splicing variants, differences in cellular localisation and varying interactivity 
of protein domains. Currently, our understanding of the mechanisms used by TRIM 
proteins to restrict viral infection and regulate a number of cellular pathways is limited. 
This is partly due to our ineffective ability to recognise the functional consequences 
of every domain that initiates ubiquitylation or addition of ubiquitin-like modifiers plus 
the nature of every E2 enzyme and their specific protein targets. Furthermore, we do 
not fully comprehend the modes of modification which result in the inhibition or 
promotion of substrate protein activities. It is anticipated that structural investigations 
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will have an increasingly prominent role in elucidating protein interactions between 
TRIM proteins and their respective cellular targets, as well as the PTMs which may 
additionally influence these reactions. Progression in this subject may assist the 
development of novel approaches aimed at preventing infectious diseases, 
autoimmune conditions, inflammatory disorders and even some cancerous 
phenotypes. 
7.3 TRIM26 ubiquitylates NTH1 within the N-terminus 
Studies in the literature have reported the existence of three isoforms of NTH1. 
However, identification of the NTH1 isoform that is expressed in mammalian cells 
lacks clarity (94). Despite this oversight, it is acknowledged that all three forms of 
NTH1 possess a total of 17 lysine residues, which are all potential sites of ubiquitin 
attachment. With this in mind, it was important to define which specific lysine was 
subject to ubiquitylation by TRIM26. To identify these ubiquitylation sites within NTH1, 
I adopted a similar strategy to our previous study (45). During this, a mass 
spectrometry based approach was used to analyse in vitro ubiquitylated NTH1 by 
TRIM26. Therefore, ubiquitylated NTH1 was separated and isolated by SDS-PAGE 
analysis, then the protein within specific gel slices was extracted and digested with 
trypsin prior to analysis. Unfortunately, when using this approach, detection of specific 
peptides containing the characteristic glycine-glycine motif generated as a 
consequence of digestion of ubiquitin was elusive. Using ArgC as an alternative 
digestive enzyme, was also unable to detect any peptides within NTH1 subject to 
ubiquitylation. Therefore, alternative approaches were undertaken. 
From a previous study in our lab, the generation of truncated version of NEIL1, 
demonstrated that a C-terminal deletion of NEIL1 lacking the final 55 amino acids was 
unable to be substantially ubiquitylated in vitro by TRIM26. Sequentially mutating 
lysine residues at the C-terminal end of the protein identified 7 lysine residues 
requiring mutation to fully suppress NEIL1 ubiquitylation. It was confirmed that both 
Mule and TRIM26 ubiquitylated the same lysine residues (45). With this in mind, I 
used a similar site directed mutagenesis technique. Despite truncated versions of 
NTH1 proving susceptible to degradation, preliminary results suggesting that the site 
of NTH1 ubiquitylation may be N-terminal were gained. This was due to the 
observation that deletion of the first 98 amino acids of NTH1 supressed TRIM26-
dependent ubiquitylation in vitro. It is worth noting that the truncated versions of NTH1 
may have been particularly susceptible to degradation because the N-terminal region 
of the protein may be required for stabilisation. Despite studies suggesting that the 
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extended N-terminal end of mammalian NTH1 may hinder its activity (88), it may have 
an additional, unidentified role in managing protein stability. 
Having attempted a mass spectrometry and a truncated protein approach, I began to 
generate site specific mutants of NTH1 in a sequential manner, with a focus on the 
N-terminal end of the protein which would then be used in combination with the in 
vitro ubiquitylation assay with TRIM26. It was anticipated that maintaining a similar 
size and charged amino acid would cause minimal disruption to the overall structure 
of NTH1. This approach concluded that TRIM26 ubiquitylation of NTH1 occurs 
predominantly on lysine 67. Substitution of this residue to arginine significantly 
impeded in vitro ubiquitylation of recombinant NTH1. The substitution of other lysine 
residues such as K42, K48 and K52, also decreased the level of ubiquitylation of 
NTH1; although less strikingly than the K67R substitution. Mutation of all four of these 
lysine residues appeared to completely supress TRIM26-dependent ubiquitylation of 
NTH1. The effect of the K67R variant on the cellular stability of NTH1 was examined 
via plasmid overexpression, which concluded that the K67R variant of NTH1 protein 
was significantly more stable than the wild type glycosylase, providing evidence that 
the stability of NTH1 is dependent on lysine 67 and further advocates that this is the 
target site for TRIM26 ubiquitylation. Overall, these investigations suggest that K67 is 
the major site of ubiquitylation of recombinant NTH1 by TRIM26 in vitro, and that other 
lysine residues within this N-terminal region of the protein act as weaker ubiquitylation 
sites. This observation that K67 with the N-terminus of NTH1 is a target for 
ubiquitylation, is in addition to reports in the literature which describe that the extended 
N-terminal region of mammalian NTH1 may have an inhibitory role on the overall 
activity of the mammalian homologue of the glycosylase (88). With this in 
consideration, it is rational to propose that the N-terminal section of NTH1 may be 
subject to regulation via several PTMs, including ubiquitylation, (as described in this 
thesis), which act to impede enzymatic activity. Regulation of the activity of BER 
glycosylases is crucial to cellular survival because unregulated action of these 
enzymes could lead to increased DNA base excision. This is particularly important 
when considering bifunctional BER glycosylases, which also incise the DNA 
backbone. Therefore, unregulated removal of damaged DNA bases and/or the 
incision of AP sites could compromise the stability of the genome by producing 
excessive DNA single strand breaks. If these are not repaired by the availability of 
downstream BER proteins, this could jeopardise genome integrity and increase the 
likeliness of mutagenesis associated with human disease progression. 
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Interestingly, the site directed mutagenesis approach I adopted to investigate the site 
of NTH1 ubiquitylation, presented the opportunity to examine the effects of a naturally 
occurring point mutation. Reports in the literature have documented the presence of 
D238Y point mutation in 6.2 % of the global population (54). The mutation is 
characterised by the substitution of an aspartate residue to tyrosine, within the 
suspected active site of NTH1. The D239Y NTH1 variant exhibited limited glycosylase 
activity and was unable to excise Tg from oligonucleotide substrates, even though 
both D239Y and WT NTH1 bind with similar affinities to DNA containing Tg. 
Interestingly, addition of D239Y to WT NTH1 results in decreased overall glycosylase 
activity, suggesting that D239Y and WT compete for binding to damaged bases and 
that there is a dominant negative effect of D239Y (54). Expression of the D239Y NTH1 
variant in human cells resulted in cellular transformation with transfected cells forming 
significantly greater numbers of colonies and a lack of focus formation. The 
observation of cellular transformation correlates to the suggestion that individuals who 
express the mutant NTH1 are likely to have increased risk of cancer. In line with this, 
cells expressing the D239Y variant exhibited significantly increased genomic 
instability via increased levels of chromatid breaks and fusions compared to cells 
expressing with WT NTH1. Related to this, D239Y expressing cells also accumulated 
DSBs perhaps as a consequence of replication fork collapse upon collision with an 
unexcised Tg or other replication-blocking lesions (54). Furthermore, expression of 
D239Y also induced increased sensitivity to DNA damaging agents. I therefore opted 
to generate recombinant D239Y variant of NTH1 and investigate its impact on TRIM26 
dependent ubiquitylation. Surprisingly, analysis showed that the D239Y NTH1 variant 
was not efficiently ubiquitylated in comparison to the WT protein, which would suggest 
that the variant is not regulated by ubiquitylation. Of course, this demands further work 
to distinguish the full effect of the D239Y substitution on NTH1 activity and capacity 
to be regulated by ubiquitylation in cells. Whilst this was not the major focus of my 
thesis, this could be an avenue for future research. It would be interesting to evaluate 
if the D239Y variant exhibits altered protein stability in the cellular context and whether 
this is specific to ubiquitylation dependent regulation by TRIM26. 
7.4 TRIM26 does not regulate steady state levels of NTH1  
Given that I had clearly demonstrated that NTH1 is a target for ubiquitylation by 
TRIM26 in vitro, I next aimed to explore the mechanisms of ubiquitylation dependent 
management of NTH1 in the cellular context, with a particular focus on the role of 
TRIM26 in modifying NTH1 protein stability. For this purpose, I opted to use a human 
colon carcinoma cell (HCT116p53+/+) line. Not only are these cells well characterised 
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in culture, but it was also hoped that since a homozygous loss-of-function germline 
mutation in the NTH1 gene predisposes to a new subtype of BER-associated 
adenomatous polyposis and colorectal cancer (175), understanding the mechanism 
of regulation of NTH1 in HCT116p53+/+ cells could prove to be clinically relevant in the 
eventual treatment of this disease. Initially, I discovered elevated levels of cellular 
NTH1 following inhibition of the proteasome by MG-132 which confirmed that NTH1 
levels are regulated in cells by ubiquitylation dependent degradation. This observation 
is supported by a proteomic screen which has identified that NTH1 is ubiquitylated, 
although the enzymes involved in the ubiquitylation process were not elucidated (34). 
Following on from this, I examined the specific role TRIM26 plays on the in cells 
ubiquitylation dependent regulation of the steady state levels of NTH1. Our previous 
publication focusing on the ubiquitylation dependent regulation of another DNA 
glycosylase, NEIL1, demonstrated that TRIM26 (and another E3 ubiquitin ligase 
Mule) were important in the control of the cellular state levels of NEIL1 (46). This is in 
contrast to observations within this study, which have shown that TRIM26 is not 
implicated in modulating the cellular steady state levels of NTH1. Despite observing 
substantial polyubiquitylation of NTH1 by TRIM26 in vitro, depletion of cellular 
TRIM26 via siRNA in HCT116p53+/+ cells had no significant impact on the steady state 
levels of the glycosylase, suggesting that unlike observations with NEIL1, TRIM26 is 
not responsible for the regulation of NTH1 in unstressed cells.  
Aside to investigating steady state levels, I also examined if TRIM26 may regulate the 
intracellular localisation of NTH1 using siRNA dependent depletion of TRIM26 in 
combination with fractionation of protein extracts from HCT116p53+/+ cells. Comparable 
to the literature, I showed that cellular NTH1 was detected in nuclear fractions 
prepared from HCT116p53+/+ cells. Further investigation suggested that NTH1 is in fact 
tightly associated with chromatin, although a small proportion of NTH1 was still visible 
in the soluble nuclear fraction. Reports in the literature also showed that isoforms of 
NTH1 are all localised to the nucleus (69), with minor levels of cytoplasmic NTH1 
believed to be predominantly localised in the mitochondria (68).  Some reports have 
recognised that NTH1 is able to repair sterically occluded sites within histone 
octamers which form the basis of chromatin (130) and further reports have suggested 
that glycosylases such as NTH1 remain bound to DNA in order to scan for damaged 
base lesions (166). My observation of the localisation of NTH1 in chromatin bound 
cellular extract fractions would support the evidence that NTH1 is indeed tightly 
associated with chromatin and potentially constantly scanning along the DNA, 
however this requires more extensive investigation, especially to explore the 
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mechanistic details of this potential association. I further discovered that an siRNA 
mediated depletion of TRIM26 results in little changes in the levels of NTH1 
associated with chromatin, and also no alteration in the cellular distribution of the 
glycosylase between chromatin bound and cytoplasmic fractions. A similar 
observation was found with NT control siRNA sequences which lacked a genomic 
target suggesting that TRIM26 siRNA does in fact have no dramatic effect on the 
cellular proteins levels of NTH1 or on cellular localisation. 
7.5 TRIM26 controls the cellular response of NTH1 to oxidative stress 
A recent study from our lab investigating NEIL1 as the glycosylase of interest, 
suggested that the induction of NEIL1 in response to elevated genotoxicity caused by 
ionizing radiation, was primarily Mule dependent and did not rely on TRIM26 protein 
(46). Since I did not observe any changes in the steady state levels or cellular 
localisation of NTH1 that were dependent on TRIM26, I proposed that TRIM26 may 
in fact control the regulation of NTH1 protein levels in response to DNA damage. This 
would be the opposite role for TRIM26 which was observed with NEIL1 regulation. To 
explore this concept, oxidative stress was induced by hydrogen peroxide that 
generates oxidative DNA base damage that requires repairing by NTH1, and 
subsequently the levels of NTH1 at particular time intervals post-treatment were 
analysed, with or without an siRNA mediated knockdown of TRIM26. This experiment 
demonstrated that the levels of NTH1 protein expression in the presence of a NT 
control siRNA sequence increased by ~1.3-fold following 0.5 h exposure to hydrogen 
peroxide. Protein levels of NTH1 remained elevated for up to 4 h post-treatment 
before then returning to the levels similar to those observed in the untreated controls 
after 6-8 h treatment. To our knowledge, this is the first reported evidence that NTH1 
protein is induced under conditions of oxidative stress. Subsequent depletion of 
TRIM26 expression resulted in a significant (~1.7-fold) increase in the protein levels 
of NTH1, which is beyond the elevated levels observed with NT control siRNA 
treatment alone, particularly at 0.5-2 h post-treatment. Whilst this is a modest increase 
in NTH1, this was statistically significant although it is worth noting that the siRNA 
mediated depletion of TRIM26 was not totally effective, with an estimated cellular 
expression of 20 % of residual TRIM26 protein remaining. This residual TRIM26 
expression may account for the modest increase in NTH1 protein post-treatment, but 
also the observation that NTH1 protein levels eventually reduce in TRIM26 depleted 
cells after initial exposure to the genotoxic agent and are similar to those observed in 
the NT control siRNA cells after 6-8 h post-treatment. Therefore, it is plausible that 
the residual expression of TRIM26, which was not fully supressed following siRNA 
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treatment, was able to eventually degrade NTH1. Alternatively, this observation could 
even be due to the presence of an additional E3 ligase enzyme that appears to be 
more active several hours following hydrogen peroxide treatment. This is credible 
given that we are already aware of a secondary E3 ligase activity specific to NTH1 
which I was not able to purify due to the stability or activity of the enzyme being 
unstable. This activity (NTH1-E31) appeared to mainly facilitate the 
monoubiquitylation of NTH1 in vitro but which may have a more pronounced role in 
the cellular context. Furthermore, to fully appreciate the effects of TRIM26 in the 
cellular context, it may be beneficial to repeat assessment of NTH1 protein levels 
following oxidative stress using a knockout of TRIM26 induced by CRISPR-Cas9 
gene editing. This may prove more effective in eliminating the residual 20 % of 
TRIM26 protein expression which could not be supressed by the effects of 
transfecting two siRNA sequences. The CRISPR-Cas9 gene editing system is 
currently being implemented in our laboratory, so the impact of TRIM26 depletion on 
NTH1 protein levels in response to oxidative DNA damage may be a line of further 
investigation. Furthermore, purification and identification of the additional E3 ligase 
enzyme which has already demonstrated specificity towards NTH1 (NTH1-E31) will 
be essential and is forming the basis for upcoming investigations. 
7.6 TRIM26 dependent ubiquitylation of NTH1 influences DNA repair kinetics 
and cell survival 
To further my investigations into the cellular role of TRIM26 following oxidative stress, 
the clonogenic assay was utilised to measure cellular survival following treatment with 
hydrogen peroxide. This is the gold standard assay for examining the impact of 
genotoxins and DNA damaging agents on cell survival. I revealed that cells exhibited 
increased survival capacity following exposure to DNA damage upon siRNA induced 
depletion of TRIM26, in comparison to NT control siRNA treated cells. Importantly, 
this observation could be recapitulated with a partial overexpression of NTH1 via a 
mammalian expression plasmid. This result promotes the logic that cells exhibit an 
increased ability to endure oxidative stress, and thus repair oxidative DNA damage, 
through modulation of NTH1 which can be manipulated by altering TRIM26 levels. 
Some observations in the literature support this speculation, with one study also 
demonstrating that overexpression of NTH1 causes resistance to hydrogen peroxide 
(184). Therefore, increased cellular levels of NTH1 are able to increase the ability of 
cells to repair oxidative DNA damage, leading to resistance to oxidative stress. 
However interestingly, another study by the same group later advocates that 
overexpression of NTH1 in TK6 cells has the opposite effect following exposure to IR; 
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with overexpression of NTH1 resulting in an exacerbation of DNA double strand break 
formation, leading to an elevated sensitivity to the cytotoxic and mutagenic effects of 
ionizing radiation (185).  Researchers suggested that the increased sensitivity was 
observed due to the attempted repair of radiation damage, presumably at clustered 
damage sites, by NTH1 which can lead to the formation of potentially lethal and 
mutagenic double strand breaks in human cells. However, it is difficult to fully agree 
with this hypothesis given the contradictory observations related to the effects of 
NTH1 overexpression depending on the source of genotoxicity used to induce cellular 
DNA damage. This highlights the necessity for further work investigating the 
regulation of cellular glycosylases in response to different genotoxic agents, which 
may reveal an increasingly dynamic role of the DNA glycosylase depending on the 
dominate type of DNA damage inflicted on the genome. Despite conflicting reports, 
both studies highlight the necessity for tight regulation of NTH1 levels to maintain 
genomic stability.  
Further to this, I utilised the alkaline single gel electrophoresis (comet) assay to 
examine cellular DNA damage repair kinetics following exposure to the genotoxic 
agent, hydrogen peroxide. This assay reveals the presence of DNA single strand 
breaks and alkali-labile sites generated directly, or as intermediates through BER. I 
demonstrated that cells with reduced levels of TRIM26 demonstrated improved ability 
to repair DNA damage induced by hydrogen peroxide. Similar to clonogenic survival 
results, increased kinetics of DNA repair in TRIM26 knockdown cells could be 
achieved by partially overexpressing NTH1. Yet again, this is alike to conflicting 
documentation in the literature which showed an association between overexpression 
of NTH1 and increased ability to repair DNA damage (185). Cumulatively, my 
observations support the concept that repair of oxidative DNA damage by NTH1 
following exposure to elevated levels of genotoxicity is TRIM26 dependent. This data 
further supports our previous findings, which highlights the importance of TRIM26 in 
co-ordinating the appropriate cellular response to DNA damage via regulation of an 
alternative BER glycosylase, NEIL1 (46). Reports in the literature further support the 
fact that DNA glycosylases need to be tightly regulated to minimise genomic 
instability.  
Overall, an increasingly dynamic role of TRIM26 is now becoming apparent, whereby 
the E3 ligase is implicated in the regulation of multiple BER glycosylases (at least two 
identified so far) with different effects in relation to the DNA damage response. 
Despite this increased knowledge, the cellular mechanism which dictates the outcome 
of ubiquitylation of either glycosylase under the regulation of TRIM26 remains to be 
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fully understood. As previously discussed, alteration of DNA damage responsive 
levels of NTH1 appears to be TRIM26 dependent, whereas management of NEIL1 
levels in response to elevated DNA damage was shown to be dependent on another 
E3 ligase, Mule. The different regulatory effects of TRIM26 on NTH1 and NEIl1 may 
be due to the different cellular roles of each glycosylase. In particular, NTH1 plays a 
role in global repair of oxidised pyrimidines, whereas NEIL1 removes these from 
single stranded DNA associated with transcription or replication. Furthermore, it is 
worth noting that additional studies regarding different types of DNA damaging agents 
are required. For example, our most recent study focused on NEIL1 induced DNA 
damage via IR (46), whereas, this study utilises hydrogen peroxide as a source of 
genotoxicity. Consequently additional studies are necessary using different sources 
of genotoxic agents to build a more comprehensive understanding of the impact of 
regulation of BER components by TRIM26 in response to different types of genomic 
damage.  
It is also worth considering that the differing roles of TRIM26 ubiquitylation of the two 
glycosylases, NTH1 or NEIL1, may be reliant on additional regulation by alternative 
post-translation modifications, which may promote or hinder the addition of ubiquitin 
moieties. However, previous reports have not documented modification of either 
NTH1 or NEIL1 via other post-translational modifications including, phosphorylation, 
methylation, acetylation or SUMOylation (25). This area may require further scientific 
investigation to discover potential association between different PTMs during the 
regulation of these DNA repair enzymes by ubiquitylation. PTMs of NTH1 could be 
identified following immunoprecipitation of the protein from cells and subsequent 
mass spectrometry analysis.  However, this analytical approach is not without 
limitations; with the level of detection depending on the mass shift the PTM causes, 
the abundance of the modified peptide, the ability of the PTM to withstand rigorous 
mass spectrometry analysis and finally the impact the PTM has on the ionization 
efficiency of the peptide. For instance, studies involving phosphorylation are generally 
restricted by the abundance of the phosphorylated protein available and the sensitivity 
of detection varies depending on the peptide sequence. Of course, there are 
techniques to enrich the detection of target proteins and so a mass spectrometry 
approach may still be a valid tactic to investigate PTMs of NTH1 in the future.  
Of course, it is entirely plausible that TRIM26 itself is also be subject to PTM 
dependent regulation which may regulate it activity towards NTH1 and NEIL1. This 
mechanism will obviously require further investigation however it will enable us to gain 
a comprehensive understanding of the molecular and cellular mechanisms employed 
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to regulate key proteins implicated in the BER pathway, particularly in response to 
genotoxic stress. Identification and understanding PTMs is crucial for gaining a 
complete comprehension of cellular biology and potentially lead to the delineation of 
dysregulated molecular defaults which could underlie the pathogenesis of human 
diseases, including cancer. Furthermore, a full understanding of the PTMs employed 
to regulate DNA damage response proteins could facilitate the discovery of novel drug 
targets which could eventually aid in the treatment of diseases. 
7.7 Future work 
Future work should focus specifically on furthering our understanding of the 
interaction and association between NTH1 and TRIM26. One area of investigation is 
to examine NTH1 activity using oligonucleotide substrates containing oxidative DNA 
base lesions (eg. Tg) and measuring the rate at which these are processed. This 
could be used to examine the effects of TRIM26-dependent ubiquitylation of NTH1, 
on the relative DNA glycosylase activity of the enzyme, which has yet to be fully 
realised in our current studies. Alike to other protocols in the literature, this technique 
could be extrapolated to further study the effects of NTH1 activity using a model of 
chromatin by generating histone octamers with oxidative DNA base lesions, such as 
5-hydroxuracil and Tg, in different orientations within the nucleosome structure. For 
instance, the DNA base lesions could remain easily accessible and facing outwards 
of the nucleosome structure, or could be occluded by facing towards the nucleosome. 
It has previously been shown that NTH1 is able to process easily accessible DNA 
base lesions at a rate which is 10-fold quicker than processing of DNA base lesions 
which are occluded within the histone octamer and are harder to access (130). It 
would be interesting to utilise this method to examine the role of TRIM26 in regulating 
the ability of NTH1 to process chromatin associated DNA base lesions. My 
expectation is that the addition of ubiquitin (8 kDa protein) to NTH1 by TRIM26 should 
prevent the DNA glycosylase binding to oxidative DNA damage within free or 
nucleosomal DNA, and potentially reduce its association with chromatin. 
In addition to this, an examination of the fluctuations of NTH1 expression throughout 
different stages of the cell cycle would be of interest.  This concept has already been 
considered using synchronised cell studies, which described increased transcription 
of NTH1 throughout the early and mid S-phase pf the cell cycle (95). However, it would 
be interesting to mediate a knockdown of TRIM26 via siRNA or CRISPR-Cas9 gene 
editing, to inspect if ubiquitylation is involved in the cell cycle dependent regulation of 
NTH1, in addition to its role in the cellular DNA damage response.  
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More importantly, it will also be imperative to assess if the ubiquitylation dependent 
regulation of NTH1 via TRIM26 occurs in alternative cell lines, other than HCT116p53+/+ 
colorectal cancer cell lines used in this study. It is worth considering that since altered 
NTH1 levels are linked to colorectal cancer due to the presence of a germline mutation 
(175), TRIM26-dependent regulation of NTH1 could be restricted to this cell line only. 
In previous studies, we have utilised U2OS osteosarcoma cell line to investigate 
NEIL1 regulation and so this could be an initial cell line employed in these further 
investigations (46). Related to this point, it will also be interesting to establish if 
TRIM26-dependent regulation of NTH1 is present in normal cells or whether it is 
limited to cancer cell lines only. This would be particularly interesting from the aspect 
of developing therapeutic strategies aimed at targeting cancer cell lines whilst sparing 
normal cells. For instance, if the TRIM26 dependent regulation of NTH1 was strictly 
observed in cancer cell lines, this could provide an avenue to specifically target this 
mechanism to affect cancer cells. For example, manipulating the ubiquitylation 
regulation of NTH1, to cause reduced levels of the glycosylase would reduce the 
ability of cancer cells to react to DNA damage induced by therapeutic agents which 
rely on inducing genomic damage, such as radiotherapy. Reduced glycosylase levels 
specifically within cancer cells, would therefore decrease their ability to withstand 
genomic damage and result in increased cancer cell death.  
In addition, investigating if the DNA damage dependent induction of NTH1 occurs in 
response to other types of genotoxic stress could prove interesting. Whilst I have 
demonstrated that induction of NTH1 by TRIM26 occurs in response to oxidative 
stress induced by hydrogen peroxide, exposure of cells to genotoxic damage via 
ionising radiation could be used to analyse NTH1 levels in cellular extracts over time. 
This, in combination with clonogenic survival assays and comet assays could be 
utilised to assess cellular survival and the effects of DNA damage repair kinetics, 
respectively. It would be interesting to observe if the alterations in NTH1 levels or 
cellular response, in terms of frequency but also kinetically, are comparable to those 
seen following exposure to hydrogen peroxide. The results of this experimentation 
could in fact demonstrate some differences due to the variation in DNA damage 
inflicted by each genotoxic source. Hydrogen peroxide treatment is largely associated 
with the generation of DNA base lesions and single strand breaks, whereas, the 
energy deposition inflicted by tracks of ionising radiation can result in clustered sites 
of complex DNA lesions located within a few nanometres of each other, including 
DSBs (92). Complex DNA damage sites are well known to represent a challenge to 
the DNA repair machinery resulting in their persistence in cells and DNA post-
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irradiation The complexity of the DNA damage associated with IR means that NTH1 
may play a key role in their repair through long-patch BER, in collaboration with other 
types of DNA damage repair pathways, including, NHEJ or HR (71, 96).  
Moreover, all of this experimentation could be extended to elucidate the role of the 
minor E3 ligase activity which I was unable to purify in this particular thesis, largely 
consistent with issues related to degradation or decreased stability of the candidate 
E3 ligase enzyme. From our preliminary studies during the initial purification of NTH1 
specific E3 ligase enzymes, it would appear that the minor E3 ligase enzyme activity 
(NTH1-E31) is mainly associated with monoubiquitylation of NTH1. This was observed 
by the induction of one, singular shift of approximately 8 kDa in molecular weight of 
substrate NTH1, following in vitro ubiquitylation with active chromatography fractions 
containing the minor candidate E3 ligase. Ideally, purification and identification of this 
additional E3 ligase enzyme will be the primary focus of any future investigations. The 
forthcoming experimentation would also aim to clarify the molecular mechanism and 
cellular implications of the ubiquitylation dependent regulation of NTH1 via this 
particular E3 ligase activity. This will be particularly interesting due to preliminary 
assays suggesting that this activity is associated with monoubiquitylation. For this 
reason, it could be anticipated that the minor E3 ligase, at least in vitro, may induce a 
different effect on NTH1 in cells, compared to TRIM26. It is reasonable to hypothesise 
that this alternative ligase activity could regulate NTH1 in a different way. For instance, 
it may influence the activity, DNA binding or cellular localisation of human NTH1. 
However, the influence monoubiquitylation may have on NTH1 is difficult to predict 
due to the multiple roles the attachment of single moieties of ubiquitin can play. For 
instance, monoubiquitylation of PCNA at stalled replication forks promotes the 
interactivity of the modified protein (14), whereas monoubiquitylation of SMAD4 
inhibits it interactivity with a signalling partner implicated in the TGFβ signalling 
pathway (44). On the other hand, monoubiquitylation influences the cellular 
localisation of Pol β  and also acts as a prerequisite for polyubiquitylation dependent 
proteasomal degradation (126). Due to the diverse roles of monoubiquitylation, it is 
clear that in order to appreciate the effects of monoubiquitylation of NTH1, 
identification of the E3 ligase responsible is required to facilitate further exploration 
into the biological consequences of this mechanism. 
7.8 Concluding remarks 
The work described in this thesis has clearly identified TRIM26 as the major E3 ligase 
in the ubiquitylation dependent regulation of the BER glycosylase, NTH1. Excitingly, 
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the outcomes of this work have now been peer-reviewed and accepted for publication 
in the Molecular and Cellular Biology scientific journal (see appendix). The regulatory 
mechanism identified is clearly important in regulating the cellular levels of NTH1 in 
response to oxidative stress. Collectively, this observation in combination with our 
previously identified role for TRIM26 in modulating the steady state protein levels of 
another BER glycosylase, NEIL1, highlights an emerging role for TRIM26 in 
controlling the cellular response to oxidative DNA damage and suggests the E3 ligase 
may act as a vital regulatory enzyme involved in the BER pathway. Of course, further 
work is necessary to fully appreciate the role of other PTMs, such as phosphorylation, 
which may act on both NTH1 and TRIM26 and are therefore important in the 
regulation of the proteins and of the BER pathway that is responsible for the cellular 
response to oxidative DNA damage. Furthermore, identification of any additional E3 
ligase activities that regulate NTH1, evidence of the existence of at least one such 
enzyme has been presented in this study, and the impact of these in terms of 
regulation of the DNA glycosylase particularly in relation to TRIM26, require thorough 
investigation.  
The outcomes of this study are particularly important as investigations regarding 
regulation of the BER pathway have largely focused on enzymes further downstream 
in the process. Furthermore, reports in the literature have not yet reported any PTMs 
which are known to specifically regulate NTH1. Understanding the molecular 
mechanisms underlying the regulation of NTH1 and of BER are important to extend 
our comprehensive understanding of the cellular DNA damage response and 
potentially assist with defining molecular defaults implicated in the pathogenesis of 
specific cancers or other human diseases. The strategies utilised here could be 
extrapolated to identify the molecular mechanisms, particularly ubiquitylation 
dependent regulation, of other proteins involved in other DNA damage response 
pathways. An increased awareness of the molecular mechanisms underlying the DNA 
damage response could improve the identification of novel drug targets, facilitate the 
development of novel therapies or improve sensitivity to current treatment regimes. 
Overall, enhancing our scientific knowledge of the DNA damage response will be 
useful for us to fully comprehend the mechanisms underlying human pathologies.  
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Chapter 9 - Appendix 
 
1. MASCOT search results showing the protein sequence coverage (in bold red, 
19%) of TRIM26, following mass spectrometry analysis of the chromatography 
fraction containing ubiquitylated NTH1, following the final ion exchange 
chromatography stage during the purification stage 
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2. Chromatogram following sequencing of the pET28-NTH1-K42, 48, 52, 67R 
plasmid DNA using the Sanger Source Bioscience sequencing service 
(Nottingham, UK). The mutated lysine residues have been highlighted in 
yellow.  
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3. Chromatogram following sequencing of the pET28-NTH1-K48, 52R plasmid 
DNA using the Sanger Source Bioscience sequencing service (Nottingham, 
UK). The mutated lysine residues have been highlighted in yellow.  
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4. Chromatogram following sequencing of the pET28-NTH1-K48R plasmid DNA 
using the Sanger Source Bioscience sequencing service (Nottingham, UK). 
The mutated lysine residues have been highlighted in yellow. 
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5. Chromatogram following sequencing of the pET28-NTH1-K42R plasmid DNA 
using the Sanger Source Bioscience sequencing service (Nottingham, UK). 
The mutated lysine residue has been highlighted in yellow. 
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6. Chromatogram following sequencing of the pET28-NTH1-K67R plasmid DNA 
using the Sanger Source Bioscience sequencing service (Nottingham, UK). 
The mutated lysine residue has been highlighted in yellow. 
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7. Chromatogram following sequencing of the pET28-NTH1-K42R plasmid DNA 
using the Sanger Source Bioscience sequencing service (Nottingham, UK). 
The mutated lysine residue has been highlighted in yellow. 
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8. Chromatogram following sequencing of the pET28-NTH1-D239Y plasmid 
DNA using the Sanger Source Bioscience sequencing service (Nottingham, 
UK). The mutated lysine residue has been highlighted in yellow. 
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9. Chromatogram following sequencing of the pCMV-3Tag-TRIM26 plasmid 
DNA using the Sanger Source Bioscience sequencing service (Nottingham, 
UK). 
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10. Mycoplasma test results confirming that the negative for HCT116 +/+ cells 
used within this investigation were mycoplasma negative. Mycoplasma testing 
was performed as part of an in-house service at the North-West Cancer 
Research Centre. The results for the HCT116p53+/+ cells used throughout this 
research project have been highlighted in yellow. 
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CHAPTER 10 - ABBREVIATIONS 
 
5’Drp 5’-deoxyribosephosphate 
8-oxoG 8-oxo-7,8-dihydrogaunine 
A adenine 
AGC automatic gain control 
APE1 AP endonuclease 1 
Bcl-2 B-cell lymphoma 2 
BER Base excision repair 
C cytosine 
CHIP carboxyl terminus of Hsc70 interacting protein 
CPDs cyclobutane pyrimidine dimers 
CSA Cockayne syndrome complementation group A 
CSB Cockayne syndrome complementation group B 
Cul Cullin 
DDB DNA binding protein 
DDB1 DNA damage binding protein 1 
DMEM Dulbeccos Modified Eagle Medium 
DNA deoxyribose nucleic acid 
DNA-PKcs DNA protein kinase catalytic subunit 
DSBs Double strand breaks 
ERCC1 excision repair cross-complementation group 1 
FaPy formamidopyrimidine 
FBS % fetal bovine serum 
FDR false discovery rate 
FEN1 flap endonuclease 
G guanine 
GGR global genome repair 
Gy gray 
H2O2 hydrogen peroxide 
HA hemagglutinin 
HCT116p5
3 +/+ 
human colon carcinoma cells 
HECT homologous to E6-AP carboxyl terminus 
HhH Helix-hairpin-helix glycosylases 
HIV human immunodeficiency virus 
HNPCC hereditary non-polyposis colorectal carcinoma 
HR homologous recombination 
HR23B homologous recombinational repair group 23B; 
JPDB JPDB buffer (50 mM Tris HCl pH8, 50 mM KCl, 1mM EDTA, 10 % 
glycerol) 
LB lysogeny broth 
LET linear energy transfer 
LIC ligation-independent cloning 
Lys lysine 
MMR mismatch repair pathway 
MPG N-methylpurine DNA glycosylase 
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MPG 3-methyl-purine glycosylase 
Mrna messenger RNA 
MS Mass spectrometry 
Mule ARF-BP1/HectH9 
MUTY A/G mismatch specific adenine glycosylase 
NEIL endonuclease VII-like proteins 
NEIL endonuclease VIII-like protein 1 
NF-Κb nuclear factor κB 
NHEJ nonhomologous end-joining 
NTH1 human endonuclease III 
O2.- superoxide anion 
OD optical density 
OGG1 8-OxoG DNA glycosylase 1 
OH Hydroxyl radicals 
PARP poly (ADP-ribose) polymerase 
PCNA proliferating cell nuclear antigen 
PCNA proliferating cell nuclear antigen 
PNKP polynucleotide kinase phosphatase 
Pol Polymerase 
PTM post-translational modifcation 
PVDF Immobilon-FL polyvinylidene diflouride 
RBR RING between RING 
RIG-1 retinoic acid inducible gene 1 
RING really interesting new gene 
RNA RiboNucleic Acid 
RNAPII RNA polymerase II 
ROS reactive oxygen species 
RPA replication protein A 
SAM S-adenosylmethionine 
SDS-
PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SSBs Single strand breaks 
STRAP serine-threonine kinase receptor associated protein 
T thymine 
TAE Tris-acetate-EDTA 
TCR transcription-coupled repair 
TDG thymine DNA glycosylase 
TFIID transcription factor IID 
TFIIH transcription factor IIH 
TFIIS transcription initiation factor IIS 
Tg Thymine glycol 
TRIM tripartite motif containing 26 
U uracil 
U2OS human female osteosarcoma cells 
UDG Uracil DNA glycosylases 
UPP ubiquitin proteosome pathway 
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UV Ultraviolet light 
WT wild type 
XP xeroderma pigmentosum (groups A–G). 
XRCC X-ray cross complementing protein 
 
 
 
 
